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List of abbreviations 
 
2OMe/PS 2-O-methyl-modified RNA AONs with phosphorothioate 
* stop codon 
A2-E N-retinylidene-N-retinylethanolamine 
AAV adeno-associated vector 
ABCA4  ATP binding cassette subfamily A, member 4 
ACHM achromatopsia 
ACTB beta-actin 
ADP adenosine diphosphate 
AF allele frequency 
ALK-001 C20-D3-vitamin A 
AMD age-related macular degeneration 
AON antisense oligonucleotide 
arCRD autosomal recessive cone-rod dystrophy 
arRP autosomal recessive retinitis pigmentosa 
ATP adenosine triphosphate 
b-FGF fibroblast growth factor, basic 
BBS Bardet-Biedl syndrome 
BCVA best-corrected visual acuity 
BEST1 bestrophin 1 
bp base pair 
BPS branch point site 
c-MYC MYC proto-oncogene, BHLH transcription factor 
CC connecting cilium 
CD cone dystrophy 
CDH23 cadherin 23 
cDNA complementary deoxyribonucleic acid 
CEP290 centrosomal protein 290 kDa 
CHM choroideremia 
CHX cycloheximide 
CHX10 Ceh-10 homeodomain-containing homolog 
CK30-NPs polylysine-based compacted DNA nanoparticles 
CNG cyclic nucleotide gated channel 
CNGB3 cyclic nucleotide gated channel beta 3 
CMV cytomegalovirus 
CNV  copy-number variant 
COL2A1 collagen type II alpha 1 chain 
COL11A1 collagen type XI alpha 1 chain 
COS7 Cercopithecus aethiops fibroblast-like cells 
CRB1 crumbs homolog 1 
CRD  cone-rod dystrophy 
CRX cone-rod homeobox 
CSNB congenital stationary night blindness 
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DGGE denaturing gradient gel electrophoresis 
dHPLC denaturing high performance liquid chromatography 
DNA deoxyribonucleic acid 
EIAV equine infectious anemia virus  
ELOVL4 elongation of very long chain fatty acids protein 4 
ERG electroretinogram 
ESCs embryonic stem cells 
ESE exonic splice enhancer 
ESS exonic splice silencer 
EVR exudative vitreoretinopathy 
ExAC  exome aggregation consortium database 
EYS eyes shut homolog 
FA fluorescein angiography 
FAF fundus autofluorescence 
ffERG full-field electroretinography 
fs frameshift 
GCL ganglion cell layer 
gnomAD genome aggregation database 
HEK293T human embryonic kidney 293 expressing the SV40 large T antigen 
hESCs human embryonic stem cells 
HIV human immunodeficiency virus 
HSF human splicing finder 
IGF-1 insulin-like growth factor-1 
INL inner nuclear layer 
IPL  inner plexiform layer 
iPSCs induced pluripotent stem cells 
IRDs  inherited retinal diseases 
IS  inner segment 
ISE intronic splice enhancer 
ISS intronic splice silencer 
kb kilobase 
KLF4 Kruppel like factor 4 
JS Joubert syndrome 
LCA Leber congenital amaurosis 
LIN28 Lin-28 Homolog A 
LV lentiviral vector 
MAF minor allele frequency 
Mb megabase 
MD macular dystrophy 
MKS Meckel-Gruber syndrome 
MLPA multiplex ligation-dependent probe amplification 
mRNA messenger-RNA 
N nucleus 
NANOG Nanog homeobox 
NBD nucleotide binding domain 
NCSS non-canonical splice site 
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NEAA non-essential amino acids 
NGS  next generation sequencing 
nm nanometer 
NMD  nonsense-mediate decay 
NMNAT1 nicotinamide nucleotide adenylyltransferase 1 
NRL neural retina leucine zipper 
nFE non-Finnish European 
nt Nucleotide 
OCT optical coherence tomography 
OCT3/4 octamer-binding transcription factor 
OAT ornithine aminotransferase 
OFD1 oral-facial-digital syndrome 1  
ONL outer nuclear layer 
OPA1 dynamin-like 120-kDa protein, mitochondrial 
OPL  outer plexiform layer 
OPN1LW opsin 1 (cone pigment), long-wave-sensitive 
OPN1MW opsin 1 (cone pigment), medium-wave-sensitive 
OPN1SW opsin 1 (cone pigment), short-wave-sensitive 
OS outer segment 
OTX2 orthodenticle homeobox 2 
PAX6 paired box 6 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PE Pseudoexon 
PEG polyethylene glycol 
PPCs photoreceptor precursor cells 
pre-mRNA precursor-Mrna 
PROM1 prominin 1 
PRPF31 pre-mRNA processing factor 31 
PRPH2  peripherin 2 
P(Y)n polypyrimidine tract 
RB1 retinoblastoma 1  
RBP4 retinol binding protein 4 
RCV1 Recoverin 
rFIV recombinant feline immunodeficiency viral (vector) 
RHO  Rhodopsin 
RmP rim protein 
RNA riboxynucleotide acid 
RP retinitis pigmentosa 
RP1 retinitis pigmentosa 1 
RPE retinal pigmented epilium 
RT-PCR reverse transcription PCR  
SAS splice acceptor site 
SC35 splice enhancer motif recognized by the human SR protein SC35 
SD standard deviation 
SDS splice donor site 
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SF2/ASF splice enhancer motif recognized by the human SR protein 
SF2/ASF 
SLS Senior-Løken syndrome 
smMIPs single-molecule molecular inversion probes 
SNV single nucleotide variant 
SON sense oligonucleotide 
SOX2 SRY-box 2 
SRp40 splice enhancer motif recognized by the human SR protein SRp40 
SRp55 splice enhancer motif recognized by the human SR protein SRp55 
SSCP single strand conformation polymorphism 
SSFL SpliceSiteFinder-Like 
STGD1 Stargardt disease type 1 
Tm melting temperature 
USH Usher syndrome 
USH2A Usher syndrome type 2A 
VEGF vascular endothelial growth factor  
VUS variant of unknown significance 
WES  whole exome sequencing 
WGS  whole genome sequencing 
WT wild-type 
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General introduction 
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1.1 Retina structure 
The human retina (from Latin rēte, meaning “net”) is a laminated network of photosensitive 
nerve cells that lies at the inner posterior surface of the eye. It develops from a pouch of the 
embryonic forebrain and invaginates to form the two-walled optic cup. The inner wall of the 
optic cup gives rise to the neuroretina, while the outer wall transforms to the retinal 
pigmented epithelium (RPE).  
The neuroretina is a multilayered tissue composed of three nuclear layers and two 
neuronal synapses that alternate. The nuclear layers are the outer nuclear layer (ONL), the 
inner nuclear layer (INL), and the ganglion cell layer (GCL), interconnected by synapses in the 
inner and outer plexiform layers (IPL and OPL, respectively) (Fig. 1). There are two main 
types of light-sensitive photoreceptors (i.e. cones and rods) and four types of specialized 
neural cells (i.e. bipolar cells, horizontal cells, amacrine cells and ganglion cells) that establish 
either vertical or horizontal connections, thus creating an intricate and dynamic neuronal 
circuit. The vertical connections between photoreceptors, bipolar cells and ganglion cells 
constitute the portion of the circuit that provides excitatory signals which are subsequently 
transmitted to the brain, while horizontal and amacrine cells are interneurons able to 
integrate and modulate the signals flowing through the vertical pathway (Fig. 1). 
 
Figure 1. Schematic overview of the retinal structure. (RPE) retinal pigmented epithelium; 
(OS) outer segment; (ONL) outer nuclear layer; (OPL) outer plexiform layer; (INL) inner 
nuclear layer; (IPL) inner plexiform layer; (GCL) ganglion cell layer. Figure adapted with 
permission from Mustafi et al. 2009.  
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Whilst for non-photoreceptor neural cells, the exact role in the retinal physiology 
remains mostly uncertain, the function of cones and rods have been well established. 
Photoreceptors are unequally present and distributed across the human retina. Cones are 
responsible for photopic vision, i.e. vision under well-lit conditions. There are ~6 million 
cones in the human retina, representing approximately 5% of the photoreceptors. They are 
highly concentrated in the central part of the retina called the fovea (~160,000/mm2) and 
decrease towards the periphery. The remaining 95% (~120 million) of human photoreceptors 
are rods, responsible for scotopic vision, i.e. vision under dim light. Rods are absent in the 
fovea but rapidly increase with a maximal density at ~20° eccentricity and subsequently 
decrease in density towards the periphery of the retina (Molday and Moritz 2015) (Fig. 2A). 
The peculiar elongated shape of photoreceptors allows a schematic division of these 
cells in four distinct compartments: the cell body, which includes the nucleus; the inner 
segment (IS); the outer segment (OS); and the synaptic terminal (Fig. 2B). Inner and outer 
segments harbor specific biological functions. In fact, while the IS fulfills the metabolic 
function, hosting the organelles and a large number of mitochondria supplying energy for 
the high metabolic demand of the photoreceptor, the OS contains unique proteins including 
the visual pigments and other components of the phototransduction cascade that allows the 
conversion of light stimuli to electrical signals.  
 
Figure 2. A. Photoreceptor distribution across the retina. B. Schematic representation of 
rod and cone photoreceptors. (OS) outer segment; (CC) connecting cilium; (IS) inner 
segment; (N) nucleus. Figure adapted with permission from Mustafi et al. 2009.  
 
The structure of the OS differs significantly between rods and cones. The rod OS is a 
cylindrical structure comprised of ~1000 membrane discs that are densely packed with the 
visual pigment rhodopsin for high-sensitivity light detection, and enclosed by a plasma 
membrane (Gilliam et al. 2012). Cones OS on the other hand consist of continuous discs 
derived from the invagination of the plasma membrane and have a conical shape. 
Membrane disc turnover in rod photoreceptors is notably fast and follows a circadian 
rhythm: every night, ~10% of rod OS discs are shed and phagocytosed by the RPE at the 
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distal end and new discs are added at the proximal end, which results in the complete 
renewal of OS within 10-15 days (Lee et al. 2001). 
The retinal pigment epithelium (RPE) is a monolayer of hexanocuboidal pigmented 
cells situated in close proximity to the photoreceptor outer segments. The apical membrane 
of the RPE faces the photoreceptor outer segments whereas the basolateral membrane 
faces Bruch’s membrane that separates the RPE from fenestrated vessels of the choroid (i.e. 
the most outer vascular layer of the eye). The RPE provides fundamental support in 
maintaining structural integrity and normal function of the retina. Among the variety of its 
functions, the visual pigment regeneration (i.e. enzymatic transition from all-trans-retinol to 
11-cis-retinal) is certainly one of the most critical for proper retinal physiology. However, 
other well-known roles of the RPE are: 1) the reduction of the phototoxic effects to the 
retina, by absorbing the excessive light that is not captured by photoreceptors via 
melanosomes (Haddad et al. 2012); 2) the regulation the transepithelial transport of ions, 
fluid, and metabolites from the subretinal space to the blood and conversely (Halford et al. 
2014); 3) the maintenance of the blood-retina barrier by forming tight junctions with 
endothelial cells (Hu 1987) and 4) the phagocytosis of shed photoreceptor outer segments to 
permit their renewal (Kevany and Palczewski 2010; Eisenberger et al. 2013). Phagocytized 
membrane discs are enzymatically digested by lysosomal activity and undigested portions of 
outer segment (e.g. lipid material) can be retained in the RPE, accumulating in lipofuscin 
granules. 
 
1.2 Genetics of inherited retinal diseases  
Inherited retinal diseases (IRDs) comprise a variety of genetic disorders differing in 
inheritance pattern, features of visual loss and ophthalmoscopic appearances. With an 
estimated incidence of about 1:2000, they are the leading cause of visual loss in the young 
(Rattner et al. 1999). 
Before the advent of molecular genetics, classification of different IRDs was 
exclusively based on clinical observations and inheritance pattern, in particular disease 
progression (stationary vs progressive) and the type of photoreceptor primarily involved in 
disease pathogenesis (rods vs cones). However, due to overlapping characteristics of many 
IRDs, especially at late stages of disease, an unambiguous classification based on these 
criteria is difficult.  
The sophisticated and highly specialized biological pathways underlying vision require 
the simultaneous cooperation of multiple proteins and this is clearly noticeable by the 
thousands of mutations in the more than 250 different genes identified in persons with IRD 
so far (RetNet, http://www.sph.uth.tmc.edu/RetNet/) (Fig. 3).   
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Figure 3. Genetic heterogeneity among the six major non-syndromic inherited retinal 
diseases. Numbers outside the ellipses correspond to the number of non-syndromic IRD 
genes responsible for the specific disease while numbers within the ellipses correspond 
either to disease-specific genes or to genes mutated in two or more diseases. The non-
redundant total of genes associated with these non-syndromic IRDs is 146. (RP) retinitis 
pigmentosa; (LCA) Leber congenital amaurosis; (CD/CRD) cone dystrophy/cone-rod 
dystrophy; (CSNB) congenital stationary night blindness; (MD) macular dystrophy; (EVR) 
exudative vitreoretinopathy. Published with permission from Prof. dr. Bernhard Weber.     
 
Over the last 25 years, extensive genotyping studies enabled a more precise 
classification of IRDs and shed light on their remarkable genetic heterogeneity. Indeed, only 
a few retinal disorders turn out to be genetically homogeneous while many others were the 
result of mutations in several different genes yet displaying similar clinical manifestations. 
The most significant example is retinitis pigmentosa (RP), for which mutations in 84 genes 
have been reported so far (Fig. 3 and RetNet, http://www.sph.uth.tmc.edu/RetNet/). 
On the other hand, variants in the same gene may lead to different clinical 
manifestations. First, they may result in different IRD phenotypes. For example, ABCA4 
variants underlie autosomal recessive Stargardt disease (STGD1) and autosomal recessive 
cone-rod dystrophy (arCRD). Second, they may lead to syndromic and non-syndromic forms 
of IRDs, like CEP290 variants underlying Leber congenital amaurosis (LCA), Senior-Løken 
syndrome (SLS), Joubert syndrome (JS) or Meckel-Gruber syndrome (MKS). Finally, several 
IRD-associated genes have been reported in more than one type of inheritance manner, for 
instance variants in RHO and RP1, which can be inherited in an autosomal recessive or an 
autosomal dominant manner.  
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1.3 Stargardt disease: genotype-phenotype correlation model 
Autosomal recessive Stargardt disease (STGD1) is the most prevalent inherited juvenile 
macular dystrophy and, with an estimated prevalence of 1:10,000 (Blacharski 1988), it is the 
most prevalent retinal disease due to variants in one gene. To date indeed, STGD1 has only 
being associated with variants in the ATP-binding cassette transporter type A4 (ABCA4) gene 
(Allikmets et al. 1997) which encodes a multidomain transmembrane protein located at the 
rim of the disc membrane in the outer segment of photoreceptors (Sun and Nathans 1997; 
Molday et al. 2000) (Fig. 4A). Limited expression of this gene has also been found in 
keratinocytes, fibroblasts and recently even in human and murine RPE (Wiley et al. 2016; 
Aukrust et al. 2016; Lenis et al. 2017). ABCA4 acts as a flippase for 11-cis and all-trans 
isomers of N-retinylidene-phosphatidylethanolamine across disc membranes, thereby 
facilitating the removal of retinal products from the disc membranes and preventing the 
accumulation of potentially toxic bisretinoid compounds (e.g. A2E) in photoreceptor and RPE 
cells (Fig. 4B). 
 
Figure 4. Protein domain structure and function of ABCA4. A. Topological model for the 
ABCA4 protein. (ECD) exocytoplasmic domain; (H1 or H2) first transmembrane segment; 
(TMD) transmembrane domain; (NBD) nucleotide binding domain. The two Walker motifs (A 
and B) and the C region which lies between them are the hallmark of ABC transporter 
superfamily members. Figure  adapted with permission from Bungert et al. 2001. B. 
Proposed function of the ABCA4 protein. A. All-trans-retinal is released by the 
photoactivated rhodopsin. B. All-trans-retinal enters the hydrophobic disc membrane (DM) 
and reacts to form a Schiff base with the amine of a phosphatidylethanolamine (PE), a 
phospholipid found on the DM outer segment. C. All-trans-retinal or the N-retinylidene-PE 
complex is transported by ABCA4 to the cytoplasmic side. All-trans-retinal is then reduced by 
all-trans-retinol dehydrogenase and transported to the RPE (not shown). (PM) plasma 
membrane. 
 
Persons with STGD1 show variable age at onset and heterogeneous phenotypes, 
ranging from early-onset STGD1, clinically resembling severe arCRD, to intermediate STGD1 
and late-onset STGD1 (Allikmets et al. 1997; Maugeri et al. 2000; Westeneng-van Haaften et 
al. 2012). In early-onset STGD1, the most severe phenotype, clinical manifestations are 
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usually observed before 10 yrs of age. Intermediate or ‘typical STGD1’ shows an onset 
between 10 and 44 yrs of age. It is characterized by bilateral central vision loss, macular 
atrophy and yellowish flecks at the level of the RPE at the posterior pole due to lipofuscin 
accumulation. Autofluorescence studies reveal macular atrophy. In late-onset STGD1 (onset 
>44 yrs), macular atrophy is accompanied by a ring of hyper autofluorescence just outside 
the atrophic region. Foveal sparing is often observed which enables affected individuals to 
have relatively good visual acuity until late in the disease process.  
These different phenotypes correlate with different combinations of ABCA4 variants 
which can be classified according to their degree of severity (Fig. 5). In particular, 
intermediate STGD1 is due to combinations of mild and severe variants or two moderately 
severe variants. This was based on the observation that some variants that were found to be 
very frequent in healthy individuals were only found in STGD1 cases in combination with 
severe variants. Early-onset STGD1 cases, described as arCRD and severe arCRD, were 
proposed to be due to combinations of moderately severe and severe or two severe 
variants, respectively. A significant part of late-onset STGD1 patients were shown to carry 
only a single severe ABCA4 variant. However, recent data point to the role of frequent mild 
variants with reduced penetrance that can be found as a second variant next to a severe 
ABCA4 variant (Zernant et al. 2017) (paragraph 1.4; chapter 6). 
 
 
Figure 5. Stargardt disease genotype-phenotype correlation model. Fundus photographs 
and fluorescein angiogram of normal and progressively severe STGD1 phenotypes due to 
specific combinations of ABCA4 variants, the severity of which correlates with the residual 
ABCA4 function. Individuals with a normal phenotype carry no (+/+) or only one ABCA4 
variant. In late-onset STGD1, macular atrophy is accompanied by a ring of hyper 
autofluorescence just outside the atrophic region and patients normally carry a combination 
of severe and mild low penetrant (lp) variants. Intermediate STGD1 shows macular atrophy 
and yellowish flecks due to lipofuscin accumulation and affected individuals carry either 
combinations of severe and mild variants or two moderately severe ABCA4 variants. Early-
onset STGD1 is the most severe phenotype, partly resembling CRD, and this is consistent 
with the genotypes found in affected patients, comprised of either a severe and a 
moderately severe, or of two severe ABCA4 variants.  
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The monogenic nature of STGD1 and the typical features displayed by STGD1 cases 
have resulted in the genotyping of a large number of cases. Recently, all reported ABCA4 
variants in 3,928 STGD1 cases were collected in a Leiden Open Variation Database 
(www.LOVD.NL/ABCA4), and in silico functional assessments were performed for the 913 
unique variants in the database (Cornelis et al. 2017). In addition, from the comparison of 
the frequency of these variants in 3,270 Caucasian IRD cases with 33,370 non-Finnish 
European control individuals, 191 nontruncating variants were significantly enriched in the 
patient cohort. Finally, assessing the homozygous occurrence of frequent variants in IRD 
cases based on the allele frequencies in control individuals confirmed the mild nature of the 
p.[Gly863Ala, Gly863del] variant and identified three additional mild variants 
(p.(Ala1038Val), c.5714+5G>A, and p.(Arg2030Gln)). The p.(Gly1961Glu) variant was 
predicted to act as a mild variant in most cases. 
  
1.4 Missing heritability in Stargardt disease 
Sanger sequencing of the 50 exons and flanking splice sites detects between 66% and 80% of 
mutant alleles in ABCA4 (Shroyer et al. 2001b; Yatsenko et al. 2001). It is considered the 
“gold standard” of mutation detection techniques although it remains prohibitive for large 
patient cohorts because of time and cost constraints. With targeted Next Generation 
Sequencing (NGS) technologies becoming affordable for many laboratories, the screening of 
many STGD1 patients is feasible, yet showing comparable percentages of mutation detection 
rate, ranging from 55-80% (Zernant et al. 2011; Zernant et al. 2014; Sciezynska et al. 2016). 
To the best of our knowledge, the largest cohort so far screened for mutations in ABCA4 was 
composed of 335 STGD1 samples, although in this study the detection rate was only 47% 
(Schulz et al. 2017). 
To date it has been estimated that approximately 25% of clinically affected STGD1 
patients lack a complete genetic diagnosis, the majority of which (~80%) only carries one 
pathogenic ABCA4 variant. This large number of mono-allelic STGD1 patients, which is higher 
than for any other monogenic condition, and is consistently observed in many studies 
regardless the ethnic background of the patients (Zernant et al. 2011; Bocquet et al. 2013; 
Chacon-Camacho et al. 2013; Riveiro-Alvarez et al. 2013; Miraldi Utz et al. 2014; Xin et al. 
2015; Zaneveld et al. 2015; Sciezynska et al. 2016), strongly argues against genetic 
heterogeneity of STGD1 yet not excluding digenic inheritance. 
The missing heritability for STGD1 could be due to:  
1) STGD1-like phenotypes due to mutations in other genes.  
Variants in peripherin 2 (PRPH2) have been associated with autosomal dominant multifocal 
pattern dystrophy, but also were found in genetically unsolved STGD patients. The variable 
expressivity and penetrance of the PRPH2 variants combined with the peculiar type and 
distribution of the flecks, strongly resembling the ones observed in the fundus 
flavimaculatus phenotype of STGD1, are the two major causes for misdiagnosis (Boon et al. 
2007). Variants in ELOVL4 (elongation of very long chain fatty acids protein 4) and PROM1 
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(prominin 1) are well known to be associated with rare autosomal dominant forms of 
Stargardt-like dystrophies (Stone et al. 1994; Kniazeva et al. 1999; Zhang et al. 2001). The 
switch from Sanger sequencing of single genes to sequence analysis of gene panels, whole 
exome or whole genome sequencing will likely increase the identification of variants in 
genes that cause STGD-like phenotypes. Indeed, NGS for all known retinal disease genes in a 
cohort of 88 unsolved STGD patients from three different ethnic backgrounds contributed to 
solve 11 patients (13%) not only by variants in PRPH2 and PROM1, but also by nucleotide 
changes in genes previously not linked to STGD such as bestrophin (BEST1), cadherin 23 
(CDH23), Crumbs homolog 1 (CRB1) and usherin (USH2A) (Zaneveld et al. 2015). 
To date, modifiers associated with STGD1 have not been reported. However, since a 
synergistic effect of pathologic ABCA4 sequence variations on an autosomal dominant form 
of Stargardt disease (STGD3) has already been demonstrated (Zhang et al. 1999), it is very 
likely that variants in other genes may play a role in ABCA4-associated disease and 
contribute to ameliorating or worsening the clinical outcome of the disease. 
 
2) Copy-number variants. Deletions or duplications spanning one or more ABCA4 exons will 
not be  
detected using standard PCR-based mutation analyses methods and therefore may explain a 
percentage of the unsolved STGD1 cases. Currently, only a few studies reported on a 
systematic analysis of copy-number variants (CNVs) in ABCA4, either by Southern blot 
analysis (Maugeri et al. 1999; Yatsenko et al. 2003) or by NGS (Zernant et al. 2014). CNVs 
were detected only in a very small proportion (~1%) of STGD1 cases and it therefore has 
been generally accepted that they do not represent a major cause of missing heritability. 
 
3) Misinterpreted variants. Non-canonical splice site (NCSS) variants are exonic or intronic 
variants 
located at the splice donor sites (SDSs) or splice acceptor sites (SASs) of an exon. The 
adjective non-canonical was introduced to distinguish these nucleotide changes from the 
ones altering canonical splice positions (two nucleotides upstream and downstream of 
exons) that in most cases result in splice defects and thereby protein-truncations (Cheung et 
al. 2017). 
NCSS variants are easily detectable by direct sequencing of the coding elements as 
intronic NCSS variants are mostly situated at positions +3 to +6 downstream of exons or at 
positions -14 to -3 upstream of exons. Exonic NCSS variants almost invariably are found 
within the first or the last two nucleotides of an exon (Shapiro and Senapathy 1987). These 
variants are often overlooked, their effect on splicing is not assayed and often classified as 
variants of unknown significance (VUS) or even non disease-causing variants. 
Synonymous variants, which usually occur in the third base of a codon, can be 
misinterpreted as they do not alter the protein sequence. However, recent work has shown 
that over 50 human diseases are associated with synonymous variants creating or 
strengthening cryptic splice sites or binding sites for transcription factors (Hunt et al. 2014). 
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ABCA4 harbors 578 synonymous variants in its sequence (http://gnomad.broadinstitute.org) 
and nearly 60 of them have been reported in STGD1 patients after ABCA4 genotyping 
(Cornelis et al. 2017). However, only a few synonymous variants have been predicted to alter 
the strength of the splice site identified and/or to be significantly enriched in STGD1 patients 
(Webster et al. 2001; Cornelis et al. 2017). Finally, since this class of variants has been 
overlooked for many years, only for a few nucleotide changes causality has been 
experimentally proven (Braun et al. 2013; Sangermano et al., unpubl.).     
 
4) Frequent coding variants. Coding variants having a high allele frequency (AF) in 
normal individuals may be wrongly deemed not to be associated with the disease. Although 
rare genetic disorders generally are due to rare sequence changes, there are exceptions. 
Variants with an AF ≥ 0.01 are normally discarded from further analyses but a comparison of 
the carrier frequency between affected and non-affected persons may still suggest a 
possible role for these variants in disease.  
Recently, sixteen common (AF ≥ 0.01) ABCA4 coding variants were genotyped in a 
cohort of 335 German STGD1 patients and in 781 ethnically matched controls to determine 
whether the allele frequency of these nucleotide changes differ between the two groups 
(Schulz et al. 2017). For each variant, risk association was computed applying a logistic 
regression model and for five variants a statistically significant independent association with 
disease risk was found. Three variants (c.1268A>G, c.5843C>T and c.6249C>T) were found to 
have a protective effect towards STGD1 while two other variants (c.5603A>T and c.5682G>C) 
increased the risk of developing the disorder. The most statistically significant protective and 
risk alleles found in this study (c.1268A>G and c.5603A>T, respectively) were already 
independently identified in previous studies, in which Spanish and Polish STGD1 patient 
cohorts were investigated, respectively (Aguirre-Lamban et al. 2011; Sciezynska et al. 2016). 
While the reason for the missing association between STGD1 and the remaining three 
common ABCA4 variants may partly be explained with the smaller number of patients 
present in both cohorts (n=92 and 128 respectively vs n=335 of the German cohort), the 
clinical relevance of the c.5603A>T variant as a risk allele seems to have become clear in a 
subsequent study.    
The c.5603A>T (p.Asn1868Ile) variant was previously considered benign due to its 
high allele frequency of 0.066 in the non-Finnish European population 
(http://gnomad.broadinstitute.org). In a recent study in which a large cohort (n=643) of 
ABCA4-associated STGD1 patients of predominately Eastern European descent were 
investigated, this common variant accounted for 15% of the ABCA4 alleles in STGD1 patients. 
This was three to four times more frequently than expected (Zernant et al. 2017). Although 
c.5603A>T was found in cis with several other frequent ABCA4 disease-causing alleles, 
notably c.5461-10T>C and c.2588G>C, also the ‘non-complex’ c.5603A>T variant was 
significantly enriched in STGD1 patients. The c.2588G>C variant was proposed to be disease-
associated only when present in a complex allele with c.5603A>T, and not alone as was 
thought in previous studies (Maugeri et al. 1999). The fact that c.2588G>C was present in a 
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complex configuration only in about 13% of healthy individuals of European ancestry is 
consistent with the benign nature of this variant when not accompanied by c.5603A>T. 
Finally, this study reported that >50% of the missing causal alleles in mono-allelic STGD1 
patients carry the common variant c.5603A>T in trans, ~80% of which are late-onset cases, 
thus distinguishing ABCA4 disease from age-related macular degeneration (AMD).  
The most frequent ABCA4 variant in STGD1 patient is c.5882G>A (p.Gly1961Glu) 
(www.LOVD.NL/ABCA4). It is a proven pathologic variant because it always co-segregates 
with the disease in families, mostly as a non-complex allele, and it affects protein function as 
determined by indirect functional tests (ATP-ase activity and ATP binding) (Simonelli et al. 
2000; Sun et al. 2000). Interestingly, this variant is associated with late-onset of disease, 
although less prominent as c.5603A>T (Zernant et al. 2017). In fact, patients harbouring 
p.Gly1961Glu or p.Asn1868Ile consistently exhibit milder spatiotemporal fleck patterns even 
at advanced age, which never progresses to the absolute confluence stage as in intermediate 
and early-onset STGD1 patients (Burke et al. 2012; Zernant et al. 2017).   
Examples of frequent causal variants in genes associated with other syndromic and 
non-syndromic retinal phenotypes can be found in CNGB3, BBS1, NMNAT1 and USH2A, 
genes underlying achromatopsia (ACHM), Bardet-Biedl syndrome (BBS), LCA and Usher 
syndrome (USH), respectively (Table 1).  
The cyclic nucleotide-gated channel, beta-3 (CNGB3) c.1148delC (p.Thr383Ilefs*13) 
variant accounts for more than 70% of all CNGB3 causal variants and it is involved in 40-50% 
of patients with ACHM (Kohl et al. 2000; Johnson et al. 2004; Kellner et al. 2004; Kohl et al. 
2005; Nishiguchi et al. 2005; Varsanyi et al. 2005; Wiszniewski et al. 2007; Thiadens et al. 
2009; Azam et al. 2010; Roosing et al. 2014). CNGB3 encodes a cone-specific protein 
involved in closure of CNG-channel in the phototransduction cascade and is located across 
the membrane of cone outer segments. Interestingly, several STGD1 patients in the 
Netherlands have been found to carry ABCA4 variants in combination with the c.1148delC 
variant in CNGB3 (Roosing S, Cremers FPM, unpubl.; Roosing et al. 2014). Furthermore, 
colocalization between ABCA4 and CNGB3 was also observed. Although it is not directly 
apparent how the two proteins may interact, additive effects of defects in these genes 
cannot be excluded.      
BBS is a clinically and genetically heterogeneous disorder characterized by a wide 
spectrum of clinical features among which RP. Among the 20 BBS-associated genes so far 
identified, BBS1 and BBS10 are the most frequently mutated and this is partly due to the 
presence of the frequent variants c.1169T>G (p.Met390Arg) and c.271insT (p.Cys91Leufs*5), 
respectively (Muller et al. 2010). Screening of 2007 isolated or arRP patients detected 
p.Met390Arg homozygously in 11 RP cases and compound heterozygously in 3. When 
extensive clinical assessment was performed, these 14 patients showed the entire clinical 
spectrum, from non-syndromic RP to full-blown BBS. Moreover, one of 1824 ethnically 
matched healthy individuals also was homozygous for this variant. These data suggested a 
hypomorphic effect of the p.Met390Arg variant and/or the presence of additional cis- or 
trans- modifiers influencing the disease phenotype (Estrada-Cuzcano et al. 2012).      
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Another frequent causal variant is c.769G>A (p.Glu257Lys), the most common variant 
in NMNAT1, encoding the nicotinamide nucleotide adenylyl-transferase 1, a gene associated 
with LCA (Chiang et al. 2012; Falk et al. 2012; Koenekoop et al. 2012; Perrault et al. 2012), 
the most severe form of retinal degeneration (Leber 1869; Franceschetti and Dieterle 1954). 
This variant was found 80-fold less frequent in a homozygous state in LCA patients than 
predicted according to the Hardy-Weinberg equilibrium (Siemiatkowska et al. 2014). In 
addition, this variant was found in a homozygous state in a patient with no ocular 
abnormalities (Siemiatkowska et al. 2014). Together, these data strongly suggest that this 
frequent variant cannot act as a fully penetrant recessive variant but rather as a 
hypomorphic variant that only is associated with LCA when in trans with a severe NMNAT1 
variant. 
Finally, the mutation that most commonly causes Usher syndrome type IIa, the 
leading cause of deaf-blindness, is a 1-bp deletion (c.2299delG; p.Glu767Serfs*21) in USH2A. 
Since mutations in USH2A cause non-syndromic RP in ~10% of the cases, this variant likely is 
the most frequent cause of RP worldwide (www.lovd.nl/USH2A). 
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Table 1. Frequent coding variants in IRD-associated genes. Allele frequencies data for 
general population were obtained from gnomAD database while patient frequencies from 
the LOVD database or published literature (a) Zernant et al. 2017; (b) Runhart, Sangermano 
et al., unpubl.; (c) Muller et al. 2010; (d) Kohl et al. 2000; (e) Johnson et al. 2004; (f) Kellner 
et al. 2004; (g) Kohl et al. 2005; (j) Nishiguchi et al. 2005; (i) Varsanyi et al. 2005; (j) 
Wiszniewski et al. 2007; (k) Thiadens et al. 2009; (l) Azam et al. 2010; (m) Chiang et al. 2012; 
(n) Falk et al. 2012; (o) Koenekoop et al. 2012; (p) Perrault et al. 2012. AF, allele frequency; 
nFE, non-Finnish European control individuals. #The c.2588G>C is proposed to only cause 
disease when in cis with c.5603A>T (p.Asn1868Ile) and in trans with a severe ABCA4 variant 
(Zernant et al. 2017). This complex c.[2588G>C, 5603A>T] allele is estimated to be present in 
~10% of all c.2588G>C alleles. 
 
Gene DNA variant Protein variant AF_nFE AF_patients Phenotype 
ABCA4 c.2588G>C p.[Gly863Ala, Gly863del] 0.008# 0.037 STGD1 
ABCA4 c.5461-10T>C p.(Thr1821Aspfs*6) 0.0002 0.030 STGD1 
ABCA4 c.5882G>A p.(Gly1961Glu) 0.004 0.073 STGD1 
ABCA4 c.5603A>T p.(Asn1868Ile) 0.066 0.120(a; b) STGD1 
BBS1 c.1169T>G p.(Met390Arg) 0.003 0.190(c) BBS 
BBS10 c.271insT p.(Cys91Leufs*5) 0.001 0.130(c) BBS 
CNGB3 c.1148delC  p.(Thr383Ilefs*13) 0.003 0.710(d-l) ACHM3 
NMNAT1 c.769G>A  p.(Glu257Lys) 0.001 0.309(m-p) LCA 
USH2A c.2299delG p.(Glu767Serfs*21) 0.001 0.085 USH2A 
 
5) Non-coding variants. A major fraction of deleterious variants could be located in the 
non-coding sequences of ABCA4, constituting 94.5% of the 128-kb sized gene, and therefore 
cannot be detected by exonic sequencing. Unraveling the role of deep-intronic variants in 
human disease-associated genes is a quite recent research field, and for STGD1 the first 
work that clearly aimed to identify and functionally prove the effect of novel non-coding 
variants in ABCA4 was published in 2013 (Braun et al. 2013). By performing haplotype 
analysis in a group of 28 unrelated mono-allelic STGD1 probands, Braun and colleagues 
identified three haplotypes (H1-3) shared among ten families. The fact that 64% of the 
unsolved samples shared no haplotype and that not more than four patients shared the 
same disease haplotype, suggested that highly recurrent deep-intronic variants were not 
present among unsolved STGD1 patients. Deep sequencing of mRNA extracted from human 
donor retina showed that 5% of ABCA4 transcripts carried minor alternate exons, each 
observed in less than 1% of the total mRNA. Sequencing of genomic regions containing these 
alternate exons in the 28 unsolved STGD1 patients revealed five deep-intronic variants 
(c.5196+1137G>A, c.5196+1216C>A, c.5196+1056A>G, c.4539+2001G>A, c.4539+2028C>T) 
located in the splice sites or the predicted alternate exons. All variants were present in trans 
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with the first pathogenic ABCA4 variant in unsolved patients. The effect of c.5196+1137G>A, 
c.5196+1216C>A and c.5196+1056A>G variants was tested by employing RNA from patient-
derived keratinocytes and RT-PCR studies revealed the generation of pseudoexons (PEs) in 
intron 36, while for c.4539+2001G>A and c.4539+2028C>T, functional studies were not 
performed. Although this was not  a systematic analysis of non-coding variants, it paved the 
way for more complete studies of non-coding elements in ABCA4 (Zernant et al. 2014; this 
thesis).  
The predicted ABCA4 promoter sequence has been investigated only in two studies 
(Zernant et al. 2014; chapter 3), but to date the rare non-coding variants identified have not 
yet been further characterized (Zernant et al. 2014). 
 
1.5 From coding to non-coding: cost-effective and high-throughput 
sequencing methodologies: targeted versus WGS 
Since the introduction of NGS technologies in 2007 the cost of DNA sequencing has 
continuously decreased. Sequencing can be restricted to the coding elements of all genes, 
together accounting for 1% of the human genome (so-called whole exome sequencing - 
WES), or be extended to the entire genome (i.e. whole genome sequencing - WGS). 
Over the years WES has been preferred over WGS for its lower price and the higher 
depth of coverage due to the restricted target to sequence, thus providing a faster and more 
cost-efficient strategy for finding rare causal variants in human disease (Ng et al. 2009). 
However the significant increase in novel genes and mutations discovered by WES did not 
fully overlap with the complete understanding of the molecular basis of genetic disorders. It 
has been estimated that at least 15% of disease-causing variants are not located within 
exons or their flanking splice sites but within regulatory regions or deep into introns. 
Moreover, WES is insufficient to reveal many genomic rearrangements. Finally, enrichment 
of coding regions relies on primer annealing and this can introduce bias against regions with 
high or low GC content and/or poor primer annealing characteristics, thus representing a 
limiting factor for the detection of causal exonic variants. 
With continuously decreasing costs, WGS is rapidly gaining relevance in routine 
diagnostic protocols. The advantage of WGS that it yields sequences of intergenic and 
intronic regions comes at the expense of an extremely large amount of sequence data that 
require additional costs regarding  storage and handling. A significant WGS study was 
performed in the UK (UK10K, https://www.uk10k.org/), and other allele frequencies from 
non-coding variants can also be found in  the gnomAD (http://gnomad.broadinstitute.org) 
and Wellderly (https://genomics.scripps.edu/browser) (Erikson et al. 2016).    
 Recently, a clearly effective compromise to avoid the risk of insufficient or excessive 
sequencing data has been targeted NGS. Like WES, targeted NGS is subject to an enrichment 
step which may affect the sequence coverage. Nowadays this approach is used to scan 
specific genes or loci  for causal sequence variants, either in patients suffering from 
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monogenic disorders (e.g., STGD1) or genetically heterogeneous conditions due to 
mutations in a limited number of genes (e.g., BBS).    
 
1.6 Functional analysis of ABCA4 missense variants 
To provide an accurate prognosis for patients affected by STGD1, it is necessary to 
determine the functional consequences of all 913 ABCA4 variants reported so far (Cornelis et 
al. 2017). This is straightforward for the about 35% protein-truncating variants so far 
identified but it is challenging for missense variants, which account for half of the ABCA4 
variants, as well as for synonymous or intronic variants. ABCA4 transports N-retinylidene-
phosphatidylethanolamine in an energy-dependent manner from the lumen to the 
cytoplasmic leaflet of the outer segment disc membrane. An assay to measure the 
transporter activity of ABCA4 has not been developed. However, extensive knowledge on its 
protein structure and function were employed to functionally assay the effect of selected 
coding sequence variants. 
 
1.6.1 In vitro functional studies 
Sun and colleagues examined the effect of 37 variants (33 missense, three small in-frame 
deletions and one frameshift) on protein folding and stability by performing Western blot 
and azido-ATP labeling (Sun et al. 2000). More than 75% of the assayed variants resulted in 
reduced amounts of protein and/or ATP binding. This study showed that some small in-
frame deletions or missense variants introducing charged amino acids into transmembrane 
domains may result in notably reduced ABCA4 protein. Also, by showing that some missense 
variants located outside the nucleotide binding domains (NBDs) resulted in reduced ATP 
binding, Sun and colleagues provided evidence that the efficiency of nucleotide binding may 
be modulated by conformational changes within or nearby transmembrane domains.        
Finally, by investigating the consequences of a subset of missense variants on retinal 
binding/transport and ATP hydrolysis, Sun and colleagues provided evidence that the two 
NBD domains had distinct roles in ABCA4, and proposed a model in which both domains 
participate in ATP hydrolysis resulting in substrate transport (Sun et al. 2000). Further 
studies demonstrated that while  NBD-1 is a general nucleotidase, NBD-2 is a specific ATP-
ase (Biswas and Biswas 2000; Biswas 2001). Based on these data, the model proposed by 
Sun and colleagues was refined: NBD-2 is the only NDB domain that binds and hydrolyzes 
ATP while NBD-1 contains a tightly bound ADP that plays a crucial role in orchestrating the 
activity of NBD-2 and therefore in substrate transport (Ahn et al. 2003).  
Alongside with the discovery of novel potentially causal ABCA4 exonic variants, 
others have contributed to expand the knowledge about the functional consequences of 
missense variants by employing a diverse repertoire of in vitro techniques such as RNA 
hybridization, Western blot, azido-ATP labeling, ATP binding, fluorescent-lipid transport 
studies and immunofluorescence (Shroyer et al. 2001a; Shroyer et al. 2001b; Suarez et al. 
2002; Quazi and Molday 2013).  
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There still is no functional assay to test the ABCA4 transporter activity, which hinders 
an accurate assessment of missense mutations or other small alterations in ABCA4.  
 
1.6.2 In vivo studies using animal models 
Animal models have also been also used to investigate the effect of several missense ABCA4 
mutations. ABCA4 was originally identified and characterized as rim protein (RmP) in frog 
and cattle rod outer segments (Papermaster et al. 1976) and therefore Xenopus laevis 
served as model organism for the first in vivo assay of four ABCA4 missense variants, two of 
which usually present as a complex allele p.[Leu541Pro; Ala1038Val] (Wiszniewski et al. 
2005). Wiszniewski and colleagues developed transgenic X. laevis tadpoles with a construct 
containing human wild-type and mutant ABCA4 cDNA under the control of the opsin 
promoter of this organism and employed immunofluorescence to show ABCA4 
mislocalization in the photoreceptor inner segments due to ABCA4 missense variants. The 
choice for an in vivo study was mainly taken to overcome the unexpected results of 
equivalent in vitro studies in COS7 cells (Monkey fibroblast-like cells), showing that not only 
the mutant but also wild-type ABCA4 appeared to be retained in the endoplasmic reticulum 
of these cells. 
Although X. laevis was not further used for in vivo studies, knock-in mice harboring 
selected ABCA4 variants have recently been generated to study the complex allele 
p.[Leu541Pro; Ala1038Val] and p.Asn965Ser (Zhang et al. 2015; Molday et al. 2017). 
 In vitro analysis of p.[Leu541Pro; Ala1038Val] revealed that both the loss-of-ATPase 
activity and misfolding could contribute to the severity of disease caused by this complex 
allele (Sun et al. 2000; Wiszniewski et al. 2005). The knock-in mice homozygous for 
p.[Leu541Pro; Ala1038Val] showed mutant ABCA4 mRNA levels comparable with wild-type 
levels but, surprisingly, only trace amounts of mutant protein was noted in the retina. 
However, similar to the Abca4−/− mice, knock-in mice showed substantial A2E and lipofuscin 
accumulation in their RPE cells but no retinal degeneration up to one year of age, suggesting 
differences in the unfolded protein response between murine and human photoreceptors 
(Zhang et al. 2015). Similar in vivo studies showed that loss of substrate-dependent ATPase 
activity and protein misfolding are mechanisms underlying STGD1 associated with the 
p.Asn965Ser variant.  
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1.7 Functional analysis of ABCA4 splice variants 
1.7.1 RNA splicing 
Splicing is a strictly regulated biochemical process in which the coding elements (exons) of 
the immature messenger RNA (pre-mRNA) need to be precisely identified and joined 
together while non-coding elements (introns) are removed from the immature transcript. 
This process results in a mature mRNA with a correct reading frame that serves as a 
template for protein synthesis.  
Correct splicing requires cis sequence elements located in the pre-mRNA itself, and 
trans factors able to bind these elements (Singh and Cooper 2012) (Fig. 6). Cleavage of the 
introns occurs mainly through the recognition of the highly conserved nucleotide sequences 
located at the 5’ end of each exon (SDS) and at the 3’ end of each exon (SAS) and a branch 
point site (BPS), a short conserved sequence containing an adenosine residue between 10 
and 50 nucleotides upstream of the SAS, necessary for the formation of the lariat structure 
(Gao et al. 2008). Additional elements influencing  splicing are exonic and intronic splice 
enhancers (ESEs, ISEs) or silencers (ESSs, ISSs), short motifs that stimulate or repress splicing 
efficiency which seem to be especially relevant for regulating alternative splicing.  
 
Figure 6. Cis and trans elements required for correct splicing. (ESE) exonic splice enhancer; 
(ISS) intronic splice silencer; (ISE) intronic splice enhancer; (ESS) exonic splice silencer; (P(Y)n) 
polypyrimidine tract. 
 
Alternative splicing is the biological process consisting of multiple and 
developmentally regulated splicing events aimed to expand the variety of transcript isoforms 
generated by one single gene. It has been estimated that alternative splicing occurs in 
approximately 95% of multi-exonic genes and this explains the significant protein diversity 
typical of eukaryotic organisms (Black 2003). Given the complexity of the splicing events and 
the plethora of signals and motifs required for proper exon recognition and introns 
exclusion, it is not surprising that this mechanism is particularly susceptible to nucleotide 
variants associated with genetic disorders. It has been estimated that about one third of 
disease-associated mutations affect pre-mRNA splicing (Lim et al. 2011; Sterne-Weiler et al. 
2011). 
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Aberrant splicing events have a large impact on protein function and have been 
reported for almost all known diseases (Wang and Cooper 2007). They may result in skipping 
of one or more exons, elongated or truncated exons. When introns are not very large, they 
can be retained between two exons as a result of a splicing variant. Alternatively, intronic 
segments can be wrongly recognized as coding sequences and retained in the mature 
transcript, thus generating “fake” exons called “pseudoexons” (PE). An overview of the 
described missplicing events are illustrated in Figure 7.  
 
Figure 7. Splice abnormalities. (int 1) intron 1; (PE) pseudoexon.    
 
1.7.2 Splice variant assay 
Canonical splice site variants are predicted to result in exon skipping, exon elongation or in 
the utilization of a cryptic splice site in the relevant exon. Assuming that all these events 
have a severe effect on ABCA4 activity, they have not been studied in detail, with a few 
exceptions (e.g., Schulz et al. 2017). Some NCSS variants have been studied previously. The 
first NCSS variant investigated was c.2588G>C, a putative mild exonic variant located at the 
beginning of ABCA4 exon 17 that was frequent in the non-Finnish European population (AF 
~0.008) and showed an increasing frequency from South-West to North-East Europe 
(Maugeri et al. 1999; Maugeri et al. 2002). Although the G>C change at position 2588 results 
in a missense change p.(Gly863Ala), splice prediction programs also suggested the creation 
of an alternative splice acceptor site 3 nt within exon 17. To confirm this, reverse 
transcription (RT)-PCR on lymphoblastoid cell mRNA of two patients heterozygous for this 
variant was performed, indeed showing a wild-type band and band with the same intensity 
missing three nucleotides (Maugeri et al. 1999). Thus, the c.2588G>C variant results at the 
protein level in the complex allele p.[Gly863Ala; Gly863del].    
 In 2000, Rivera and collaborators tested five other ABCA4 NCSS variants 
(c.3050+5G>A; c.3522+10T>G; c.4253+5G>A; c.5461-10T>C; c.5714+5G>A) by amplifying the 
regions encompassing these variants and the adjacent exon(s) from patient genomic DNA, 
and subsequently cloning these small fragments into minigenes (Rivera et al. 2000). The 
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three +5 variants resulted in aberrant splicing events while the +10 and -10 variants showed 
no splice defect. For c.3522+10T>G, the absence of incorrect splicing was consistent with its 
splice prediction, as this variant does not modify the strength of the exon 23 SDS. This was 
not the case for c.5461-10T>C, the third most frequent ABCA4 variant, for which the T>C 
change in the polypyrimidine tract of the exon 39 SAS mildly reduced the strength of the 
related acceptor site according to five independent splice prediction programs. Only thirteen 
years later, when transcript analysis of ABCA4 RNA extracted from patient-derived 
photoreceptor progenitor cells or fibroblasts was performed, the pathogenic role of c.5461-
10T>C was finally unraveled, i.e. exon 39 or exon 39 and 40 skipping as a result of the exon 
39 SAS weakening (chapter 4; Aukrust et al. 2017).    
The pathogenicity of rare variants is often difficult to demonstrate statistically and 
needs to be experimentally assessed. The absence or limited amount of ABCA4 transcript in 
somatic tissues and the inaccessibility of neural retina of patients has forced researchers to 
develop patient-specific photoreceptor precursors to investigate the role of splicing variants 
(chapter 4). Unfortunately, this strategy is costly and at this moment cannot be used for a 
large-scale systematic functional analysis of variants.  
Taken together, these observations point towards the importance of splice assays as 
a cost-effective way to investigate the unknown effects of splice variants. Studying the exon 
40 skipping caused by the NCSS variant c.5714+5G>A and comparing this event in two 
differently sized splice constructs, we found that one major reason for splice assay 
inaccuracy was the limited amount of ABCA4 genomic sequence included in the splice 
vector. Starting from this observation, we generated a set of 29 large splice vectors (coined 
midigenes) containing up to 11.7 kb of wild-type ABCA4 genomic sequence. These midigenes 
served as templates to mutagenize all reported ABCA4 NCSS variants and to test their effect 
at pre-mRNA level after transfection in HEK293T cells in one study. Interestingly, this 
improved approach allowed us to detect splice defects previously not observed using regular 
minigenes (chapter 5).    
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1.8 Therapeutic strategies for Stargardt disease 
As for other hereditary forms of blindness, there is as yet no effective therapy for STGD1. To 
date, STGD1 patients can only benefit from low-vision aids to maximize the use of their 
peripheral and paracentral vision and being advised on photoprotection to slow down the 
progression of vision loss. When STGD1 patients develop choroidal neovascularization as a 
consequence of macular degeneration, they are treated by intravitreal injections of 
Ranibizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) 
(Battaglia Parodi et al. 2015).  
Although many aspects of the ABCA4 function still need to be elucidated, there is 
enough knowledge regarding the biochemical mechanisms underlying all-trans retinol 
regeneration and the pathophysiology of the cells involved in STGD1 (RPE and 
photoreceptors) to develop innovative therapies aiming to prevent or delay vision loss. This 
background, the large number of affected cases and its monogenic nature, have led to the 
fact that STGD1 currently is subject to more clinical trials than any other IRD, with 
pharmacological approaches, gene replacement and stem cell therapy. 
 
1.8.1 Pharmacological therapy targeting lipofuscinogenesis  
The toxic metabolite in Stargardt disease is A2E, a dimer of retinol (vitamin A) and a major 
component of lipofuscin. Pharmacological research aims therefore to arrest lipofuscin 
formation by developing drugs that reduce its excessive accumulation. So far, three 
compounds have been developed (ALK-001, fenretinide and A1120), the effects of which are 
still under clinical investigation. 
 
ALK-001 (C20-D3-vitamin A) is a deuterated form of vitamin A. The simple substitution of 
hydrogen atoms with deuterium isotopes slows the rate of vitamin A dimerization and 
subsequent generation of A2E, finally resulting in reduced lipofuscinogenesis (Charbel Issa et 
al. 2015). Preclinical studies in Abca4 knockout mice showed that ALK-001 prevents vitamin 
A dimerization and lipofuscin formation without any side effects on retina function (Ma et al. 
2011; Charbel Issa et al. 2015). ALK-001 passed clinical trial phase 1, showing safety and 
proper biodistribution in line with preclinical studies. The compound is currently in phase 2, 
where the efficacy and long-term safety will be evaluated in a group of STGD1 patients 
(https://clinicaltrials.gov/; Id: NCT02402660).  
 
Fenretinide (N-(4-hydroxyphenyl)retinamide) is a synthetic analogue of retinol which acts as 
a competitor for the binding to its carrier protein, retinol-binding protein 4 (RBP4). 
Fenretinide has better affinity for the binding with RPB and facilitates the removal of this 
protein, as the complex will be excreted via urine. Low concentrations of circulating RBP will 
reduce retinol concentration in the eye, resulting in decreased biosynthesis of A2E (Berni 
and Formelli 1992; Malpeli et al. 1996; Mata et al. 2013). A preclinical study in Abca4 
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knockout mice recapitulated the in vitro results that showed a dose-dependent efficacy in 
the clearance of A2E (Weng et al. 1999; Radu et al. 2005).  
Fenretinide successfully completed clinical trial phase 1 and it entered in phase 2 for 
the treatment of geographic atrophy in patients with dry AMD (Mata et al. 2013). However, 
the encouraging data coming from phase 2 have been somehow downsized by reports of 
possible adverse effects as a consequence of long-term exposure to the drug, in particular 
increased apoptosis of the RPE (Samuel et al. 2006), hemangiosarcomas in mice (Cohen et al. 
2009), and teratogenic properties (Turton et al. 1992; Decensi et al. 2007).  
 
A1120 (2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid) is perhaps 
the least investigated of these three therapeutic compounds. Like fenretinide, it is a RBP4 
antagonist and a preclinical study in a Abca4 knockout mice showed the efficacy of A1120 in 
reducing circulating levels of Rbp4 and inhibiting the accumulation of A2E and other 
bisretinoids (Dobri et al. 2013).  
 
1.8.2 ABCA4 gene augmentation  
Gene augmentation for STGD1 aims to deliver the wild-type cDNA of ABCA4 to 
photoreceptors carrying mutant ABCA4, allowing adequate and long-lasting expression of 
the functional transcript/protein to slow or prevent further retinal degeneration. The gene 
of interest can be delivered to the target cells either via viral or non-viral approaches and 
this choice generally is made taking into account either the size of the cDNA to deliver and 
the characteristics of the cells that need to be targeted. 
 
Viral delivery: adeno-associated and lentiviral vectors  
Over the years, viral vectors have been preferred over non-viral vectors for their ability to 
package the therapeutic gene or sequence in capsid proteins, thereby shielding it 
throughout its entry into the target cell and nucleus. Indeed, several physical and chemical 
barriers protect our genetic information from interaction with exogenous genetic material 
(Lipinski et al. 2013). Currently, the most promising results in STGD1 gene therapy have been 
obtained using adeno-associated viruses or lentiviruses. 
Adeno-associated viral vectors (AAVs) so far have been the most employed viral 
vectors for human gene therapy, including IRDs (Warrington and Herzog 2006; Allocca et al. 
2008). Their low immunogenicity, long-term non-integrating transgene expression, ability to 
transduce non-diving cells and photoreceptor-specific tropism of serotype AAV2/8 (Auricchio 
et al. 2001; Stieger et al. 2008; Mussolino et al. 2011; Vandenberghe et al. 2011) make them 
a very effective and attractive tool for gene therapy studies (Colella and Auricchio 2012; 
Vandenberghe and Auricchio 2012). Their main downside though is their limited cargo 
capacity of 4.7 kb, hampering their employment for the delivery of large expression 
cassettes such as the one containing ABCA4 cDNA. 
AAV-based delivery systems were too beneficial to be abandoned, and heterologous 
AAV genomes were shown to form intermolecular concatemers in the nucleus of host cells 
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(Duan et al. 1998). A dual-hybrid approach was developed (Ghosh et al. 2008; Ghosh et al. 
2011) and the ABCA4 expression cassette was split in two halves, packaged into two 
different AAV vectors and re-assembled by combining homologous recombination and a 
trans-splicing biological mechanism (Trapani et al. 2014). The percentage of re-assembly 
using dual-hybrid AAV was higher than all pre-existing strategies for large gene transduction 
(i.e. oversized AAVs, transplicing AAVs and overlapping AAVs) and subretinal administration 
of this vector in the mouse model of STGD1 improved the retinal phenotype (Trapani et al. 
2014).     
Lentiviral vectors (LVs) have a packaging capacity of ~8 kb and they can also 
transduce non-dividing cells, therefore being suitable for gene delivery in photoreceptors 
(Lois et al. 2002; Gouze et al. 2003; Kingsman 2003; Kostic et al. 2003). However, the 
reduced tropism of LVs observed for photoreceptors of adult mice (Kostic et al. 2003; Gruter 
et al. 2005) initially limited the use of LVs in ocular gene therapy. However, since human 
eyes differ from rodent eyes, lentiviral transduction in non-human primates was anyway 
explored by subretinally injecting recombinant feline immunodeficiency viral (rFIV) vector 
expressing the β-galactosidase gene in the eyes of cynomolgus monkeys, and showed the 
ability of LVs to transduce the non-human primates (Lotery et al. 2002). 
To avoid the generation of LVs that may replicate in human cells, the employment of 
vectors derived from primate LVs (e.g. HIV) has been replaced by using non-primate LVs, 
such as those derived from equine infectious anemia virus (EIAV) (Maury et al. 1998; Olsen 
2001). These studies led to development of StarGen (Oxford Biomedica, Sanofi), an EIAV-
based LV carrying the human ABCA4 gene under a constitutive cytomegalovirus (CMV) 
promoter. Preclinical studies in Abca4 knockout mice reported successful tropism in 
photoreceptors and a significantly reduced A2E accumulation (Kong et al. 2008), as well as 
long-term safety and acceptable biodistribution in macaques and rabbits following 
subretinal injection (Binley et al. 2013). This allowed StarGen to enter phase I/II clinical trial 
in 2011 (http://www.clinicaltrials.gov/; Id: NCT01367444). 
 
Non-viral delivery: nanoparticles  
Non-viral vectors are widely appreciated for their reduced or absent toxicity and 
immunogenicity, their large transgene capacity and simple and relatively inexpensive clinical 
grade production (Charbel Issa and MacLaren 2012), but the absence of a specific cellular 
tropism and their need to be continuously administrated, framed them as a poorly valuable 
option compared to viral retinal gene delivery (Andrieu-Soler et al. 2006). Despite all 
attempts to increase their efficiency by using either chemical or physical approaches, partial 
efficacy was observed exclusively for the delivery to the RPE (Kachi et al. 2005; Johnson et al. 
2008; Souied et al. 2008).  
A breakthrough might come from the development of polylysine-based compacted 
DNA nanoparticles CK30-NPs. This innovative strategy consists of compacting the gene to 
deliver with polyethylene glycol (PEG)-substituted 30-mer lysine peptides (CK30PEG) (Liu et 
al. 2003). Major advantages of these carriers are their minimal diameter (8–20 nm), which 
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allows them to promptly access the nucleus of target cells (Liu et al. 2003) and a very wide 
packaging limitation, as they have been successfully tested with plasmids up to 20 kb in 
length (Fink et al. 2006). 
Compared to previous non-viral methods, nanoparticles showed superior efficacy 
with respect to ocular gene transfer (Farjo et al. 2006). Subretinal administration of CK30-
NPs resulted in extensive photoreceptor transduction (Kumar-Singh 2008) in the absence of 
detectable immune response or toxicity (Farjo et al. 2006; Ding et al. 2009), driving long-
term episomal gene expression after subretinal delivery to the mouse eye (Conley and Naash 
2010).  
Preclinical studies reported the effectiveness of CK30-NPs in rescuing rodent models 
of RP (Cai et al. 2009; Cai et al. 2010). In humans instead, nanoparticles have been employed 
in a clinical trial of cystic fibrosis, showing favorable safety and efficacy profile (Konstan et al. 
2004).  
Nanoparticles for ABCA4 gene delivery have been tested in a mouse model of STGD1 
(Han et al. 2012). After subretinal injection of the CK30-NPs carrying the human ABCA4 gene, 
transgene expression was detected in photoreceptors for up to 8 months after injection, 
which led to improved recovery of dark adaptation and reduced lipofuscin accumulation. 
These preclinical results provide the first evidence of effective non-viral vector-mediated 
delivery of large genes to the photoreceptor cell layer. 
 
1.8.3 Stem-cell therapy 
Stem-cell therapy for the treatment of STGD1 aims to regenerate the atrophic RPE layer, 
allowing the differentiation of this polarized epithelium from human embryonic stem cells 
(hESCs). Preclinical studies have already shown promising results as hESC-derived RPE cells 
injected into mouse models of retinal degeneration integrated with the native RPE 
improving visual function (Lu et al. 2009). Importantly, no evidence of tumor formation or 
spread to other areas of the body was observed, meaning that cells stably recognized and 
joined the original tissue.   
Two prospective phase I/II clinical trials were established to assess the safety and 
tolerance of subretinal transplantation of hESC-RPE cells in nine patients with STGD1 and 
nine with dry AMD, (ClinicalTrials.gov Id: NCT01345006/NCT01469832) the results of which 
have already been published (Schwartz et al. 2016). No adverse events resulting from the 
cellular therapy were reported. In all treated eyes, no sign of acute transplant rejection, 
hyperproliferation, teratoma formation or apparent dedifferentiation of the cells was found 
and vascularization remained unaltered up to one year post-transplantation. The few 
adverse events were mainly due to the surgical procedure and the systemic 
immunosuppression. Visual function was also evaluated at six and 12 months as indirect 
indication of safety. Among the eight STGD1 patients who had visual acuity assessed at six 
months, three eyes improved by at least 15 letters, four eyes remained stable, and one eye 
lost 11 letters. Results remained stable after 12 months. 
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Although results look encouraging, further investigation is needed due to the small 
sample size, relatively short follow-up time, and lack of a control group. Above all, it is 
essential to further demonstrate safety and efficacy, improve methodologies of 
implantation, and address concerns related to immunosuppression. At the moment, a 
second clinical trial is ongoing (ClinicalTrials.gov Id: NCT02445612) to better assess the long-
term safety and tolerability of hESC-RPE transplantation in Stargardt patients.  
 
1.8.4 Antisense oligonucleotide-based therapy 
The increasing amount of ABCA4 non-coding variants leading to splice defects (e.g. 
pseudoexon, chapters 7 and 8) has highlighted the potential of an alternative therapeutic 
approach, i.e. to modulate ABCA4 pre-mRNA splicing based on the use of antisense 
oligonucleotides (AONs). AONs are small molecules (~15-25 nt), complementary to their pre-
mRNA target, that are able to interfere with splicing in multiple ways, by either including or 
excluding (pseudo)exons or inducing transcript degradation (Hammond and Wood 2011; 
Arechavala-Gomeza et al. 2014).  
The first clinical trial using splice-switching AONs was conducted in subjects affected 
by Duchenne muscular dystrophy (Koo and Wood 2013), a severe genetic disorder caused by 
mutations in DMD, a large gene made of 79 exons. In more detail, AONs were employed to 
induce single or multiple exon skipping in this gene and to reframe the mutated transcript, 
thereby allowing the creation of a partially functional protein (Aartsma-Rus et al. 2002; 
Aartsma-Rus 2010).  
The first IRD gene on which AONs were tested was centrosomal protein (CEP290). Its 
most recurrent deep-intronic variant c.2991+1655A>G, found in up to 15% of all LCA 
patients in many Western countries (den Hollander et al. 2006; Perrault et al. 2007; Vallespin 
et al. 2007; Coppieters et al. 2010), results in the creation of a strong cryptic splice donor site 
and subsequent inclusion of the cognate PE, therefore representing a suitable target for 
AON therapy. In vitro and in vivo preclinical studies showed the safety and efficacy of AONs 
to restore correct splicing, increasing the CEP290 protein levels and correcting a cellular 
phenotype present in patient-derived fibroblast cells and optic cups (Collin et al. 2012; 
Gerard et al. 2012; Garanto et al. 2016; Parfitt et al. 2016). Furthermore, AON-based splice 
correction has shown to be effective in cell lines from individuals carrying deep-intronic 
variants in USH2A (Slijkerman et al. 2016) or OPA1 (Bonifert et al. 2016). 
The relative simple chemical synthesis and the possibility to chemically modify the AON 
backbone in order to increase stability, cellular uptake and affinity, has made AONs also 
commercially attractive, especially for ocular disorders. An example is Fomivirsen 
(Vitravene™), used for the treatment of cytomegalovirus retinitis, a serious viral eye 
infection (Roehr 1998).   
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Aim of this thesis 
The main purpose of this thesis is to unravel the missing heritability in ABCA4-associated 
STGD1. We employed a palette of genotyping methods to scan for missing nucleotide 
variants in this gene and wherever possible, we characterized the functional effect of the 
identified variants.  
Chapter 1 provides background information on retinal structure, genetics of IRDs and the 
state of the art of STGD1 genetics and therapy.  
Chapter 2 describes the screening of a cohort of genetically unexplained STGD1 probands for 
five previously identified deep-intronic variants and for deletions in ABCA4.  
In chapter 3, the third most frequent ABCA4 variant, c.5461-10T>C, was functionally 
characterized. Induced pluripotent stem cells and photoreceptor precursor cells were 
derived from STGD1 patients carrying c.5461-10T>C in heterozygous or homozygous 
manner. RT-PCR studies revealed that skipping of exon 39, or exons 39 and 40, resulted in 
aberrant ABCA4 mRNA predicted to terminate the protein prematurely. 
Chapter 4 describes the design and generation of a complete set of sizeable wild-type ABCA4 
expression constructs, so called midigenes. They allowed a comprehensive assessment of 
the effect of all 44 reported and three novel non-canonical splice-site ABCA4 variants thus 
far identified.    
Chapter 5 reports on the identification of the frequent c.5603A>T (p.Asn1868Ile) variant in 
27 of 67 mono-allelic STGD1 patients. In several families, siblings of probands that also 
carried bi-allelic variants showed variable disease expression or are asymptomatic. Both 
findings point towards the existence of modifiers unrelated to the ABCA4 locus.        
Chapter 6 describes the targeted ABCA4 locus sequencing in a cohort of 45 mono-allelic 
STGD1 patients to identify missing non-coding variants. Six rare deep-intronic variants were 
identified in 24 probands and all resulted in splice abnormalities, in particular the generation 
of pseudoexons. Antisense oligonucleotides (AONs) were able to significantly correct the 
splice defects caused by these six variants.  
Chapter 7 describes the functional characterization of two neighboring deep-intronic 
variants previously reported as V4 and V5 (Braun et al. 2013), whose effect on the ABCA4 
transcript was still unknown. By RT-PCR analysis of photoreceptor precursor mRNA, we show 
that both variants resulted in the generation of the same pseudoexon in ABCA4 intron 30. In 
addition, AONs efficiently reversed the pseudoexon inclusion in patient-derived 
photoreceptor precursor cells.    
Finally, chapters 8 and 9 provide the general discussion and summary.   
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Abstract 
Variants in ABCA4 are responsible for autosomal recessive Stargardt disease and cone-rod 
dystrophy. Sequence analysis of ABCA4 exons previously revealed one causative variant in 
each of 45 probands. To identify the ‘missing’ variants in these cases, we performed 
multiplex ligation-dependent probe amplification-based deletion scanning of ABCA4. In 
addition, we sequenced the promoter region, fragments containing five deep-intronic splice 
variants, and 15 deep-intronic regions containing weak splice sites. Heterozygous deletions 
spanning ABCA4 exon 5 or exons 20-22 were found in two probands, heterozygous deep-
intronic variants were identified in six probands, and a deep-intronic variant was found 
together with an exon 20-22 deletion in one proband. Based on ophthalmologic findings and 
characteristics of the identified exonic variants present in trans, the deep-intronic variants 
V1 and V4 were predicted to be relatively mild and severe, respectively. These findings are 
important for proper genetic counseling and for the development of variant-specific 
therapies. 
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Introduction 
The ATP-binding cassette, sub-family A, member 4 (ABCA4) protein is located at the rim of 
the outer segment discs in rods and in the cell membrane of cones. Variants in ABCA4 (MIM* 
601691) were associated with autosomal recessive Stargardt disease (STGD1) (Allikmets et 
al. 1997b). Subsequently, different combinations of ABCA4 variants have been linked to a 
spectrum of phenotypes ranging from mild macular dystrophy to severe early-onset 
panretinal dystrophy (Allikmets et al. 1997a; Cremers et al. 1998; Maugeri et al. 1999; 
Klevering et al. 2004). In the proposed genotype-phenotype correlation model, a 
combination of a mild and a severe ABCA4 variant causes STGD1 (Maugeri et al. 1999), the 
most frequent associated disease, whereas a moderate and a severe variant gives rise to a 
more severe phenotype, cone-rod dystrophy (CRD) (Cremers et al. 1998). Two severe 
variants in ABCA4 result in a panretinal CRD (Cremers et al. 1998; Klevering et al. 2004).  
A significant subset of individuals with classic STGD1 however carries only one or no 
ABCA4 variant (Maugeri et al. 1999). A proportion of these cases may be explained by the 
identification of variants in genes that are associated with retinal dystrophies resembling 
STGD1. ELOVL4 (Edwards et al. 2001) and PRPH2 (Poloschek et al. 2010) contain variants 
which are responsible for autosomal dominant STGD. Furthermore, the ‘missing’ variants in 
STGD1 patients may be the result of the limitations of the employed molecular genetic 
analysis. Homozygous ABCA4 deletions disrupting the open reading frame are not expected 
to account for the ‘missing’ variants in STGD1 as they would result in a panretinal dystrophy. 
Heterozygous deletions, however, can have been missed as PCR-based mutation scanning 
and Sanger sequencing of ABCA4 exons would not detect small heterozygous deletions. 
Southern blot analysis revealed heterozygous deletions of exon 18 (Yatsenko et al. 2003) and 
exons 20-22 (Maugeri et al. 1999).  
Deep sequencing of the ABCA4 mRNA of healthy retinal tissues revealed several low-
expressed alternative transcripts of ABCA4 (Braun et al. 2013). Sequence analysis of rarely 
used deep-intronic splice sites in STGD1 individuals identified variants at five splice junctions 
(i.e., V1 through V5), causing intron retention or premature termination of an exon (Braun et 
al. 2013). The variants V6 and V7 reported in the same study are not deep-intronic and can 
be identified using regular exon analysis. 
Previously, we employed a palette of genotyping methods to scan for exonic 
ABCA4 variants and deletions (Maugeri et al. 1999; Jaakson et al. 2003). In this study, we 
have expanded our genotyping studies to identify the second variant in maculopathy 
cases with one ABCA4 allele. 
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Methods 
Forty-five probands with one heterozygous ABCA4 variant (33 STGD1, four STGD1/CRD, 
five arCRD, three ar cone dystrophy (CD); Supplemental Table S1), a cohort of 81 STGD1 
probands with two ABCA4 variants and nine additional STGD1 probands without ABCA4 
variants, were ascertained in The Netherlands, the majority of which originates from the 
Southeast. One hundred and sixty-seven ethnically matched healthy control samples were 
collected in The Netherlands.  
Clinical data were collected from the medical records. From the patients with an 
intronic variant, data were collected focused on the age at diagnosis, best corrected visual 
acuity (BCVA) using Snellen visual acuity, ophthalmoscopy, and full-field 
electroretinography (ffERG). FfERG was performed using Dawson-Trick-Litzkow electrodes 
and the RETI-port system (Roland Consults, Stasche & Finger GmbH, Brandenburg an der 
Havel, Germany), and the recordings were performed in accordance with the guidelines of 
the International Society for Clinical Electrophysiology of Vision (ISCEV) (Marmor et al. 
2009). The inclusion criteria for STGD1 were the presence of progressive retinal dystrophy 
with beaten-metal appearance and/or yellow-white pisciform flecks and/or 
autofluorescent depositions under the RPE. Inclusion criteria for CRD were a progressive 
decline of visual acuity, and on ERG a reduction of both cone and rod responses, with 
cone responses equally or more severely reduced. Exclusion criteria were an onset >40 
years, extinguished scotopic or photopic responses on ERG, and congenital nystagmus. 
This study was approved by the local medical ethics committees and adhered to the 
tenets of the Declaration of Helsinki. All participants provided signed, informed consent 
for participation in the study, retrieval of medical records, and use of blood and DNA for 
research. 
Blood samples were obtained of probands, their parents, and when possible, affected 
and unaffected siblings. DNA was isolated from peripheral blood lymphocytes by standard 
procedures. Multiplex ligation-dependent probe amplification (MLPA) reagents were 
obtained according to the manufacturer’s instructions (SALSA MLPA kit P151-P152 ABCA4; 
MRC-Holland, Amsterdam, The Netherlands). Primers used to perform Sanger sequencing of 
all coding regions including the intron-exon boundaries and the putative promoter region 
(hg19 chr1:94,587,564-94,586,601; c.-963>c.1) of ABCA4 are described in Supplemental 
Table S2. Supplemental Table S3 lists the primers employed to perform Sanger sequencing of 
the deep-intronic variants (V1-V5). Sanger sequencing of the 15 regions encompassing rarely 
used splice sites was performed using previously described primers (Braun et al. 2013). The 
variants reported in this study were submitted to the locus-specific database for ABCA4 at 
http://www.lovd.nl/ABCA4. 
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Results and Discussion 
An overview of the genetic analyses performed previously and in this study is provided in 
Supplemental Table S1. Sequence analysis of the promoter region did not yield any variants. 
An in-frame deletion of exons 20-22 (c.2919-?_3328+?del; p.S974Qfs*64) was identified 
previously by Southern blotting (Maugeri et al. 1999). As part of a diagnostic deletion 
scanning protocol, DNAs of 27 patients with retinal dystrophies and one heterozygous 
ABCA4 variant were fully analyzed for heterozygous ABCA4 deletions using MLPA, which 
yielded two probands carrying the exon 20-22 deletion in a heterozygous state (A-IV:2 and F-
II:1; Fig. 1; Table 1). A-IV:2 is a member of a previously described multiplex family 
segregating several monogenic and multifactorial retinal dystrophies (Klevering et al. 2004). 
She was diagnosed with STGD1/CRD and carried the c.768G>T variant on the other allele, 
which is a frequent causative ABCA4 variant (Maugeri et al. 1999). The exon 20-22 deletion 
was also found in a second cousin (A-IV:1) who carried the c.5461-10T>C variant in a 
heterozygous state. Finally, another family member with STGD1 (A-III:3) carried this deletion, 
but no second ABCA4 variant was detected. As described previously, III:1 and III:3 also carry 
the same maternal haplotype containing ABCA4 (Klevering et al. 2004). Ophthalmological 
investigations were not carried out for III:1. In Family F, this deletion was found together 
with a heterozygous missense variant (p.C1488R) and a heterozygous deep-intronic splice 
variant (see below). 
Using MLPA probes spanning exon 5, a novel heterozygous deletion with unknown 
boundaries (c.443-?_570+?del), resulting in a predicted truncated protein (p.G148Vfs*89) 
was detected in a STGD1 proband and an affected sibling of Family B (Fig. 1). Both also 
carried the c.768G>T variant in a heterozygous state. The identification of heterozygous 
ABCA4 deletions of exon 5 and exons 20-22 explained six cases of three families (Fig. 1). 
The 45 probands with one heterozygous ABCA4 allele, as well as a group of nine STGD 
individuals without any pathogenic ABCA4 variant, were analyzed for the presence of five 
deep-intronic variants (V1 through V5) and analyzed for sequence variants at the splice sites 
of 15 additional cryptic exons (Braun et al. 2013). The deep-intronic variant c.5196+1137G>A 
(V1) was detected in isolated cases of two families (Families F and H; Fig. 1; Table 1). In 
Family F, the proband also carried a heterozygous missense variant (p.C1488R) and a 
heterozygous deletion of exons 20-22, but segregation analysis was not possible due to 
unavailability of parental DNAs. The second deep-intronic variant identified in our cohort 
was c.4539+2001G>A (V4), which was found in a heterozygous state in five probands 
(Families C-E, G and I; Fig. 1; Table 1). In two STGD1 siblings of family C, V4 was found 
together with the heterozygous splice site variant c.5584+6T>C. The CRD phenotype in the 
sporadic patient in Family D is very likely caused by heterozygous variant V4 together with a 
heterozygous variant that is in linkage disequilibrium with the splice-site variant c.5461-
10T>C. Individual II:1 of Family E carries the severe heterozygous missense variant p.A1794D 
and V4, together causing STGD1/CRD. Two siblings of Family G with STGD1/CRD carry the 
heterozygous missense variant p.L1631P together with the heterozygous variant V4. The 
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bull’s eye phenotype in a sporadic case of Family I is caused by the heterozygous variant V4 
and the heterozygous missense variant p.G1961E. The analysis of the remainder of the 
variants or alternatively spliced exons did not yield additional variants in our cohort. None of 
the deep-intronic variants were identified in the nine STGD cases without exonic ABCA4 
variants. 
 Using Sanger sequencing, we did not identify variants V1 and V4 in 167 ethnically 
matched controls. In the 45 retinal disease probands with one heterozygous exonic ABCA4 
allele and in nine STGD cases with no ABCA4 variant, we did not find the deep-intronic 
variants V2, V3 and V5, nor any variants in the 15 regions encompassing weak splice sites 
(Braun et al. 2013). For STGD cases with no ABCA4 variant, we should bear in mind that the 
genetic defects can very well reside in other genes. 
The clinical characteristics of five unrelated patients with intronic variants from 
Families E through I are shown in Supplemental Table S4. They are all of Caucasian descent. 
These patients were diagnosed between the age of 12 and 23 years (mean: 18.4 years). The 
mean follow-up of disease was 25 years (range: 12-49 years). Patients from Families F and H 
showed the intronic variant V1. The proband from Family F carried an exon 20-22 deletion in 
trans, a protein-truncating (severe) allele (Maugeri et al. 1999). She shows a STGD1 
phenotype with a CRD pattern and a BCVA at last visit (age 35 years) of 20/600. The patient 
from Family H carried a nonsense variant in trans, and showed a typical STGD1 phenotype. 
His BCVA at last visit was 20/400 (age 32 years). Based on these results, V1 is deemed to 
have a mild effect on the function of ABCA4. Employing RNA extracted from keratinocytes 
derived from a STGD1 proband carrying V1 and p.T1526M (E.M.S., personal communication), 
Braun et al. (2013) identified intronic RNA insertions due to V1 in a significant fraction of 
RNA. Assuming that the ABCA4 RNA splicing in keratinocytes is similar to that in the retina, 
this argues for a severe effect of V1, which is in contradiction with our assessment. V1 was 
very recently found as the most frequent deep-intronic variant (10/233) in STGD1 probands 
with one ABCA4 variant (Zernant et al. 2014) and not present in 368 European controls. It 
was deemed nonpathogenic as it was present in 8/200 (4%) African-American controls and 
only found in 1/46 (2%) African-American STGD1 cases with one ABCA4 variant. However, 
the c.2588G>C variant in ABCA4, previously shown to be a mild allele, was found in a 
heterozygous state in 3% and 6% of Dutch and Swedish STGD1 cases, respectively (Maugeri 
et al. 1999; Maugeri et al. 2002). The V1 variant c.5196+1137G>A is present at an 
orthologous position in Macaca mulatta as the major allele, and shown not to affect exon 
36/exon 37 splicing (Zernant et al. 2014). This result does not rule out pathogenicity of V1 in 
humans, however, as differences in RNA splicing have been reported between, for example, 
human patients and a ‘humanized’ knock-in mouse that carries the same segment of human 
CEP290 with a deep-intronic variant (Garanto et al. 2013). 
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Figure 1. Pedigrees with retinal dystrophies and ABCA4 variants. A–B: Families with retinal 
dystrophies due to compound heterozygous exonic ABCA4 variants and intragenic deletions. 
Family A is adapted from Klevering et al. (2004), and contains several monogenic and 
multifactorial retinal dystrophies. A heterozygous deletion of exons 20-22 was found in A-
IV:1, A-IV:2 and A-III:3. The latter patient does not carry a second ABCA4 variant. In Family B, 
a heterozygous deletion spanning exon 5 was identified. C-I: Families with retinal 
dystrophies due to combinations of exonic ABCA4 variants and deep-intronic variants. The 
exception is proband F-II:1, who carried a deletion spanning exon 20-22, together with a 
missense mutation, and a deep intronic variant V1. Segregation analysis was not possible for 
Families B-F. ABCA4 variants: M1: c.768G>T; M2: c.5461-10T>C; M3: p.(S974Qfs*64); M4: 
p.(G148Vfs*89); M5: c.4539+2001G>A (V4); M6: c.5584+6T>C; M7: p.(A1794D); M8: 
c.5196+1137G>A (V1); M9: p.(C1488R); M10: p.(L1631P); M11: p.(Q1292*); M12: 
p.(G1961E). 
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Patients from Families E, G and I showed the intronic variant V4. Patients from 
Families E and I carried the p.A1794D and p.G1961E variants in trans, respectively, both of 
which were deemed to be mild variants in previous studies as they were identified in typical 
STGD1 cases that carried protein-truncating variants on the other allele (Maugeri et al. 1999; 
Burke et al. 2012). The proband from Family E at her last visit had a BCVA of 20/1200 (age 67 
years) and showed a STGD1/CRD picture. The proband from Family I showed a CD 
phenotype. Based on these data, it is proposed that V4 has a severe effect on ABCA4 
function. 
 
Table 1. Retinal dystrophies-associated variants identified in ABCA4 
Family Diagnosis ABCA4 allele 1  
(DNA) 
ABCA4 allele 1  
(Protein) 
ABCA4 allele 2  
(DNA) 
ABCA4 allele 2 
(Protein) 
A STGD1/CRD c.768G>T p.(?) c.2919-?_3328+?del p.(S974Qfs*64) 
B STGD1 c.768G>T p.(?) c.443-?_570+?del p.(G148Vfs*89) 
C STGD1 c.5584+6T>C p.(?) c.4539+2001G>A (V4) p.(?) 
D CRD c.5461-10T>C p.(?) c.4539+2001G>A (V4) p.(?) 
E STGD1/CRD c.5381C>A p.(A1794D) c.4539+2001G>A (V4) p.(?) 
F STGD1/CRD c.2919-?_3328+?del/c.4462T>C p. (S974Qfs*64)/(p.C1488R) c.5196+1137G>T (V1) p.(?) 
G STGD1/CRD c.4892T>C p.(L1631P) c.4539+2001G>A (V4) p.(?) 
H STGD1 c.3874C>T p.(Q1292*) c.5196+1137G>T (V1) p.(?) 
I CD c.5882G>A p.(G1961E) c.4539+2001G>A (V4) p.(?) 
 
Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in 
NM_000350.2, with the initiation codon as codon 1. To determine the correct mutation 
nomenclature, http://www.LOVD.nl/mutalyzer, Alamut Visual version 2.4 (Interactive 
Biosoftware, Rouen, France), and http://www.hgvs.org/mutnomen/ were employed. 
 
As reverse-transcription polymerase chain reaction analysis using lymphoblast RNA 
from patients carrying V4 did not yield consistent results (data not shown), there is no 
experimental proof for this assumption. In the absence of detailed RNA analysis, we cannot 
be sure that V4 is disease-causing, and it is still possible that the causative variant is in 
linkage disequilibrium with V4. Although we did not perform haplotype analysis for V4, it is 
plausible that all probands carrying this variant share a common haplotype. Our findings, 
together with the frequent occurrence of V4 in trans with exonic ABCA4 variants in a Belgian 
STGD1 cohort (E. de Baere, personal communication), strongly suggest that V4 is a founder 
mutation. 
In contrast to the cohort from Iowa, the remaining deep-intronic splice variants V2, 
V3 and V5 were not identified in our cohort. We also did not identify variants in the 15 
additional regions containing infrequently used deep-intronic splice sites as described 
elsewhere (Braun et al. 2013). From the initial cohort of 127 probands with STGD or 
STGD/CRD, 88 cases (69%) are currently solved with two ABCA4 alleles, which is a 
remarkable difference to the Iowa cohort in which 91.8% of the cases were explained.   
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Identification of a second ABCA4 variant is of high significance for the relevant 
patients as this clearly implicates ABCA4 as the underlying gene, and thereby autosomal 
recessive inheritance of the gene defects. In view of the high frequency of heterozygous 
ABCA4 variants in healthy individuals, that is, up to 1/20 individuals (Maugeri et al. 1999), 
the presence of one allele can be coincidental and the genetic cause situated in another 
gene. Affected persons with two ABCA4 variants also are eligible for experimental 
treatments based on gene augmentation. Moreover, the nine persons from families C 
through I carrying heterozygous deep-intronic variants V1 or V4 in principle are eligible for a 
novel type of treatment based on correcting erroneously spliced RNAs, using antisense 
oligonucleotides. In fibroblasts and immortalized lymphocytes of patients with Leber 
congenital amaurosis, the potential of this approach was shown by reversing the effect of a 
deep-intronic splice defect in CEP290 (Collin et al. 2012). The ‘correction’ of one of two 
alleles may be beneficial and the added advantage of this approach versus ABCA4 gene 
augmentation is that overexpression of the ABCA4 gene is not possible.   
 In conclusion, in this study we identified previously ‘hidden’ ABCA4 alleles in nine of 
45 (20%) families with retinal dystrophies, leaving 36 of the 45 (80%) probands with one 
heterozygous exonic ABCA4 allele unexplained. To identify additional putative intronic 
ABCA4 variants in the remaining mono-allelic cases, intronic DNA sequencing can be 
combined with mRNA analysis of differentiated retinal-like cells derived from patient’s 
somatic cells. 
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Supplemental Table 1. Genotyping studies in retinal dystrophy patients with one ABCA4 
variant. DGGE, denaturing gradient gel electrophoresis; MLPA, multiplex ligation-dependent 
probe amplification; NGS, fluidigm-based next generation sequencing; SSCP, single strand 
conformation polymorphism. 
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Proband
/ 
Family 
Pheno- 
type 
MA2002/ 
SSCP/ 
DGGE 
Sanger 
sequencing 
ABCA4 
MLPA 
NGS 
PRPH2 
sequencing 
Analysis 
del exon 
20-22 
Promoter 
Analysis 
Analysis 
V1-5; 
V8-V21 
1 STGD1 yes 
  
yes yes yes Yes yes 
2 STGD1 yes 
  
yes yes yes Yes yes 
3 STGD1 yes 
  
yes yes yes Yes yes 
4 STGD1 yes 
  
yes yes yes Yes yes 
5/A STGD1/CRD 
 
yes 
  
yes yes Yes yes 
6 STGD1 
 
yes 
  
yes yes Yes yes 
7 CRD yes yes 
  
yes yes Yes yes 
8 STGD1 yes 
  
yes yes yes Yes yes 
9 CRD yes 
  
yes yes yes Yes yes 
10 CRD yes 
  
yes yes yes Yes yes 
11 CD 
 
yes 
  
yes yes Yes yes 
12 STGD1 
 
yes yes 
 
yes yes Yes yes 
13 STGD1 
 
yes yes 
 
yes yes Yes yes 
14 STGD1 
 
yes yes 
 
yes yes Yes yes 
15 STGD1 
 
yes yes 
 
yes yes Yes yes 
16 STGD1 
 
yes yes 
 
yes yes Yes yes 
17 STGD1 
 
yes yes 
 
yes yes Yes yes 
18 CRD yes 
  
yes yes yes yes yes 
19 CD 
 
yes yes 
 
yes yes yes yes 
20 STGD1 
 
yes yes 
 
yes yes yes yes 
21 STGD1 
 
yes yes 
 
yes yes yes yes 
22 STGD1 
 
yes yes 
 
yes yes yes yes 
23 STGD1 
 
yes yes 
 
yes yes yes yes 
24 STGD1 yes 
  
yes yes yes yes yes 
25 STGD1 yes yes yes yes yes yes yes yes 
26 STGD1 
 
yes yes 
 
yes yes yes yes 
27 STGD1 
 
yes yes 
 
yes yes yes yes 
28 STGD1 
 
yes yes 
 
yes yes yes yes 
29 STGD1 
 
yes yes 
 
yes yes yes yes 
30 STGD1 yes 
   
yes yes yes yes 
31 STGD1 
 
yes yes 
 
yes yes yes yes 
32 STGD1 
 
yes yes 
 
yes yes yes yes 
33 STGD1 
 
yes yes 
 
yes 
 
yes yes 
34 STGD1 
 
yes yes 
 
yes yes yes yes 
35 STGD1 
 
yes yes 
 
yes yes yes yes 
36 STGD1 yes 
   
yes yes yes yes 
37 STGD1 
 
yes yes 
 
yes yes yes yes 
38/B STGD1 yes yes yes yes yes yes yes yes 
39/C STGD1 yes 
  
yes yes yes yes yes 
40/D CRD yes 
  
yes yes yes yes yes 
41/E STGD1/CRD yes 
  
yes yes yes yes yes 
42/F STGD1/CRD 
 
yes yes 
 
yes yes yes yes 
43/G STGD1/CRD 
 
yes yes 
 
yes yes yes yes 
44/H STGD1 
 
yes yes 
 
yes yes yes yes 
45/I CD 
 
yes yes 
 
yes yes yes yes 
Total 
 
17 31 27 14 45 44 45 45 
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Supplemental Table S4. Clinical characteristics of the patients included in this study at findings at first diagnosis and most recent visit 
Patient Gender AaD (y) BCVA Fundus ffERG* Diagnosis AlV (y) BCVA Fundus ffERG* Diagnosis 
E-II:1 F 18 20/200 Macular pigment 
changes, yellow flecks 
reaching up to vascular 
arcades 
Photopic: N 
Scotopic: 
RE: MR, LE: N 
STGD1 67 20/1200 Large RPE atrophic 
regions 
Photopic: ND 
Scotopic: RE: 
SR, LE: ND 
STGD1 with 
CRD 
pattern 
F-II:1 F 23 20/50 Parafoveal 
hypopigmentation and 
yellow-white flecks in 
posterior pole 
Photopic and 
scotopic: N 
STGD1 35 20/600 Profound chorioretinal 
atrophy macula and 
midperiphery. 
Intraretinal 
pigmentations in the 
macula 
Photopic: N, 
Scotopic: RE: 
MR, LE: SR 
STGD1 with 
CRD 
pattern 
G-II:2 F 12 NP NP NP STGD1 48 20/400 Large RPE atrophic 
regions 
Photopic: SR, 
Scotopic: N 
STGD1 with 
CRD 
pattern 
H-II:1 M 18 20/100 Subtle flecks 
perimaculair 
Photopic and 
scotopic: N 
STGD1  32 20/400 Macular RPE atrophy, 
midperiphery flecks 
NP STGD1 
I-II:1 F 21 20/100 Bull’s eye, no flecks Photopic and 
scotopic: N 
Bull’s eye 
maculopathy 
35 20/400 Bull’s eye, no flecks Photopic: RE: 
MR, LE: SR 
Scotopic: N 
CD 
AaD, Age at diagnosis; AlV, age at last visit; BCVA, best corrected visual acuity (Snellen); CD, cone dystrophy; CRD, cone-rod dystrophy; STGD1, 
Stargardt disease type 1; ffERG, full-field electroretinogram; F, female; M, male;  LE, left eye; RE, right eye. *The abbreviations reflect the 
amplitude: N, normal (equal to or above the lower 5% of the range for a normal population: photopic ≥78uV, scotopic ≥263uV); MR, 
moderately reduced (1-5% of normal range: photopic ≥69 uV and <78 uV, scotopic ≥195 uV and <263 uV); SR, severely reduced (<1% of normal 
range: photopic <69 uV, scotopic <195uV). ND, not detectable; NP, not performed. 
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Abstract 
Purpose: This study aimed to elucidate the functional effect of the ABCA4 variant c.5461-
10T>C, one of the most frequent variants associated with Stargardt disease (STGD1). 
Design: Case series 
 
Participants: Seventeen persons with STGD1 carrying ABCA4 variants and one control 
person. 
 
Methods: Haplotype analysis of four homozygotes and 11 heterozygotes for c.5461-10T>C 
and sequence analysis of the ABCA4 gene for a homozygous proband. Fibroblasts were 
reprogrammed from three persons with STGD1 into induced pluripotent stem cells (iPSCs). 
iPSCs were differentiated into photoreceptor progenitor cells (PPCs). The effect of the 
c.5461-10T>C variant on RNA splicing by reverse transcription-PCR was analyzed using PPC 
mRNA. In vitro assays were performed with minigene constructs containing ABCA4 exon 39. 
We analyzed the natural history and ophthalmologic characteristics of four persons 
homozygous for c.5461-10T>C.  
 
Main outcome measures: Haplotype and rare variant data for ABCA4, RNA splice defects, 
age at diagnosis, visual acuity, fundus appearance, visual field, electroretinogram (ERG), 
fluorescein angiography and fundus autofluorescence findings. 
 
Results: The frequent ABCA4 variant c.5461-10T>C has a subtle effect on splicing based on 
prediction programs. A ‘founder’ haplotype containing c.5461-10T>C was found to span ~96 
kb of ABCA4 and did not contain other rare sequence variants. Patient-derived PPCs showed 
skipping of exon 39 or exons 39/40 in the mRNA. HEK293T cell transduction with minigenes 
carrying exon 39 showed that the splice defect was due to the c.5461-10T>C variant. All four 
subjects carrying the c.5461-10T>C variant in a homozygous state showed a young age of 
onset STGD1, with low visual acuity at presentation and an abnormal cone ERG. All four 
developed a severe cone-rod dystrophy before the age of 20 and were legally blind by the 
age of 25. 
 
Conclusions: The ABCA4 variant c.5461-10T>C is located on a ‘founder’ haplotype lacking 
other disease-causing rare sequence variants.  In vitro studies revealed that it leads to mRNA 
exon skipping and ABCA4 protein truncation. Given the severe phenotype in persons 
homozygous for this variant, we can conclude that this variant results in the absence of 
ABCA4 activity. 
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Introduction 
Bi-allelic variants in the gene encoding the ATP-binding cassette transporter type A4 (ABCA4) 
have been identified in ~75% of cases with autosomal recessive Stargardt disease (STGD1) 
(Allikmets et al. 1997; Lewis et al. 1999; Maugeri et al. 1999; Rivera et al. 2000; Webster et 
al. 2001) and in ~30% of patients with autosomal recessive cone-rod dystrophy (CRD) 
(Maugeri et al. 2000). In severe CRD cases, the phenotype can resemble retinitis pigmentosa. 
More recently, late-onset STGD1 (Westeneng-van Haaften et al. 2012) and STGD1 cases with 
a fine granular pattern with peripheral spots upon autofluorescence examination (Fritsche et 
al. 2012) have been associated with the presence of one or two ABCA4 variants. The clinical 
variability observed in ABCA4-associated cases can be explained by a genotype-phenotype 
correlation model in which the residual activity of the mutant ABCA4 protein determines the 
clinical phenotype (van Driel et al. 1998; Maugeri et al. 1999). Persons with severe CRD carry 
two ABCA4 null alleles, whereas persons with STGD1 carry two moderately severe variants 
or a combination of a mild and a severe variant (van Driel et al. 1998; Maugeri et al. 1999). 
The ABCA4 protein has been proposed to act as a flippase for 11-cis and all-trans isomers of 
N-retinylidene-phosphatidylethanolamine across disc membranes, thereby facilitating the 
removal of retinal products from the disc membranes and preventing the accumulation of 
potentially toxic bisretinoid compounds (e.g., A2E) in photoreceptor and retinal pigment 
epithelial (RPE) cells (Beharry et al. 2004; Molday et al. 2009).   
To provide an accurate prognosis for persons with ABCA4 variants, it is important to 
assess the functional consequences of the ~1000 ABCA4 variants that have been reported to 
date. This is straightforward for protein-truncating variants (i.e., stop mutations, frameshift 
mutations, canonical splice-site mutations), but much more difficult for rare missense 
mutations (i.e., amino acid substitutions) and non-canonical splice variants (i.e., RNA splice 
variants outside the conserved intronic dinucleotides at the ends of introns) with an unclear 
functional effect. The pathogenicity of selected amino acid substitutions has been studied by 
assessing mutant ABCA4 protein stability, ATP-binding properties, ATPase activity and 
mislocalization (Sun et al. 2000; Shroyer et al. 2001; Suarez et al. 2002; Wiszniewski et al. 
2005).  
An unusually high proportion of STGD1 cases from northern Europe and the United 
States (~30%) shows only one ABCA4 variant, despite comprehensive Sanger sequencing and 
deletion analysis of the 50 protein coding exons (Lewis et al. 1999; Maugeri et al. 1999; 
Rivera et al. 2000; Webster et al. 2001; Zernant et al. 2014; Bax et al. 2015). Very recently, 
deep-intronic variants (i.e., variants not located near the coding exons) have been identified 
that can explain a proportion of these so-called missing mutations (Braun et al. 2013; 
Zernant et al. 2014; Bauwens et al. 2015; Bax et al. 2015). The identification of both ABCA4 
alleles and experimental proof that they have an effect on ABCA4 function also are crucial 
for the selection of persons with STGD1 for upcoming gene-specific trials, such as gene 
augmentation  
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(i.e.,https://clinicaltrials.gov/ct2/show/NCT01367444?term=ABCA4&rank=8 and https://clini
caltrials.gov/ct2/show/NCT01736592?term=ABCA4&rank=12) or other types of treatment. 
The identification of mRNA abnormalities is hampered by the photoreceptor-specific 
expression of ABCA4 (Allikmets et al. 1997). This is particularly important for non-canonical 
splice variants with unknown effects on splicing. The third most frequent ABCA4 variant, 
c.5461-10T>C (previously denoted as IVS38-10T>C) (S. Cornelis and F.P.M.C., unpubl.), on the 
basis of prediction programs has a very small effect on splicing efficiency. In our classical 
STGD1 patients, it is found very often together with the mild c.2588G>C 
(p.Gly863Ala)/(p.Gly863del) variant, suggesting that c.5461-10T>C represents a severe 
ABCA4 variant. 
In this study, we investigated the effect of the c.5461-10T>C variant on splicing by 
analyzing mRNA from photoreceptor progenitor cells (PPCs) derived from persons with 
STGD1 who carry this variant in a homozygous or heterozygous state. In addition, we 
performed in vitro minigene splicing studies to show that this variant results in truncation of 
the predicted ABCA4 protein.  
 
Methods 
Subjects and clinical evaluation 
We ascertained 15 persons with STGD1 carrying the c.5461-10T>C variant in a homozygous 
state (patients 1–4) or compound heterozygous state (patients 5–15) from The Netherlands 
and Germany. In addition, we studied two individuals with STGD1 with a single ABCA4 allele 
(patients 16 and 17) and a control. Genotype data for patients 1 through 17 can be found in 
Supplemental Table S1. This study was approved by the institutional review board and 
adhered to the tenets of the declaration of Helsinki. We studied all recent and available 
retrospective data of patients 1 through 4. This included history on initial symptoms, age at 
diagnosis, regression of Snellen best-corrected visual acuity (converted in Fig. 1 to equivalent 
logarithm of the minimum angle of resolution visual acuity), and description of the fundus 
abnormalities. Thereafter, we also examined available color vision testing results, visual 
fields (Goldmann), fundus photography, fluorescein angiography, fundus autofluorescence 
imaging (confocal scanning laser ophthalmoscope [Spectralis; Heidelberg Engineering, 
Heidelberg, Germany]), spectral-domain optical coherence tomography (Spectralis), and full-
field electroretinogram (ff-ERG). 
 
Molecular genetic analyses 
In silico analysis of the ABCA4 c.5641-10T>C variant on splicing 
The possible effect of the non-canonical splice variant c.5461-10T>C in ABCA4 on splicing 
was assessed by the use of five algorithms (SpliceSiteFinder, MaxEntScan, NNSPLICE, 
GeneSplicer, Human Splicing Finder) via Alamut Visual software version 2.7 (Interactive 
Biosoftware, Rouen, France; http://www.interactive-biosoftware.com). 
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Haplotype analysis 
Eighteen single nucleotide polymorphisms (SNPs) were selected from within the ABCA4 gene 
and flanking sequences on the basis of their high degree of heterozygosity in the Dutch 
population (average minor allele frequency, 0.39; Genome of the Netherlands; 
http://www.nlgenome.nl/). Polymerase chain reaction (PCR) primers were designed to 
analyze amplicons of approximately 270 bp containing these SNPs. Reaction mixtures (25 μl) 
contained Taq DNA Polymerase, 1 U/μl (cat. no. 11647679001, Roche, Basel, Switzerland), 
10X PCR buffer containing MgCl2, 25 mM MgCl2, 10 mM dNTPs (deoxynucleotide 
triphosphate), 10 μM of each primer pair and of 50 ng genomic DNA. Polymerase chain 
reaction analyses were performed by using the Veriti Thermal Cycler (Thermo Fisher 
Scientific, Waltham, MA), and PCR conditions were a first denaturation step of 95°C for 5 
minutes followed by 35 cycles of melting (95°C for 30 seconds), annealing (58°C for 30 
seconds) and extension (72°C for 45 seconds) steps, with a final elongation of 72°C for 5 
minutes. Polymerase chain reaction products were Sanger sequenced in a 3100 or 3730 DNA 
Analyzer (Thermo Fisher Scientific). Primer details are given in Supplemental Table S2. 
 
Haloplex targeted ABCA4 enrichment and sequence analysis 
For patient 1, the ABCA4 locus was enriched by using a custom Haloplex Target Enrichment 
kit (Agilent, Santa Clara, CA). Probes were designed with SureDesign (Agilent) to target a 
365-kb region (chr1:94337885-94703604, GRCh37/hg19 assembly) encompassing the entire 
ABCA4 gene and flanking regulatory elements that have been conserved in different species 
(Ahituv et al. 2005). This study used multispecies comparison in order to map cis-regulatory 
domains of genes assuming they are located in regions of synteny. The 365-kb region 
corresponds to a region of synteny. The probes covered more than 98% of the targeted 
regions, and gaps in coverage corresponded to repeat-rich regions. Subsequently, samples 
were sequenced by using Illumina sequencing technology (Miseq; Illumina, San Diego, CA) to 
obtain 2x250-bp reads. Data analysis was performed with CLC Bio Software (CLC Bio 
Genomics Workbench; Qiagen, Hilden, Germany). Reads were aligned against a reference 
genome (GRCh37/hg 19 assembly), and variants were identified and annotated by a custom-
designed workflow. Variants were considered for further filtering only if they were present 
in at least one forward and one reverse read, in a minimum of 20% of all reads, and with a 
minimum coverage of five reads. The variants were annotated further by Alamut Batch 
(Interactive Biosoftware) and RegulomeDB (http://www.regulomedb.org). Variants were 
filtered on the basis of population frequency, as determined by Genome of the Netherlands, 
a database containing genomic sequences from ~500 control individuals from the 
Netherlands (Genome of the Netherlands 2014), and Exome Aggregation Consortium 
(Cambridge, MA), a dataset of 60,706 unrelated individuals sequenced as part of various 
disease-specific and population genetic studies (available at: http://exac.broadinstitute.org; 
accessed November 10, 2015).   
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Patient-derived fibroblast reprogramming 
Skin biopsy samples from three persons with STGD1 and from one control were collected, 
washed in phosphate-buffered saline (cat. no. P5493, Sigma Aldrich, St. Louis, MO, USA), 
dissected and processed as described in the Supplemental Materials. After approximately 
one month, a pure culture of fibroblasts was reprogrammed by following the protocol 
described in the Supplemental Materials. Briefly, fibroblasts were transduced with four 
lentiviral vectors containing the stemness-related genes OCT3/4, NANOG, KLF4 and c-MYC 
and cultured in stem cell-specific medium for one month. Subsequently, induced pluripotent 
stem cell (iPSC) colonies were picked and expanded on Vitronectin-coated plates (cat. no. 
A14700, Thermo Fisher Scientific) in Essential E8 medium (cat. no. A1517001, Thermo Fisher 
Scientific). 
 
iPSC differentiation into photoreceptor progenitor cells (PPCs)  
iPSC clumps were cut with the StemPro Ez-passage disposable stem cell passaging tool® (cat. 
no. 23181-010, Thermo Fisher Scientific) and cultured in ultra low attachment 24 well-plates 
(cat. no. corn3473 VWR, Amsterdam, The Netherlands) to form embryoid bodies (EBs) for 4 
days. EB medium consisted of DMEM/F-12 containing 10% (v/v), Knock-out serum 
replacement (KOSR, cat. no. 10828-028, Thermo Fisher Scientific) supplemented with non-
essential amino acids (NEAA, cat. no. M7145, Sigma Aldrich), L-glutamine (cat. no. G8541, 
Sigma Aldrich), B27 supplements (cat. no. 12587010, Thermo Fisher Scientific), N2 
supplements (cat. no. 17502048, Thermo Fisher Scientific), 5 ng/mL insulin-like growth 
factor-1 (IGF-1, cat. no. I3769, Sigma Aldrich), 1 ng/ml Dickkopf-related protein-1 (DKK-1, 
cat. no. SRP3258, Sigma Aldrich) and 1 ng/ml Noggin (Nog, cat. no. SRP3227, Sigma Aldrich). 
EBs were then transferred to attachment culture conditions on Matrigel (cat. no. 
corn354230 VWR)-coated plates and cultivated for two weeks in PPC intermediate medium, 
consisting of DMEM/F-12 containing L-glutamine, NEAA, B27 supplements, N2 Supplements, 
10 ng/ml IGF-1, 5 ng/ml, recombinant fibroblast growth factor basic (bFGF cat. no. F0291, 
Sigma Aldrich), 10 ng/ml DKK-1 and 10 ng/ml Nog. Two weeks after the start of the 
differentiation the PPC final medium, consisting of PPC intermediate medium, with 40 ng/ml 
3,3’,5-Triiodo-L-thyronine sodium salt (T3, cat. no. T6397 Sigma Aldrich), 20 mM Taurine 
(cat. no. T0625, Sigma Aldrich), 2 ng/ml recombinant FGF acidic (aFGF, cat. no. 231-BC-025, 
R&D systems, McKinley Place, MN, USA ) and 10 µM DAPT (cat. no. D5942, Sigma Aldrich) 
was added. 
 
RNA isolation and cDNA synthesis 
All RNA isolations and cDNA synthesis were performed as follows. Total RNA was isolated by 
using the NucleoSpin® RNA Clean-up Kit (cat. no. 740955-50, Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s protocol. RNA was quantified and cDNA was 
synthesized from 1 µg of RNA by using the iScriptTM cDNA synthesis Kit (cat. no. 1708891, 
Bio-rad, Hercules, CA, USA) following the manufacturer’s instructions. 
 
70 
 
iPSC and PPC characterization by quantitative PCR (q-PCR) and immunofluorescence 
RNA isolation and cDNA synthesis were performed as described above. Primers for the q-
PCR are listed in Supplemental Table S3. q-PCR was performed with the GoTaq® Real-Time 
qPCR Master Kit (cat. no. A6002, Promega, Madison, WI, USA). Samples were processed in 
an Applied Biosystem® 7900HT FAST REAL-TIME PCR SYSTEM (Thermo Fisher Scientific). Each 
sample was assayed in triplicate and normalized against the expression of the housekeeping 
gene GUSB. Relative quantification was based on the 2-(ΔΔCt) method (Livak and Schmittgen 
2001), with fibroblasts and undifferentiated iPSCs as calibrators for the characterization of 
iPSCs and PPCs, respectively.  
For immunofluorescence, cells cultivated in slide-flasks (cat. no. 10439672, Thermo 
Fisher Scientific) were fixed for 20 min in 4% (w/v) paraformaldehyde at room temperature. 
Antigen retrieval was required for all experiments, and donkey serum (6% (v/v) in Tris 
buffered saline (TBS) and 0.5% (v/v) Triton X-100) was used during the blocking and for the 
dilution of the antibodies. Primary and secondary antibodies used for both iPSC and PPC 
characterization are listed in Supplemental Table S4. The slides were incubated with the 
primary antibody overnight at 4°C. The sections were washed three times for 5 min with TBS 
and incubated for 2 h at 37°C with the secondary antibody. This was followed by three 
further washes of 5 min in TBS and then the slides were mounted with Vectashield-
containing DAPI mounting medium (cat. no. H-1200, Vector Laboratories inc., Burlingame, 
CA, USA) and observed in a microscope Zeiss Imager Z2 (Zeiss, Oberkochen, Germany). 
Images were captured with the software “Zen Pro 2012”.  
 
ABCA4 transcript analysis 
PPCs were harvested from P1, P16, P17 and one healthy control, after 45 days of 
differentiation. Reverse transcription-PCR (RT-PCR) was performed by using a forward 
primer located in ABCA4 exon 36 (5’-CCACCTACTGGGTGACCAAC-3’) and a reverse primer 
located in ABCA4 exon 41 (5’-AACAATGGGCTCCTTAGTGG-3’). All reaction mixtures (50 μl) 
contained 10 μM of each primer pair, Taq DNA Polymerase, 1 U/μl (cat. no. 11647679001, 
Roche), 10X PCR buffer without MgCl2, 25 mM MgCl2, 10 mM dNTPs, and 50 ng cDNA. PCR 
reaction was performed by using Veriti® Thermal Cycler (Thermo Fisher Scientific) and PCR 
conditions were a first denaturation step of 94°C for 5 min followed by 35 cycles of melting 
(94°C for 30 s), annealing (58°C for 30 s), and extension (72°C for 1 min) steps, with a final 
elongation step of 72°C for 5 min. The RT-PCR products were run on a 1.5% (w/v) agarose gel 
and the resulting bands were excised and purified with the NucleoSpin®Gel & PCR cleanup 
kit (cat. no. 740609.250, Macherey-Nagel) according to the manufacturer’s protocol. Finally, 
100 ng of the purified nucleic acid was analyzed by Sanger sequencing, in a 3100 or 3730 
DNA Analyzer (Thermo Fisher Scientific). 
 
Generation of minigenes and in vitro splice assays 
To amplify two segments of the genomic region encompassing exon 39 of the ABCA4 gene, 
we designed PCR primers located in introns 38 (forward) and 40 (reverse), as described in 
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Supplemental Table S5. The primers were designed with Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0). PCR reaction mixtures (50 μl) contained 10 μM of each 
primer pair, a high-fidelity Taq polymerase AccuPrime™ Taq DNA Polymerase System (cat. 
no. 12339-016, Invitrogen, Carlsbad, CA, USA), 10X AccuPrime™ PCR buffer II, and 200 ng 
genomic DNA from P1 and a healthy control. The resulting PCR products were run on a 1% 
(w/v) agarose gel, their bands excised and the nucleic acid purified with the NucleoSpin®Gel 
& PCR cleanup kit (cat. no. 740609.250, Macherey-Nagel), according to the manufacturer’s 
protocol. 150 ng of each purified insert was cloned into the pDONR201 vector by using the 
Gateway® BP Clonase Enzyme Mix (cat. no. 11789021, Thermo Fisher Scientific).  
A plasmid containing the genomic region encompassing exons 3–5 of RHO inserted at 
the EcoRI/SalI sites in the pCI-NEO vector (Gamundi et al. 2008) was adapted to the Gateway 
cloning system and used for in vivo splicing assays. The plasmid was digested with EcoNI and 
PflMI (cat. no. R0521S, New England Biolabs, Ipswich, MA, USA), resulting in the removal of 
exon 4 and part of the flanking intronic sequences, and blunted using Large (Klenow) 
fragment DNA polymerase I (cat. no. M0210S, New England Biolabs) according to 
manufacturer’s instructions. Subsequently, a blunt-end Gateway cloning cassette containing 
attR1 and attR2 sites and the pCI-neo vector was ligated by using the Rapid DNA Ligation Kit 
(cat. no. 11635379001, Roche) in order to generate pCI-NEO-RHO exon3,5/DEST. The 
different pDONR cloned constructs were validated by Sanger sequencing and 150 ng of each 
was cloned into the destination vector pCI-NEO-RHO exon3,5/DEST by using the Gateway LR 
Clonase enzyme mix (cat. no. 11791043, Thermo Fisher Scientific). Four minigene constructs 
were generated, two with the wild-type and two with the c.5461-10T>C variant.  
HEK293T cells (ATCC® CRL-3216™) were grown in DMEM supplemented with 10% 
(v/v) Fetal calf serum (FCS, cat. no. F7524, Sigma Aldrich), 1% (v/v) Na pyruvate (cat. no. 
S8636, Sigma Aldrich) , Penicillin/streptomycin (cat. no. P4333, Sigma Aldrich). Cells were 
seeded in 12-well plates at a density of 2.5 X 105 cells/well and transfected the day after 
with 1 μg of each minigene plus FuGENE HD Transfection Reagent (cat. no. E2311, Promega) 
with a DNA (μg) /liposome (µl) ratio of 1:3, according to the manufacturer’s instructions. 
Medium was replaced after 24 hrs and cells were harvested 48 hrs post-transfection. Total 
RNA isolation and cDNA production was performed as described before. All RT-PCR reactions 
were performed as described above and PCR conditions were a first denaturation step of 
94°C for 5 min followed by 35 cycles of melting (94°C for 30 s), annealing (58°C for 30 s) and 
extension (72°C for 1 min) steps, with a final elongation step of 72°C for 5 min. The splicing 
efficiency of exons of interest was determined by RT-PCR with forward and reverse primers 
residing in exons 3 and 5 of RHO (Supplemental Table S5). The RT-PCR products were 
resolved on a 2% (w/v) agarose gel, the resulting bands were excised and the nucleic acid 
purified by using NucleoSpin®Gel & PCR cleanup (Macherey-Nagel) and Sanger sequencing 
was performed on 100 ng of each purified band, by employing the same primers used in the 
PCR reaction. 
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Results  
Clinical characteristics of patients carrying the homozygous c.5461-10T>C ABCA4 mutation 
Clinical characteristics of patients with the homozygous c.5461-10T>C variant are shown in 
Table 1. All patients presented with loss of central vision early in life, and were diagnosed 
with Stargardt disease between 6 and 14 years  of age.  On follow-up, visual acuity showed a 
sharp decline to severe visual impairment within two or three years from first complaints 
(Fig. 1), leading to legal blindness (VA 20/500 or lower) in early adulthood. Fig. 2 depicts 
fundus, fundus angiography, fundus autofluorescence and OCT images in several disease 
stages of P2, as well fundus photographs of P3 and P4 after 30 years of follow-up. 
Fundoscopy at diagnosis revealed a maculopathy in all four with perimacular lipofuscin 
deposits extending towards the mid-periphery (fundus flavimaculatus) (especially in P1 and 
P3, data not shown). Through the years the central lesions evolved into atrophy of the 
retinal layers, RPE and choriocapillaries (Figures 2G-I). In the mid-periphery RPE mottling 
occurred followed by atrophy in all four, with hyperpigmentation in P1 (data not shown) and 
P3 (Fig. 2H). 
At presentation, ERG cone responses were reduced in all four, suggesting early 
generalized cone disease. On follow-up cone dysfunction developed into progressive loss of 
cone and rod responses, leading to a non-detectable ERG in P1-P3. Colour vision defects 
varied from normal to defects in the red-green or blue-yellow axis at the first visit. Later 
colour vision disturbances became more diffuse. Goldmann perimetry performed in P1 and 
P3 revealed large central scotomas.  
 
Figure 1. Best corrected visual acuity (BCVA) in four persons with Stargardt disease with 
homozygous c.5461-10T>C ABCA4 mutation. BCVA (Snellen) was converted to equivalent 
logMAR visual acuity. LogMAR 0.5 = 20/60 Snellen, LogMAR 1.0 = 20/200 Snellen, LogMAR 
1.4 = 20/500 Snellen= Blindness (WHO criteria). Age of onset for these persons was between 
6 and 14 years; legal blindness was observed in all four patients before the age of 25. 
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Haplotype and sequence analysis 
To investigate whether four c.5461-10T>C homozygous and 11 heterozygous persons with 
STGD1 shared an identical genomic segment, we performed haplotype analysis by using 18 
SNPs located in and outside the ABCA4 gene (Supplemental Fig. S1). Eight SNPs were present 
in a homozygous state in the four c.5461-10T>C homozygotes and the corresponding 
haplotype was also found in a heterozygous state in the 11 cases carrying c.5461-10T>C. 
Therefore, we defined the minimal shared haplotype between rs548122 (g.94,565,430) and 
rs35270729 (g.94,469,543) of chromosome 1, spanning 95.9 kb. These data suggest that the 
c.5461-10C>T variant resides on a ‘founder’ haplotype spanning exons 6 to 44 of the ABCA4 
gene. To investigate further if c.5461-10T>C was the only rare variant present in the shared 
haplotype, we performed targeted next-generation sequencing of the entire ABCA4 genomic 
locus for P1, at an average depth of coverage of 62X, which did not identify additional rare 
variants. None of these variants, except c.5461-10T>C, was present at an allele frequency 
<0.01 in GoNL and ExAC, strongly suggesting that the c.5461-10T>C variant is the only rare 
variant in the shared haplotype. 
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Table 1. Clinical characteristics of patients homozygous for c.5461-10T>C 
Patient, 
gender, 
age (y) 
Age at 
diagnosis 
(y) 
Initial 
symptoms 
Age at 
diagnostic 
exam (y) 
BCVA 
(Snellen) 
Fundus Color vision Visual field Fluorescein 
angiography 
Fundus auto-
fluorescence 
ffERG 
Rod 
function 
ffERF 
 Cone 
function 
P1, M, 52 14  Decreased 
visual 
acuity 
17 
 
20/200 
 
Fundus flavimaculatus, peripapillar 
atrophy  
Red-green deficiency Relative central 
scotoma 
Dark choroid NP N 
 
Reduced 
40 
 
2/200 Central and peripheral chorioretinal 
atrophy with bone spicules 
NP Absolute  
central scotoma 
NP NP NR NR 
P2, M, 20 6  Decreased 
visual 
acuity 
6 
 
20/100 
 
No (fishtail) flecks. Hypopigmented 
juxtafoveal. 
NP NP Dark choroid NP N Reduced 
17 
 
20/600 Central to midperipheral atrophy. NP NP NP Hypo-
autofluorescent 
macula, with 
spotty hypo-
autofluorescence 
along vascular 
arcades  
NR NR 
P3, F, 43 12 Decreased 
visual 
acuity 
12 
 
20/60 Bulls’-eye maculopathy with fundus 
flavimaculatus 
Panel D15: saturated 
version: normal;  
desaturated: B-Y 
defect 
Absolute 
central 
scotoma, with 
intact periphery 
(30 yrs) 
NP NP 12 yrs: 
Mildly 
reduced 
25 yrs: 
mildly 
reduced 
12 yrs:  
Near normal;  
25 yrs: 
significantly 
reduced 
42 
 
20/1000 Large atrophic RPE lesions with 
hyperpigmentations in the 
posterior pole, hypo-and 
hyperpigmentations in the 
periphery 
NP Absolute 
central scotoma 
with intact 
periphery 
NP Central and 
peripheral large 
atrophic laesions 
NR NR 
P4, M, 46 9 Decreased 
visual 
acuity 
9 20/200 Maculopathy Panel D15: Saturated 
version: normal; 
desaturated version: 
diffusely abnormal; 
HRR mildly abnormal 
Unknown NP NP Normal Significantly 
reduced  
40 CF (-10D) Pronounced atrophy posterior pole, 
atrophic lesions periphery with RPE 
alterations 
Panel D15:  saturated 
version: diffusely 
abnormal 
NP NP NP Severely 
reduced 
NR 
 
B-Y: blue-yellow color defect, BCVA: Best corrected visual acuity, CF: counting fingers, ffERG: full-field electroretinogram, F: female, HRR: Hardy 
Rand and Rittler, M: male, NP: not performed, N: normal, NR: non-recordable, RPE: retinal pigment epithelium, y: years. 
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Figure 2. Chorioretinal images for three Stargardt patients with homozygous c.5461-10T>C 
ABCA4 mutation. Images for P2 (A-F), P3 (G,H), and P4 (I). A. Fluorescein angiography OS, at 
age 8 years. Dark choroid sign. B. Fundus photograph OS, at age 10 years. Hypopigmentated 
macula, no flecks. C. Autofluorescence OS, at age 14 years. Atrophic macula, 
hypoautofluorescence up to arcades and peripapillary. D. Optical coherence tomography OS, 
at age 14 years. Loss of retinal pigment epithelium (RPE) layer. E. Autofluorescence OS, at 
age 17 years. Atrophic macula, hypoautofluorescence up to periphery. F. Fundus photograph 
OS, at age 17 years. Central to midperipheral  atrophy. G. Autofluorescence OS, at age 42 
years. Central and peripheral large atrophic lesions. H. Fundus photograph OS, at age 42 
years. Large atrophic lesions with hyperpigmentation. I. Fundus photograph mosaic, at age 
40 years. Pronounced atrophy posterior pole, atrophic lesions and RPE alterations in the 
periphery. 
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Generation of induced pluripotent stem cells and photoreceptor progenitor cells  
Control and patient fibroblast lines were successfully reprogrammed into iPSCs. q-PCR 
analysis on all cell lines confirmed the expression of the pluripotency markers LIN28, 
NANOG, OCT3/4 and SOX2, normalized against GUSB expression (Supplemental Fig. S2), 
which was comparable between control and patient cell lines. ABCA4 was used as negative 
control. To corroborate the gene expression results we performed immunofluorescence 
staining that showed expression of OCT3/4, NANOG, SSEA4 and TRA-1-81 (Supplemental Fig. 
S3).  
Control and patient iPSC lines were successfully differentiated into photoreceptor-
like cells by a 60-day protocol in which cells cultured on Matrigel-coated dishes, were kept in 
PPC-specific medium until the end of the experiment. Samples for q-PCR were taken before 
the differentiation (iPSCs) and at one and two months of differentiation. Adult neural retina 
cDNA was used for comparison of gene expression. The expression of neural (PAX6) and 
photoreceptor progenitor (CRX and CHX10) markers in the cell line derived from P1 
increased after one month of differentiation and remained constant up to two months of the 
differentiation (Fig. 3B). In the control line the expression of the same genes was much lower 
than in the patient and after two months their expression decreased (Figures 3A,B). In both 
cell lines the expression of the blue and red/green cone (OPN1SW and OPN1M/LW, 
respectively) and rod  (RHO, NRL and RCV1) markers increased after one and two months, 
except for OPN1SW that in the control decreased in the second month (Figures 3A,B). ABCA4 
expression was very low in fibroblasts and iPSCs, and increased considerably upon 
differentiation into PPCs, where it remained constant until the second month (Supplemental 
Fig. S4). The expression of ABCA4 increased consistently in both patient-derived cell lines 
after one month of differentiation. In P1, the moderately high ABCA4 expression was 
comparable to the high CRX, CHX10 and OPN1SW expression (Fig. 3B). OPN1M/LW and RCV1 
expression was also confirmed by immunofluorescence staining (Figures 3C,D). Fig. 3E clearly 
shows the different densities of progenitor (PAX6-positive, in green) and photoreceptor 
(ABCA4-positive, in red) cells in the culture after two months of differentiation.  
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Figure 3. Retinal gene expression profiles and immunofluorescence of patient-derived 
photoreceptor progenitor cells (PPCs). Gene expression profile of A. control- and B. patient-
derived PPCs after one and two months of differentiation compared with induced 
pluripotent stem cells (iPSCs) and adult neural retina. The appearance of PPCs can be 
deduced by the increase in expression of PAX6, CRX and CHX10. The differentiation into 
photoreceptor-like cells is shown by the increased expression of ABCA4, NRL, OPN1SW, 
OPN1M/LW, RCV1 and RHO after one month of differentiation. In the control the expression 
of the genes CRX, CHX10, ABCA4 and OPN1SW increased after one month but it decreased in 
the second month of differentiation. On the other hand expression of genes for green/red 
cones (OPN1M/LW) and rods (RCV1, NRL and RHO) consistently increased in the second 
month. In the patient sample the expression remained constant during the differentiation, 
with the exception of CRX and RCV1, for which the expression decreased, and NRL, 
OPN1M/LW and RHO for which expression increased. Immunofluorescence staining of 
patient cells showed cone cells expressing OPN1M/LW (C.) and rods expressing RCV1 (D.). E. 
Co-expression of PAX6 and ABCA4 showed the different density of PPCs (PAX6-positive) and 
photoreceptor-like cells (ABCA4-positive). The dotted box represents the magnified area of 
the figures on the left side. DAPI was used to nuclear staining (blue). Scale bars 50 µm.  
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ABCA4 transcript analysis 
The five algorithms employed to assess the effect of c.5461-10T>C on splicing consistently 
predicted a very subtle weakening of the splice acceptor site of ABCA4 exon 39 
(Supplemental Fig. S5A). To investigate the role of the c.5461-10T>C variant on RNA splicing, 
we analyzed total RNA derived from 30-day differentiated PPCs of persons with STGD1 who 
carried this variant in a homozygous or heterozygous state. Since the variant is located in 
ABCA4 intron 38, we performed an RT-PCR of ABCA4 exons 36 to 41. We found the expected 
wild-type 584-bp fragment in a control PPC line, adult human neural retina, P16, carrying 
c.5461-10T>C and an unknown second ABCA4 variant, and P17, carrying c.1822T>A 
(p.Phe608Ile) and an unknown second ABCA4 allele (Fig. 4A). P1 and P16 showed bands of 
460 bp and 330 bp, which upon Sanger sequence analysis revealed deletions of exon 39 and 
of exon 39 and 40 (Fig. 4B). ABCA4 exons 39 and 40 consist of 124 and 130 nucleotides, 
respectively, and therefore the loss of exon 39 and the loss of exons 39 and 40 are predicted 
to result in shifts of the open reading frame and premature stop codons, i.e. 
p.Thr1821Valfs*13 and p.Thr1821Aspfs*6, respectively. 
 
 
 
Figure 4. The c.5461-10T>C variant results in skipping of exons 39 or of exons 39 and 40 in 
mRNA of photoreceptor progenitor cells (PPCs). A. RT-PCR of ABCA4 exons 36 to 41 shows a 
single expected 584-bp fragment in a control PPC (C), adult neural retina (R), Patient 16 
(P16), heterozygous for c.5461-10T>C and an unknown second allele, and Patient 17 (P17), 
carrying c.1822T>A (p.Phe608Ile) and an unknown second allele. Patients 1 (P1) and 16 
(P16), who carried the variant in homozygous and heterozygous states, respectively, show 
fragments of 460 bp and 330 bp, suggesting deletions of exon 39 or of exon 39 and 40 (black 
arrowheads). RT-PCR of GUSB was performed as a control. B. Sanger sequence analysis of 
the mutant fragments shows the exon 39 (upper panel) or exons 39/40 (lower panel) 
skipping events. 
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In vitro splice assays using ABCA4 minigenes 
To investigate the splicing defect observed in the PPCs in more detail, we generated two 
minigenes by PCR using control and P1 genomic DNAs, i.e. MG1 and MG2 (Fig. 5A). The 
minigenes contain exon 39 and were designated -10C for the mutant and -10T for the 
control sequences. Sanger sequencing revealed no de novo variants in these constructs due 
to the PCR-based cloning procedure. To assess whether the minigene constructs 
recapitulated the splice defects observed in PPCs and whether we could pinpoint the genetic 
defect, HEK293T were transfected with mutant and control minigenes. Both control 
minigenes MG1-10T and MG2-10T showed partial skipping of exon 39 (Figures 5B,C); the 
mutant minigenes MG2-10C and MG2-10C showed 100% skipping of ABCA4 exon 39 (Figures 
5B,C). 
 
 
Figure 5. In vitro splice studies reveal the c.5461-10T>C variant to underlie exon 39 
skipping. A. Schematic representation of the ABCA4 genomic region of Patient 1 (P1, from 
exon 38 to 41) and of the structure of the minigenes generated in this study (MG1 and 
MG2). The c.5461-10T>C variant is highlighted in the black box. The 19 additional variants in 
introns 38, 39, and 40 were found after Sanger sequence analysis (data not shown). B. RT-
PCR of RHO exons 3-5 in HEK293T cells 48 hrs post-transfection. The mutant MG1-10C and 
MG2-10C were transfected in parallel with two control minigenes (MG1-10T, and MG2-10T). 
MG1-10T and MG2-10T show fragments of ~410 bp, corresponding to normal splicing (RHO 
exon 3/ABCA4 exon 39/RHO exon 5) and a fragment of ~290 bp, corresponding to the size of 
the RHO exons spliced together without ABCA4 exon 39. The mutant minigenes MG1-10C 
and MG2-10C showed 100% skipping of ABCA4 exon 39. C. Sanger sequence analysis of the 
RT-PCR fragments confirmed the exon 39 skipping. 
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Discussion 
By employing stem cell technology and in vitro splice assays we showed that the frequent 
ABCA4 c.5461-10T>C variant is associated with exon 39 or exons 39/40 skipping, which 
results in truncated ABCA4 proteins. Haplotype and sequence analysis in 15 persons with 
STGD1 strongly suggested that this variant is part of a shared ‘founder’ haplotype spanning a 
sizeable part of the ABCA4 gene. In addition, no other rare single nucleotide variants were 
detected in this shared haplotype which could explain the observed splice defects. The 
c.5461-10T>C variant is found almost exclusively in the European population (26/33,243 
persons vs. 1/27,272 persons in non-Europeans) (Exome Aggregation Consortium (ExAC), 
Cambridge, MA; http://exac.broadinstitute.org; September 2015 accessed). Importantly, 
STGD1 or CRD patients carrying two c.5461-10T>C variants or one c.5461-10T>C variant and 
another causal ABCA4 variant are now eligible for new treatments. 
 The clinical data of four homozygotes for c.5461-10T>C corroborate that this variant 
results in the absence of ABCA4 activity, as all patients showed a young age of onset STGD1 
with rapid deterioration of central vision and progressive cone-rod loss of ERG responses 
leading to legal blindness before the age of 25 years. Moreover, in a recent study of 34 bi-
allelic ABCA4 cases with early-onset STGD1 (Lambertus et al. 2015), the c.5461-10T>C variant 
was found in 17 of 68 (25%) alleles and thereby was the most frequent ABCA4 variant. The 
second-most frequent variant in this group was c.768G>T (p.?) identified in 9/68 (13.2%) of 
alleles, which has also been deemed to have a severe effect(Maugeri et al. 1999). 
 In silico predictions indicate that the c.5461-10T>C variant had a small effect on 
splicing (Supplemental Fig. S5). A strong effect of a thymine to cytosine change in the 
thymine/cytosine stretch of splice acceptor sites on splicing however is not unprecedented, 
as shown for the VCAN c.4004-5T>C (p.?) variant, which has previously been found to result 
in exon 8 skipping in persons with autosomal dominant Wagner disease in the 
Netherlands(Mukhopadhyay et al. 2006).  
 To explain the strong effect of the c.5461-10T>C variant we checked for other 
sequence elements in or near exon 39. At position c.5461-51, the at-risk haplotype carries an 
adenine deletion, which is situated 5 nt downstream of the predicted branch point sequence 
at -56. We cannot exclude the possibility that it has a subtle effect on the strength of the 
exon 39 splice acceptor site. Likewise, other upstream variants could influence splicing. As 
depicted in Supplemental Fig. S6, significant levels of exon 39 skipping (see Fig. 5B) in 
constructs with the wild-type T nucleotide suggest that RHO exon 3-5 splicing is at least as 
efficient as RHO exon 3-ABCA4 exon 39-RHO exon 5 splicing. The splice donor site of exon 39 
is predicted to be relatively strong, but it does carry a conspicuously large number of 
alternative splice donor sites. As shown in Supplemental Fig. S5B, three additional splice 
donor sites are predicted very near the canonical splice donor site of exon 39. The presence 
of three alternative splice donor sites at the exon 39/intron 39 junction may render exon 39 
susceptible to exon skipping. None of the other 48 splice donor sites in ABCA4 carries more 
than one alternative splice donor site and only five exons (10, 15, 23, 26, 42) contain one 
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extra splice donor site residing in the last 10 nucleotides of the exons or the first 11 
nucleotides of the adjacent introns. Sanger sequence analysis of introns 38, 39, and 40 in P1 
ruled out the presence of other single nucleotide variants and deletions that could have an 
effect on splicing, but we cannot exclude the existence of other rare copy-number variants in 
and outside of the exon 38 – exon 41 region that were missed in the Sanger and Haloplex-
based sequencing. 
 The c.5461-10T>C variant was previously tested for its effect on splicing using the 
pSPL3b exon-trapping vector (Rivera et al. 2000), but no effect on splicing was observed. The 
reason may be that only 69 nt of upstream and 52 nt of downstream sequences of exon 39 
were cloned into the minigene construct. Although less plausible, it is also possible that 
there are species- or cell line-specific differences in the splicing machineries, as shown for 
other intronic mutations(Garanto et al. 2015). We employed HEK293T cells, derived from 
human embryonic kidney, whereas Rivera et al. used COS9 cells, derived from monkey 
kidney fibroblasts (Rivera et al. 2000). 
Finally, in the ABCA4 cDNA of PPCs derived from P1 we also found exon 40 to be 
spliced out from part of the mRNA. This can possibly be attributed to the order of splicing. 
Intron 39 is relatively small and possibly is spliced out at an early stage (Pulyakhina et al. 
2015). Thereby exon 39/40 skipping may be considered as a ‘bystander effect’.  
ABCA4 is a transmembrane protein situated at the rim of the photoreceptor outer 
segment discs and in the cell membranes (Sun and Nathans 1997; Molday et al. 2000). 
During in vitro iPSC differentiation into PPCs, its high peak of expression is therefore 
expected when the outer segments of photoreceptor cells are formed. It is interesting to 
note that the peak of ABCA4 expression in iPSC-differentiated PPC cultures appeared after 
one month of differentiation. The q-PCR analysis after one month of differentiation clearly 
showed the expression of genes that are typically upregulated in PPCs and cone 
photoreceptors, indicating the presence of only these two types of cells. The same analysis 
performed after two months of differentiation showed an increase of rod photoreceptor 
cells and a decrease of PPCs. These data suggest that ABCA4 is produced mainly by 
progenitor and blue cone photoreceptor cells. In the control PPCs, ABCA4 expression 
appeared to be derived from PPCs rather than photoreceptors (Fig. 3A). 
 In conclusion, we found that the frequent ABCA4 c.5461-10T>C variant results in the 
skipping of exons 39 and/or exons 39 and 40. As both splicing events result in the absence of 
significant parts of ABCA4 protein, the c.5461-10T>C variant can be considered to result in 
the absence of functional ABCA4. Accordingly, persons carrying this variant in both gene 
copies show an early age of onset form of STGD1, with a rapid progression and a poor visual 
prognosis in the second and third decades. 
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Supplemental Material 
Supplemental Tables S2-S5 were not included in this thesis and they can be found online at 
the following link: http://www.aaojournal.org/ 
 
Supplemental Methods: Patient-derived fibroblast reprogramming 
Skin biopsies from two persons with STGD1, one homozygous (P1) and one heterozygous 
(P16) for c.5461-10T>C, as well as one control, were collected, washed in PBS (cat. no. 
P5493, Sigma Aldrich, St. Louis, MO, USA), dissected with a scalpel and incubated for 1-3 h at 
37˚C in a solution of 1000 U/ml Collagenase type II (cat. no. LS004176, Worthington 
Biochemical Corporation, Lakewood, NJ, USA) and Penicillin/streptomycin (cat. no. P4333, 
Sigma Aldrich) in DMEM (cat. no. D0819, Sigma Aldrich). The digestion was then stopped by 
the addition of 20% (v/v) fetal calf serum (FCS, cat. no. F7524, Sigma Aldrich) and the cell 
suspension was incubated in a medium containing DMEM and 20% FCS for 7 days at 37˚C 
and 5% (v/v) CO2.  
After about one month, a pure culture of fibroblasts was reprogrammed as follows. 
Fibroblasts were transduced at 80% confluence with four lentiviral vectors containing the 
pluripotency genes OCT3/4, NANOG, KLF4 and c-MYC. Transduced cells were incubated for 
24 hrs at 37˚C, the lentiviruses were removed and cells washed three times with PBS. The 
following day, the transduced cells were transferred onto murine embryonic fibroblast 
(MEF)-coated plates and cultured for one month at 37˚C and 5% CO2 in a stem cell medium 
containing DMEM/Ham’s F-12 (cat. no. 1445C, Sigma Aldrich), 20% (v/v) Knock-out serum 
replacement (KOSR, cat. no. 10828-028, Thermo Fisher Scientific), MEM Non-essential amino 
acids (NEAA, cat. no. M7145, Sigma Aldrich), L-glutamine (cat. no. G8541, Sigma Aldrich), β-
mercaptoethanol (cat. no. M3148 Sigma Aldrich), β-FGF (cat. no. F0291, Sigma Aldrich). One 
month after transduction, iPSC colonies were picked and expanded on Vitronectin-coated 
plates (cat. no. A14700, Thermo Fisher Scientific) in Essential E8 medium (cat. no. A1517001, 
Thermo Fisher Scientific). 
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Supplemental Figure S1. The c.5461-10T>C variant resides on an ancestral ‘founder’ 
haplotype spanning a large part of the ABCA4 gene. Haplotype analysis was performed in 
four homozygous and 11 heterozygous persons with Stargardt disease for c.5461-10T>C. All 
the subjects were investigated for 18 single nucleotide polymorphisms (SNPs), which are 
frequent variants in the Dutch population, in and outside the ABCA4 gene. Eight SNPs were 
present in a homozygous state in the four c.5461-10T>C homozygotes and this shared 
haplotype was also found in a heterozygous state in the 11 cases heterozygous for c.5461-
10T>C, defining a minimal shared region of 95.9 kb between the SNPs rs35270729 and 
rs548122 (highlighted with black boxes). The maximum shared region, spanning 128.2 kb, 
was defined between the SNPs rs12121974 and rs4147804 (highlighted with grey boxes). 
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Supplemental Figure S2. Quantitative PCR (q-PCR) analysis of cDNA derived from induced 
pluripotent stem cells (iPSCs). The expression of the pluripotency genes LIN28, NANOG, 
OCT3/4 and SOX2 (normalized against GUSB) in iPSCs was clearly increased compared with 
the patient fibroblasts. ABCA4 was used as a negative control of the reprogramming and its 
expression remained very low during the whole experiment. 
 
 
 
 
 
 
Supplemental Figure 3. Induced pluripotent stem cells (iPSCs) show expression of 
pluripotency markers. Expression was observed for A. OCT3/4 (red) and NANOG (green), B. 
TRA-1-81 (green), C. SSEA4 (green). The dotted box represents the magnified area of the 
figures on the left side. DAPI was used for nuclear staining (blue). Scale bars 50 μm. 
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Supplemental Figure S4. ABCA4 expression levels in fibroblasts, induced pluripotent stem 
cells (iPSCs) and photoreceptor progenitor cells (PPCs). In comparison with GUSB 
(expression set at 1), ABCA4 expression is very low in fibroblasts and iPSCs and consistently 
increased after one month (PPCs 1 m) of differentiation into PPCs. The expression slightly 
decreased after two months (PPCs 2 m). 
 
Supplemental Figure S5. In silico splice predictions of the strength of ABCA4 exon 39 splice 
sites. The five algorithms employed to assess the effect on splicing are depicted in green for 
the splice acceptor site and in blue for the splice donor site. A. The predicted effect of 
c.5461-10T>C on splicing is a very subtle weakening of the canonical splice acceptor site of 
ABCA4 exon 39. B. The canonical splice donor site of ABCA4 exon 39 and three alternative 
splice donor sites (aSDS 1-3). 
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Supplemental Figure S6. In silico splice prediction of the strength of ABCA4 exon 39 splice 
sites and RHO exon 3 donor and exon 5 acceptor splice sites. The five algorithms employed 
to assess the effect on splicing are depicted in green for the splice acceptor site and in blue 
for the splice donor site. The canonical splice donor site of RHO exon 3 is predicted to be 
slightly stronger than that of exon 39; the reason might be the presence of alternative splice 
donor sites (Supplemental Figure 5B). The splice acceptor site of RHO exon 5 is not predicted 
to be stronger than that of exon 39. 
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Supplemental Table S1. ABCA4 variants in persons P1-P17 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
ID 
Allele 1  
cDNA variant 
Allele 1  
protein variant 
Allele 2  
cDNA variant 
Allele 2 
protein variant 
P1 c.5461-10T>C p.? c.5461-10T>C p.? 
P2 c.5461-10T>C p.? c.5461-10T>C p.? 
P3 c.5461-10T>C p.? c.5461-10T>C p.? 
P4 c.5461-10T>C p.? c.5461-10T>C p.? 
P5 c.5461-10T>C p.? c.768G>T p.? 
P6 c.5461-10T>C p.? c.2588G>C p.(Gly863Ala)/p.(Gly863del) 
P7 c.5461-10T>C p.? c.5882G>A p.(Gly1961Glu) 
P8 c.5461-10T>C p.? c.2588G>C p.(Gly863Ala)/p.(Gly863del) 
P9 c.5461-10T>C p.? c.[1622T>C; c.2870A>G] p.[Leu541Pro; Ala1038Val] 
P10 c.5461-10T>C p.? c.768G>T p.? 
P11 c.5461-10T>C p.? c.3703A>G p.(Asn1235Asp) 
P12 c.5461-10T>C p.? c.[1622T>C; c.2870A>G] p.[Leu541Pro; p.Ala1038Val] 
P13 c.5461-10T>C p.? c.768G>T p.? 
P14 c.5461-10T>C p.? c.768G>T p.? 
P15 c.5461-10T>C p.? c.768G>T p.? 
P16 c.5461-10T>C p.? ? ? 
P17 c.1822T>A p.(Phe608Ile) ? ? 
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Chapter 4 
 
ABCA4 midigenes reveal the full splice 
spectrum of all reported non-canonical splice 
site variants in Stargardt disease 
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Introduction 
Technological advancements have enabled the cost-effective detection of sequence 
variations in human genomes (Carss et al. 2017). Millions of single-nucleotide variants (SNVs) 
have been reported per individual, many thousands of which are rare and can be involved in 
rare monogenic disorders. Unfortunately, the enormous progress made in SNV detection has 
not been accompanied by the development of functional assays to investigate the effects of 
SNVs in a robust manner. Although it is very challenging to predict the effect of missense 
variants on protein function, characterizing putative splice variants is feasible. In the absence 
of patient cells, or if the gene of interest is not expressed in available somatic cells, in vitro 
splice assays are widely used. In these assays, small genomic fragments carrying potential 
disease-associated variants are tested for splice abnormalities. However, with the increasing 
detection of non-coding variants located within large introns, it is apparent that minigene 
assays are inadequate for testing the effects of deep-intronic variants without an intact 
genomic context, i.e., flanking exons and cis-acting elements that influence exon recognition. 
The ATP-binding cassette transporter type A4 (ABCA4) is a 128-kb gene consisting of 
50 exons and characterized by retina-specific expression (Allikmets et al. 1997). It encodes a 
multidomain transmembrane protein localized at the outer segments of photoreceptor cells 
(Sun and Nathans 1997; Molday et al. 2000). The estimated incidence of individuals with 
ABCA4-associated inherited retinal diseases is 1/10,000 (Blacharski 1988). ABCA4 variants 
have been observed in the vast majority (95%) of patients with autosomal recessive (ar) 
Stargardt disease (STGD1), ~30% of patients with ar cone-rod dystrophy (CRD) and ~5% of 
patients with ar panretinal dystrophy (Cremers et al. 1998; Maugeri et al. 1999, 2000). The 
phenotypic heterogeneity observed in individuals with ABCA4-associated retinal dystrophies 
can be explained by a genotype-phenotype correlation model, in which the residual activity 
of the mutant ABCA4 protein determines the clinical outcome. Typical STGD1 patients are 
usually characterized by a combination of a severe and a mild variant or two moderately 
severe variants, while patients affected by more severe phenotypes such as CRD and 
panretinal dystrophy carry a severe and a moderately severe variant or two severe variants, 
respectively (Cremers et al. 1998; Maugeri et al. 1999, 2000). 
In order to provide an accurate prognosis for people with ABCA4-associated disease, 
it is essential to assess the functional consequences of all variants. Thus far, functional 
studies have been limited to selected missense variants that were studied at the protein 
level (Sun et al. 2000; Suarez et al. 2002; Quazi and Molday 2013), and only a small number 
of splice site variants have been examined (Rivera et al. 2000; Shroyer et al. 2001; 
Wiszniewski et al. 2005; Schulz et al. 2017). While the high impact of protein-truncating 
ABCA4 variants (nonsense, frameshift, canonical splice site variants) is clear, the effect of 
non-canonical splice site (NCSS) variants still remains largely unknown. These are either 
exonic or intronic variants located at the splice donor sites and splice acceptor sites. Intronic 
NCSS variants at splice donor sites are mostly situated at positions +3 to +6 downstream 
from exons, while intronic NCSS variants at splice acceptor sites are located at positions −14 
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to −3 upstream of exons. Exonic ABCA4 NCSS variants can only be found within the first or 
the last two nucleotides of an exon (Cornelis et al. 2017), which agrees with in silico 
predictions (Shapiro and Senapathy 1987). 
Very recently, all published ABCA4 variants from 3928 retinal dystrophy cases were 
collected in a Leiden Open Variation Database (www.LOVD.nl/ABCA4), and an in silico 
pathogenicity assessment was provided for the 913 unique variants (Cornelis et al. 2017). 
Forty-four NCSS variants were identified that together account for 10% of all published 
ABCA4 alleles associated with STGD1 (Cornelis et al. 2017), and 41% of all ABCA4 alleles in 
patients with STGD1 from the Radboudumc in Nijmegen (N Bax, S Lambertus, FPM Cremers, 
and CB Hoyng, unpubl.). In silico programs assessing the pathogenicity of NCSS variants 
cannot always predict the effect of pre-mRNA splicing. For instance, the second most 
frequent ABCA4 variant, c.5461−10T>C, was predicted to be a mild variant, but it led to 
skipping exon 39, or exons 39 and 40, when tested in patient-derived photoreceptor 
precursor cells and a minigene assay (Sangermano et al. 2016), and in fibroblasts (Aukrust et 
al. 2017). It thereby could be classified as a severe ABCA4 variant. 
In view of the large number of NCSS variants in ABCA4 with unknown functional 
effect, we designed a protocol to prepare sizeable multi-exon ‘midigenes’ in order to test the 
consequences of all ABCA4 NCSS variants in their ‘natural context,’ resulting in a robust in 
vitro splice assay system. We generated a nearly complete library of overlapping wild-type 
midigenes from the ABCA4 gene, which allowed us to systematically assess the effect of 47 
NCSS variants on RNA splicing. 
 
Results 
A large minigene enables accurate RNA analysis of the non-canonical splice site variant 
c.5714+5G>A 
Previous genotype-phenotype studies in a large family with individuals showing 
pseudodominant ar retinitis pigmentosa (RP) due to a homozygous c.4539+1G>T ABCA4 
splice variant, or ar CRD due to compound heterozygous c.4539+1G>T and c.5714+5G>A 
ABCA4 variants, led to the hypothesis that the NCSS variant c.5714+5G>A had a moderately 
severe effect (Cremers et al. 1998). Intriguingly, HEK293T cells transfected with small wild-
type and mutant minigenes that contained only exon 40 showed partial skipping of exon 40 
for the wild-type construct and full exon 40 skipping due to the c.5714+5G>A variant (Fig. 
1A). Since our previous work (Cremers et al. 1998) and recent statistical analysis (Cornelis et 
al. 2017) suggested this variant had a moderate or mild effect on ABCA4 function, 
respectively, it seemed unlikely that the c.5714+5G>A variant would result in full exon 40 
skipping. We noticed a similar artifact while studying the effect of another NCSS variant, 
c.5461−10T>C (Sangermano et al. 2016), so we hypothesized that the rhodopsin (RHO) exon 
3 splice donor site and RHO exon 5 splice acceptor site are relatively strong (Human Splicing 
Finder scores of 87.5 and 90.7, respectively), resulting in erroneous exon 40 skipping. When 
we used larger minigenes containing exons 39 through 41, the erroneous exon 40 skipping in 
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the wild-type construct was not observed anymore, and the mutant construct showed 
normal RNA product in addition to the exon 40 skipping product (Fig. 1B), as expected for a 
moderately severe variant. 
 
 
 
 
Figure 1. Large minigene enables accurate RNA analysis of the ABCA4 non-canonical splice 
site variant c.5714+5G>A. A. Minigene containing the genomic region encompassing ABCA4 
exon 40 (MG_ex40, black rectangle) and flanked by rhodopsin (RHO) exons 3 and 5 (open 
boxes) was designed to investigate the effect of the non-canonical splice site variant 
c.5714+5G>A. Reverse-transcription polymerase chain reaction (RT-PCR) performed using 
primers (open arrowheads) targeting RHO exons 3 and 5 showed an expected 404-bp wild-
type fragment and a 274-bp fragment corresponding to exon 40 skipping (Δ) in control 
minigene (+5G) and full exon 40 skipping in mutant minigene (+5A). B. Larger minigene 
containing the genomic region encompassing ABCA4 exons 39–41 (MG_ex39–41) was 
designed to investigate the same variant. RT-PCR using primers (black arrowheads) targeting 
exons 39 and 41 showed a single 260-bp wild-type fragment in the control minigene, while in 
the mutant minigene fragments of 260 and 130 bp corresponding to wild-type and exon 40 
skipping were found. 
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Generation of ABCA4 wild-type midigene library 
In view of these results and our goal to robustly test all reported NCSS variants identified in 
ABCA4, we generated multiple-exon splice vectors using DNA from a bacterial artificial 
chromosome (BAC) clone (CH17-325O16) spanning the entire ABCA4 gene. In this way, a 
library of 29 overlapping wild-type midigenes (BA1–BA29) was generated (Fig. 2) by PCR 
amplification of fragments that were cloned in a Gateway-adapted vector containing the 
RHO exons 3, 4, and 5 (pCI-NEO-RHO) with the recombination sequences located between 
RHO exons 3 and 4 and between exons 4 and 5. The insert sizes for these constructs ranged 
from 4.0 to 11.7 kb, with, on average, three ABCA4 exons per construct. The maximal 
capacity of the vector is 12 kb. Hereafter, the pCI-NEO-RHO BA clones will be denoted as BA# 
clones. 
ABCA4 exons 1 and 50 were not contained in these clones, as they lack a splice 
acceptor and donor site, respectively. Due to difficulties in long-range PCR amplification at 
the 3′ end of the gene, we were also unable to amplify a genomic fragment containing exons 
46–49. Instead, regular minigenes were generated for exons 48 (MG30) and 49 (MG31) using 
control genomic DNA as template. The midi- and minigenes together covered ~92% of the 
128-kb ABCA4 gene and 48 out of 50 exons (Fig. 2). 
In all constructs, each ABCA4 exon was flanked by at least one upstream and one 
downstream ABCA4 exon, with the exception of BA1, BA4, BA6, BA8, BA10, BA29, MG30, 
and MG31. For constructs BA4, BA6, BA8, and BA10, the limitation was due to the large sizes 
of intron 6 (15.4 kb) and 11 (14.4 kb). BA5 and BA9 did not contain any exon, as they were 
generated to cover the middle parts of introns 6 and 11, respectively. 
Sequence analysis of the wild-type BA clones revealed many polymorphisms but no 
deleterious variants due to the PCR amplification of the insert when compared to the human 
genome reference GRCh37/hg19 assembly. Nevertheless, despite the use of a proofreading 
high-fidelity DNA polymerase, we found minor sequence variations (Supplemental Table S1). 
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Figure 2. Overview of the wild-type midigene splice constructs of ABCA4 and locations of 
all 47 non-canonical splice site variants. Exons are represented here as black rectangles. 
Employing bacterial artificial chromosome DNA and Gateway sequence-tagged primers, we 
amplified 29 genomic fragments and cloned these into the pCI-NEO-RHO Gateway-adapted 
vector (BA1–BA29). Genomic DNA from control persons (MG30 and MG31) and a patient 
carrying c.6729+5_6729+19del (MG30) were used to clone wild-type and mutant fragments. 
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Selection of ABCA4 non-canonical splice site variants 
The list of the 47 analyzed NCSS variants, their allelic frequencies, and predicted effect on 
splicing can be found in Supplemental Table S2. The majority of these variants (70%, n = 33) 
are located in non-coding elements; 30% (n = 14) are located in coding regions. Highly 
mutated intronic positions at the splice donor site were at the +5 (n = 12) and +3 (n = 6) 
positions. We did not observe significant “hotspots” at the splice acceptor site, although 
positions −3 and −10 were most frequently mutated (n = 3 each). 
 
Generation of mutant midigenes 
Eighteen BA clones were used to insert 46 NCSS variants (Fig. 2; Supplemental Fig. S1). 
Fifteen clones carry at least two flanking ABCA4 exons surrounding the tested NCSS variant, 
thereby allowing RT-PCR using ABCA4 primers instead of RHO primers. For three variants, 
this was not possible. c.160+5G>C and c.5312+3A>T were analyzed using a combination of a 
RHO exon 3 forward primer with ABCA4 exons 4 or 40 reverse primers, respectively. As 
c.768G>T resided in BA4, RT-PCR could only be performed using RHO exons 3 and 5 primers. 
Eleven BA clones and MG31 were not used for mutagenesis purposes in this study. 
For variant c.6729+5_+19del, we did not perform mutagenesis as the wild-type and mutant 
minigenes were made using genomic DNA from a patient carrying this variant in a 
heterozygous manner. 
 
Splice defects due to non-canonical splice site variants 
We provided experimental evidence of splice defects for 44 out of 47 NCSS variants. For the 
RT-PCR control, cDNA from 18 wild-type BA clones was used (Fig. 2). Upon RT-PCR, 15 wild-
type BA clones showed a single band corresponding to the expected splicing pattern, 
whereas BA1, BA12, and BA26 showed extra bands corresponding to alternative splice 
products (Supplemental Fig. S2). A comprehensive overview of all the splice assays for the 47 
NCSS variants described in this study, as well as their sequencing analysis, can be found in 
Supplemental Figures S2 and S3. Representative results for nine variants are described 
below (Fig. 3; Supplemental Fig. S3). 
Variants c.160+5G>C, c.161G>T, c.302+4A>G, and c.303−3C>G were located in or 
near exons 2 and 4 and were introduced in BA1 (Figs. 2, 3A–F). Variant c.160+5G>C was 
predicted to significantly reduce the strength of the exon 2 splice donor site and likely cause 
exon skipping (Supplemental Table S2). RT-PCR using a primer at the 5′ side of exon 2 
therefore was not useful. Hence, we used primers in RHO exon 3 and ABCA4 exon 4. The 
wild-type BA1 showed two main bands of 399 and 271 bp. Sanger sequence analysis showed 
that these were the expected mRNA fragment and a fragment in which exon 3 was skipped, 
respectively (Fig. 3A,B). c.160+5G>C showed a complex splicing pattern, i.e., correct and 
three main aberrant splice products, that after pGEM-T cloning and Sanger sequencing 
revealed bands of 305, 285, and 271 bp, which represented the skipping of exon 2, a 14-nt 
elongation of exon 2 along with skipping of exon 3, and skipping of exon 3, respectively (Fig. 
3A–C). Exon 2 elongation can be explained by the presence of a cryptic splice donor site 14-
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nt downstream from the actual splice site. The cryptic donor site is not shown in Figure 3C as 
it can only be seen in the genomic DNA sequence. RT-PCR spanning ABCA4 exons 2–4 
showed a wild-type 289-bp band for BA1. The introduction of variants c.161G>T and 
c.302+4A>C both showed a unique 147-bp band corresponding to skipping of exon 3, while 
c.303−3C>G showed two bands of 291 and 149 bp, corresponding to a dinucleotide 
elongation of exon 4 and to the same elongation along with the skipping of exon 3, 
respectively (Fig. 3D–F). The exon 4 elongation can be explained by the creation of a cryptic 
splice acceptor site due to the C>G change. The cryptic acceptor site is not shown in Figure 
3F as it can only be seen in the genomic DNA sequence. The skipping of exon 3 in the wild-
type BA1 clone probably was not an artifact, as we also observed exon 3 skipping in human 
retina RNA (Supplemental Fig. S2, BA1, panel C). 
Variant c.768G>T is the second most frequent NCSS variant (allele frequency 0.106) in 
STGD1 cases in the Radboudumc, Nijmegen (N Bax, S Lambertus, FPM Cremers, and CB 
Hoyng, unpubl.). Splice predictions showed a significant weakening of the exon 6 splice 
donor site (Fig. 3I). For the wild-type and c.768G>T mutant BA4 clone, RT-PCR encompassing 
RHO exons 3 and 5 was performed, which yielded a wild-type band of 472 bp for BA4 and a 
35-nt elongation of exon 6 for c.768G>T (Fig. 3G,H), explained by the presence of a cryptic 
splice donor site 36-nt downstream (Fig. 3I). The reading frame shift results in a predicted 
truncated protein, p.(Leu257Valfs*17). To validate this result ‘ex vivo’, we generated 
photoreceptor precursor cells (PPCs) from somatic cells of a STGD1 patient carrying 
c.768G>T in a homozygous state. RT-PCR analysis of RNA from this patient and of normal 
human retina are shown in Supplemental Figure S4. The PPC results are identical to those 
observed in the in vitro splice assay in HEK293T cells. 
The novel variant c.1937+13T>G was not predicted to result in a splicing defect (Fig. 
3L), but surprisingly, in 86% of mRNA products, a 12-nt elongation of exon 13 was observed 
for BA11 carrying c.1937+13T>G (Fig. 3J,K). This led to a premature stop codon, resulting in 
p.(Phe647*) (Fig. 3L). 
For exon 30, the penultimate nucleotide substitutions c.4538A>G and c.4538A>C 
were introduced into BA20, and HEK293T cell transfection resulted in four fragments after 
pGEM-T cloning (Fig. 3M). In addition to the correct mRNA (fragment 1), a 30-nt elongation 
due to the presence of a strong cryptic intronic splice donor site (fragment 2, Fig. 3M,O), a 
deletion of 73 nt from the 3′ end of exon 30 (fragment 3, Fig. 3N), and a 30-nt elongation in 
combination with a 114-nt deletion from the 5′ end of exon 30 (fragment 4, Supplemental 
Figs. S2, S3) were found. Fragments 3 (227 bp) and 4 (216 bp) could not be resolved. The 
exon 30 deletions were the result of partially overlapping cryptic splice donor and acceptor 
sites, the non-canonical sequences (AG/GT) of which reside at exonic positions c.4465–4468 
(Supplemental Fig. S2, BA20, panel D). 
Six fragments were observed for c.5898+5del introduced in BA27, but we were only 
able to sequence three after pGEM-T cloning: bands of 717 and 780 bp corresponded to 107-
nt and 170-nt elongations of exon 42 due to the use of cryptic splice donor sites at positions 
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c.5898+108 and +171, respectively, while a 1104-bp fragment corresponded to the entire 
retention of intron 42 (Fig. 3P,Q). 
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Figure 3. Overview of splice defects due to nine non-canonical splice site variants in 
ABCA4. All wild-type and mutant midigenes were transfected in HEK293T cells and their RNA 
subjected to RT-PCR. (A,B) RT-PCR for wild-type and c.160+5G>C mutant BA1 midigene 
showed complex splicing defects when using primers in RHO exon 3 and ABCA4 exon 4. Five 
defects (fragments 2 through 6) were observed next to the wild-type fragment 1. Asterisks 
denote fragments for which we obtained no sequence information. The RT-PCR products 
showed skipping of exon 2, exon 3, or exons 2 and 3. C. Sequencing of pGEM-T-cloned 
fragment 4 revealed a 14-nt insertion due to the activation of a cryptic splice donor site in 
intron 2 and the absence of exon 3. The triangle points to the +5G>C variant. (D,E) RT-PCR 
products of wild-type and mutant BA1 containing NCSS variants residing at splice sites of 
exons 3 and 4. Primers in ABCA4 exons 2 and 4 reveal exon 3 skipping and/or exon 4 
elongation. Note that the wild-type vector BA1 shows exon 3 skipping (fragment 5), which is 
more pronounced when using a forward RHO exon 3 primer (A) compared to using a forward 
ABCA4 exon 2 primer (D). F. Sanger sequence of gel-purified fragment 3 shows a 2-nt 
elongation at the 3′ end of exon 4 due to the activation of a cryptic splice acceptor site in 
intron 3. Sanger sequencing results for all fragments without an asterisk are provided in 
Supplemental Figure S3. (G,H) RT-PCR and Sanger sequencing of RNA extracted from 
c.768G>T mutant BA4 midigene showed a 35-nt exon 6 elongation. I. Human Splice Finder 
(HSF) splice site scores (blue arrowheads) for wild-type and mutant sites. (J,K) RT-PCR, gel 
analysis, and Sanger sequencing showed the wild-type product and a 12-nt exon 13 
elongation due to c.1937+13T>G. M and WT denote mutant and wild-type splice products. L. 
Details of the exon elongation defect. As represented by the HSF prediction software, the 
scores of the normal and intronic splice donor sites (SDSs) are not changed due to this 
variant. Most of the RT-PCR product consists of the exon elongation which introduces a 
premature stop codon. (M–O) Variants at the penultimate position of exon 30 (c.4538A>G 
and c.4538A>C) resulted in a correct mRNA (fragment 1), a 30-nt exon 30 elongation due to 
the presence of a strong cryptic intronic splice donor site (fragment 2), a deletion of 73 nt of 
the 3′ end of exon 30 (fragment 3), and a 30-nt exon 30 elongation in combination with a 
114-nt deletion of the 5′ end of exon 30 (fragment 4). Fragments 3 (227 bp) and 4 (216 bp) 
could not be resolved. The exon 30 deletions are the result of a cryptic splice donor and 
acceptor sites that overlap at exonic positions c.4465–4468 (Supplemental Fig. S2, BA20). P. 
RT-PCR of BA27 carrying the c.5898+5del variant resulted in at least two exon 42 elongation 
products of 717 and 780 bp, as well as intron 42 retention. Q. The exon elongation products 
were due to the reduction of the strength of the exon 42 splice donor site, as shown with 
red numbers, in combination with the presence of nearby cryptic intronic splice donor sites 
with strong predicted scores. Only HSF and SpliceSiteFinder (SSF)-like scores are provided. 
Note that SSF-like is the only software that predicts the rare splice donor sites (positions 
c.5898+108 and c.5899−23) that contain the canonical GC sequence instead of GU. Intron 42 
retention likely is due to the very strong splice donor site (HSF 98.0) flanking exon 43. The 
open arrowhead denotes the 1-bp deletion. 
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Classification of non-canonical splice site variants according to the splice defects 
The percentage of correctly spliced ABCA4 RNA product for NCSS variants was calculated by 
using a capillary electrophoresis system (Fig. 4; Supplemental Table S3; Supplemental Fig. 
S5). Three variants, c.4634G>A, c.5196+3_5196+8del, and c.5585−10T>C, showed 100% 
correctly spliced ABCA4 mRNAs. We could rule out pathogenicity for the last two variants 
but not for c.4634G>A p.(Ser1545Asn), as this variant is significantly enriched in >3000 
Caucasian STGD1 patients compared to the non-Finnish ExAC population (Cornelis et al. 
2017). Sixteen variants showed between 4.3% and 79.6% normal RNA and were tentatively 
classified as severe, moderately severe, and mild, while the remaining 26 NCSS variants did 
not show any normal RNA and were thus deemed severe variants. For c.2382+5G>C and 
c.2588G>C, no quantification was performed as the wild-type BA12 clone also showed exon 
skipping. Based on the Sanger sequence validation, we were able to annotate all the variants 
at the RNA level and predict their effect at the protein level (Table 1). 
We correlated the predicted effect of the NCSS variants with the phenotypes in 
reported cases and, when the variants were not present in a homozygous state, with the 
severity of the second allele. For 25 of 47 variants, sufficient clinical data were available, and 
in all these cases, our predicted effect of the NCSS variants correlated with the observed 
phenotypes (Supplemental Table S4). 
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Figure 4. Percentages of remaining normal ABCA4 transcripts due to non-canonical splice 
site variants based on capillary electrophoresis system analyses. The percentages of normal 
ABCA4 transcript for 45 non-canonical splice site variants are represented by black bars. 
Nineteen variants showed varying fractions (4.3%–100%) of correct ABCA4 mRNA. Four of 
them also result in missense changes as depicted, but only p.(Ser1545Asn) and 
p.(Lys2160Glu) are likely to have an effect on protein function, as significant amounts of 
ABCA4 protein will be produced. For the remaining 26 variants (in the square box), no 
residual RNA was observed. (#) For this variant, densitometric scanning was performed. 
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Table 1. In vitro tested non-canonical splice site variants and their observed RNA and predicted protein effects  
DNA variant RNA effect Protein effect % correctly 
spliced mRNA 
Classification based 
on RNA splice study 
c.160+5G>C r.[=, 67_160del, 161_302delins(14)] p.[=, Ile23Alafs*24, His55Asnfs*63] 34,3 Moderate 
c.161G>T r.161_302del p.(Cys54Serfs*14)  0 Severe 
c.302+4A>C r.161_302del p.(Cys54Serfs*14) 0 Severe 
c.303-3C>G r.[161_302delinsag, 302_303insag] p.[Cys54*, Leu102Alafs*14]  0 Severe 
c.768G>T r.768_769ins(35) p.(Leu257Valfs*17) 0 Severe 
c.859-9T>C   r.[=, 859_1356del] p.[=, Phe287_Arg452del] 75,7 Mild 
c.1100-6T>A r.1099_1100insgcag p.(Thr367Serfs*6)  0 Severe 
c.1937+13T>G r.[1937_1938ins(12), =] p.[Phe647*, =]  14# Severe 
c.2382+5G>C* r.[=, 2161_2382del] p.[=, His721_Val794del] 47,9# Moderate 
c.2588G>C* r.[2588g>c, 2588_2590delcag] p.[Gly863Ala, Gly863del] 60# Mild 
c.2919-10T>C  r.[=, 2919_3050del] p.[=, Leu973_His1017delinsPhe] 61,1 Moderate 
c.2919-6C>A r.[=, 2919_3050del] p.[=, Leu973_His1017delinsPhe] 79,6 Mild 
c.3050+5G>A  r.2919_3050del p.(Leu973_His1017delinsPhe) 0 Severe 
c.3522+5del r.[=, 3329_3522del]  p.[=, Arg1111Aspfs*7] 53,0 Moderate 
c.3607G>A r.3523_3607del p.(Thr1176Metfs*2) 10,9 Severe 
c.3607+3A>T r.3523_3607del p.(Thr1176Metfs*2) 0 Severe 
c.3812A>G r.3608_3813del p.(Gly1203Aspfs*10) 0 Severe 
c.3813G>C  r.3608_3813del p.(Gly1203Aspfs*10)  0 Severe 
c.3862+3A>G r.[=, 3814_3862del] p.[=, Ile1272Valfs*101] 53,4 Moderate 
c.4128G>A r.4128_4129ins(12) p.(Gln1376_Ile1377ins4)  0 Severe 
c.4253+4C>T r.4129_4253del p.(Ile1377Hisfs*3) 7,8 Severe 
c.4253+5G>A r.4129_4253del p.(Ile1377Hisfs*3) 0 Severe 
c.4253+5G>T r.[4129_4253del, =] p.[Ile1377Hisfs*3, =] 5,4 Severe 
c.4538A>G  r.[4539_4540ins(30), 4467_4539del] p.[Arg1513_Arg1514ins10, Cys1490Glufs*12] 0$ Severe 
c.4538A>C  r.[4539_4540ins(30), 4467_4539del, 4538a>c] p.[Pro1513_Arg1514ins10, Cys1490Glufs*12, Gln1513Pro] 4,3$ Severe 
c.4634G>A r.4634g>a p.(Ser1545Asn) 100 Benign 
c.4667G>C  r.4635_4667del p.(Ser1545_Gln1555del) 0 Severe 
c.4773G>C  r.[4668_5018del, 4668_4773del] p.[Tyr1557_Val1673del, Tyr1557Alafs*18] 0 Severe 
c.4773+3A>G  r.[4668_4773del, =] p.[Tyr1557Alafs*18, =] 24,6 Severe 
c.4773+5G>A  r.[4668_4773del, =, 4668_5018del] p.[Tyr1557Alafs*18, =,  Tyr1557_Val1673del] 29,1 Severe 
c.5196+3_5196+6del r.4849_5196del p.(Val1617_Ile1732del) 0 Severe 
c.5196+3_5196+8del r.= p.(=) 100 Benign 
c.5312+3A>T r.5197_5312del p.(Asn1734Glyfs*14) 0 Severe 
c.5313-3C>G r.5312_5313insag p.(Trp1772Aspfs*7) 0 Severe 
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The nomenclature of all variants is according to the Human Genome Variation Society recommendations for the description of the sequence 
variants. Complex effects at both the RNA and protein levels were included between square brackets. The products were listed according to 
their abundance based on capillary electrophoresis-based analysis (Supplemental Table S3). For variants c.2382+5G>C and c.2588G>C, 
nomenclature does not include the skipping of ABCA4 exon 15 (*). The c.2588G>C variant previously was classified as a mild allele (Maugeri et 
al. 1999). For variants c.1937+13T>G and c.2382+5G>C, the percentage of correctly spliced mRNA was determined by densitometry, and for 
variant c.2588G>C by direct analysis of Sanger sequence traces (#). For variants c.4538A>C and c.4538A>G, the percentage of correctly spliced 
mRNA was not entirely determined due to likely comigrating gel fragments of similar size ($). (=) Wild-type. 
c.5460+5G>A r.5313_5460del p.(Trp1772Argfs*9) 0 Severe 
c.5461-10T>C r.5461_5714del p.(Thr1821Aspfs*6) 0 Severe 
c.5461-8T>G  r.5461_5714del p.(Thr1821Aspfs*6) 0 Severe 
c.5584G>C  r.5461_5714del p.(Thr1821Aspfs*6) 0 Severe 
c.5584+5G>A r.[5461_5714del, 5461_5584del] p.[Thr1821Aspfs*6, Thr1821Valfs*13] 0 Severe 
c.5584+6T>C r.[5461_5714del, 5461_5584del] p.[Thr1821Aspfs*6, Thr1821Valfs*13, Glu1863Leufs*33] 0 Severe 
c.5585-10T>C r.= p.(=) 100 Benign 
c.5714+5G>A r.[=, 5585_5714del] p.[=, Glu1863Leufs*33] 39,8 Moderate 
c.5836-3C>A r.5835_5836ins(30) p.(Lys1945_Ile1946Pheins10)  0 Severe 
c.5898+5del r.[5898_5899ins(494), 5898_5899ins(170)] p.(Cys1967Valfs*24) 4,5 Severe 
c.6478A>G r.[6478a>g, 6387_6479del] p.[Lys2160Glu, Ser2129_Lys2160delinsArg] 55,2 Moderate 
c.6479+4A>G r.6387_6479del p.(Ser2129_Lys2160delinsArg) 0 Severe 
c.6729+5_6729+19del r.6480_6729del p.(Phe2161Cysfs*3) 0 Severe 
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Discussion 
Splice site variants cause 15%–20% of human genetic disease (Matlin et al. 2005), and an 
increasing number of deep-intronic variants have been identified through targeted gene 
sequencing and whole-genome sequencing (www.dbass.soton.ac.uk) (Buratti et al. 2011; 
Carss et al. 2017). Contrary to canonical splice site variants, which in about two-thirds of 
cases result in exon skipping (Cheung et al. 2017), the effect of NCSS variants can vary 
tremendously, depending on the sequence alteration itself and its sequence environment. In 
recent studies, large-scale analyses of variants in or near consensus splice site sequences 
were performed using minigene constructs containing small exons flanked by minimal 
intronic sequences (Cheung et al. 2017). The maximum insert size of the tested genomic 
segments measured 170 bp, as the analysis of spliced sequences was performed by short-
read next-generation sequencing. Although this type of study enabled high-throughput 
analysis of randomly designed splice site sequences (Rosenberg et al. 2015) or naturally 
occurring NCSS variants (Cheung et al. 2017), the size constraint of the employed constructs 
represents a major limitation to fully assess the effect of NCSS variants. As shown here, it is 
important to study NCSS variants in the context of their upstream or downstream introns 
and exons, as their effect often is influenced by other intronic cis-regulatory elements or 
affects exons located at considerable distances. 
We have performed a systematic in vitro analysis of all reported and three novel 
NCSS variants in ABCA4 that are associated with STGD1 by generating midigenes: large, 
multiple-exon splice vectors. Forty-four of 47 variants resulted in splicing defects. The most 
frequently observed defect, seen in 29 (62%) of the NCSS variants, was single or multiple-
exon skipping. For eight (17%) variants, we observed the simultaneous occurrence of 
different splice defects, e.g., exon skipping/elongation, skipping/retention, 
elongation/retention and truncation/elongation. Six NCSS variants (13%) resulted in exon 
elongation. 
The majority of NCSS variants (n = 35; 75%) affected the splice donor site. This 
concurs with the observation that the majority (65%) of pseudoexon mRNA insertions 
associated with human diseases also concern the activation of splice donor sites 
(www.dbass.soton.ac.uk) (Buratti et al. 2011). The longer intronic consensus sequences of 
splice acceptor sites (−3 to −14 for splice acceptor site vs. +3 to +6 for splice donor site) in 
which pyrimidine to pyrimidine substitutions have relatively little effect on the predicted 
splice strengths, may explain why variants that affect the splice acceptor site are generally 
less disruptive. The severe NCSS defect previously shown for c.5461−10T>C (exon 39 or exon 
39 and 40 skipping) (Sangermano et al. 2016) prompted us to investigate the effect of two 
similar rare variants, i.e. c.2919−10T>C and c.5585−10T>C. We found that c.2919−10T>C 
resulted in exon skipping in 39% of the ABCA4 transcripts, while c.5585−10T>C showed no 
splice defects. The predicted reductions of the corresponding splice acceptor site splice 
scores all were minor. These contrasting results suggest that the effect of a NCSS variant also 
depends on the sequence context, e.g., the strengths of nearby splice acceptor and donor 
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sites, the size of the flanking exons, and possibly exonic and intronic splice enhancer (ESE, 
ISE) and silencer motifs (ESS, ISS). 
The effect of still unknown sequence motifs on splicing is also illustrated by our 
findings for c.1937+13T>G. This is not a typical NCSS variant as it is located downstream from 
the exon 13 splice donor site consensus sequence. As illustrated in Figure 3, J through L, this 
change does not lower the strength of the normal exon 13 splice donor site, nor does it 
create a stronger predicted downstream splice donor site. Nevertheless, it resulted in a 12-
nt elongation of exon 13 and introduced a premature stop codon in 86% of the transcripts, 
based on Sanger sequencing. The Alamut ESEfinder did not predict this variant to create a 
splice enhancer (Cartegni et al. 2003; Smith et al. 2006). Follow-up studies are required to 
investigate the nature of this apparently unknown sequence motif that influences splicing. 
Importantly, this result also illustrates that the assessment of rare non-coding variants 
identified in diagnostic testing cannot fully rely on in silico predictions. 
The generation of multiple-exon splice constructs in which most of the introduced 
NCSS variants were flanked by one or more upstream and downstream exons allowed us to 
investigate the full spectrum of splice defects. This is illustrated by two +5delG variants, 
c.3522+5del in Supplemental Figure S2 and c.5898+5del in Figure 3, P and Q, which not only 
showed multiple exon elongation but also retention of introns 23 and 42, respectively. The 
exon elongations could be explained by similarities shared by both introns, as they both 
carry multiple strong cryptic splice donor sites, small downstream introns (intron 23, 1081 
bp; intron 42, 494 bp), and strong splice donor sites located at the 3′end of the following 
exon. The importance of the presence of the sequence context was also found for NF1 as the 
extent of exons 36 and 37 skipping due to a variant in exon 37 was determined by the 
presence of exons 34–38 in the splice construct (Baralle et al. 2006). 
The observation that NCSS variants with an effect on RNA splicing resulted in a maximum of 
79.6% of normal RNA leads us to believe that there may be a threshold for alleles to behave 
as ‘mild’ alleles. In our experiments, that threshold is ~80% (Fig. 4). In cases where there is 
more than 80% normal RNA, the variants will likely be benign and will not contribute to the 
phenotype in patients with STGD1. Similarly, there likely are thresholds for moderately 
severe and severe alleles. However, as the clinical data of patients carrying NCSS variants 
were not described consistently, we could not accurately assign these thresholds. A similar 
threshold model was recently described for the remaining normal CEP290 protein in patients 
with Leber congenital amaurosis and various syndromic phenotypes, as a result of different 
combinations of coding and deep-intronic variants (Drivas et al. 2015). 
The 29 BA constructs contain large (4.0–11.7 kb) segments of ABCA4. We could not 
clone genomic fragments larger than 11.7 kb due to the size constraint (12 kb) of the 
Gateway cloning system. We therefore cloned introns 6 and 11 in different overlapping 
fragments and performed transcript analysis using RHO primers. Constructs containing the 
first and last exon were not generated as they lack a splice acceptor and donor site, 
respectively. A difficult region to amplify was the 3′ part of the gene encompassing intron 
48–exon 50. The absence of both flanking ABCA4 exons triggered splicing artifacts due to the 
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presence of a strong RHO splice donor and acceptor site, as we observed erroneous exon 
skipping in MG_ex40 (Fig. 1). 
Natural skipping of ABCA4 exons 3, 15, and 39/40 was observed by others (Braun et 
al. 2013) and by us (Supplemental Fig. S2), suggesting that the midigenes mimic the in vivo 
situation. An accurate comparison of the skipping events for exons 3 and 39/40 between 
wild-type midigene and human retina is not possible, as they result in frameshifts and the 
corresponding mRNAs are subject to nonsense-mediated decay in the human retina. 
Validating multiple splice products can be time-consuming as gel-purification and 
Sanger sequencing are hampered by contaminations from other fragments, thus requiring 
plasmid cloning and additional Sanger sequencing. A more general drawback of the in vitro 
splice assay is that, despite the observed splicing similarities between wild-type BA clones 
and human retina, splicing in HEK293T cells may not always mimic the splice defects as they 
might occur in the retina of patients. Other studies have indicated that indeed there are 
retina-specific splice factors (Murphy et al. 2016; Parfitt et al. 2016). 
The use of bacterial artificial chromosome clones facilitated the generation of large, 
multiple-exon wild-type splice vectors. In an alternative approach, a 5.6-kb BRCA1 minigene 
was constructed by cloning six consecutive fragments carrying exons 19–27 that, in the 
human genome, span 28.7 kb (Acedo et al. 2015). Our approach can readily be applied to 
generate midigenes from all human genes, as BAC clones are available for this purpose 
(https://bacpacresources.org/) (Osoegawa and de Jong 2004). These wild-type midigenes 
not only allow the accurate assessment of large splice defects due to NCSS variants but can 
also be used to test deep-intronic variants hypothesized to result in pseudoexon insertions 
(R Sangermano, A Garanto, M Khan, RWJ Collin, and FPM Cremers, unpubl.). 
We observed sizeable exon elongations in significantly occurring RNA products due to 
c.160+5G>C, c.768G>T, c.1937+13T>G, c.4538A>G, and c.4538A>C variants. Splice 
modulation using antisense oligonucleotides (AONs) may be an option to redirect the 
splicing back to the natural splice sites. AONs have already demonstrated their therapeutic 
potential for several eye disease-associated genes, such as CEP290 (Collin et al. 2012; Gerard 
et al. 2012; Garanto et al. 2016; Parfitt et al. 2016), USH2A (Slijkerman et al. 2016), or OPA1 
(Bonifert et al. 2016), and have a great potential as therapeutic molecules for inherited 
retinal diseases. 
In conclusion, we generated a complete set of sizeable wild-type ABCA4 splice vectors, which 
allowed us to gain insight into the severity of the poorly explored class of NCSS ABCA4 
variants on a gene-wide scale. By assessing the functional consequences of putative splice 
defects, STGD1 patients can obtain a more accurate molecular diagnosis and thereby 
become eligible for novel therapies. Our approach can be used for all human genes to 
effectively test putative splice defects. Besides from NCSS variants, midigenes are also 
especially suited for testing rare deep-intronic variants and their effect on splicing in a 
reliable manner, as 90% of introns are <11 kb (Sakharkar et al. 2004) and thereby completely 
fit into midigenes, together with all cis-acting splice factor binding motifs and flanked by 
their natural exons. 
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Methods 
STGD1 patients 
Patient 1 is a 40-yr-old female who was diagnosed with typical STGD1 at the age of 16. 
Sanger sequence analysis of all 50 ABCA4 exons and a MLPA analysis (MRC Holland P151 and 
P152) revealed heterozygous variants identified as two non-canonical splice site variants, the 
previously described c.859−9T>C and the novel c.303−3C>G. Patient 2 is a 37-yr-old male 
with STGD1 who was diagnosed at the age of 35 but had been suffering from reduced visual 
acuity since the age of 22. Sanger sequence analysis of all 50 ABCA4 exons revealed the 
coding variant c.70C>T [p.(Arg24Cys)] and a novel intronic variant 13-bp downstream from 
exon 13 (c.1937+13T>G). Patient 3 is a 53-yr-old female with STGD1 who was diagnosed at 
the age of 49. Sanger sequence analysis of all 50 ABCA4 exons revealed a novel homozygous 
c.5461−8T>G variant. All three patients display extensive areas of retinal pigment epithelium 
atrophy throughout the posterior pole, extending beyond the vascular arcades. On 
electroretinography, the cone and rod responses were significantly and equally reduced in 
patients 2 and 3 at the age of diagnosis. 
 
Generation of wild-type and mutant minigenes for exons 39–41, 40, 48, and 49 
Wild-type minigenes for exons 39–41, 40, 48, and 49 were generated by amplifying genomic 
DNA encompassing these exons from genomic DNA of an anonymous control person. 
Mutant minigenes for c.5714+5G>A and c.6729+5_+19del variants were generated by 
amplifying these regions from the genomic DNA of two patients carrying these ABCA4 
variants. Primer details can be found in Supplemental Tables S5 and S6. Minigenes were 
generated according to a previously described protocol (Sangermano et al. 2016). 
 
Generation of ABCA4 wild-type midigene library 
The BACPAC Resource Center (BPRC) at the Children’s Hospital Oakland Research Institute 
(Oakland, CA) provided the bacterial artificial chromosome clone, CH17-325O16 (insert 
g.94,434,639–94,670,492), containing the entire ABCA4 gene. Using NucleoBond Xtra Midi 
EF (cat. no. 740420.250, Macherey-Nagel), BAC DNA was isolated and used as a template to 
generate large wild-type ABCA4 fragments by PCR. PCR primers were designed using Primer3 
software (http://bioinfo.ut.ee/primer3-0.4.0) and their specificity verified by using Human 
BLAT searches (https://genome.ucsc.edu/cgi-bin/hgBlat) (Kent 2002; Supplemental Table 
S6). PCR reaction mixtures (50 μL) contained 0.5 μM of each forward and reverse primer, 0.2 
mM dNTPs, Phusion High-Fidelity DNA Polymerase (cat. no. M0530L, New England Biolabs), 
1× Phusion GC Buffer, 3% DMSO, and 2.5 ng BAC DNA. PCR reaction was performed by using 
the Veriti Thermal Cycler (Thermo Fisher Scientific). All PCRs were performed using the 
following thermocycling conditions: initial denaturation at 98°C for 30 sec; 15–20 cycles of 
denaturation at 98°C for 10 sec each, annealing at 57°C, and extension at 72°C (1 min/kb); 
with a final extension at 72°C for 15 min. The PCR-amplified products were analyzed on a 
0.6% (w/v) agarose gel. Amplified bands were excised, and the NucleoSpin Gel and PCR 
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cleanup kit (cat. no. 740609.250, Macherey-Nagel) was used to purify the DNA fragments, 
according to the manufacturer’s protocol.  
Two hundred nanograms of each purified fragment were cloned into the pDONR201 
vector (Invitrogen) by using the Gateway BP Clonase Enzyme Mix (cat. no. 11789021, 
Thermo Fisher Scientific). The generated wild-type entry clones (denoted Bacterial Artificial 
Chromosome ABCA4 [BA] clones) were digested with restriction enzymes and validated by 
Sanger sequencing (Supplemental Table S7), and each BA entry clone was transferred into 
the Gateway-adapted destination vector pCI-NEO-RHO as previously described (Sangermano 
et al. 2016). 
 
Selection of candidate ABCA4 non-canonical splice site variants 
Of the 47 ABCA4 NCSS variants investigated in this study, 43 were selected from the Leiden 
Open-source Variation Database (www.LOVD.nl/ABCA4) (Cornelis et al. 2017), and three 
were found in STGD1 patients (c.303−3C>G for patient 1, c.1937+13T>G for patient 2, 
c.5461−8T>G for patient 3) during routine diagnostic studies in the Radboudumc. 
c.2919−10T>C was a recently published novel NCSS variant (Schulz et al. 2017). Forty-six of 
the NCSS variants comply with the following three inclusion criteria: (1) located in intronic 
positions −14 to −3 (splice acceptor site), or +3 to +6 (splice donor site) or at the first or the 
last 2 nucleotides of exons; (2) a reduction in the strength of the mutant splice site 
compared to its wild-type reference when calculated by at least one of five algorithms 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder) (Shapiro 
and Senapathy 1987; Reese et al. 1997; Pertea et al. 2001; Yeo and Burge 2004; Desmet et 
al. 2009) via Alamut Visual software version 2.7 (Interactive Biosoftware; www.interactive-
biosoftware.com); and (3) an allele frequency of ≤0.005 in the gnomAD browser (accessed 
May 31, 2017) (Lek et al. 2016). Variant c.1937+13T>G is not located in the splice donor site 
consensus sequence, and the five splice prediction programs did not show any reductions in 
canonical and downstream splice sites. It was selected for a splice assay as it was the only 
rare intronic ABCA4 variant located outside the NCSS consensus sequences but within 20 bp 
of an exon junction that was identified in routine Sanger sequencing of ~300 STGD1 cases. 
 
Generation of ABCA4 mutant constructs 
Site-directed mutagenesis was performed on wild-type BA entry clones as depicted in Figure 
2. Mutagenesis primers were designed by using the online tool QuikChange Primer Design 
(http://www.genomics.agilent.com/primerDesignProgram.jsp?toggle=uploadNow&mutate=t
rue&_requestid=1039517) and their GC content and temperature verified by using the 
online software Multiple Primer Analyzer 
(https://www.thermofisher.com/nl/en/home/brands/thermo-scientific/molecular-
biology/molecular-biologylearning-center/molecular-biology-resource library/thermo-
scientificweb-tools/multiple-primer-analyzer.html) (Supplemental Table S8). The 
mutagenesis PCR reaction mixture (50 μL) contained 0.5 μM of each forward and reverse 
primer, 0.2 mM dNTPs, 1 U Phusion High-Fidelity DNA Polymerase (cat. no. M0530L, New 
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England Biolabs), 1× Phusion HF Buffer, 2× Q-solution (cat. no. 1005485, Qiagen), and 20 ng 
wild-type entry clone. All PCRs were performed using the following thermocycling 
conditions: initial denaturation at 94°C for 5 min; 15 cycles of denaturation at 94°C for 30 sec 
each, annealing between 55°C and 75°C, and extension at 72°C (1 min/kb), with a final 
extension at 72°C for 20 min. PCR-amplified products were incubated with DpnI restriction 
enzyme (cat. no. R0176S, New England Biolabs) for 4.5 hrs, followed by heat inactivation at 
65°C for 20 min to remove the wild-type plasmid DNA. Digested products were first run on a 
0.6% (w/v) agarose gel to check for the presence of a unique linear fragment, corresponding 
to the mutant construct. Each of the NCSS variant mutants had their sequences validated 
(Supplemental Table S9), and finally, each validated mutant construct was cloned into the 
Gateway-adapted destination vector pCI-NEO-RHO as previously described (Sangermano et 
al. 2016). 
 
In vitro splice assay and transcriptional analysis 
To assess the effect of the NCSS variants on splicing, HEK293T cells (CRL-3216, ATCC) were 
transfected with wild-type and mutant constructs. Transfection, RNA isolation, and cDNA 
synthesis protocols were previously described (Sangermano et al. 2016). ABCA4 transcript 
analysis was generally carried out by performing RT-PCR analysis using ABCA4 exonic primers 
(Supplemental Table 
S10). To test the effect of NCSS variants located in or near exons that could not be flanked by 
other ABCA4 exons, e.g., due to the large size of some introns, primers were used from RHO 
exons 3 and 5. RT-PCR using primers targeting RHO exon 5 was used as a control for 
transfection efficiency (Supplemental Table S10). 
All reaction mixtures (50 μL) contained 0.2μM of each primer pair, 1 U Taq DNA 
Polymerase (cat. no. 11647679001, Roche), 1×PCR buffer with MgCl2, 1 mM MgCl2, 0.2 mM 
dNTPs, 1× QSolution (cat. no. 1005485, Qiagen), and 50 ng cDNA. PCR conditions were a first 
denaturation step of 94°C for 5 min, followed by 35 cycles of melting (94°C for 30 sec each), 
annealing (58°C for 30 sec), and extension (72°C for 5 min) steps, with a final elongation step 
of 72°C for 2 min. The RT-PCR products were run on a 2% (w/v) agarose gel and the resulting 
bands were excised and purified with the NucleoSpin Gel & PCR cleanup kit (cat. no. 
740609.250, Macherey-Nagel) according to the manufacturer’s protocol. Finally, 100 ng of 
the purified nucleic acid were analyzed by Sanger sequencing in a 3100 or 3730 DNA 
Analyzer (Thermo Fisher Scientific). For complex RT-PCR band patterns, 4 μL of the RT-PCR 
products, containing between 1 and 2 μg of DNA, were further cloned via the pGEM-T Easy 
Vector System I (cat. no. A1360 Promega) according to the manufacturer’s protocol. 
To determine the fraction of correctly spliced product, quantitative analysis of the 
RT-PCR bands was performed using the Fragment Analyzer Auto Capillary Electrophoresis 
System (Advanced Analytical Technologies, Inc.). RT-PCR of three constructs with no splice 
defects, 16 constructs with partial splice defects, and three constructs with no correctly 
spliced RNAs were performed in duplicate. Human retina cDNA was used as the control, as 
several ‘natural’ exon skipping event in human retina have been reported previously 
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(Supplemental Tables S3, S11; Supplemental Figs. S5, S6; Braun et al. 2013). For variants 
c.1937+13G>T, c.2382+5G>C, and c.2588G>C, the fraction of correctly spliced product was 
assessed by densitometric analysis using Image J software (Schneider et al. 2012). The 
analysis was performed in duplicate and values were normalized for the size of the different 
fragments present in each RT-PCR product mixture (Supplemental Table S12). 
 
ABCA4 transcript analysis of patient-derived photoreceptor precursor cells 
Fibroblasts from a patient carrying the non-canonical splice site variant c.768G>T in a 
homozygous state were successfully reprogrammed in iPSCs and further differentiated into 
photoreceptor precursor cells as previously described (Sangermano et al. 2016). 
Photoreceptor precursor cells were harvested, total RNA extracted, and RT-PCR performed 
by using a forward primer located in ABCA4 exon 4 (5′-TCATGAATGCACCAGAGAGC-3′) and a 
reverse primer located in ABCA4 exon 7 (5′-ACGGCTGTCTAGGAGTGTGG-3′). Gel resolution, 
excision, and purification of the bands and Sanger sequencing were performed as previously 
described (Sangermano et al. 2016). 
 
Data access 
The raw sequencing data for all wild-type splicing constructs (WT_BA), mutant splicing BA 
constructs (BA_c.), and RT-PCR fragments (RT_BA) from splice assays in HEK293T cells from 
this study have been submitted to the NCBI BioProject 
(https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA417900. 
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Chapter 5 
 
The common ABCA4 variant p.Asn1868Ile 
shows non-penetrance and variable 
expression of Stargardt disease when 
present in trans with severe variants 
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Purpose: To identify the second disease-causing allele in mono-allelic STGD1 patients and to 
evaluate the clinical spectrum of STGD1 in individuals carrying the common ABCA4 variant 
c.5603A>T (p.Asn1868Ile). 
 
Methods: The coding regions of ABCA4 were sequenced in 67 mono-allelic STGD1 probands. 
In case p.Asn1868Ile was detected, segregation analysis was performed if possible. 
Ophthalmologic data were assessed of probands and affected siblings carrying the non-
complex p.Asn1868Ile. One asymptomatic sibling carrying the same ABCA4 variants as its 
proband was clinically examined. The penetrance of p.Asn1868Ile was calculated employing 
allele frequency data of ABCA4 variants in non-Finnish European individuals. 
 
Results: The p.Asn1868Ile variant was found in cis with known coding variants in 14/67 
probands. In 27/67 (40%) probands, we identified the ‘non-complex’ p.Asn1868Ile variant in 
combination with known ABCA4 variants of which the far majority were predicted to be 
severe variants, and in 22/27 probands the trans configuration could be established. Among 
the 27 probands and 4/5 STGD1 siblings carrying p.Asn1868Ile, 42% manifested late-onset 
disease (>44 yrs). We identified five asymptomatic siblings carrying a combination of a 
severe ABCA4 variant and p.Asn1868Ile. In one of these siblings, ophthalmologic 
examinations were performed, which did not reveal any STGD1 characteristics. Based on the 
cumulative allele frequency of severe ABCA4 variants in healthy non-Finnish European 
individuals, we calculated a penetrance for p.Asn1868Ile of between 1.0 and 2.4%. 
  
Conclusions: A significant fraction of genetically unexplained STGD1 cases carries 
p.Asn1868Ile as a second variant. Our findings suggest exceptional differences of disease 
expression or even non-penetrance of this ABCA4 variant, pointing towards an important 
role for genetic or environmental modifiers in STGD1.  
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Introduction 
Autosomal recessive Stargardt disease (STGD1, MIM 248200) represents the most common 
hereditary macular dystrophy (estimated prevalence 1:10,000) (Blacharski 1988) and is 
characterized by lipofuscin deposits in the retinal pigment epithelium (RPE) presenting as 
yellow-white flecks, and progressive atrophy of the macular retinal pigment epithelium 
(Stargardt 1909; Franceschetti 1965). STGD1 is caused by sequence variants in the 
transmembrane ATP-binding cassette transporter type A4 (ABCA4, MIM 601691) (Allikmets 
et al. 1997). Different combinations of ABCA4 variants give rise to several phenotypes, which 
can partly be attributed to differences in the residual activity of the ABCA4 protein (Cremers 
et al. 1998; Martinez-Mir et al. 1998; van Driel et al. 1998; Maugeri et al. 1999; Maugeri et 
al. 2000; Maugeri et al. 2002). A combination of disease-causing ABCA4 alleles may therefore 
result in a severe, early-onset STGD1 phenotype (i.e., onset ≤10 years of age), (Fujinami et al. 
2015; Lambertus et al. 2015) which is often observed as rapidly progressive cone-rod 
dystrophy (Cremers et al. 1998; Klevering et al. 2004), in classical STGD1 (Maugeri et al. 
1999), or in late-onset STGD1 (Westeneng-van Haaften et al. 2012; Fujinami et al. 2013; van 
Huet et al. 2014). In about half of the patients with late-onset STGD1 (onset >44 years of 
age) only one disease-causing allele was identified, despite the sequence analysis of all 
coding variants (Westeneng-van Haaften et al. 2012). 
In mono-allelic STGD1 cases, the second variant can reside in introns, outside of 
splice sites, as they are not detected by standard sequencing methods (Braun et al. 2013; 
Zernant et al. 2014; Bauwens et al. 2015; Bax et al. 2015). A very small fraction of these 
unidentified defects comprise copy number variants which elude detection by PCR-based 
sequencing techniques (Yatsenko et al. 2003; Zernant et al. 2011; Zernant et al. 2014; Lee et 
al. 2016). Identification of disease-causing alleles and insight into their associations with 
differences in disease presentation and severity is essential for the counseling of patients, 
and becomes increasingly important as research on therapeutic approaches is rapidly 
evolving.   
Recently, a frequent ABCA4 coding variant, c.5603A>T (p.Asn1868Ile), which thus far 
was considered benign due to its high minor allele frequency (MAF) of 7% in the general 
population, was found to be associated with STGD1 (Schulz et al. 2017; Zernant et al. 2017). 
This variant was found to be phenotypically expressed only when in trans with a deleterious 
mutation (i.e., presence of variants on different alleles), and explained >50% of all mono-
allelic cases and ~80% of late-onset cases in a US cohort (Zernant et al. 2017). In addition, 
the c.2588G>C (p.[Gly863Ala, Gly863del]) variant was proposed to act as a mild pathogenic 
variant only when in cis with p.Asn1868Ile (i.e., presence of variants on the same allele). 
In this study, we investigated STGD1 probands with a single disease-causing ABCA4 
allele for the presence of the p.Asn1868Ile variant, performed segregation analysis through 
the inclusion of unaffected family members to distinguish ‘complex’ p.Asn1868Ile alleles 
from ‘non-complex’ alleles, and performed ophthalmologic studies to evaluate the full 
spectrum of phenotypes associated with the p.Asn1868Ile variant. In addition, we calculated 
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the penetrance for the p.Asn1868Ile variant by employing allele frequencies of severe 
ABCA4 variants. 
 
Methods 
Study population and genetic analysis 
We ascertained 67 clinically suspected STGD1 patients in whom one disease-causing variant 
in the ABCA4 gene had been identified, from eight ophthalmic centers in the Netherlands 
(n=64) and one center in Germany (n=3). Between 1998 and 2017 these subjects were 
screened for disease-causing variants in the coding regions and flanking splice sites of ABCA4 
and recently, for 63 subjects, ~95% of the entire ABCA4 gene (exons and introns) was further 
sequenced by using a custom Haloplex Target Enrichment kit (Agilent, Santa Clara, CA, USA) 
as described previously (Sangermano et al. 2016). All variants identified by Haloplex-based 
ABCA4 sequencing were confirmed using Sanger sequencing. We investigated mono-allelic 
probands for the presence of the p.Asn1868Ile variant and rare (MAF <0.005) deep-intronic 
variants. Four DNA samples were analyzed using non-haloplex based alternative techniques 
(Supplemental Methods S1 a).  
Segregation of the sequence variants identified in the probands was studied by 
sequencing the corresponding genomic DNA fragments in relatives (Supplemental Table S1). 
Subsequently, 27 probands and 3 affected siblings carrying the ‘non-complex’ p.Asn1868Ile 
variant were clinically evaluated. Participants gave informed consent after an explanation of 
the nature of the study. The study procedures were performed according to approval of the 
medical ethics committee of the Radboud university medical center and the tenets of the 
Declaration of Helsinki. 
 
Clinical evaluation 
Patient’s medical records were reviewed and available clinical data were collected, 
comprising age at onset and initial symptoms, age at diagnosis, best-corrected visual acuity 
(BCVA) and findings on ophthalmoscopy. Age of onset was defined as the age at which the 
initial symptoms were noted by the patient. In asymptomatic subjects and in cases where 
age at onset was not noted in the patient file, we used the age at which macular 
abnormalities were first diagnosed by an ophthalmologist. 
Furthermore, we examined available data acquired by fundus photography, fundus 
autofluorescence (FAF) imaging using a confocal scanning laser ophthalmoscope (cSLO; 
Spectralis; Heidelberg Engineering, Heidelberg, Germany), spectral domain-optical 
coherence tomography (OCT) (Spectralis) or time-domain OCT (Stratus, Carl Zeiss Meditec, 
Dublin, CA), fluorescein angiography (FA) and full-field electroretinography (ffERG) according 
to the International Society for Clinical Electrophysiology of Vision standards. We assessed 
presence of foveal sparing, which we defined as RPE atrophy encircling a structurally and 
functionally (BCVA≥20/200) preserved fovea by ≥180⁰, by evaluation of FAF and OCT. 
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One asymptomatic sibling who carried the same combination of ABCA4 variants as 
the respective proband, was clinically examined by measurement of BCVA and performance 
of fundus photography, FAF and OCT.  
 
ABCA4 allele frequency calculations and p.Asn1868Ile penetrance estimates 
To assess the penetrance of the common variant p.Asn1868Ile when present in trans with a 
severe ABCA4 variant, we employed allele frequency (AF) data in ~33,000 non-Finnish 
European (nFE) control subjects in Exome Aggregation Consortium (Lek et al. 2016) (ExAC) 
(available at: http://exac.broadinstitute.org; accessed September 01, 2017), as at least 24/27 
patients belong to this population. The AF of the ‘non-complex’ p.Asn1868Ile was calculated 
based on its total AF minus the AF of c.5461-10T>C and 10% of the AF of c.2588G>C, which 
are believed to be in cis with p.Asn1868Ile (Zernant et al. 2017). 
We calculated a minimal as well as a more ‘realistic‘ cumulative AF of severe ABCA4 
variants. In the minimal calculation, we determined the sum AF of all protein-truncating 
variants and added the AF of non-canonical splice-site variants that resulted in less than 25% 
of normally spliced ABCA4 (Sangermano et al. 2018). To determine a more realistic sum AF 
for all severe ABCA4 variants we added the AF of two other variant groups: variants that are 
found in a homozygous state or in trans with a mild variant in STGD1 patients (Supplemental 
Methods S1 b). 
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Results 
In 14/67 mono-allelic probands, we found p.Asn1868Ile to be in cis with causal protein-
coding or splice-site variants, i.e., c.5461-10T>C (n=9), c.2588G>C (n=3), c.4469G>A (n=1) 
and c.818G>A (n=1). In 27/67 mono-allelic probands we detected a p.Asn1868Ile variant that 
was not part of a ‘complex’ allele. In 22 patients we could establish the trans configuration 
of the identified variants (Table 1, Fig. 1, and Supplemental Fig. S1), either due to 
segregation analysis (n=19) or because the p.Asn1868Ile variant was found in a homozygous 
state (n=3).  
In four probands (I-II:3, J-II:2, Y-II:1 and AA-II:1) we could not exclude the presence of 
other variants in cis with p.Asn1868Ile as we did not sequence the non-coding regions of 
ABCA4. 
Among the 27 probands, 19 carried p.Asn1868Ile together with a protein truncating 
mutation due to a stop-gain (n=4), a frameshift (n=4), a canonical splice site variant (n=1), or 
because of non-canonical splice site variants elsewhere shown to result in protein 
truncations (n=10) (Table 1)  (Sangermano et al. 2016; Sangermano et al. 2018). Among the 
remaining seven variants, there were six different missense variants in seven probands and 
one non-canonical splice site variant (c.5714+5G>A) with a moderately severe effect on 
splicing (Sangermano et al. 2018). Among these missense variants, p.Gly1961Glu in the vast 
majority of STGD1 cases acts as a mild variant (Cella et al. 2009; Burke et al. 2012; Zernant et 
al. 2017) while p.Phe608Ile is considered a severe variant (Cornelis et al. 2017). For the 
remaining missense variants (p.Glu1087Lys, p.Cys1488Arg, p.Gly1972Arg, p.Met2143Arg), 
the effect on protein function is unclear. 
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Table 1. Clinical and genetic characteristics of STGD1 patients carrying c.5603A>T (p.Asn1868Ile) 
Subject / Sex / Age 
(yrs) 
Age at 
onset 
(yrs) 
 
Genotype 
Fundus and imaging features 
Latest visual 
acuity Disease duration 
at latest visit 
(yrs)n 
ABCA4 variant(s) in 
trans with c.5603A>T 
Structural and functional effect on ABCA4 
protein of variants in trans with c.5603A>T RE LE 
A-II:4 / ♀ / 79a,b 71  c.768G>T p.(Leu257Valfs*17)
k S Yellow-white pisciform flecks throughout the posterior pole 20/25 20/20 4 
B-II:1 / ♂ / 68a,b,c 54  c.768G>T p.(Leu257Valfs*17)
k S Yellow-white pisciform flecks throughout the posterior pole and mid-
periphery with chorioretinal atrophy in macula  
20/200 20/200 9 
B-II:3 / ♀ / 64 19  c.768G>T p.(Leu257Valfs*17)
k S 58yrs: extensive chorioretinal atrophy and pigmentary changes in 
macula with yellow-grey pisciform flecks throughout posterior pole 
and midperiphery  
CFl 20/400 41 
C-II:1 / ♂ / 60 41  c.768G>T p.(Leu257Valfs*17)
k S Yellow-white pisciform flecks throughout the posterior pole and mid-
periphery with parafoveal chorioretinal atrophy 
20/20 20/20 8 
C-II:2 / ♀ / 57 45
h 1  c.768G>T p.(Leu257Valfs*17)k S Yellow-white pisciform flecks throughout the posterior pole and 
extensive chorioretinal atrophy with foveal sparing 
20/50 20/20 10 
D-II:1 / ♂ / 68 61  c.768G>T p.(Leu257Valfs*17)
k S 62yrs: yellow-white pisciform flecks throughout the posterior pole 
and parafoveal chorioretinal atrophy with foveal sparing  
68yrs: chorioretinal atrophy in macula with a few surrounding 
pisciform yellow-white flecks   
CF 20/130 7 
D-II:3 / ♂ / 58 52
h  c.768G>T p.(Leu257Valfs*17)k S Predominantly perimacular pisciform yellow-white flecks and mottled 
decreased FAF in macula with preserved fovea  
20/20 20/22 6 
E-II:3 / ♀ / 68a,b,c 56  c.4462T>C p.(Cys1488Arg) NA Foveal changes with perimacular and peripapillary irregular yellow-
white flecks and mottled decreased FAF in macula 
20/400 20/400 8 
F-II:2 / ♂ / 45 32  c.1822T>A p.(Phe608Ile) S Foveal changes with perimacular and peripapillary irregular yellow-
white flecks and mottled decreased FAF in macula (Figure 3A-C) 
20/66 20/66 9 
G-II:2 / ♂ / 73c 69  c.5762_5763dup p.(Ala1922Trpfs*18) S Chorioretinal atrophy with foveal sparing and hyper- and 
hypoautofluorescent flecks throughout posterior pole and 
midperiphery on FAF (Figure 4A-C) 
20/25 20/40 4 
H-II:3 / ♂ / 66d 30  c.2919-?_+3328+?del p.(Ser974Glnfs∗64) S Perimacular irregular yellow-white flecks and beaten bronze atrophy 
in macula (no OCT/FAF) 
20/125 HMm‖ 
 
20 
I-II:3 / ♀ / 62e 18  c.768G>T p.(Leu257Valfs*17)
k S Parafoveal pigmentary changes with yellow-white pisciform flecks 
throughout the posterior pole and mild atrophy in macula (no 
OCT/FAF) 
20/50 20/33 11 
J-II:2 / ♂ / 58j 56  c.[5461-10T>C; 
5603A>T] 
p.[Thr1821Valfs*13, Thr1821Aspfs*6; 
Asn1868Ile] 
S Pigmentary changes in macula, perimacular yellow-white flecks and 
chorioretinal atrophy with in RE foveal sparing, in both eyes 
surrounded by an area of increased background FAF 
20/32 20/330 1 
K-II:1 / ♀ / 47 23  c.5914G>Ai,j p.(Gly1972Arg) NA Foveal changes and perimacular yellow-white flecks (no OCT/FAF) 20/200 20/125 6 
L-II:1 / ♀ / 50 31h  c.768G>Ti p.(Leu257Valfs*17)k S Foveal changes with perimacular yellow-white irregular flecks and 
mottled decreased FAF in macula 
20/200 20/200 15 
M-II:1 / ♀ / 69 53  c.6155del p.(Asn2052Thrfs*9) S Foveal changes with yellow-white pisciform flecks throughout the 
posterior pole and mid-periphery and chorioretinal atrophy with 
foveal sparing; Attenuated arterioles 
20/50 20/100 16 
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Subject / Sex / Age 
(yrs) 
Age at 
onset 
(yrs) 
 
Genotype 
Fundus and imaging features 
Latest visual 
acuity Disease duration 
at latest visit 
(yrs)n 
ABCA4 variant(s) in 
trans with c.5603A>T 
Structural and functional effect on ABCA4 
protein of variants in trans with c.5603A>T RE LE 
N-II:1 / ♀ / 72a,b,c,g 45
h  c.3874C>Ti p.(Gln1292*) S 45yrs: yellow-white pisciform flecks throughout the posterior pole 
71yrs: extensive chorioretinal atrophy in macula of RE after years of 
foveal sparing, chorioretinal atrophy with foveal sparing in LE 
2/300 20/20 26 
O-II:1 / ♀ / 39 32  c.768G>T p.(Leu257Valfs*17)
k S Foveal changes with perimacular yellow-white irregular flecks, and 
mottled FAF in macula with preserved fovea 
20/22 20/20 7 
P-II:1 / ♀ / 39c 32  c.6428T>G p.(Met2143Arg) NA Foveal changes with perimacular yellow-white irregular flecks and 
mottled decreased FAF in macula surrounded by a zone of increased 
background FAF 
20/50 20/100 3 
Q-II:1 / ♀ / 48 42
h  c.5714+5G>A p.[=, Glu1863Leufs*33)k M Foveal changes with perimacular yellow-white irregular flecks and 
mottled decreased FAF in macula 
20/30 20/32 4 
R-II:1 / ♂ / 32 30
h  c.5917delGi p.(Val1973*) S Perimacular ring of increased FAF around a zone of mottled 
decreased FAF, with preserved fovea and normal fovea reflex; A few 
mild hyperfluorescent flecks in posterior pole 
20/28 20/22 1 
S-II:1 / ♀ / 31 26  c.1822T>A p.(Phe608Ile) S Foveal changes with perimacular yellow-white irregular flecks and 
mottled decreased FAF in macula 
20/200 20/50 4 
T-II:1 / ♂ / 45c 36  c.3259G>A p.(Glu1087Lys) NA Foveal pigmentary changes and yellow-white pisciform flecks 
throughout the posterior pole and mid-periphery with chorioretinal 
atrophy in macula 
20/66 20/600 9 
U-II:1 / ♀ / 41 37
h  c.1938-1G>A p.(?) S Perimacular yellow-white pisciform flecks and mottled decreased FAF 
in macula with relatively spared fovea 
20/40 20/66 3 
V-II:1 / ♀ / 31 27
h  c.5882G>A p.(Gly1961Glu) M Mottled decreased FAF in macula, surrounded by a zone of increased 
background FAF and few hyperfluorescent flecks in macula 
CF 20/100 4 
W-II:1 / ♀ / 55 42  c.768G>T p.(Leu257Valfs*17)
k S Perimacular yellow-white irregular flecks and a zone of increased 
background FAF in macula with foveal mottled decreased FAF 
20/130 20/200 13 
X-II:1 / ♀ / 36c 20  c.4506C>A p.(Cys1502*) S Perimacular yellow-white irregular flecks with chorioretinal atrophy in 
macula 
20/200 20/125 12 
Y-II:1 / ♀ / 53j 47
h  c.[5461-10T>C; 
5603A>T] 
p.[Thr1821Valfs*13, Thr1821Aspfs*6; 
Asn1868Ile] 
S Perimacular yellow-white irregular flecks; Parafoveal chorioretinal 
atrophy with relative foveal sparing in RE, and mottled decreased FAF 
with foveal sparing in LE 
20/25 20/20 6 
Z-II:1 / ♀ / 51 21  c.4234C>T
i p.(Gln1412*) S 22yrs: Abnormal foveal reflex with macular pigmentary changes 
44yrs: Perimacular yellow-white irregular flecks and chorioretinal 
atrophy in macula 
20/500 CF 23 
AA-II:1 / ♂ / 63 57  c.[4469G>A; 5603A>T] p.[Cys1490Glufs*12; Asn1868Ile]
k S Yellow-white pisciform flecks throughout the posterior pole 20/20 20/20 1 
BE, both eyes; CF, counting fingers; fs, frameshift; FAF, fundus autofluorescence; HM, hand motion, LE, left eye; M, mild effect; NA, not applicable; RE, right eye; S, severe effect (truncating alleles); yrs, years; ♀, female; ♂, male; *premature stop. 
Previously mentioned cases: a) Westeneng et al., 2012;(Westeneng-van Haaften et al. 2012) b) Lambertus, Lindner, Bax et al., 2016;(Lambertus et al. 2016b) c) Lambertus, Bax, Groenewoud et al., 2016;(Lambertus et al. 2016a) d) Klevering et al., 
2004(Klevering et al. 2004) and Bax et al., 2015(Bax et al. 2015); e) Hoyng et al., 1996;(Hoyng et al. 1996) f) Sangermano et al., 2016;(Sangermano et al. 2016) and g) van Huet et al., 2014.(van Huet et al. 2014) h) age at diagnosis; i) trans 
configuration could not be established by segregation analysis or homozygosity; j) also CNGB3 c.1148delC heterozygous; k) based on in vitro splice assays (Sangermano et al. 2018); l) Coats’ disease; m) amblyopic eye; n) Defined as time since onset 
of complaints. For more clinical details regarding initial symptoms, fluorescein angiogram, and full-field electroretinography we refer to Supplemental Table S2. 
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Figure 1. ABCA4 variant c.5603A>T (V1) is associated with variable age at onset and 
putative non-penetrance of Stargardt disease. Segregation analysis of ABCA4 variants in 
STGD1 families (A-D) with multiple affected individuals showed that all four families carry 
the compound heterozygous variants V1 and c.768G>T. As expected for an autosomal 
recessive inherited Mendelian trait, all affected and genetically tested individuals in families 
(A-D) carry two ABCA4 variants in trans, whereas unaffected individuals carry one or no 
variant. However, in families (E-H), reduced penetrance or even non-penetrance occurs. 
Family H is part of a previously described multi-generation pedigree (Klevering et al. 2004; 
Bax et al. 2015). Proband H-II:3 and the unaffected sibling H-II:1 carry V1 and c.2919-
?_3328+?del, while unaffected individual H-II:2, the spouse of H-II:1, is compound 
heterozygous for V1 and c.[5461-10T>C; 5603A>T]. For H-I:1, the variants where deduced by 
haplotype analysis. 
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Clinical evaluation 
Segregation-analysis in eight siblings affected by STGD1 identified five individuals who 
carried the same causal variants as the respective probands. In two families, we found 
affected siblings carrying different combinations of disease-causing ABCA4 alleles 
(Supplemental Fig. S1). Detailed clinical characteristics of 30/32 subjects carrying 
p.Asn1868Ile are depicted in Table 1, and Supplemental Table S2. For two individuals (A-II:1 
and A-II:2) who carried the same variants as the respective proband, clinical data were not 
available.  
The mean age of onset was 41 years (SD, 15 years). The disease was diagnosed in 
three asymptomatic patients: in two cases during clinical examination due to a family history 
of STGD1, and in one subject due to routine examination by an optician. None of the 
subjects manifested early-onset STGD1 (age at onset ≤10 years). Eighteen subjects 
manifested the classical STGD1 phenotype (age at onset 11-44 years). Age at onset was 
above the age of 44 years in 13 patients (42%). Seven out of 12 clinically evaluated subjects 
showed the typical late-onset STGD1 phenotype of sharply demarcated chorioretinal 
atrophy in a foveal sparing pattern.  
Flecks were absent in two patients as assessed by ophthalmoscopy and retinal 
imaging. A third patient (G-II:2), who was initially diagnosed with AMD and an epiretinal 
membrane at the age of 69, exhibited widespread hypo- and hyperautofluorescent lesions 
on a FAF while flecks were absent on fundus photography and ophthalmoscopy (Fig. 2). 
 
 
Figure 2. Retinal imaging of a patient with a very late onset of STGD1. A. Fundus 
photography showed no signs of flecks in patient G-II:2 at the age of 72, 3 years after disease 
onset. (B-C) FAF performed in the same patient, at the same time, showed widespread hypo- 
and hyper-autofluorescent lesions. FAF and OCT showed perifoveal chorioretinal atrophy 
with foveal sparing.   
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Variable age at onset and incomplete penetrance 
As exemplified by Family B (Fig. 1), the age at onset between affected siblings can vary 
tremendously (19 and 54 years of age). In B-II:1, the initial symptom of a scotoma in the right 
eye occurred at the age of 54, whereas his sibling B-II:3 first had visual complaints at the age 
of 19. Although B-II:3 suffers from concurrent Coats’ disease, it is unlikely that this explains 
the significantly different age at onset, as Coats’ disease was not observed until the age of 57 
and affected only the right eye.  
Even more surprisingly, we found five apparently asymptomatic persons in four 
STGD1 families that carried the same compound heterozygous variants as their affected 
siblings (Family E-H, Fig. 1). The unaffected person H-II:2 coincidently also carried a severe 
ABCA4 variant (‘complex’ allele: c.[5461-10T>C; 5603A>T]) and c.5603A>T (p.Asn1868Ile). 
For some asymptomatic siblings (E-II:1 and H-II:1), in view of the large gap between the age 
at onset of the affected sibling and the current age of the asymptomatic sibling, it is 
plausible that they remain unaffected and can be considered non-penetrant. Others (F-II:1 
and G-II:4) may develop STGD1 later in life, considering their current ages and age of the 
respective probands. In one of the latter subjects, F-II:1, current manifestation of STGD1 was 
excluded during ophthalmologic examination (Fig. 3D-F): fundus image, FAF and OCT showed 
no abnormalities at the age of 46, and BCVA was 20/20 in both eyes. His sibling F-II:2 
reported initial symptoms at the age of 32 and was diagnosed with STGD1 at the age of 38 
(Figures 3A-C). No additional asymptomatic cases were clinically examined so we cannot 
exclude the possibility that they manifest mild STGD1 phenotypes. 
 
Figure 3. Retinal imaging of one affected and one unaffected sibling harboring the same 
combination of ABCA4 variants. (A-C) Patient F-II:2 shows foveal changes with perimacular 
and peripapillary irregular yellow-white flecks, mottled decreased FAF in the macula and 
central RPE atrophy at the age of 41 years, 9 years after disease onset. (D-F) Asymptomatic 
sibling F-II:1 shows no abnormalities on fundus photography, FAF and OCT at the age of 46 
years.    
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p.Asn1868Ile shows a very low penetrance in the Caucasian population 
Based on previous findings (Zernant et al. 2017) and the results of this study, we can 
conclude that p.Asn1868Ile represents a mild ABCA4 variant that in the majority of cases 
only results in STGD1 when present in trans with a severe ABCA4 variant.   
As we do not know all ABCA4 variants that are in linkage disequilibrium with 
p.Asn1868Ile, we can only estimate the frequency of the ‘non-complex’ p.Asn1868Ile 
variant. Zernant et al. (2017) indicated that 10% of c.2588G>C alleles carry p.Asn1868Ile in 
cis and this ‘complex’ allele probably acts as a fully penetrant mild allele if present in a 
compound heterozygous state with a severe ABCA4 variant (Zernant et al. 2017). In the same 
study, consistent with our data, the frequent non-canonical splice site variant c.5461-10T>C 
was always found in cis with p.Asn1868Ile. The maximum AF among ~66,000 nFE control 
alleles (in ExAC) for the ‘non-complex’ p.Asn1868Ile variant thereby is 0.0645 (Table 2A). 
Based on their AF among ~66,000 nFE control alleles, we also determined the 
cumulative AF of protein-truncating variants that in the majority of cases result in exon 
skipping and likely in absence of ABCA4 activity (Table 2B). Next, we added the allele 
frequencies of all non-canonical splice site variants that resulted in less than 25% normally 
spliced RNA (Sangermano et al. 2018). This resulted in our low estimate of the total AF of 
severe ABCA4 variants in nFE (0.0027; Table 2B), which yields an estimated prevalence of 
individuals with one severe ABCA4 variant and p.Asn1868Ile of 0.000349 (Table 2D).  
Additionally, we determined a more realistic cumulative AF of severe ABCA4 variants 
by adding two other variant groups as described in Supplemental Methods S1 b. First, the 
sum AF of other non-truncating variants that were at least 100 times more frequent in 
STGD1 patients vs. controls and occurred with one of the two frequent known ‘mild’ variants 
c.2588G>C and c.5882G>A, or occurred in at least one patient with disease onset before 10 
years of age is 0.0003. Second, in ~66,000 nFE control alleles, the non-redundant total AF of 
other variants found in trans with one of the five statistically ‘mild’ ABCA4 variants in STGD1 
cases is 0.0037. The cumulative AF of these presumed severe ABCA4 variants thereby is 
0.0067 (Table 2C), which suggests a prevalence of individuals carrying both a severe variant 
and p.Asn1868Ile of 0.000865 (Table 2D) in the nFE population.  
The prevalence of STGD1 is estimated at 1 in 10,000 individuals (Blacharski 1988), 
and in the Nijmegen STGD1 cohort, STGD1 due to a severe ABCA4 variant and p.Asn1868Ile 
was observed in 25/300 (8.3%) probands (Table 2E). Given a total population in the 
Netherlands of 17,150,000 people, STGD1 due to this combination of variants is expected in 
~143 persons. If the nFE AF are comparable to those in the Netherlands, we can conclude 
that the penetrance of the ‘non-complex’ p.Asn1868Ile variant, when present in 
combination with a severe ABCA4 variant, ranges between 1.0% and 2.4%, based on our 
maximum and minimum total AFs for severe ABCA4 variants, respectively (Table 2F).  
As these calculations are based on a few assumptions, we also calculated the 
penetrance based on alternative assumptions regarding the prevalence of STGD1, the 
frequency of severe ABCA4 variants, and ABCA4 variant data from late-onset STGD1 cases in 
the ExAC database (Supplemental Results S2). When taking into account uncertainties in 
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these factors of the calculation, and in the unlikely situation that they would act in concert, 
the penetrance of p.Asn1868Ile ranges between 0.24% and 30.4%. 
 
Table 2. Non-Finnish European ExAC allele frequencies for c.5603A>T and severe ABCA4 variants 
A. Allele frequency c.5603A>T 0.06573 
 Estimated allele frequency c.[5641-10T>C; 5603A>T]* 0.00039 
 Estimated allele frequency c.[2588G>C; 5603A>T]** 0.00081 
 Maximum allele frequency ‘non-complex’ c.5603A>T 0.06453 
   
B. Σ allele frequency ABCA4 protein-truncating and canonical splice site variants 0.00198 
 Σ allele frequency ABCA4 severe non-canonical splice site variants*** 0.00083 
 Minimum Σ allele frequency for severe ABCA4 variants 0.00271 
   
C. Σ allele frequency non-truncating ABCA4 variants found in trans with mild ABCA4 
variants (c.2588G>C, c.3113C>T, c.5714+5G>A, c.58882G>A, c.6089G>A)# or 
found in STGD1 cases with onset < 10 yrs 
0.00399 
 ‘Maximum’ Σ allele frequency for severe ABCA4 variants 0.00670 
   
D. Minimum estimate frequency STGD1 cases with severe variant and c.5603A>T  0.000349 
 Maximum estimate frequency STGD1 cases with severe variant and c.5603A>T 0.000865 
   
E. STGD1 total prevalence 0.0001 
 Proportion STGD1 cases in Nijmegen carrying severe variant and c.5603A>T 0.0833 
 Estimated NL population prevalence STGD1 cases with severe variant and 
c.5603A>T 
0.00000833 
 Estimated number of STGD1 cases in the NL with severe variant and c.5603A>T 143 
   
F. Theoretical number of STGD1 cases in the NL with severe variant and c.5603A>T 
based on minimum Σ allele frequency for severe ABCA4 variants 
5,991 
 Penetrance based on minimum Σ allele frequency for severe ABCA4 variants 0.0239 
 Theoretical number of STGD1 cases in the NL with severe variant and c.5603A>T 
based on ‘maximum‘ Σ allele frequency for severe ABCA4 variants 
14,829 
 Penetrance based on maximum Σ allele frequency for severe ABCA4 variants 0.0096 
 
*Assuming complete linkage disequilibrium between c. 5603A>T and 5641-10T>C (Zernant et 
al. 201722; this study).  
**Based on the observation that in an age-related macular degeneration cohort, 10% of 
individuals with c.2588G>C also carry c.5603A>T22. 
***Based on in vitro splice assays of non-canonical splice site variants (Sangermano et al. 
2017). #As determined by Cornelis et al. 20178. 
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Discussion 
By combining ABCA4 sequence analysis and segregation analysis of the identified variants, 
we detected the common variant p.Asn1868Ile as the second allele in 40% of mono-allelic 
cases in our genetically unexplained STGD1 cohort. In the vast majority of the cases, 
p.Asn1868Ile was found in trans with severe ABCA4 variants, thus pointing towards the mild 
nature of this exonic variant in STGD1. In agreement with a previous study (Zernant et al. 
2017), we found that a high proportion of these p.Asn1868Ile carriers manifest the late-
onset STGD1 phenotype. However, among our cases, age at onset was highly variable. 
Strikingly, we identified four apparently asymptomatic individuals and one unaffected 
individual, all of whom carried the same combination of ABCA4 variants as their affected 
sibling. The very low calculated penetrance of p.Asn1868Ile (i.e. 1.0-2.4%) in addition to the 
observed variability in age at onset and phenotypes among individuals carrying the same 
combinations of ABCA4 variants, lead us to hypothesize that cis or trans acting genetic 
modifiers or environmental factors greatly influence ABCA4 gene expression and thereby the 
clinical presentation of STGD1. 
 As yet, very little is known about the potential nature, role and mechanisms of 
modifiers in STGD1. One group studied gene expression variation in the human retina and 
found that ABCA4 showed 1.5-fold higher expression in males compared to females 
(Chowers et al. 2003). Males carrying a high-expressed mild ABCA4 allele thereby may be 
less prone to develop STGD1. In our study, there indeed is an overrepresentation of females 
(20/32, 63%) among patients carrying p.Asn1868Ile. Furthermore, the putative non-
penetrant sibling is male in three out of four families, and the only two unaffected females 
are siblings of male G-II:2 in whom STGD1 manifested at an extraordinary old age. Further 
research is needed to identify possible modifiers, explain the mechanisms whereby they 
modify gene expression and, most interestingly, explore their potential as therapeutic 
targets.   
Clinical overlap with other macular diseases along with inconclusive results of genetic 
analyses can make the diagnosis of late-onset STGD1 particularly challenging, as illustrated 
by case G-II:2 who first experienced symptoms at the age of 69. The identification of the 
second disease-causing allele, whereby a significant fraction of late-onset STGD1 cases is 
now genetically explained, strengthens the assumption that late-onset STGD1 represents a 
distinct disease entity that should not be confused with AMD (Zernant et al. 2017). An 
accurate diagnosis is essential for appropriate counseling of patients regarding prognosis 
and heritability, and is relevant for putative therapies, e.g., either recommendation or 
dissuading of vitamin A supplement use in AMD and STGD1, respectively. Moreover, several 
therapeutic trials in STGD1 patients are ongoing (http://www.clinicaltrials.gov, last accessed 
23-07-2017), requiring identification of both disease-causing ABCA4 alleles.  
Assessment of non-penetrance has a few limitations. First, this study showed that 
age at onset can vary tremendously even among sibling carrying the same ABCA4 variants. 
Therefore, non-penetrance cannot easily be confirmed by clinical examination of unaffected 
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persons carrying bi-allelic disease-causing ABCA4 variants. Also, we observed that some  
STGD1 cases carrying the ‘non-complex’ p.Asn1868Ile in trans showed relatively early age at 
onset. It is possible that variants in other genes modify the expression of STGD1. 
Second, although we have experimentally proven the veracity of a non-penetrance 
phenomenon, we are conscious of the fact that these values cannot be considered as 
definitive. Most importantly, late-onset STGD1 currently may be underdiagnosed or 
misdiagnosed due to the clinical overlap with AMD. In an AMD cohort (n= 698) from the 
Radboudumc, we however did not observe persons with a combination of a severe ABCA4 
variant and p.Asn1868Ile, suggesting that this cannot be a major factor.  
 
Conclusions 
Identification of genetic variants underlying STGD1 is essential to provide accurate 
counseling to patients and relatives and to drive therapeutic approaches. A significant 
proportion of STGD1 patients carry p.Asn1868Ile, which is associated with late-onset STGD1 
and a variable disease expression. In line with these findings, we calculated an exceptionally 
low penetrance of the p.Asn1868Ile variant, which may be explained by the action of cis or 
trans acting genetic modifiers or non-genetic factors in STGD1.  
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Supplemental Material 
Supplemental Methods S1  
a) Alternative genetic analyses 
Four DNA samples were not analyzed using Haloplex sequencing. Patient I-II:3 was 
previously analyzed by linkage analysis (Hoyng et al. 1996), allele-specific primer extension 
analysis by Asper Biotech in 2002, followed by Sanger sequencing of the identified variants. 
Patients Y-II:1 and AA-II:1 were analyzed for ABCA4 variants using Sanger sequencing of the 
50 coding exons and flanking intronic sequences. Patient Y-II:1 was also analyzed using 
multiplex ligation-dependent probe amplification analysis according to the manufacturer’s 
instructions (SALSA MLPA kit P151-P152 ABCA4; MRC-Holland, Amsterdam, The 
Netherlands). The DNA of patient J-II:2 was analyzed by whole exome sequencing (WES). 
Exome enrichment was performed using the Agilent SureSelectXT Human All Exon 50Mb kit 
(Agilent Technologies, Santa Clara, CA) and WES was performed on the Illumina HiSeq2000 
platform by BGI (Copenhagen, Denmark) as previously described (Haer-Wigman et al. 2017). 
 
b) ABCA4 allele frequency calculations  
The allele frequency (AF) of the ‘non-complex’ p.Asn1868Ile was calculated based on its total 
AF in non-Finnish European (nFE) control subjects minus the AF of c.5461-10T>C and 10% of 
the AF of c.2588G>C, which are believed to be in cis with p.Asn1868Ile (Zernant et al. 2017). 
Other variants have been found in cis with p.Asn1868Ile, but their cumulative nFE AF likely is 
negligible and were therefore not taken into account.  
We calculated a minimal and a more ‘realistic‘ cumulative AF of severe ABCA4 
variants as follows. In the minimal calculation, we determined the cumulative nFE AF of all 
protein-truncating variants (i.e., stop-gain mutations, frameshift mutations, canonical splice-
site variants) and added the sum AF of non-canonical splice-site variants (i.e., RNA splice 
variants outside the conserved intronic dinucleotides at the ends of introns) that resulted in 
less than 25% of normally spliced ABCA4 (Sangermano et al. 2018). To determine a more 
realistic sum AF for all severe ABCA4 variants we added two other variant groups.  
First, as published elsewhere (Cornelis et al. 2017) we identified non-truncating 
variants that were at least 100 times more frequent in STGD1 patients vs. controls and 
occurred with one of the two frequent known ‘mild’ variants c.2588G>C and c.5882G>A, or 
occurred in at least one patient with disease onset before 10 years of age. 
Second, based on the premise that mild variants always carry a severe ABCA4 variant 
in trans in STGD1 cases, we selected other variants found in trans with one of five 
statistically ‘mild’ ABCA4 variants in STGD1 cases, i.e., c.[2588G>C; 5603A>T], c.5882G>A, 
c.3113C>T, c.5714+5G>A and c.6089G>A, and determined their total AF in ~66,000 nFE 
control alleles. 
 
 
 
134 
 
Supplemental Results S2  
Penetrance calculations using other assumptions 
As our penetrance calculations are based on a few assumptions, we also calculated the 
penetrance based on lower and higher prevalences of STGD1, a higher prevalence of late-
onset STGD1 in our population, a higher estimate of the cumulative frequency of severe 
ABCA4 variants, and the possibility that the ExAC database also contains ABCA4 variant data 
from late-onset STGD1 cases. 
 
a) Prevalence of STGD1 among individuals carrying p.Asn1868Ile and a severe variant is twice 
as high (Table 2E) 
As some participants showed disease onset in their sixties, and as foveal sparing may cause 
a prolonged asymptomatic course, late onset STGD1 may be underdiagnosed. Also, patients 
with late-onset STGD1 may be misdiagnosed due to clinical overlap with other macular 
diseases. If the prevalence of STGD1 due to the combination of p.Asn1868Ile with a severe 
ABCA4 variant would be twice as high, the penetrance of this combination of variants  
would be between 1.92% [2*0.96%] and 4.78% [2*2.39%]. 
 
b) Prevalence of STGD1 is higher; proportion of STGD1 cases carrying p.Asn1868Ile and a 
severe variant stays the same (Table 2E) 
To date, only one STGD1 prevalence has been published (Blacharski 1988). If its prevalence 
is two times higher, the penetrance of p.Asn1868Ile, when found in combination with a 
severe ABCA4 variant, would be between 1.92 and 4.78%. 
 
c) Prevalence of STGD1 is lower (Table 2E) 
If the STGD1 prevalence is two times lower, the penetrance of p.Asn1868Ile, when found in 
combination with a severe ABCA4 variant, would be between 0.48% [0.5*0.96%] and 1.2% 
[0.5*2.39%]. 
 
d) Sum frequency of severe ABCA4 variants is higher than our highest estimate (Table 2C) 
Our estimate of the sum frequency of severe variants may be underestimated as we cannot 
rule out the possibility that a combination of a moderately severe variant with 
p.Asn1868Ile can also result in STGD1. If our highest estimate of the sum frequency of 
severe and moderately severe variants is twice as high (0.0134), the penetrance of 
p.Asn1868Ile, when found in combination with a severe ABCA4 variant, would range 
between 0.48% [0.5*0.96%] and 1.2% [0.5*2.39%]. 
 
e) ExAC database contains STGD1 cases (Table 2A-C) 
The control population (ExAC) may contain late-onset STGD1 cases. Even with our highest 
estimate of the sum of severe ABCA4 variants, the prevalence of persons with 
p.Asn1868Ile and a severe variant will be lower than 1/1000 individuals. In the non-Finnish 
European control individual group this would represent less than 33 persons. If this would 
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be the case, it would have a minor effect on p.Asn1868Ile allele frequency (maximum 
decrease from 0.065 to 0.064), and a moderate effect on the sum allele frequencies of 
severe variants (maximum decrease from 0.00271 to 0.00171 and from 0.0067 to 0.0057). 
The prevalence of persons with p.Asn1868Ile/severe variant would then range between 
[0.064x0.00171] 0.00010944 and [0.064x0057] 0.0003648, which would then result in 
penetrance of p.Asn1868Ile, when found in combination with a severe ABCA4 variant, 
between [143/6256] 2.3% and [143/1879] 7.6%. 
 
In conclusion, the minimal penetrance estimation based on all the minimizing factors – lower 
STGD1 prevalence and a higher severe ABCA4 variant frequency – would come down to 
0.96%*0.5*0.5 = 0.24%. If we assume that all the maximizing factors apply, i.e. 
underestimation of the late-onset prevalence, underestimation of the total STGD1 prevalence 
and contamination of ExAC, the maximal penetrance would be 7.6%*2*2 = 30.4%. Therefore, 
taking into account the cumulative effect of all variables in the calculation, the penetrance of 
the p.Asn1868Ile lies between 0.24% and 30.4%. 
 
Supplemental Table S1. Primers for ABCA4 variant segregation analysis 
 Forward (5'-> 3') Reverse (5'-> 3') Product size (bp) 
Ex6F_6R ACACAAGGTATTCCCAGGTTC AAGGATTGTCCAGAACACCA 396 
Ex13F_13R CAGAGTCACATTGTGGCTAATATT TCTAAAGACATGGAAGCCTTG 467 
Ex14F_14R CCTCTACCAGGTACAGAGC AGATGTCACGCTCTCCTTG 389 
Ex19F_23R CACCACCTTGTGAGTCTTCC GTGAGTGGACATGATGATGG 5551 
Ex22F_22R CACCCTCCACAGCCCCTTAAC AAATGGCAGGTGAGAGAGTG 264 
Ex27F_27R GCTACCAGCCTGGTATTTCATTG GTTATAACCCATGCCTGAAG 493 
Ex28F_28R ACCCTGCTTATTATGTTCCCC CAGTGAAGTGGGAAGGTCAG 378 
Ex30F_30R CACACCTAGTCAGTCACAAAAC ACTCAGGAGATACCAGGGAC 451 
Ex39F_39R CTGCAAGGACTCTCTGTCTG CAACAAGGTCCCCTCCTAG 367 
Ex40F_40R CCAGGTCTGTGGGGTGAG CTCCTGAGGAAAGAAATGACC 279 
Ex41F_41R GGACACTGTACAGCCAGC TGTTCTATAGAAGGAAAATGGC 247 
Ex42F_42R CGAGATGTCTCAGTACTCACCAC CATATGTGACTTGCATTATGGC 349 
Ex43F_43R CTTACCCTGGGGCCTGAC CTCAGAGCCACCCTACTATAG 277 
Ex45F_45R GTTTGGGGTGTTTGCTTGTC ACCTATTTCCCCAACCCAAGAG 257 
Ex46F_47R CTTCTGTCAGCTCATCCTCCA CTCTTCCAAGTGTCAATGGAG 455 
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Supplemental Table S2. Clinical characteristics of patients carrying c.5603A>T (p.Asn1868Ile) 
 
Subject / Sex / Age 
(yrs) 
Age at 
onset 
(yrs) 
Initial symptoms Fundus and imaging features Dark choroid on 
fluorescein 
angiography 
Full-field ERG
i
 Latest visual acuity Disease 
duration at 
latest visit 
(yrs)
l
 
Rod 
function 
(RE/LE) 
Cone 
function 
(RE/LE) 
RE LE 
A-II:4 / ♀ / 79a,b 71 Metamorphopsia Yellow-white pisciform flecks throughout the posterior pole Yes N N 20/25 20/20 4 
B-II:1 / ♂ / 68a,b,c 54 Scotoma RE Yellow-white pisciform flecks throughout the posterior pole and mid-periphery 
with chorioretinal atrophy in macula  
Yes SR SR 20/200 20/200 9 
B-II:3 / ♀ / 64 19 ↓VA 58yrs: extensive chorioretinal atrophy and pigmentary changes in macula with 
yellow-grey pisciform flecks thoughout posterior pole and midperiphery  
Yes NP NP 
CF
j
 
20/400 41 
C-II:1 / ♂ / 60 41 ↓VA + 
metamorphopsia 
Yellow-white pisciform flecks throughout the posterior pole and mid-periphery 
with parafoveal chorioretinal atrophy 
NP N (45yrs) N (45yrs) 20/20 20/20 8 
C-II:2 / ♀ / 57 45h Nyctalopia Yellow-white pisciform flecks throughout the posterior pole and extensive 
chorioretinal atrophy with foveal sparing 
NP NP NP 20/50 20/20 10 
D-II:1 / ♂ / 68 61 Scotoma 62yrs: yellow-white pisciform flecks throughout the posterior pole and parafoveal 
chorioretinal atrophy with foveal sparing   
68yrs: chorioretinal atrophy in macula with a few surrounding pisciform yellow-
white flecks 
Yes N (63yrs) NP 
(63yrs) 
CF 20/130 7 
D-II:3 / ♂ / 58 52h None Predominantly perimacular pisciform yellow-white flecks and mottled decreased 
FAF in macula with preserved fovea  
NP NP NP 20/20 20/22 6 
E-II:3 / ♀ / 68a,b,c 56  
↓VA 
Foveal changes with perimacular and peripapillary irregular yellow-white flecks 
and mottled decreased FAF in macula 
Yes N N 20/400 20/400 8 
F-II:2 / ♂ / 45 32 ↓VA Foveal changes with perimacular and peripapillary irregular yellow-white flecks 
and mottled decreased FAF in macula (Figure 3A-C) 
Yes N N 20/66 20/66 9 
G-II:2 / ♂ / 73c 69 ↓VA + central 
scotoma 
Chorioretinal atrophy with foveal sparing and hyper- and hypoautofluorescent 
flecks throughout posterior pole and midperiphery on FAF (Figure 4A-C) 
NP N (72yrs) N/MR 
(72yrs) 
20/25 20/40 4 
H-II:3 / ♂ / 66d 30 ↓VA Perimacular irregular yellow-white flecks and beaten bronze atrophy in macula (no 
OCT/FAF) 
Yes N N 20/125  20 HMk 20 
I-II:3 / ♀ / 62e 18 ↓VA + central 
scotoma 
Parafoveal pigmentary changes with yellow-white pisciform flecks throughout the 
posterior pole and mild atrophy in macula (no OCT/FAF) 
No N N 20/50 20/33 11 
J-II:2 / ♂ / 58j 56 ↓VA Pigmentary changes in macula, perimacular yellow-white flecks and chorioretinal 
atrophy with in RE foveal sparing, in both eyes surrounded by an area of increased 
background FAF 
NP NP NP 20/32 20/330 1 
K-II:1 / ♀ / 47 23 ↓VA Foveal changes and perimacular yellow-white flecks (no OCT/FAF) Yes NP NP 20/200 20/125 6 
L-II:1 / ♀ / 50 31h ↓VA Foveal changes with perimacular yellow-white irregular flecks and mottled 
decreased FAF in macula 
Yes N (31yrs) N (31yrs) 20/200 20/200 15 
M-II:1 / ♀ / 69 53 ↓VA Foveal changes with yellow-white pisciform flecks throughout the posterior pole 
and mid-periphery and chorioretinal atrophy with foveal sparing; Attenuated 
arterioles 
Yes MR 
(53yrs) 
N (53yrs) 20/50 20/100 16 
N-II:1 / ♀ / 72a.b.c.g 45h ↓VA 45yrs: yellow-white pisciform flecks throughout the posterior pole  
71yrs: extensive chorioretinal atrophy in macula of RE after years of foveal sparing, 
chorioretinal atrophy with foveal sparing in LE 
Yes SR 
(69yrs) 
SR 
(69yrs) 
2/300 20/20 26 
O-II:1 / ♀ / 39 32 Metamorphopsia 
LE 
Foveal changes with perimacular yellow-white irregular flecks, with preserved 
fovea and mottled FAF in macula 
NP NP NP 20/22 20/20 7 
P-II:1 / ♀ / 39c 32 ↓VA Foveal changes with perimacular yellow-white irregular flecks and mottled NP N N 20/50 20/100 3 
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Subject / Sex / Age 
(yrs) 
Age at 
onset 
(yrs) 
Initial symptoms Fundus and imaging features Dark choroid on 
fluorescein 
angiography 
Full-field ERG
i
 Latest visual acuity Disease 
duration at 
latest visit 
(yrs)
l
 
Rod 
function 
(RE/LE) 
Cone 
function 
(RE/LE) 
RE LE 
decreased FAF in macula surrounded by a zone of increased background FAF 
Q-II:1 / ♀ / 48 42h Unknown Foveal changes with perimacular yellow-white irregular flecks and mottled 
decreased FAF in macula 
Yes NP NP 20/30 20/32 4 
R-II:1 / ♂ / 32 30h None Perimacular ring of increased FAF around a zone of mottled decreased FAF, with 
preserved fovea and normal fovea reflex. A few mild hyperfluorescent flecks in 
posterior pole 
NP N N 20/28 20/22 1 
S-II:1 / ♀ / 31 26 ↓VA Foveal changes with perimacular yellow-white irregular flecks and mottled 
decreased FAF in macula 
Yes N (28yrs) N (28yrs) 20/200 20/50 4 
T-II:1 / ♂ / 45c 36 ↓VA Foveal pigmentary changes and yellow-white pisciform flecks throughout the 
posterior pole and mid-periphery with chorioretinal atrophy in macula 
NP NP NP 20/66 20/600 9 
U-II:1 / ♀ / 41 37h None Perimacular yellow-white pisciform flecks and mottled decreased FAF in macula 
with relatively spared fovea 
NP N (37yrs) NP 
(37yrs) 
20/40 20/66 3 
V-II:1 / ♀ / 31 27h ↓VA Mottled decreased FAF in macula, surrounded by a zone of increased background 
FAF and few hyperfluorescent flecks in macula 
NP SR 
(27yrs) 
N (27yrs) CF 20/100 4 
W-II:1 / ♀ / 55 42 ↓VA Perimacular yellow-white irregular flecks and a zone of increased background FAF 
in macula with foveal mottled decreased FAF 
NP N (42yrs) N (42yrs) 20/130 20/200 13 
X-II:1 / ♀ / 36c 20 ↓VA + central 
scotoma 
Perimacular yellow-white irregular flecks with chorioretinal atrophy in macula No N N 20/200 20/125 12 
Y-II:1 / ♀ / 53 47h Scotoma RE Perimacular yellow-white irregular flecks; Parafoveal chorioretinal atrophy with 
relative foveal sparing in RE, and mottled decreased FAF with foveal sparing in LE 
Yes NP NP 20/25 20/20 6 
Z-II:1 / ♀ / 51 21 ↓VA + 
protanomaly 
22yrs: abnormal foveal reflex with macular pigmentary changes  
44yrs: perimacular yellow-white irregular flecks and chorioretinal atrophy in 
macula 
NP N/NP 
(20yrs) 
N/NP 
(20yrs) 
20/500 CF 23 
AA-II:1 / ♂ / 63 57 Unknown Yellow-white pisciform flecks throughout the posterior pole NP N N 20/20 20/20 1 
 
BE, both eyes; CF, counting fingers; ERG, electroretinography; FAF, fundus autofluorescence; HM, hand motion; LE, left eye; NP, not 
performed; RE, right eye; VA↓, decrease in visual acuity; ♀, female; ♂, male. Previously mentioned cases: a) Westeneng et al., 2012; b) 
Lambertus, Lindner, Bax et al., 2016; c) Lambertus, Bax, Groenewoud et al., 2016; d) Klevering et al., 2004 and Bax et al., 2015; e) Hoyng et 
al., 1996; f) Sangermano et al., 2016; g) van Huet et al., 2014; h) age at diagnosis; i) ERG results of latest visit, unless stated otherwise; N, 
normal amplitude (equal to or above the lower 5% of the range for a normal population); MR, moderately reduced amplitude (1%–5% of 
normal range); SR, severely reduced amplitude (<1% of normal range); j) Coats’ disease; k) amblyopic eye; l) Defined as time since onset of 
complaints. 
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Supplemental Figure S1. Stargardt siblings presenting with different ABCA4 genotypes. Based on haplotype analysis in family I with three siblings 
affected by STGD1 two decades ago (Hoyng et al. 1996), and ABCA4 sequence analysis, we were able to identify the causal variants in two of three siblings, 
i.e., the variants c.768G>T (p.Leu257Valfs*17) and c.2588G>C (p.[Gly863Ala, Gly863del]), that previously were designated as severe and mild ABCA4 
variants, respectively (Maugeri et al. 1999; Maugeri et al. 2002). As expected, the c.2588G>C variant was found to be in cis with c.5603A>T (p.Asn1868Ile) 
thereby forming the complex allele c.[2588G>C; 5603A>T]. The affected person I-II:3 only carried the c.768G>T variant and was genetically unexplained. 
With the possibility that the p.Asn1868Ile variant may have been overlooked as a causal variant, we tested its presence in all family members and found it to 
be present in a homozygous state in the unaffected mother I-I:2 and in a compound heterozygous manner in I-II:3. In the mother, one of these variants is 
present in cis with c.2588G>C, which thereby constitutes a penetrant mild ABCA4 allele. In I-II:3 it is present in a compound heterozygous configuration 
together with the severe variant c.768G>T. All siblings experienced initial symptoms at the age of 18 to 19 years. However, at the age of 29 years BCVA of I-
II:3 had declined to 20/50 in the right eye and 20/33 in the left eye, whereas BCVA at the same age in I-II:2 was 20/80 in the right eye and 20/125 in the left 
eye and in I-II:1 below 20/100 in both eyes.   
 In Family J, J-II:1 carries the ‘complex’ allele c.[5461-10T>C; 5603A>T] and p.(Val643Gly). The non-canonical splice site variant c.5461-10T>C is known 
to result in exon 39 or exon 39/40 skipping and protein truncation (Sangermano et al. 2016); p.Val643Gly is a variant with unknown significance. Her brother 
(J-II:2), showing late-onset STGD1, carries the same ‘complex’ allele c.[5461-10T>C; 5603A>T] in combination with p.Asn1868Ile. The initial symptom of 
vision loss occurred at the age of 56 and 51 years in J-II:1 and J-II:2, respectively. They manifested similar phenotypes with central chorioretinal atrophy 
surrounded by a ring of increased FAF and a few hyperfluorescent flecks, although J-II:1 at the age of 57 exhibited foveal sparing, whereas J-II:2 at the age of 
53 (first visit) showed more advanced disease with a BCVA of 20/100 in the best eye. 
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Abstract  
In 20% of persons with autosomal recessive Stargardt disease (STGD1), only one of the two 
expected causal variants could be detected in the coding sequence of ABCA4. By ABCA4 
locus sequencing, we identified six novel causal deep-intronic variants in 24 out of 45 (53%) 
mono-allelic STGD1 patients. Using in vitro splice assays, five variants resulted in pseudoexon 
inclusion, which was confirmed in patient-derived fibroblasts for c.769-784C>T and c.859-
506G>C. Intriguingly, the c.4253+43G>A variant induced exon 28 skipping. The two most 
prevalent variants, c.769-784C>T and c.4253+43G>A, only showed a partial splice defect in 
vitro, which correlated well with a late average age at disease onset in the respective 
patients. Antisense oligonucleotides targeting the aberrant splice processes resulted in a 
significant correction of the splice defects. Together, our data demonstrate the importance 
of assessing non-coding variants in genetic diseases, and show the great therapeutic 
potential of correcting the associated splice defects. 
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Introduction 
In the last decade, next-generation sequencing (NGS) has not only allowed a much faster 
identification of novel disease genes (Ng et al. 2009, Nikopoulos et al. 2010, Carss et al. 
2017), but also has transformed molecular diagnostic testing (Abu-Safieh et al. 2013, 
Beryozkin et al. 2015, Weisschuh et al. 2016, Haer-Wigman et al. 2017). Thus far, the 
emphasis was on coding and flanking splice site sequences that harbor the majority of 
genetic defects. These studies were able to identify the underlying defects in 40 – 60% of all 
patients in genetically heterogeneous diseases, such as intellectual disability, hearing 
impairment and inherited retinal diseases (IRDs) (Neveling et al. 2012, Neveling et al. 2013, 
Gilissen et al. 2014). The remaining defects are suspected to reside in the remaining part of 
the genome (98%) that contains non-coding sequences. Whole-genome sequencing can 
identify the majority of non-coding sequence variants (Carss et al. 2017), but it will be very 
challenging to pinpoint the causal variants in the absence of comprehensive assays that 
reveal the resulting mRNA and/or protein defects.   
For diseases that are due to mutations in a single gene, the yield of mutations 
generally is higher. This is true for Stargardt disease (STGD1) (MIM 248200) which is caused 
by mutations in the gene encoding the ATP binding cassette type A4 (ABCA4) (MIM 601691) 
(Allikmets et al. 1997), as bi-allelic variants can be found in the majority of the cases (Zernant 
et al. 2014). Besides STGD1, ABCA4 is also mutated in ~30% of cases with autosomal 
recessive cone-rod dystrophy (Maugeri et al. 2000) and in a small percentage of cases with 
generalized dystrophy mimicking retinitis pigmentosa (Cremers et al. 1998). ABCA4 thereby 
is the most frequently mutated gene underlying IRD. Patients with an onset <11 years often 
display generalized retinal dysfunction at the age of diagnosis and have a poor prognosis 
(Lambertus et al. 2015, Fakin et al. 2016). A frequent coding variant, p.Asn1868Ile, was 
recently shown to be present in ~10% of STGD1 cases. Often, these cases carried a severe 
mutation in trans and showed late-onset disease (Zernant et al. 2017). The remaining 
mutations in ABCA4 rarely consist of heterozygous deletions (Maugeri et al. 1999; Yatsenko 
et al. 2003; Bax et al. 2015). In addition, mutations in a few other genes have been found to 
underlie STGD-like phenotypes (Zaneveld et al. 2015).  
Currently, more than 200 pathogenic deep-intronic variants in 77 different human 
disease-associated genes have been identified, the majority of which results in pseudoexon 
(PE) inclusion (Liquori et al. 2016; Vaz-Drago et al. 2017). Deep-intronic ABCA4 variants that 
have been identified over the last few years account for some of the missing heritability in 
STGD1 (Braun et al. 2013; Zernant et al. 2014; Bauwens et al. 2015; Bax et al. 2015). By 
employing patient-derived keratinocytes, it was shown that some of these variants 
strengthen weak alternative splice sites or create new cryptic splice sites, ultimately 
resulting in PE inclusions (Braun et al. 2013). Alternatively, the PE inclusions may result from 
the strengthening or creation of exonic splicing enhancers (ESEs) due to the intronic 
nucleotide change. Employing patient-derived photoreceptor precursor cells (PPCs), we 
were recently able to show that two neighboring intronic variants in ABCA4 
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(c.4539+2001G>A an c.4539+2028C>T) strengthen different ESEs that result in the inclusion 
of the same 345-nt PE, causing a disruption of the reading frame (p.Arg1514Leufs*36) 
(chapter 7). 
 PE inclusions due to deep-intronic variants are very attractive targets for antisense 
oligonucleotide (AON)-based splicing correction. Splicing modulating AONs are small RNA 
molecules able to bind complementarily to the pre-mRNA and therefore allow the exclusion 
or inclusion of (pseudo)exons to the mRNA (Hammond and Wood 2011). In the field of IRDs, 
these molecules have shown therapeutic potential for deep-intronic mutations in several 
genes such as CEP290 (Collin et al. 2012; Gerard et al. 2012; Garanto et al. 2016; Parfitt et al. 
2016), USH2A (Slijkerman et al. 2016) or OPA1 (Bonifert et al. 2016). A phase1/2 clinical trial 
using AONs to treat CEP290-associated Leber congenital amaurosis has recently commenced 
(NCT03140969). 
In this study, we employed ABCA4-associated STGD1 as a model to assess the 
challenges that need to be faced in order to identify pathogenic non-coding variants. For this 
purpose, we sequenced the ABCA4 locus in 45 mono-allelic STGD1 patients. Selected non-
coding variants were tested by midigene-based in vitro splice assays and two were also 
analyzed using patient-derived fibroblasts. Subsequently, several AONs were designed and 
successfully applied to redirect erroneous splicing. 
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Results 
Identification and selection of deep-intronic variants for splicing assay 
Sequence analysis of 41 Dutch mono-allelic STGD1 cases revealed the already known first 
allele in all cases, illustrating the high sensitivity of our locus sequencing approach. In two 
probands, we found the previously identified c.4539+2001G>A and c.5196+1137G>A 
(originally denoted V4 and V1, respectively) (Braun et al. 2013). After removal of previously 
identified variants, 253 rare ABCA4 variants (allele frequency (AF) ≤ 0.01 in control 
individuals) remained, consisting of 92 independent novel variants (Supplemental Table S1). 
In the four British mono-allelic STGD1 cases analyzed by whole genome sequencing (WGS), 
nine novel rare (AF ≤ 0.01) independent ABCA4 variants remained (Supplemental Table S1).  
Eleven non-coding variants were selected for splice assays (Supplemental Table S2). 
Seven of these (c.768+7329A>G, c.858+526T>G, c.859-506G>C, c.1555-5008C>T, 
c.4539+1100A>G, c.4539+1106C>T, c.6148-421T>C) were selected as they were located at 
cryptic splice sites or created a new putative splice site with a relative strength of at least 
75% of the maximal score in two of five algorithms, and showed an increased splice 
prediction score of at least 2%. Three variants, which belonged to two alleles (c.769-784C>T 
and c.[4253+43G>A; 6006-609T>A]), were enriched among the mono-allelic cases, i.e., in 
seven and nine of 45 probands, respectively. Finally, the c.1937+435C>G variant was 
selected because it was located in the genomic sequence of an alternate exon 13 (Chr1: 
94,527,737-94,527,644) that was previously described (Braun et al. 2013). 
  
Four novel deep-intronic variants result in PE generation through the strengthening of 
splice sites 
To test the functional effect of the 11 selected non-coding variants, seven ABCA4 wild-type 
midigene constructs previously described as BA4, BA6, BA7, BA9, BA11, BA19 and BA21 
(Sangermano et al. 2018) and the newly designed BA30 (Supplemental Table S3), were 
mutagenized. Upon RT-PCR and Sanger sequence validation, four variants (c.768+7329A>G, 
c.1555-5008C>T, c.6006-609T>A, c.6148-421T>C) had no effect (Supplemental Fig. S1). 
Variant c.858+526T>G did not show a PE insertion compared to the WT midigene, but did 
yield four weak smaller fragments (Supplemental Fig. S1). In the absence of sequence 
results, their relevance is unknown. Previously, a similar pattern was observed for c.859-
9T>C (Supplemental Fig. S2) (Sangermano et al. 2018). Variant c.858+526T>G was found to 
be in cis with a complex allele containing a protein-truncating mutation (p.[Trp273*; 
Asn1868Ile]) in patient E-II:1, as determined by segregation analysis. The remaining six 
variants resulted in clear splice defects (Fig. 1, Supplemental Fig. S2) that altogether allowed 
us to detect the second variant in 24/45 (53%) mono-allelic probands (Table 1). 
The deep-intronic variant c.769-784C>T was found in 7/45 mono-allelic cases and 
thus enriched in our cohort. This variant is located in the 15.4-kb sized intron 6, and was 
predicted to increase the strength of an intronic splice acceptor site (at position 
g.94,549,775). In addition, a strong splice donor site was situated 161 nt downstream. Due 
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to the very large size of intron 6, wild-type BA6 only contains half of intron 6 and exon 7. RT-
PCR was therefore performed using primers in the flanking RHO exon 3 which is part of the 
splice vector, and ABCA4 exon 7. The wild-type construct showed main bands of 134 and 400 
bp, corresponding to the expected wild-type mRNA fragment and an RT-PCR artefact that 
was explained by an aberrant splicing process between RHO exon 3 and the midigene. 
However, the mutant c.769-784C>T construct showed an additional clear band of 296 bp, 
corresponding to the inclusion of a 162-nt PE from position c.769-778 to 769-617 (Fig. 1B 
and Supplemental Fig. S2). This PE contains a premature stop codon that is predicted to lead 
to premature termination of protein synthesis. Capillary electrophoresis quantification of 
mutant mRNA revealed that the PE fragment only accounts for ~7% of the total ABCA4 pre-
mRNA (Supplemental Table S4). However, in this particular case, the results of the capillary 
analysis were not completely corresponding to what was observed in the gel (Fig. 2B). We 
therefore used an alternative method to semi-quantify the bands using Fiji (Schindelin et al. 
2012). After image analysis we observed that the amount of PE in the NT cells transfected 
with the mutant midigene was variable between replicates, representing ~26% of the ABCA4 
PCR fragments (Supplemental Table S5). This suggests a mild effect at the RNA and thus 
protein level (r.[=, 768_769ins(162)]; p.[=, Leu257Aspfs*3]).  
The deep-intronic variant c.859-506G>C was predicted to significantly strengthen a 
cryptic intronic splice acceptor site and is accompanied by a downstream splice donor site. 
RT-PCR in wild-type BA7 using primers located in ABCA4 exons 7 and 8 yielded a band of 254 
bp corresponding to the correctly spliced pre-mRNA, whereas for the mutant c.859-506G>C 
midigene, an additional band of 310 bp corresponding to a 56-nt PE insertion (c.859-503 – 
c.859-448) was found (Fig. 1B and Supplemental Fig. S2). This insertion is predicted to result 
in a frameshift, and the mutant pre-mRNA accounted for 75.5% of total splice products 
(Supplemental Table S4), indicating the deleterious effect of this variant at the RNA and 
(predicted) protein level (r.[858_859ins(56), =]; p.[Phe287Thrfs*32, =]). 
Deep-intronic variants c.4539+1100A>G and c.4539+1106C>T were predicted to alter 
the same cryptic splice donor site located at position g.94,493,901. A very strong splice 
acceptor site was located at position g.94,493,968. Both variants were mutagenized in the 
wild-type (WT) BA21 construct and RT-PCR was performed using primers in ABCA4 exons 30 
and 32. Strikingly, besides the expected 68-nt PE fragment (PE30.1) due to the splice 
acceptor site at position c.4539+1033 and the splice donor site at position c.4539+1100, a 
larger 112-nt PE (PE30.2) carrying the same splice donor but another acceptor located at 
position g.94,494,012 was also observed (Fig. 1B and Supplemental Fig. S2). Interestingly, 
the relative ratios of these two PEs significantly differ between the midigene constructs 
carrying c.4539+1100A>G and c.4539+1106C>T. Overall, PE30.1 accounted for 60.6% and 
93.1% of the total transcript in c.4539+1100A>G or c.4539+1106C>T respectively, while 
PE30.2 was only present in 20.1% and 3.8% of the cDNA products, respectively 
(Supplemental Table S4). As both c.4539+1100A>G and c.4539+1106C>T showed only a 
minor fraction of correctly spliced products (19.1% and 3.0%) and because PE30.1 and 
PE30.2 are both predicted to lead to a frameshift, these variants were both deemed to have 
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a severe deleterious effect (r.[4539_4540ins(68), 4539_4540ins(112), =]; p.[Arg1514Glyfs*3, 
Arg1514Valfs*31, =]). 
 
 
Figure 1. Generation and assessment of splicing defects using midigenes. A. Schematic 
representation of the five wild-type midigenes used that were cloned between exon 3 and 5 
of Rhodopsin in pCI-Neo-RHO. Position of the mutations present in six mutant midigenes is 
indicated. B. Assessment of the splicing defects upon midigene transfection in HEK293T cells. 
Five PE inclusions and one exon skipping were detected in the mutant (MUT) constructs 
compared to the wild-type (WT). MQ stands for the negative control of the PCR reaction. 
Rhodopsin (RHO) amplification was used as a transfection and loading control. 
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Table 1: Persons with STGD1 carrying causal non-coding variants in ABCA4 
Patient_ID Gender Age at 
onset 
(yrs) 
Segregation 
confirmed 
Allele1 DNA Allele1 protein Allele 2 DNA Allele 2 protein 
A-I:2 F 38 Yes c.1822T>A p.(Phe608Ile) c.[769-784C>T; 5603A>T] p.[=, Leu257Aspfs*3; Asn1868Ile] 
B-I:2 F 10 Yes c.768G>T p.(Leu257Valfs*17) c.859-506G>C p.[Phe287Thrfs*32, =] 
C-I:2 F 48 Yes c.768G>T p.(Leu257Valfs*17) c.[769-784C>T; 5603A>T] p.[=, Leu257Aspfs*3; Asn1868Ile] 
D-III:1 M 44 Yes c.4363T>C p.(Cys1455Arg) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
E-II:1 F 7 Yes c.[818G>A; 5603A>T] p.[Trp273*; Asn1868Ile] c.4539+1100A>G p.[Arg1514Valfs*31, Arg1514Glyfs*3, =] 
F-II:2 F 20 Yes c.1822T>A p.(Phe608Ile) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
G-I:2 F 51 Yes c.1822T>A p.(Phe608Ile) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
H-I:2 F 53 Yes c.[5461-10T>C; 5603A>T] p.[Thr1821Valfs*13, Thr1821Aspfs*6; 
Asn1868Ile] 
c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
I-II:3 F 73* Yes c.4577C>T p.(Thr1526Met) c.[769-784C>T; 5603A>T] p.[=, Leu257Aspfs*3; Asn1868Ile] 
J-II:3 M 61 Yes c.768G>T p.(Leu257Valfs*17) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
K-II:1 M 62 Yes c.6155del  p.(Asn2052Thrfs*9) c.[769-784C>T; 5603A>T] p.[=, Leu257insAspGln*; Asn1868Ile] 
L-II:1 M 61 Yes c.[5461-10T>C; 5603A>T] p.[Thr1821Valfs*13, Thr1821Aspfs*6; 
Asn1868Ile] 
c.[769-784C>T; 5603A>T] p.[=, Leu257insAspGln*; Asn1868Ile] 
M-II:1 M 18 Yes c.4539+2001G>A (V4) p.(Arg1514Leufs*36) c.[4253+43G>A; 5603A>T] p.[=, Ile1377Hisfs*3, Asn1868Ile] 
N-II:3 M 31 Yes c.4773+1G>A p.(?) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
O-I:1 M 49 Yes c.3113C>T p.(Ala1038Val) c.859-506G>C p.[Phe287Thrfs*32, =] 
P-II:3 F 4 Yes c.5196+1137G>A (V1) p.(Met1733Glufs*78) c.859-506G>C p.[Phe287Thrfs*32, =] 
Q-II:1 M 70 Yes c.4539+1G>T p.(?) c.[769-784C>T; 5603A>T] p.[=, Leu257Aspfs*3; Asn1868Ile] 
R-II:1 M 52 n.t c.4539+1G>T p.(?) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
S-II:1 F 64 n.t c.768G>T p.(Leu257Valfs*17) c.[769-784C>T; 5603A>T] p.[=, Leu257Aspfs*3; Asn1868Ile] 
T-II:1 F 35 n.t c.[2588G>C; 5603A>T] p.[Gly863Ala, Gly863del; Asn1868Ile] c.1937+435C>G p.[=, Ser646Serfs*25] 
U-II:1 M 9 n.t c.768G>T p.(Leu257Valfs*17) c.1937+435C>G p.[=, Ser646Serfs*25] 
V-II:1 F 15 n.t c.[2588G>C; 5603A>T] p.[Gly863Ala, Gly863del; Asn1868Ile] c.4539+1100A>G p.[Arg1514Valfs*31, Arg1514Glyfs*3, =] 
W-II:1 n.a. 11* n.t c.[1622T>C; 3113C>T] p.[Leu541Pro; Ala1038Val] c.4539+1106C>T p.[Arg1514Valfs*31, Arg1514Glyfs*3] 
X-II:1 n.a. 52* n.t c.4469G>A p.(Cys1490Tyr) c.[4253+43G>A; 6006-609T>A] p.[=, Ile1377Hisfs*3] 
*Unknown age of onset. Current age; n.t., not tested; Based on Sangermano et al. 2018.
152 
 
c.1937+435C>G results in PE generation through the disruption of putative splice silencers  
The c.1937+435C>G variant did not alter the strength of a cryptic splice site. Instead, it was 
predicted to disrupt an ESE (SC35) motif, and, more importantly, to inactivate two splice 
silencer motifs and to lower the predicted strength of a third one (Supplemental Fig. S3). 
This variant was located within the genomic sequence of a low-abundance ABCA4 splice 
variant containing intron 13 sequences that was reported previously (Chr1: 94,527,737-
94,527,644) (Braun et al. 2013). RT-PCR using primers spanning ABCA4 exons 13 and 14 
revealed a 134-nt PE insertion between positions c.1937+396 and c.1937+529 in mutant 
BA11 compared to wild-type (Fig. 1B and Supplemental Fig. S2). Although the splice defect 
caused by this variant disrupted the reading frame (r.[=, 1937_1938ins(134)]; p.[=, 
Ser646Serfs*25]), the fraction of mutant transcript was low (8.6%) (Supplemental Table S4). 
 
Variant c.4253+43G>A results in exon skipping through the disruption of putative splice 
silencers 
The c.4253+43G>A variant, located just downstream of exon 28, was present in nine 
mono-allelic STGD1 patients. This variant does not weaken the canonical splice donor site of 
exon 28, and also does not affect any other cryptic splice sites in silico. It does however 
reduce the strength of one ESE motif (SC35) and creates another one (SF2/ASF), and at the 
same time disrupts one splice silencer motifs and reduces the strength of another one 
(Supplemental Fig. S4). c.4253+43G>A was found in cis with the previously reported rare 
variant c.6006-609T>A (Zernant et al. 2014) in all nine probands. The latter variant however, 
despite some minor alterations in the prediction of surrounding splice sites, showed no 
effect in the in vitro splice assay (Supplemental Fig. S2). Variant c.4253+43G>A however did 
show a clear splice defect. Using ABCA4 primers in exons 26 and 29, the mutant midigene 
BA19 carrying c.4253+43G>A yielded bands of 495 and 370 bp, the first corresponding to the 
correctly spliced product, and the second to a product in which exon 28 was skipped (Fig. 1B 
and Supplemental Fig. S2). This deletion of 125 bp is predicted to lead to a frameshift and 
although both WT and mutant midigenes showed some skipping of exon 28, in the mutant 
construct this was significantly higher compared to WT (26.1% vs 2.8%, Supplemental Table 
S4). The fact that in all nine probands, a severe variant was found in trans, in combination 
with a late age of onset, suggests a mild effect of this variant (r.[=, 4129_4253del(125)]; p.[=, 
Ile1377Hisfs*3]. All six non-coding variants segregated in families of affected probands. An 
overview of the allele frequency and of the splice defects caused by these six variants can be 
found in Supplemental Table S6.  
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Single molecule Molecular Inversion Probe-based sequence analysis of intronic ABCA4 
regions 
Five out of six intronic ABCA4 variants (c.769-784C>T, c.859-506G>C, 
c.4253+43G>A, c.4539+1100A>G, and c.4539+1106C>T) were analyzed for their recurrence 
in 412 genetically unsolved STGD1 cases from France (n=224) and Germany (n=188), by 
employing a single molecule Molecular Inversion Probe (smMIPs) technique (Hiatt et al. 
2013). Recurrence for the c.1937+435C>G variant was not assessed since the splice defect 
due to this variant was found after the smMIPs had been designed. Three variants were 
found in a heterozygous state in this cohort: c.769-784C>T in five cases, c.4253+43G>A in 28 
cases, and c.4539+1106C>T in one case (Supplemental Table S6). Variants c.859-506G>C and 
c.4539+1100AG were not detected in the 412 cases. 
 
Antisense oligonucleotide-based exclusion of PEs 
We employed AONs to modulate splicing and restore the mRNA transcript. For five of the 
variants (c.769-784C>T, c.859-506G>C, c.1937+435C>G, c.4539+1100A>G and 
c.4539+1106C>T) we designed three different AONs that all aim to result in PE exclusion. In 
order to promote this, AONs were designed to have a similar length, melting temperature 
and GC content, and they were mainly targeting SC35 and SRSF5 motifs with high scores. In 
contrast, for the c.4253+43G>A variant, only two AONs were designed, blocking splice 
silencer motifs in order to reinforce inclusion of exon 28 to the ABCA4 transcripts. We 
hypothesized that the variant was creating a motif that was causing exon skipping. A 
summary of the sequences and characteristics of the AONs is provided in Supplemental 
Table S7. The effect of the AONs at RNA level was assessed by RT-PCR and subsequently 
semi-quantified using capillary analysis (Supplemental Fig. S5 and Supplemental Table S4). 
For c.769-784C>T, AON2 completely restored correct splicing, whereas AON3 had a 
partial effect (Fig. 2B). Capillary analysis however also revealed a 100% restoration for AON3, 
as the aberrant band did not reach the detectable threshold following AON administration. 
However after Fiji semi-quantification a PE was still detected in 14% of the total amount of 
ABCA4 transcripts. When using AON1, splice redirection was observed, i.e., the PE-
containing transcript was converted into correctly spliced product. Both in the analysis of the 
WT and the mutant midigene however, an additional faint band could be observed. The 
band was cloned into a pGEMT vector and sequence analysis revealed only partial PE 
skipping. It appeared that the 5’ 68 nt of the PE were skipped, while 3’ 94 nt remained. Given 
the position of AON1, this AON most likely blocks the splice acceptor site of the PE, 
triggering the use of an alternative downstream splice acceptor site. Even though the 
capillary analysis did not pick up this band, gel semi-quantification using Fiji determined that 
1,61% and 3,3% of the total amount of ABCA4 transcripts corresponded to the partial PE 
created by AON1 in WT and MUT transfected cells, respectively.   
For c.859-506G>C, two AONs (AON1 and AON2) corrected the splicing defect (Fig. 
2B). For the c.1937+435C>G variant, all three AONs completely restored normal splicing (Fig. 
2B). In addition, we observed that the 134-nt PE could also naturally be included in the WT 
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construct, as the band was also present in the non-treated and the sense oligonucleotide 
(SON)-treated samples. Since in this particular case, the PE is also spliced in when 
transfecting the WT construct, the variant apparently enhances the PE recognition. Finally, 
the two neighboring variants (c.4539+1100A>G and c.4539+1106C>T) resulted in the 
activation of a splice donor site causing the insertion of two overlapping PEs (PE30.1: 68 nt 
and PE30.2: 112 nt) to the ABCA4 mRNA. AONs were designed that could target both 
mutations. AON1 and AON2 correctly restored splicing while AON3 did not show any rescue 
(Fig. 2B). For all AONs, no potential splicing defect was detected in the WT transcript upon 
AON delivery. 
 
AON-based PE exclusion using patient-derived fibroblast cells 
To investigate whether the AON-based splice correction that we observed in the midigene 
assays would also occur in a cellular context relevant to the patient, we generated fibroblast 
cell lines from a proband compound heterozygous for c.[769-784C>T; 5603A>T] and 
c.1822T>A (p.Phe608Ile) (Patient A-I:2), and from a STGD1 proband carrying c.859-506G>C 
and a putative deletion on the other allele (Patient DNA14-33085; not listed in Table 1). We 
first checked whether the splicing defect identified using midigenes was also found in those 
cells, and whether it was affected by nonsense-mediated decay (NMD). Our results showed 
that in both cases, the PEs were detected and that it corresponded to the same PE that was 
identified previously (Fig. 3).   
Fibroblasts were transfected with the corresponding AONs and subjected to 
cycloheximide (CHX) treatment to block NMD. In both cases, the same AONs that restored 
splicing in the midigenes showed rescue in fibroblasts (Fig. 3). For c.769-784C>T, AON2 was 
the most effective, correcting 100% of the transcripts according to the capillary analysis 
(Supplemental Fig. S6 and Supplemental Table S8) and the RT-PCR (Fig. 3). AON3 also 
showed rescue but approximately 7% of PE could still be detected. AON1 also resulted in PE 
skipping but induced an alternative splicing event, similar to what has been observed 
previously in the midigene assay. In contrast to the observations in HEK293T cells, this 
transcript was now clearly detected, and represented 56.4% of all the transcripts in the 
capillary analysis. Interestingly, the insertion of this partial PE (marked as artefact in Fig. 3) 
was also detected in control fibroblasts. Sequence analysis revealed that the upper band of 
the artefact corresponded to the partial PE, while the lower was a heteroduplex consisting of 
the WT and partial PE-containing transcripts. A band of approximately 450 nt was also 
detected in the fragment analyzer, but upon pGEMT cloning of all products, we only 
obtained the expected bands. We thus assume that this band corresponds to 
heteroduplexes formed between the different transcripts.  
As was shown for c.769-784C>T, ABCA4 mRNA was also barely detected in the 
fibroblasts carrying c.859-506G>C when they were not subjected to CHX treatment (Fig. 3). 
After CHX incubation, a PE of 56 nt was detected that, upon delivery of AON1 and AON3, 
was almost completely absent from the transcripts. As shown above for the midigene splice 
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assay, AON2 was not able to restore normal splicing. None of the AONs produced any 
alteration in the WT transcript when delivered to the control fibroblast cells. 
 
AON-based exon inclusion  
To correct for the splice defect of c.4253+43G>A, a completely different approach was used. 
In this case, the AONs were designed to promote exon 28 inclusion. AONs spanning the 
variant were designed under the hypothesis that the mutation creates a motif that promotes 
the skipping of exon 28. Two AONs were delivered to the midigene-transfected HEK293T 
cells. To assess whether the AON was inducing the inclusion of exon 28, the ratio between 
correct and Δexon 28 transcript was calculated with Fiji (Schindelin et al. 2012), or using the 
corrected peak area obtained in the capillary analysis (Supplemental Fig. S5). Using both 
methods, we observed that following administration of AON2, in approximately 10% extra of 
the ABCA4 transcripts, exon 28 was spliced in (Fig. 2). AON1 also showed some splice 
redirection but the differences were less evident (Supplemental Table S4).  
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Figure 2. Antisense oligonucleotide rescue using midigenes in HEK293T cells. A. Position of 
the AONs and sizes of the pseudoexons introduced by the mutations. B. Assessment of the 
splicing correction by RT-PCR upon AON delivery. Wild-type (WT) midigenes and mutant 
(MUT) midigenes were co-transfected with different AONs and a SON, except the non-
transfected cells  lane (NT). For each mutation introducing a pseudoexon, at least one AON 
was able to redirect splicing. In the case of exon 28 skipping, a 10% inclusion was achieved 
with one of the AONs. MQ denotes the negative control of the PCR reaction and HEK for the 
untransfected HEK293T. Rhodopsin (RHO) amplification was used as a transfection and 
loading control. 
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Figure 3. Antisense oligonucleotide rescue in fibroblasts derived from STGD1-affected 
individuals carrying c.769-784C>T or c.859-506G>C. Fibroblast cells from a control (CON) 
and a STGD1 individual were transfected with three AONs and a SON. In order to detect the 
pseudoexon cells were subjected to cycloheximide (+CHX) treatment. Only the non-
transfected cells were not subjected to CHX treatment (-CHX). The MQ lane contains the 
negative control of the PCR reaction. Actin (ACTB) was used as a loading control. 
 
 
159 
 
Discussion 
To identify missing non-coding variants in mono-allelic STGD1 cases, we performed targeted 
ABCA4 locus sequencing in 41 Dutch probands and WGS in four British probands. We found 
deep-intronic variants that were described previously (c.5196+1137G>A and 
c.4539+2001G>A) by us and others (Braun et al. 2013; Zernant et al. 2014; Bauwens et al. 
2015; Bax et al. 2015), each in one proband. Based on the identified variants’ in silico splice 
site strength predictions, their prevalence in our patient cohort, and midigene splice assay 
results, we identified six novel pathogenic intronic variants in 24 probands. Four deep-
intronic variants (c.769-784C>T, c.859-506G>C, c.4539+1100A>G, c.4539+1106C>T) 
strengthen cryptic splice sites at non-canonical nucleotide positions and thereby resulted in 
PEs, contrary to most of the published deep-intronic splice site variants that create canonical 
splice sequences (Liquori et al. 2016, Vaz-Drago et al. 2017). Variant c.1937+435C>G 
disrupted a splicing silencer motif resulting in PE formation and is located in one of the low-
expressed alternate exons observed previously (Braun et al. 2013). This 94-nt sequence 
contains a proper splice acceptor site but no consensus splice donor site sequence. The 134-
nt PE that we identified in the midigene assay has the same splice acceptor site and a ‘GC’-
type canonical splice donor site. c.4253+43G>A disrupted predicted splice silencers and 
created an ESE, and led to partial skipping of the upstream exon 28. Interestingly, we 
identified two probands (M-II:1 and P-II:3) that carried deep-intronic variants in both alleles, 
the first of which was found previously (Bax et al. 2015). 
All novel variants were predicted to result in protein truncation, but they were not all 
predicted to be severe ABCA4 variants, as some only affect a small proportion of the mRNA. 
Two variants, c.768-784C>T and c.4253+43G>A, were found in seven and nine probands, 
respectively. Testing of 412 other genetically unexplained STGD1 cases from France and 
Germany revealed 34 cases heterozygous for one of the identified deep-intronic variants, 28 
of which carried c.4253+43G>A. AONs were able to (partially) correct the observed splice 
defects in HEK293T cells and, for two variants, in patient-derived fibroblasts. 
Fourteen previously identified first alleles in the 24 probands are protein-truncating 
variants and thus assumed to have a severe effect, i.e. c.768G>T (n=5), c.818G>A (n=1),  
c.4539+1G>T (n=2), c.4539+2001G>A (n=1), c.4773+1G>A (n=1), c.5196+1137G>A (n=1), 
c.5461-10T>C (n=2), c.6155del (n=1). The amino acid substitution p.Phe608Ile (n=3) is one of 
the most frequent missense mutations in Dutch cases and can be classified as severe as it 
was found together with mild ABCA4 variants in persons with intermediate STGD1. 
p.Cys1490Tyr (n=1) was previously found in trans with a mild variant in a STGD1 subject and 
also can be considered severe. The complex allele p.[Leu541Pro; Ala1038Val] (n=1) and the 
p.Ala1038Val variant (n=1) were classified as severe and mild, respectively (Zhang et al. 
2015, Cornelis et al. 2017). p.Thr1526Met (n=1) was previously found in a homozygous state 
in an intermediate STGD1 case and thus classified as moderately severe. Two probands 
carried the mild complex allele c.[2588G>C; 5603A>T] (Zernant et al. 2017). The missense 
mutation p.Cys1455Arg (n=1) has an unknown severity. By using this knowledge, the ages at 
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onset of the probands, and the mRNA analysis in the HEK293T and fibroblast cells, we can 
hypothesize on the severity of the identified intronic variants. The c.859-506G>C, 
c.4539+1100A>G, and c.4539+1106C>T variants all show PE insertion in the majority of 
ABCA4 transcripts and can thus be considered severe variants. These findings correlate very 
well with the age at onset of the probands: when combined with a severe variant in trans, 
the age at onset was ≤ 10 years; if in trans with a mild variant, the age at onset was between 
15 and 49 years (Table 1).  
For c.1937+435C>G, the picture is more complicated. The splice defect observed in 
an in vitro splice assay was mild, and the two probands carrying this variant carry either a 
severe variant p.(Leu257Valfs*17) (U-II:1) or a mild allele p.[Gly863Ala, Gly863del; 
Asn1868Ile] (T-II:1). The ages at onset are 9 and 35 yrs, respectively, which argues for a 
severe nature of c.1937+435C>G in U-II:1 and a moderate-to-severe nature in T-II:1. This is 
discordant with the observed partial PE insertion in HEK293T cells. A similar observation was 
recently made while studying the effect of the c.4539+2001G>A or c.4539+2028C>T variants, 
previously labeled as ‘V4’ and ‘V5’ (Braun et al. 2013). Minigene splice assays in HEK293T 
cells and mRNA analysis of patient-derived fibroblasts showed hardly any mRNA containing a 
345-nt PE. By employing patient-derived photoreceptor precursor cells grown under NMD-
suppressing conditions however, we observed up to 15% (V5) and 25% (V4) of PE-containing 
mRNA (chapter 7). Based on their heterozygous presence in the corresponding STGD1 cases 
and their moderate-to-severe (V5) or severe (V4) nature, about two times these percentages 
were expected. We hypothesize that the photoreceptor precursor cells had not yet reached 
a differentiation stage that closely mimicked the human retina situation. It is also of interest 
that, while c.1937+435C>G is predicted to disrupt, c.4539+2001G>A and c.4539+2028C>T is 
predicted to activate ESEs. Possibly, the action of these splicing motifs requires specific 
factors that are exclusively present in mature photoreceptors. 
Recently, it was recognized that c.2588G>C (p.[Gly863Ala, Gly863del]) only acts as a 
penetrant mild pathogenic variant when present in cis with c.5603A>T (p.Asn1868Ile) 
(Zernant et al. 2017). The common non-complex p.(Asn1868Ile) variant, with an allele 
frequency in non-Finnish European controls of 0.07, was found as a second ABCA4 variant in 
up to 50% of mono-allelic STGD1 cases and strongly associated with late-onset STGD1 
(Zernant et al. 2017). In our cohort of 65 mono-allelic STGD1 probands, p.Asn1868Ile was 
found in 25 (38%) of the probands and five of their affected siblings. All together had an 
average age at onset of 41.0 years (chapter 5). It is plausible that p.Asn1868Ile also 
contributes to the pathogenicity of c.769-784C>T, as it was consistently found in cis with the 
latter. Based on the relatively high frequency of c.769-784C>T in non-Finnish European 
controls (AF 0.00426 in 15,014 alleles in gnomAD [http://gnomad.broadinstitute.org/]), its 
partial effect on splicing, and the very late age of onset observed in compound 
heterozygotes carrying c.[769-784C>T; 5603A>T] (57.2 yrs; range: 38-71 yrs), we consider 
that c.769-784C>T, without c.5603A>T in cis, is not causative.  
It is interesting to note that c.4253+43G>A also shows a relatively high non-Finnish 
European AF (0.00598 in 126,098 alleles in gnomAD). Although c.4253+43G>A, with one 
161 
 
exception (M-II:1), was consistently found in cis with c.6006-609T>A, we did not observe a 
splice defect for the latter variant in vitro. As discussed above for three other variants, this 
could be due to the lack of retina-specific splice factors in the tested cells. It is also possible 
that another - thus far missed - deep-intronic variant, acts in concert with c.4253+43G>A. In 
the one proband with c.4253+43G>A who lacked c.6006-609T>A, the c.5603A>T 
(p.Asn1868Ile) variant was found in cis. The age at onset of the cases carrying c.4253+43G>A 
ranged from 18 to 61 years (average 41 yrs), which is five years older than the average age of 
onset that was observed for compound heterozygous cases carrying p.Asn1868Ile in a 
previous report (36.3 yrs; Zernant et al. 2017). Interestingly, the earliest age at onset (18 yrs) 
was observed in proband M-II:1 carrying c.[4253+43G>A; 5603A>T], which argues against a 
contribution of c.6006-609T>A to pathogenicity. Based on the high AF of c.4253+43G>A in 
controls, its frequency in the Nijmegen STGD1 cohort, and our estimate of the sum 
frequency of all severe ABCA4 variants in the general population, we estimate that 
c.4253+43G>A, when present in trans with a severe ABCA4 variant, has a penetrance of 
~15%. 
Twelve AONs were used for PE skipping (Supplemental Table S7). Six of them were 
able to correct more than 90% of the splicing defect, three were able to do it partially, two 
did not work and one was able to modulate splicing but created a new PE. In general terms, 
all AONs had similar properties. The two AONs that did not work at all, were the only ones 
targeting the intronic part flanking the PE. This indicates that targeting intronic parts may be 
more challenging than the splice sites or (pseudo)exonic regions, as previously reported 
(Aartsma-Rus et al. 2012). In terms of motifs, all (partially) effective AONs targeted an SC35 
motif. 
 The use of AONs to redirect splicing and therefore exclude PEs has been used for 
several IRD-associated genes (Collin et al. 2012; Gerard et al. 2012; Bonifert et al. 2016; 
Garanto et al. 2016; Parfitt et al. 2016; Slijkerman et al. 2016). However, in this study, 
several technical challenges were observed. For the c.859-506G>C variant, the design of the 
AONs was limited to very small parts of the PE given the fact that the majority was found to 
be highly similar to many other regions in our genome. Therefore, in order to avoid potential 
off-targets, we could not target the 3’ part of the PE. In addition, using midigenes for c.768-
784C>T we observed variability between replicates, probably due to differences in the 
transfection efficiencies or passage of the cells. Nevertheless, these differences were not 
identified by the capillary analysis system, thus we decided to perform an additional 
approach for semi-quantification using the electrophoresis pictures. For the 
c.4539+1100A>G and c.4539+1106C>T we successfully redirected the splice defect with the 
same AONs. Previously, we observed that one single mismatch was enough to reduce the 
correction efficiency (chapter 7). Therefore, the strategy for c.4539+1100A>G and 
c.4539+1106C>T consisted of generating AONs that were common to both mutations, 
however this also limited the targetable regions. Nevertheless, we were able to find at least 
one AON per mutation that was able to efficiently redirect splicing.  
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The approach for the c.4253+43G>A was different, as we aimed to reinforce AON-
based exon inclusion. We designed the AONs targeting the mutant sequence. We were able 
to at least promote 10% of exon insertion. AONs have been widely used for (pseudo)exon 
skipping, but only limited for exon inclusion. Therefore, the fact that a 10% correction was 
detected opens new avenues to screen additional regions to identify the appropriate target 
to restore splicing more efficiently. 
Considering that we previously identified known deep-intronic variants in seven 
mono-allelic probands (Bax et al. 2015) and in two probands in this study, and that we found 
six new deep-intronic variants in 24 probands in this study, a total of eight deep-intronic 
variants genetically explain 33/52 (63.5%) of our original cohort of mono-allelic STGD1 cases. 
The absence of causal variants in the remaining 19 unsolved mono-allelic cases could be due 
to: i) the presence of heterozygous copy-number variations, as only 11 were tested using 
CNV analysis, ii) missed non-coding variants residing in non-covered sequences, iii) too 
stringent selection criteria when using splicing algorithms, iv) incomplete sensitivity of the 
midigene in vitro splice assay, and v) genocopies in view of the high AF of ABCA4 variants (5-
10%) in the general population (Maugeri et al. 1999, Jaakson et al. 2003, Cornelis et al. 
2017). In conclusion, we identified causal deep-intronic variants in 24/45 (53%) of our 
unexplained mono-allelic STGD1 cases, two of which (c.769-784C>T and c.4253+43G>A) are 
very frequent in our STGD1 cohort and are associated with late-onset of disease. Moreover, 
we hypothesize that they show strongly reduced penetrance unless there is an additive 
effect of a cis variant (c.5603A>T with c.769-784C>T) or, regarding c.4253+43G>A, the action 
of an as yet unidentified cis variant or non-ABCA4 locus modifier. Interestingly, all the 
observed splice defects could be rescued with at least one of the tested AONs, which 
provides a basis for the development of new therapeutic strategies for individuals with 
STGD1 carrying these variants. 
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Methods 
Samples  
Forty-five mono-allelic STGD1 patients were genotyped. Forty-one were ascertained from 
seven different medical centers in the Netherlands and Germany while four were 
ascertained in the United Kingdom, as part of the UK 10K sequencing project 
(https://www.uk10k.org/). Each patient manifested a STGD1 phenotype, characterized by 
yellow-white – often pisciform – flecks in the retinal pigment epithelium of the posterior 
pole which are hyperautofluorescent and/or progressive atrophy of the macular retinal 
pigment epithelium and/or a dark choroid on fluorescein angiography, as determined by 
experienced ophthalmologists. Age at onset for patients with intronic variants are given in 
Table 1. Age of onset was defined as the age at which the initial symptoms were noted by 
the patient. 
A cohort of 412 French and German STGD1 patients with one or no ABCA4 variant 
was genotyped by using smMIPs to assess the recurrence of causal non-coding variants 
described in this study.  
Written informed consent prior to participation in the study was obtained which 
adhered to the Declaration of Helsinki. 
 
ABCA4 sequence analysis and selection of candidate splice variants 
For 41 mono-allelic patients, the entire 128-kb ABCA4 gene (Chr1: 94,458,393 - 94,586,688) 
and approximately 117 kb proximal and 120 kb distal (total region: Chr1: 94,337,885 – 
94,703,604) were enriched by using a custom Haloplex Target Enrichment kit (Agilent, Santa 
Clara, CA) followed by NGS. Probes to target the 365-kb region were designed with 
SureDesign (Agilent) and they covered >98% of the targeted regions; gaps in coverage 
corresponded with repeat-rich regions. Subsequently, samples were sequenced by using 
Illumina sequencing technology (Miseq, Illumina, San Diego, CA, USA) to obtain 2x250 bp 
reads. Data analysis was performed with CLC Bio Software (CLC Bio Genomics Workbench, 
Qiagen, Hilden, Germany). Reads were aligned against a reference genome (GRCh37/hg 19 
assembly) and variants were identified and annotated by a custom-designed workflow. 
Variants were only considered for further filtering if they were present in at least one 
forward and one reverse read, in a minimum of 20% of all reads and with a minimum 
coverage of five reads. The variants were further annotated by Alamut Batch v2.7 
(Interactive Biosoftware). Prior to locus sequencing, the 41 patients were sequenced for 
variants in the coding and flanking splice site regions using Sanger sequencing and 29/41 
cases also were analyzed for the presence of heterozygous CNVs using Multiplex Ligation 
Probe Amplification (MLPA). Probands carrying the p.Asn1868Ile common variant as a non-
complex second allele (as based on segregation analysis) were excluded from this patient 
group earlier. 
Four mono-allelic patients (GC20009, GC20637, GC17027, GC21017) underwent WGS 
as part of the National Institute for Health Research (NIHR) BioResource- Rare Diseases study 
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(Carss et al. 2017) using the Illumina TruSeq DNA PCR-Free Sample preparation kit (Illumina, 
Inc.) and sequenced using an Illumina HiSeq 2500, generating minimum coverage of 15× for 
approximately 95% of the genome. Reads were aligned to the Genome Reference 
Consortium human genome build 37 (GRCh37) using Isaac Genome Alignment Software 
(version 01.14; Illumina, Inc.). Single nucleotide variants and small indels were identified 
using Isaac Variant Caller (version 2.0.17). Structural variants were identified using two 
independent algorithms: Isaac Copy Number Variant Caller (Canvas, Illumina), and Isaac 
Structural Variant Caller (Manta, Illumina) as previously described (Carss et al. 2017). 
Variant prioritisation and filtering was performed as previously described (Carss et al. 
2017). In the first instance, coding variants with an AF <0.01 in control datasets including the 
NIHR BioResource Rare Diseases cohort and the Exome Aggregation Consortium (ExAC) 
database and passing standard quality filters were prioritised. A white list of previously 
reported pathogenic mutations in relevant genes normally excluded by these filters were 
investigated (e.g., higher AF ABCA4 variants: c.2588G>C, c.5882G>A, c.5461-10T>C. An in-
house curated database of known and candidate IRD-associated genes was used to prioritise 
candidate bi-allelic variants in simplex and recessive families.    
In all 45 samples, after exclusion of known first alleles, candidate variants were 
selected according to two inclusion criteria: i) presence in the ABCA4 gene region (Chr1: 
94,458,393 - 94,586,688), and ii) an AF less than or equal to 0.01 in Genome of the 
Netherlands (GoNL; http://www.nlgenome.nl), UK 10K project (https://www.uk10k.org/), 
and non-Finnish European gnomAD (http://gnomad.broadinstitute.org/) population 
frequency databases.  
In silico splice prediction for all variants was performed by using five algorithms 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder) (Shapiro 
and Senapathy 1987; Reese et al. 1997; Pertea et al. 2001; Yeo and Burge 2004; Desmet et 
al. 2009) via Alamut Visual software v2.7, by comparing splicing scores for WT and variant 
nucleotides. Inclusion criteria for splicing assays were: i) the presence of a variant splice 
score >75% of the scoring range for at least two prediction programs, ii) a difference 
between WT and variant splice score >2% of the scoring range in at least two algorithms 
identified in i). A few variants did not meet these criteria but were found enriched in our 
STGD1 cases or were located in alternate exons previously described (Braun et al. 2013) and 
therefore were included in the splice assays. 
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Midigene-based splice assay  
For eleven non-coding variants the functional effect was assessed by midigene-based 
splicing assays employing seven wild-type BA clones previously described (Sangermano et al. 
2018) and the newly designed BA30. All constructs contained ABCA4 genomic sequences 
from the bacterial artificial chromosome clone CH17-325O16 (insert g.94,434,639-
94,670,492) and they served as templates to generate mutant constructs by site-directed 
mutagenesis, which subsequently were validated by Sanger sequencing (Supplemental 
Tables S9 and S10). Wild-type and mutant constructs were transfected in HEK293T cells and 
the extracted total RNA was subjected to reverse transcription (RT)-PCR (Supplemental Table 
S11) as previously described (Sangermano et al. 2018). 
 
Segregation studies 
For 17 unrelated Dutch probands, genomic DNA of 45 family members was employed to 
confirm segregation of non-coding variants.   
 
Single molecule Molecular Inversion Probe-based sequence analysis of intronic ABCA4 
regions 
To test the occurrence of five intronic ABCA4 variants (c.769-784C>T, c.859-506G>C, 
c.4253+43G>A, c.4539+1100A>G, c.4539+1106C>T) in 412 genetically unsolved STGD1 cases 
from Lille, France (n = 224) and Regensburg, Germany (n = 188), we designed smMIPs based 
on a previously developed cost-effective sequencing protocol (Hiatt et al. 2013) 
(Supplemental Table S12). STGD1 samples from a French cohort previously were 
prescreened using a mutation scanning technique, dHPLC or NGS (i.e., sequence analysis of 
inherited retinal disease-associated variants, including ABCA4). The STGD1 cases from a 
German cohort were previously sequenced using a custom-designed GeneChip CustomSeq 
Resequencing Array (RetChip) (Affymetrix, Santa Clara, CA, USA) or NGS on an ION Torrent 
semiconductor personal sequencing machine (Life Technologies, Darmstadt, Germany) upon 
multiplex-PCR amplification of the fragments with the STARGARDT MASTR kit (Multiplicom, 
Niel, Belgium) (Schulz et al. 2017).  
The genomic positions of the intronic variants were obtained from the UCSC genome 
browser (hg19; https://genome.ucsc.edu), and were used to design smMIPs using an in-
house pipeline. For each intronic ABCA4 variant, we designed two (overlapping) smMIPs, one 
on the plus strand and one on the minus strand. Each smMIP contains 78 nt and targets 
about 110 bp of genomic sequences based on the position of two annealing arms. The two 
annealing arms (denoted extension and ligation probes, together 40 nt) are connected using 
a common linker sequence of 38 nt which includes a 8-nt random tag that serves as the 
‘single molecule’ identifier. The 8-nt random tags enable the recognition of individual 
capture events and thereby point to random sequencing errors. The probes were designed 
for each DNA strand separately to ensure coverage from the plus and minus strands. The 78-
mer smMIPs were synthesized by Integrated DNA Technologies (IDT, Leuven, Belgium). All 
probes were pooled in equal amount (i.e., 1 µM), and thereafter used to prepare the 
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sequencing libraries according to a protocol described by O’Roak et al. 2012 (O'Roak et al. 
2012).  
We sequenced 412 STGD1 patients by using bar-coded PCR primers in two series. 
Bar-coded libraries were pooled, and after purification were sequenced using Illumina 
NexSeq500 using two Mid output kits (maximum of 130 million reads). The paired end 
sequencing reads were combined into 152-nt forward-reverse-reads (fr-reads), and were 
mapped to the reference genome. Next, the sm tags were exploited to group fr-reads. The 
resultant fr-read groups were used to make a highly accurate consensus read referred to as 
single molecule consensus reads (smc-reads), which were used for variant calling. The 
variant calling and annotation was performed using the in-house pipeline. The smc-read 
average ranged from 14 to 1587, with an average coverage of 489x.  
 
Antisense Oligonucleotides  
For each deep-intronic variant causing a PE inclusion three AONs were designed 
(Supplemental Table S7). The design of the therapeutic molecules was performed as 
described elsewhere (Aartsma-Rus 2012; Garanto and Collin 2018). Briefly, for each variant, 
the sequence of each PE plus the flanking regions (50 bp) were selected for further analyses. 
First the RNA structure and the exon splicing enhancers (ESEs) were predicted. 
Subsequently, AONs were designed taking several parameters into account (free energy, Tm, 
%GC, binding region, etc). For the c.4253+43G>A variant, two AONs were designed to bind 
directly on the mutant sequence. In addition, a sense oligonucleotide (SON) was 
synrthesized. All oligonucleotides had a phosphorothioate backbone with a 2-O-methyl sugar 
modification  (2OME/PS) and were synthesized by Eurogentec.  
All oligonucleotides (AONs and SON) were resuspended in PBS at a concentration of 
100 µM (stock solution). The final concentration used in all the experiments was 0.5 µM. 
 
In vitro rescue studies in HEK293T cells using midigenes and AONs 
Around 400,000 HEK293T cells were seeded in each well of a 6-well plate. The next day, each 
well was transfected with 1,5 µg of either the wild-type or the mutant construct. In total, 
eleven wells were transfected with one of the midigene constructs, while one well was left 
untransfected (HEK293T control). Of note, variants c.4539+1100A>G and c.4539+1106C>T 
result in the insertion of the same PEs and therefore were inserted in the same wild-type 
construct and were treated with the same AONs. Twenty-four hours post-transfection, each 
well was trypsinized and subdivided in 5 wells of a 24-well plate. Once cells were attached, 
the cells of each well were transfected with the respective AON, the SON, or was left 
untransfected (NT). Transfections were performed using FuGENE® HD Transfection Reagent 
(Promega) using a ratio 3:1 (3 µl of reagent for each µg of DNA) for midigenes and 1:10 for 
AONs (1 µl of reagent for each 10 µl of AON). Forty-eight hours post-AON delivery, cells were 
harvested and RNA isolation was performed using NucleoSpin® RNA kit (Macherey-Nagel). 
Subsequently, 1 µg of RNA was used for cDNA synthesis using iSCRIPT cDNA synthesis kit 
(Bio-Rad). cDNA was diluted to 20 ng/µl by adding 30 µl of MQ, and 50 ng (2,5 µl) was used 
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for the PCR analysis. All PCR reactions were prepared at a final volume of 25 µl. The 
conditions for all PCR reactions were as follows: 2 min at 94°C, followed by 35 cycles of 30 s 
at 94°C, 30 s at 58°C and 2 min at 72°C, a final elongation step of 5 min at 72°C was 
performed. Subsequently, 10 µl of each reaction were loaded onto a 2%-agarose gel. 
Rhodopsin amplification was used as transfection and loading control. All experiments were 
performed in two independent replicates. Primer sequences can be found in the 
Supplemental Table S11. 
 
Rescue studies using antisense oligonucleotides in fibroblasts 
Approximately 500,000 fibroblast cells were seeded in each well of a 6-well plate (6 wells per 
cell line). The next day, cells were transfected with either 0.5 µM of one of the AONs or SON, 
or transfected with empty liposomes (NT). Forty-four hours post-transfection medium was 
removed and medium containing cycloheximide (CHX) was added in order to block non-
sense mediated decay (NMD). Four hours later cells were harvested and subjected to RNA 
isolation as previously described. For cDNA synthesis, 1 µg of RNA was used using 
Invitrogen™ SuperScript™ IV VILO™ Master Mix (Thermo Fisher Scientific). cDNA was diluted 
to 20 ng/µl by adding 30 µl of MQ. For each PCR reaction, 80 ng (4 µl) of cDNA were used, 
except for actin (50 ng). All PCR reactions were prepared at a final volume of 25 µl. The 
conditions for all ABCA4 PCR reactions were as follows: 2 min at 94°C, followed by 40 cycles 
of 30 s at 94°C, 30 s at 58°C and 2 min at 72°C, a final elongation step of 5 min at 72°C was 
performed. For actin, the conditions were as follows: 2 min at 94°C, followed by 35 cycles of 
30 s at 94°C, 30 s at 58°C and 30s at 72°C, a final elongation step of 2 min at 72°C. 
Subsequently, 20 µl of each ABCA4 reaction were loaded onto a 2%-agarose gel. Ten 
microliter of the amplified actin product was used as loading control. All experiments were 
performed in two independent replicates. Primer sequences are indicated in Supplemental 
Table S11. 
 
Capillary Analysis 
In order to  quantify the ratios between correct and aberrant transcripts we loaded the RT-
PCR samples onto a Fragment Analyzer Auto Capillary Electrophoresis System (Advanced 
Analytical Technologies, Inc.). Midigenes-derived RT-PCR products were diluted 1:10 
whereas fibroblast-derived RT-PCRs were diluted 1:4. In both cases 2 µl was used for 
capillary analysis. Analysis of the peaks was performed using the corrected peak area 
parameter and only the peaks corresponding to the expected bands were taken into 
account.  
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Supplemental Figure S3. Enhancer and silencer motif variation caused by c.1937+435C>G. 
The c.1937+435C>G variant disrupts one SC35 enhancer and two intronic splice silencers 
(ISS1 and ISS3), and reduces the strength of ISS2. n.d., not detected. 
 
 
 
 
 
Supplemental Figure S4. Enhancer and silencer motif variation caused by c.4253+43G>A. 
The c.4253+435G>C variant weakens one SC35 and creates one SF2/ASF enhancer. It also 
weakens one intronic splice silencers (ISS1) and disrupts ISS2. n.d., not detected. 
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Supplemental Figure S5. Semiquantification by capillary analysis of the AON-based splicing correction in HEK293T. RT-PCR were subjected to 
capillary analysis and the ratio between the wild-type (WT) and the pseudoexon (PE) peaks was calculated for each mutation using the WT and 
the mutant (MUT) construct. In the case of the c.4539+1100A>G and c.4539+1106C>T both PEs were counted as one to calculate the ratio. In 
addition, given that same AONs were used they were placed together in the same graph. For the exon inclusion approach the amount of exon 
skipping is depicted in two ways, the skipping of exon 28 and 27+28 separately or both counted as one exon skipping event. 
 
 
 
 
 
 
Supplemental Figure S6. Semiquantification by capillary analysis of the AON-based splicing correction in patient-derived fibroblast cells. The AON 
rescue was assessed by RT-PCR and subsequently semi-quantified by capillary analysis. In this figure, the ratio between the pseudoexon (PE) and the 
wild-type (WT) peaks for two mutations is depicted both in control (CON) and patient-derived (STGD1) fibroblast cells. For the c.769-784C>T variant a 
new PE was detected upon delivery of AON1 (AON-induced PE). This PE was the result of partial PE exclusion. 
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Supplemental Table S2. Splice prediction analysis of 11 candidate non-coding variants. Non-coding variants were selected for splice assays if 
they were located at putative splice sites with a relative strength of at least 75% of the maximal score [0-max] in at least two out of five splice 
prediction programs, and which led to an increased splice prediction scores of at least 2% compared to the wild-type (wt) (green cells). 
*Variants selected because of their recurrency in the 45 mono-allelic STGD1 cases. #Variant selected because located in the genomic sequence 
of an alternate exon 13 (Chr1: 94,527,737-94,527,644) that was previously described (Braun et al. Hum Mol Genet 22:5136-5145, 2013). n.a., 
not applicable 
 
 
Supplemental Table S6. Allele frequency, observed RNA, predicted protein effects and recurrency in several validation cohorths for six 
causal ABCA4 intronic variants. AF, allele frequency; n.a., not applicable since the region was not covered. 
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Supplemental Table S7. Antisense oligonucleotide sequences and characteristics. 
Variant AON # Sequence (5’  3’) Length (nt) T  (°C) %GC 
Position 
relative to PE 
Motif(s) targeted 
c.769-784C>T 
1 GAUGGAAUCACUGAUCCUAG 20 49,7 45 Acceptor site SC35 and SRSF5 
2 AGCUCCAGAGACUGAUGUGA 20 51,8 50 PE SC35, SRSF5 and SRSF6 
3 CUCACCACUGCUCCUGC 17 51,9 65 Donor site SC35 
c.859-506G>C 
1 GACUGAGCAAUACUCCGUC 19 51,1 53 Acceptor site SRSF5 
2 AUCACAGAGUGACCCCUAG 19 51,1 53 Acceptor site Branch point, SRSF2 and SRSF5 
3 CUGAGCAAUACUCCGUCUG 19 51,1 53 Intronic SRSF5 and covers the mutation 
c.1937+435C>G 
1 CUCCCAGGAACCAGACCUA 19 53,2 53 Acceptor site SC35 ad SRSF5 
2 GCUCAUCCAACACAUUCCUC 20 51,8 58 PE SRSF1 and SRSF5 
3 CCUGGGAUGGGAGUGUC 17 51,9 65 Donor site SC35 and SRSF5 
c.4253+43G>A 
1 GACCCAGGUGUCCCAAACCCA 21 58,3 62 Intronic NA and covers the mutation* 
2 AGCAUGUGACCCAGGUGUCCC 21 58,3 62 Intronic NA and covers the mutation* 
c.4539+1100A>G 
& 
c.4539+1106C>T 
1 GUAAUCUGUUCUGGACUU 18 43,5 39 PE SC35, SRSF5 and SRSF6 
2 UAGAACUCCCAGGACAGG 18 50,3 56 PE SC35 and SRSF5 
3 CUAAAUCCCCCAGGAGAU 18 50,0 50 Intronic SC35 
All SON GAGGAAUGUGUUGGAUGAGC 20 51,8 50 PE NA 
 
T, melting temperature calculated using OligoCalc (http://biotools.nubic.northwestern.edu/OligoCalc.html).  
*, these two AONs were designed to promote exon inclusion rather than skipping, thus ESEs were not assessed. 
NA, not applicable; PE, pseudoexon 
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Abstract 
Sequence analysis of the coding regions and splice site sequences in inherited retinal 
diseases is not able to uncover ~40% of the causal variants. Whole-genome sequencing can 
identify most of the non-coding variants, but their interpretation is still very challenging, in 
particular when the relevant gene is expressed in a tissue-specific manner. Deep-intronic 
variants in ABCA4 have been associated with autosomal recessive Stargardt disease (STGD1), 
but the pathogenic mechanism is unknown. By generating photoreceptor precursor cells 
(PPCs) from fibroblasts obtained from individuals with STGD1, we demonstrated that two 
neighboring deep-intronic ABCA4 variants (c.4539+2001G>A and c.4539+2028C>T) result in a 
retina-specific 345-nt pseudoexon insertion (predicted protein change: p.Arg1514Leufs*36), 
likely due to the creation of exonic enhancers. Administration of antisense oligonucleotides 
(AONs) targeting the 345-nt pseudoexon can significantly rescue the splicing defect observed 
in PPCs of two individuals with these mutations. Intriguingly, an AON that is complementary 
to c.4539+2001G>A rescued the splicing defect only in PPCs derived from an individual with 
STGD1 with this but not the other mutation, demonstrating the high specificity of AONs. In 
addition, a single AON molecule rescued splicing defects associated with different 
neighboring mutations, thereby providing new strategies for the treatment of persons with 
STGD1. As many genes associated with human genetic conditions are expressed in specific 
tissues and pre-mRNA splicing may also rely on organ-specific factors, our approach to 
investigate and treat splicing variants using differentiated cells derived from individuals with 
STGD1 can be applied to any tissue of interest. 
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Introduction 
Stargardt disease (STGD1 [MIM: 248200]) is an autosomal recessive retinal disorder 
characterized by a predominantly juvenile-onset macular dystrophy associated with central 
visual impairment and progressive bilateral atrophy of the retinal pigment epithelium. The 
accumulation of lipofuscin deposits around the macula or in the posterior pole of the retina 
is one of the hallmarks of STGD1 (Stargardt 1909; Fishman et al. 1999). STGD1 is caused by 
variants in ABCA4 that encodes the ATP-binding cassette transporter type A4 (ABCA4 [MIM: 
601691]), a transmembrane protein localized at the rims of the photoreceptor disks that 
transports vitamin A derivatives in the visual cycle (Allikmets et al. 1997; Molday et al. 2006; 
Zernant et al. 2014). Besides STGD1, variants in ABCA4 can also lead to other subtypes of 
retinal disease ranging from bull’s eye maculopathy to autosomal recessive cone-rod 
dystrophy (arCRD [MIM: 604116]) (Cremers et al. 1998; Maugeri et al. 2000) and pan-retinal 
dystrophies (Cremers et al. 1998; Martinez-Mir et al. 1998; Shroyer et al. 2001; Duncker et 
al. 2015), depending on the severity of the alleles.  
Bi-allelic ABCA4 variants can be identified in approximately 80% of the cases with 
STGD1 (Allikmets et al. 1997; Lewis et al. 1999; Maugeri et al. 1999; Rivera et al. 2000; 
Webster et al. 2001; Zernant et al. 2011; Fujinami et al. 2013; Schulz et al. 2017; Zernant et 
al. 2017), and 30% of cases with arCRD (Maugeri et al. 2000), after sequencing coding 
regions and flanking splice sites. In general, individuals with arCRD or pan-retinal dystrophy 
carry two severe ABCA4 alleles, whereas individuals with STGD1 carry two moderately 
severe variants or a combination of a mild and a severe variant (van Driel et al. 1998; 
Maugeri et al. 1999). It has been hypothesized that the majority of the missing ABCA4 
variants in individuals with STGD1 reside in intronic regions of the gene, and indeed, over 
the last few years, several groups have demonstrated the existence of such deep-intronic 
variants (Braun et al. 2013; Zernant et al. 2014; Bauwens et al. 2015; Bax et al. 2015; Lee et 
al. 2016; Schulz et al. 2017). In 2013, Braun and colleagues (Braun et al. 2013) described two 
variants in intron 30 (c.4539+2001G>A and c.4539+2028C>T, hereafter denoted M1 and M2, 
respectively) that supposedly could affect ABCA4 pre-mRNA splicing, but without providing 
experimental evidence. M2 thus far was identified in 13 cases (Braun et al. 2013; Zernant et 
al. 2014; Lee et al. 2016; Schulz et al. 2017). M1 has been found in 31 cases and interestingly 
was particularly frequent in the Dutch and Belgian populations (Braun et al. 2013; Zernant et 
al. 2014; Bauwens et al. 2015; Bax et al. 2015; Lee et al. 2016). 
Currently, several clinical trials for STGD1 are being conducted, employing different 
therapeutic strategies: i) gene replacement therapy by delivering the complete ABCA4 cDNA 
(~6.8 kb) via a lentiviral vector (ClinicalTrials.gov: NCT01367444 and NCT01736592); ii) 
subretinal transplantation of human embryonic stem cell-derived retinal pigmented 
epithelial cells (hESC-RPE) (NCT02445612 and NCT02941991); and iii) administration of C20-
D3-retinylacetate (NCT02402660). Each of these approaches have their limitations, and so 
far, no efficacy data have been reported from these clinical trials. An elegant alternative 
approach for some allelic subtypes of STGD1 would involve the modulation of ABCA4 pre-
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mRNA splicing by using antisense oligonucleotides (AONs). AONs are small molecules, 
complementary to their pre-mRNA target, that are able to interfere with splicing by either 
including or skipping (pseudo)exons (Hammond and Wood 2011). AONs have already been 
tested in vitro and in vivo to redirect aberrant splicing caused by a recurrent deep-intronic 
variant in CEP290 that leads to Leber congenital amaurosis (LCA [MIM: 611755]) (Collin et al. 
2012; Gerard et al. 2012; Garanto et al. 2016; Parfitt et al. 2016), one of the most severe 
subtypes of retinal disease. In addition, AON-based splice correction has been demonstrated 
in cell lines from individuals carrying deep-intronic variants in USH2A (MIM: 608400) 
(Slijkerman et al. 2016) and OPA1 (MIM: 605290) (Bonifert et al. 2016). 
In this study, we employed induced pluripotent stem cell (iPSC) technology to identify 
the splicing defect caused by the two neighboring ABCA4 variants (M1 and M2) in intron 30, 
and describe that the inclusion of the identified pseudoexon (PE) can be mitigated by 
administration of AONs to photoreceptor precursor cells derived from individuals with 
STGD1. 
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Methods 
Study design 
The objectives of this work are to: 1) detect the splice defect(s) caused by two neighboring 
variants in ABCA4 using photoreceptor precursor cells (PPCs) derived from affected 
individuals and 2) design and assess a splice modulation-based therapy to correct this splice 
defect using AONs. Skin biopsies were obtained of a healthy individual, and two affected 
individuals (P1 and P2) each carrying one of the deep-intronic mutations in a heterozygous 
manner. Fibroblast cells were grown, reprogrammed into iPSCs and subsequently 
differentiated to PPCs. RNA analysis by RT-PCR was performed to reveal the insertion of a PE 
into the ABCA4 mRNA transcript. Four AONs and a sense oligonucleotide (SON) were 
designed to block exonic splicing enhancers (ESEs). Upon AON delivery, RNA analysis by RT-
PCR was performed to assess the efficacy of the splicing redirection for each AON comparing 
non-treated and AON-treated samples. Two different concentrations of AONs were 
delivered to the cells. All experiments were performed simultaneously and under the same 
conditions for all cell lines. RNA analysis was performed in triplicate. 
 
Subjects 
Skin biopsies were collected from one Dutch control individual, a Dutch individual with 
STGD1 (P1) carrying the ABCA4 variants c.4539+2001G>A (p.?) (M1) and c.4892T>C 
(p.Leu1631Pro) (M3) (Bax et al. 2015), and a person with STGD1 from the USA (P2) carrying a 
complex allele containing c.302+68C>T (p.?) and c.4539+2028C>T (p.?) (M2) and the deletion 
c.6148-698_6670delinsTGTGCACCTCCCTAG (p.?) (M4) on the other allele (Lee et al. 2016). 
Our research was conducted according to the tenets of the Declaration of Helsinki. The 
procedures for obtaining human skin biopsies to establish primary fibroblasts cell lines were 
approved by the local Ethical Committee. Written informed consent was gathered from all 
participating individuals. 
 
Reprogramming of fibroblast cells to generate iPSCs 
The culturing of fibroblast cells from the skin biopsies and their reprogramming into induced 
pluripotent stem cells (iPSCs) were previously described (Sangermano et al. 2016). In 
essence, four lentiviral vectors containing the pluripotency genes OCT3/4, NANOG, KLF4 and 
c-MYC were employed for the transduction of fibroblasts (Takahashi and Yamanaka 2006). 
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iPSC differentiation into photoreceptor precursor cells (PPCs)  
After reaching confluence, iPSC clumps were digested with Accutase (cat. no. A6964, Sigma-
Aldrich, St. Louis, MO, USA) and plated in a 12-well plate to form a monolayer. Upon 
reaching confluence, Essential-Flex E8 medium was changed into CI medium (Flamier et al. 
2016), consisting of DMEM/F12, supplemented with non-essential amino acids (NEAA, cat. 
no. M7145, Sigma Aldrich), B27 supplements (cat. no. 12587010, Thermo Fisher Scientific, 
Waltham, MA, USA), N2 supplements (cat. no. 17502048, Thermo Fisher Scientific), 100 
ng/µl insulin-like growth factor-1 (IGF-1, cat. no. I3769, Sigma Aldrich), 10 ng/μl recombinant 
fibroblast growth factor basic (bFGF cat. no. F0291, Sigma Aldrich), 10 μg/μl Heparin (cat. no. 
H3149-10KU Sigma-Aldrich) and 200 μg/ml human recombinant COCO (cat. no. 3047-CC, 
R&D Systems, Minneapolis, MN, USA). The medium was changed every day for one month, 
after which the cells were collected and characterized.  
 
RNA isolation and cDNA synthesis 
All RNA isolations were performed with the NucleoSpin® RNA Clean-up Kit (cat. no. 740955-
50, Macherey-Nagel, Düren, Germany) according to manufacturer’s protocol. RNA was 
quantified by nanodrop. One microgram of total RNA was used for all cDNA synthesis 
reactions. For quantitative PCR analysis (qPCR) and for semi-quantitative RT-PCR analysis, 
cDNA was synthesized by the SuperScript™ VILO™ Master Mix (cat. no. 11755050, Thermo 
Fisher Scientific), following manufacturer’s instructions. 
 
iPSC and PPC characterization  
q-PCR was performed to assess the pluripotency markers (in iPSCs) and differentiation 
markers (in PPCs) as described elsewhere (Sangermano et al. 2016). All primers used for the 
q-PCR analysis are listed in Supplemental Table S1. 
 
ABCA4 transcript analysis 
After 30 days of differentiation, PPCs derived from normal individuals and from persons with 
STGD1 were harvested. Reverse transcription-PCR (RT-PCR) analysis was performed using 
primers located in exon 2 (forward) and exon 5 (reverse); exon 30 (forward) and exon 31 
(reverse); exon 33 (forward) and exon 35 (reverse); or exon 44 (forward) together with exon 
46 (reverse) and exon 49 (reverse) of ABCA4. Actin (ACTB) primers were used as a control. 
Primer sequences are listed in Supplemental Table S1. All cDNA reactions were diluted to 20 
ng/µl by adding 30 µl of distilled water. For RT-PCR analysis, 80 ng of cDNA was used for all 
the ABCA4 reactions and 40 ng for the ACTB analysis. All reaction mixtures (25 μl) contained 
10 μM of each primer pair, Taq DNA Polymerase 1 U/μl (cat. no. 11647679001, Roche), 10X 
PCR buffer with MgCl2, supplemented with 1 mM MgCl2, 2 µM dNTPs, and 80 or 40 ng cDNA. 
PCR conditions for ABCA4 fragments from exon 30 to 31 were as follows: 94°C for 2 min, 35 
cycles of 30 s at 94°C, 30 s at 58°C and 90 s at 72°C, followed by a final step of 2 min at 72°C. 
For ABCA4 exon 44 to 46 or 49, as well as ACTB amplification, PCR was performed in the 
same conditions except for an elongation time of 30 s. Twenty-five microliters of the ABCA4 
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PCR product (exons 30 to 31), 15 µl of all the other ABCA4 products, and 10 µl of the actin 
amplicon were resolved on a 2% (w/v) agarose gel. The resulting bands were excised and 
purified with the NucleoSpin®Gel & PCR cleanup kit (cat. no. 740609.250, Macherey-Nagel) 
according to manufacturer’s protocol. Purified PCR products were analyzed via Sanger 
sequencing, in a 3100 or 3730 DNA Analyzer (Thermo Fisher Scientific).  
 
Antisense oligonucleotide (AON) design 
The sequence of the PE plus 50 base pairs flanking both sides were analyzed as described 
previously (Aartsma-Rus 2012; Garanto and Collin 2018). Briefly, the overall RNA structure of 
the region of interest was analyzed with the Mfold software, in order to identify partially 
open and closed regions. Splice enhancer motifs were determined using ESE finder 3.0. 
Special attention was paid to SC35 regions, as it has been demonstrated that there is a 
positive correlation between the presence of such motifs and the efficacy of AONs (Aartsma-
Rus 2012). Overall, this analysis led to the design of four AONs, two that overlap with the 
highest scoring SC35 motif (AON2 and AON3), one near the 5’-end of the PE (AON4), and one 
that overlaps with the c.4539+2001G>A mutation (AON1). The final AON sequences were 
also evaluated for the free energy of the molecule alone, the possibility to form dimers, and 
their interaction with the region of interest. For this, the RNA secondary structure tool of 
RNAstructure web server for RNA Secondary Structure Prediction  was used. We ensured 
that all AONs had a free energy value above -4 on their own, above -14 as a dimer, and 
between 21 and 28 for the AON-region binding. This was calculated by using the estimated 
energy of the region of interest minus the energy of the AON bound to the region. All AON 
sequences had a length of 19 nucleotides with a Tm above 46°C and a GC content between 
40% and 65%. The exact sequences and their properties are listed in Table 1. AONs were 
chemically modified by adding a phosphorothioate backbone and a 2-O-methyl sugar 
modification 2OMe/PS to each nucleotide and were purchased from Eurogentec (Liège, 
Belgium). AONs were dissolved in PBS to a final concentration of 100 µM. A SON was 
ordered with the same chemistry to be used as a negative control.  
 
Table 1. Antisense oligonucleotide (AON) characteristics.  
Name Sequence 5’ -> 3’ Length (bp) % GC Tm (°C) 
AON1 ACAGGAGUCCUCAGCAUUG 19 53 51.1 
AON2 UUUUGUCCAGGGACCAAGG 19 53 51.1 
AON3 CUGUUACAUUUUGUCCAGG 19 42 46.8 
AON4 GGGGCACAGAGGACUGAGA 19 63 55.4 
SON CAAUGCUGAGGACUCCUGU 19 53 51.1 
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AON treatment  
Following differentiation, PPCs were treated with AONs (0.5 and 1 µM) by mixing the naked 
AONs directly with the culturing medium. After 24 hrs, cycloheximide (CHX, cat. no. C4859, 
Sigma Aldrich) was added at a final concentration of 0.1 mg/ml and cells were incubated for 
another 24 hrs. Forty-eight hours after AON delivery, cells were harvested, rinsed in PBS, and 
RNA was isolated. cDNA synthesis was performed using 1 µg of RNA, as described above. RT-
PCR analysis was performed as described in the “ABCA4 transcript analysis” section. The 
ratio between correctly and aberrantly spliced variants was assessed by using Fiji software 
(Schindelin et al. 2012). For the analysis of the nucleotide traces, we used ContigExpress 
software. 
 
Statistical analysis 
All results are represented as mean ± SD. Comparisons were performed using a two-tailed 
Mann-Whitney test. Statistically significant results were indicated with an asterisk (*) when 
p<0.05. 
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Results 
Deep-intronic variants c.4539+2001G>A and c.4539+2028C>T result in pseudoexon 
insertion 
To determine whether variants c.4539+2001G>A (p.?) (M1) and c.4539+2028C>T (p.?) (M2) 
result in aberrant splicing of ABCA4 pre-mRNA, fibroblast cell lines were generated from two 
unrelated individuals with STGD1. Individual P1 was diagnosed with STGD1 and carried M1 
and the missense variant M3, c.4892T>C (p.Leu1631Pro), in trans (Webster et al. 2001). 
Individual P2 was also diagnosed with STGD1 and carried M2 and a deep-intronic variant 
c.302+68C>T (p.?) in cis. In addition, P2 carried a genomic deletion, c.6148-
698_6670delinsTGTGCACCTCCCTAG (p.?), denoted M4, which was present on the other 
allele (Lee et al. 2016). In addition, a fibroblast line from a healthy control was generated. All 
cells were cultured in the absence and presence of cycloheximide (CHX), a compound used 
to suppress nonsense-mediated decay of RNA products carrying protein-truncating 
mutations. RT-PCR analysis with primers located in exons 30 and 31 revealed only one clear 
product, corresponding to the expected product encompassing exons 30 and 31 (Fig. 1). No 
aberrantly spliced products were detected in the fibroblasts from the individuals with 
STGD1.  
Recent studies have shown that the retina has a complex splicing system, resulting in 
a tissue- or even cell type-specific recognition of splice sites and subsequent inclusion of 
(pseudo)exons (Murphy et al. 2016; Parfitt et al. 2016). To further investigate potentially 
retina-specific splicing defects caused by the two deep-intronic ABCA4 mutations, control 
and STGD1 fibroblasts were reprogrammed into induced pluripotent stem cells (iPSCs) via 
lentiviral transduction of the Yamanaka factors (Takahashi and Yamanaka 2006). 
Quantitative PCR (q-PCR) (Supplemental Fig. S1A) validated the pluripotency of the iPSCs. 
Subsequently, these iPSCs were differentiated for one month into photoreceptor precursor 
cells (PPCs). We used the protocol described previously by Flamier and colleagues (Flamier et 
al. 2016) to obtain a mixed population of cone precursors and retinal pigment epithelial 
(RPE) cells. Characterization of PPCs derived from a control and affected individuals P1 and 
P2 revealed a significantly increased expression of ABCA4, being ~35 times higher in the 
control PPCs than control iPSCs and ~10 and 8 times higher in P1- and P2-PPCs, respectively, 
compared with P1- and P2-iPSCs. High expression of neural retinal precursor markers PAX6, 
OTX2, and CRX (the latter one only in control and P1) indicated the still immature stage of 
PPCs, while the enrichment of RPE65 mRNA and increase of VMD2 mRNA confirmed the 
presence of some RPE cells. Increased expression of OPN1SW, PDE6H, and NRL in all cell 
lines also indicated the presence of more mature cone and rod cells. PDE6C and RHO were 
only slightly enriched in P1 and P2, while RCV1 (photoreceptor marker), NR2E3 (precursor of 
rod cells) and OPN1MLW (green and red cone marker) were increased only in P2 
(Supplemental Fig. S1B). 
As ABCA4 was robustly expressed in all three differentiated cultures, we performed RT-PCR 
analysis from exon 30 to exon 31, which showed aberrant transcripts in both P1- and P2-
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derived PPCs upon CHX treatment, but not in control PPCs (Fig. 1A). Semi-quantification of 
the ratio between correctly and aberrantly spliced variants in the CHX-treated samples 
revealed that ~25% of ABCA4 transcripts in P1 carrying M1 and ~15% of ABCA4 transcripts in 
P2 carrying M2 were aberrant (Fig. 1B). A more detailed analysis of all bands by Sanger 
sequencing revealed a PE of 345 nt containing a premature stop codon (Fig. 2), which is 
predicted to result in the truncated protein product p.Arg1514Leufs*36. Interestingly, both 
variants included the same PE in the mRNA transcript upon CHX treatment. Once the 
sequence was identified, we studied the effect of both variants on splicing. According to all 
prediction softwares, neither M1 nor M2 changed the strength of the splice acceptor and 
donor site (see Fig. 2). The splice donor site of the 345-nt PE contains ‘GC’ as canonical splice 
site sequence, which is recognized only by the SpliceSiteFinder-Like (SSFL) software. Further 
in silico predictions showed that M1 enhances an exonic splicing enhancer SF2 site and 
creates a new SRp55 motif, whereas M2 creates one SC35 and two SRp40 motifs (Fig. 2).  
Subsequent in-depth analysis of all the bands observed by RT-PCR revealed one band 
that contained heteroduplexes of the correctly spliced transcript together with the one 
containing the PE (Fig. 1). Moreover, an extra faint band lacking the last 73 bp of exon 30 
was found in all samples treated with CHX, including the control. A relatively weak splice 
donor site (Human Splicing Finder [HSF] score: 75.9) explains this alternative transcript that 
was also detected in the heteroduplex band (Fig. 1). This splice product (r.4467_4539del, 
[p.Cys1490Glufs*12]) was also identified as a result of non-canonical splice site variants at 
the ‘natural’ splice donor site of exon 30. Interestingly, this new donor site was previously 
reported as a splice acceptor site (HSF score: 89.6) creating an isoform lacking the first 114 
bp of exon 30 (Gerber et al. 1998).  
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Fig. 1. Identification of the splice defect caused by variants M1 and M2. A. Reverse transcription (RT)-PCR on mRNA extracted from control, P1 
(carrying variants M1: c.4539+2001G>A and M3: c.4892T>C) and P2 (carrying variants M2: c.4539+2028C>T and M4: c.6148-
698_6670delinsTGTGCACCTCCCTAG)-derived fibroblasts and photoreceptor precursor cells (PPCs) using primers in exons 30 and 31 of ABCA4. 
For both P1- and P2-derived PPCs, some aberrantly spliced bands were detected, especially after cycloheximide (CHX) treatment (+). Actin 
(ACTB) RT-PCR was used as a control. Heteroduplexes contain transcripts with the pseudoexon together with the correct spliced transcript 
(exons 30 and 31) and the truncated splice variant of exon 30 that lacks the 3’ 73 nt of exon 30 (r.4467_4539del, p.Cys1490Glufs*12). B. Semi-
quantification of the ratio of correctly and aberrantly spliced ABCA4 transcript for each cell line with and without CHX.  
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Fig. 2. In silico characterization of the effect caused by two deep-intronic variants. Schematic representation of the boundaries of the 345-bp 
pseudoexon, with the location of the variants M1 (c.4539+2001G>A) and M2 (c.4539+2028C>T), the genomic positions of the splice sites, the 
splicing events detected, and the splice site predictions for both acceptor and donor sites. The dashed line represents the splicing from a 
cryptic splice donor site in exon 30 at position g.94,495,074 (GRCh37/hg19) to the normal splice acceptor site of exon 31 (r.4467_4539del 
[p.Cys1490Glufs*12]). The predicted values of the splice acceptor and donor sites in the control and mutant situations did not show any 
difference. In the middle panels, the effects of the variants enhancing or creating new ESE motifs are depicted. SSFL: SpliceSiteFinder-like; HSF: 
Human Splicing Finder. 
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The c.302+68C>T variant does not result in qualitative differences of the mRNA 
In seven STGD1 cases with M2 in whom this was investigated, c.302+68C>T (p.?) was found 
in cis (Braun et al. 2013; Zernant et al. 2014; Lee et al. 2016). To study the contribution of 
this variant to STGD1 pathology, we performed RT-PCR of mRNA from control PPCs and P1-
and P2-PPCs, treated and untreated with CHX, as well as from adult retina mRNA. As shown 
in Supplemental Fig. S2, PCR primers located in exons 2 and 5 generated a canonical splice 
product of 459 nt, as well as a smaller fragment of 317 nt, in all PPCs and in human retina. 
Validation of the bands by Sanger sequencing revealed that the 317-nt fragment was lacking 
exon 3 (size: 142 bp). No other splice products were observed, indicating that the 
c.302+68C>T variant does not result in the activation of cryptic splice sites and/or exonic 
splice enhancers.  
 
Antisense oligonucleotides block M1 and M2-associated pseudoexon insertion 
Once the molecular mechanism associated with M1 and M2 variants was elucidated, we 
aimed to design a therapeutic approach, based on splicing modulation, to skip the PE. An 
attractive and efficient method is the use of AONs, small RNA molecules that are able to 
enter in the cell, bind to the pre-mRNA, and modify the splicing pattern. In order to increase 
their binding affinity and avoid RNaseH activation (and therefore transcript degradation), we 
used 2-O-methyl-modified RNA AONs with phosphorothioate (2OMe/PS) backbones, as 
previously reported (Collin et al. 2012; Gerard et al. 2012; Garanto et al. 2016; Slijkerman et 
al. 2016). In total we designed four AONs to block several SC35 motifs or the newly created 
SRp55 motif due to M1 (AON1; Fig. 3A). In addition, a sense oligonucleotide (SON), 
complementary to AON1 and containing the same chemical modifications as the other AONs 
but not able to bind to the pre-mRNA, was designed in the same region. AONs and SON were 
delivered to ~1-month differentiated-PPCs and after 48 hrs, the RNA was analyzed. As 
expected, CHX treatment increased the presence of aberrantly spliced transcript in the non-
treated cells (Figures 3B and 3C). In addition, there were no differences between the non-
treated and the SON-treated cells. We found that AON4 was efficiently able to produce up to 
~75% PE skipping in both cell lines at two different concentrations (Fig. 3D), while AON1 was 
very efficient only in the M1 cell line. AON2 showed variable efficacy and was less effective 
at a higher concentration, while AON3 was poorly able to redirect splicing both at 0.5 µM 
and 1 µM (Figures 3B, 3C and 3D). One explanation for AON2 and AON3 showing such 
different behavior despite targeting the same region could be the AON properties (Table 1). 
AON3 compared with AON2 has a low GC content and Tm, which might affect the stability 
and binding capacity, therefore explaining its low efficiency.      
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Assessment of the AON efficacy 
P1-derived PPCs carried M1 and M3 in trans; P2-derived PPCs carried M2 and M4 in trans. In 
order to determine whether the observed decrease in PE-containing transcripts resulted in 
an increase of wild-type ABCA4 transcripts, we analyzed the ABCA4 mRNA levels of all alleles 
(Fig. 4). We sequenced the region encompassing M3 (c.4892T>C [p.Leu1631Pro]) from 
genomic DNA of a control person and P1 (Fig. 4A) and we sequenced the cDNA of control 
person-derived PPCs and P1-derived PPCs without and with CHX treatment, as well as the 
sample treated with 1 µM of AON4 (Fig. 4B). By assessing the nucleotide traces in each peak 
using ContigExpress software, it was observed that the ratio between both alleles in genomic 
DNA of P1 was ~1:1 (Fig. 4C). In contrast, the cDNA sequences showed that the ratio of 
c.4892T (M1 allele) and c.4892C (M3 allele) was ~2:1 in the absence of CHX. The fact that the 
M3 allele is not predicted to undergo NMD and that it is lower expressed compared to M1 
suggests an allelic imbalance between the M1 and M3 alleles. When treating the cells with 
CHX, the levels of the M1 allele increased to a ratio of ~3:1, indicating that the M1 allele with 
the 345-nt insertion is subjected to NMD. Finally, the amount of M1 allele-derived mRNA 
after AON treatment increased to a ratio ~4:1, suggesting that the AON was able to really 
convert aberrantly spliced transcripts into correctly spliced transcripts, thereby increasing 
the wild-type mRNA levels of this allele.  
To analyze the mRNA products of alleles M2 and M4 in P2-derived PPCs, we amplified 
them separately to identify the mRNA defect due to variant M4 (c.6148-
698_6670delinsTGTGCACCTCCCTAG [p.?]). By conducting a PCR from exon 44 to exon 49, we 
could determine that M4 results in an in-frame mRNA deletion of exons 45 to 48, resulting in 
a predicted shorter protein p.Val2050_Gln2243del (Fig. 4D). Given the fact that this deletion 
does not alter the reading frame, the M4 allele is not predicted to undergo NMD. In order to 
detect and compare the effect of NMD and AON-rescue in both alleles, we performed a PCR 
using two reverse primers and cDNA of P2-derived PPCs (Fig. 4D). Our results showed that 
the allele carrying the M4-associated mRNA deletion was expressed at similar levels in P2 
PPCs with and without CHX, suggesting that the mRNA from allele M4 was not degraded by 
NMD (Fig. 4E). Also in the presence of AON4, no changes were observed. When we 
specifically amplified the M2-mRNA allele, we did identify an increase after CHX treatment. 
This indicates that the M2-associated mRNA carrying the 345-nt insertion undergoes NMD as 
was previously shown. The fact that upon AON treatment, the level of the M2-associated 
mRNA allele increased clearly indicates that more wild-type transcript without the 345-nt 
insertion was produced. The M2-associated mRNA level increased up to ~50% when 
compared to the control mRNA level (Fig. 4E). 
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Fig. 3. Effect of antisense oligonucleotide delivery at mRNA in photoreceptor precursor 
cells. A. Schematic representation of the pseudoexon, indicating the location of the variants, 
the SC35 motifs with the highest scores and the positions of the antisense oligonucleotides 
(AONs). B. RNA analysis on AON-treated cells. RT-PCR from exon 30 to exon 31 of ABCA4 
mRNA in control, P1 (M1: c.4539+2001G>A and M3: c.4892T>C), and P2 (M2: 
c.4539+2028C>T and M4: c.6148-698_6670delinsTGTGCACCTCCCTAG)-derived 
photoreceptor precursor cells (PPCs) upon AON delivery. Actin (ACTB) mRNA amplification 
was used to normalize samples. NT-: non-treated and in the absence of cycloheximide (CHX); 
NT+: non-treated in the presence of CHX; A1: AON1; A2: AON2; A3: AON3; A4: AON4; S: SON 
and MQ: PCR negative control. Heteroduplexes contain transcripts with the pseudoexon 
together with the correct spliced transcript (exons 30 and 31) and the truncated splice 
variant of exon 30 that lacks the 3’ 73 nt of exon 30 (r.4467_4539del, p.Cys1490Glufs*12). C. 
Semi-quantification of the ratio of correctly versus aberrantly spliced transcripts in all P1 and 
P2 samples. D. Percentage of correction of each AON compared to the NT+ based on the 
ratio observed in C. Statistical differences in the efficacy of the AONs for M1 and M2 are 
indicated with an asterisk (*: p<0.05 using Mann-Whitney test). All jistograms illustrate the 
average ± standard deviation. 
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Fig. 4. AON rescue in photoreceptor precursor cells based on the analysis of the mRNA-
alleles associated with variants M1/M3 and M2/M4. (A-C) Assessment of the mRNA 
product carrying variant M3, c.4892T>C (p.Leu1631Pro) which is in trans with M1. A. 
Chromatograms of the reverse sequence of genomic DNA (gDNA) in a control and individual 
P1 carrying M1 and M3. B. Chromatograms of the sequence of the cDNA of the 
photoreceptor precursor cells (PPC) from the control cell line and from P1 PPCs in the 
absence (-) or presence (+) of cycloheximide (CHX) and 1 µM of AON4 (+AON4). The arrow 
indicates the position of the double peak where the M3 variant is located. C. Graphical 
representation of the traces of each nucleotide in the sequence using ContigExpress 
software. (D-E) Semi-quantification of mRNA products associated with variants M2 and M4 
in P2. D. P2 PPCs carry M2 and c.6148-698_6670delinsTGTGCACCTCCCTAG 
(p.Val2050_Gln2243del) in trans. RT-PCR of the control (CON) and P2 PPCs without (-) or 
with (+) CHX and AON4 at 1 µM using the same forward primer in exon 44 and a reverse 
primer in exon 46 (that is not present in M4 genomic DNA nor in the mRNA product) and a 
reverse primer in exon 49. The upper band represents the correct spliced transcript from 
exon 44 to 46 corresponding to the M2 allele, while the lower band is the resulting transcript 
caused by the multi-exon deletion. An RT-PCR product of ACTB was used as loading control. 
E. Graphical representation of the semi-quantification of the bands observed in D. The 
mRNA product observed in the control (exons 44 to 46) was set at 100%, while the mRNA 
product from the M4 allele (exons 44 to 49) was set at 50% in the P2-PPCs –CHX condition. 
The mRNA product from allele M4 is not sensitive to NMD suppression. The correctly spliced 
transcripts from allele M2 increase upon NMD suppression (+CHX vs -CHX) of cultured PPCs 
and increase even more upon AON4 treatment.  
197 
 
Discussion 
In this study we showed that two neighboring deep-intronic variants in ABCA4, 
c.4539+2001G>A and c.4539+2028C>T, result in a retina-specific inclusion of a 345-nt PE in a 
proportion of ABCA4 transcripts. This PE, which is predicted to lead to protein truncation 
(p.Arg1514Leufs*36), was found as a low-abundance alternative splice form of ABCA4 when 
performing deep RNA sequencing of human macula RNA (Braun et al. 2013). RT-PCR product 
quantification revealed more PE insertion due to M1 than to M2. We listed the 12 published 
individuals with STGD1 carrying bi-allelic ABCA4 variants among which was M1 (n=12) in 
Supplemental Table S2 (Bauwens et al. 2015; Bax et al. 2015). Considering the assessment of 
the severity of the variants present in trans, there is little doubt that M1 acts as a severe 
variant. Based on the clinical and genetic data available for four persons with STGD1 carrying 
M2 (Supplemental Table S2) (Lee et al. 2016), it could also act as a severe variant, but the 
dataset is too small to draw a definite conclusion. We thus would expect that the amount of 
mutant mRNA in P1 carrying M1, who carries a missense variant in trans, should be equal to 
the amount of correct product. This is not the case, yet this comparison is difficult, as smaller 
products amplify more effectively and NMD suppression may be incomplete. Nevertheless, 
by Sanger sequencing validation of the second allele we observed that in PPCs, the M1 
mRNA allele is higher expressed and subjected to NMD, since it is increased upon CHX 
treatment. Intriguingly, we also noticed an allelic imbalance between the M1 and M3 alleles 
in the cells of P1. As M3 is a missense change that is not predicted to undergo NMD, the fact 
that it appears to be lower expressed compared to M1 suggests that there may be a 
difference in the transcriptional regulation between the two ABCA4 alleles. Alternatively, the 
mRNA stability of the M3 allele may be reduced. Thus the pathogenicity of the M3 allele may 
not only be due to the amino acid substitution, but rather to other, yet unknown, factors. 
The PE insertion due to M2 is less prominent than that of M1, which may suggest that it has 
a less severe character. However, we cannot exclude the possibility that other cis-acting 
variants missed during locus sequencing (Zernant et al. 2014) act in concert with these intron 
30 variants. In addition, other as yet unknown cell-type specific mechanisms may play a role. 
One likely explanation is that the PPCs that were generated may not yet fully reflect the in 
vivo situation of the retina, as these were cultured for only 30 days. Given that some 
protocols in which cells have been differentiated for a longer time resulted in a more mature 
type of photoreceptor cells (Meyer et al. 2011; Tucker et al. 2013; Zhong et al. 2014; Parfitt 
et al. 2016), a longer differentiation of cells derived from P2 (and perhaps also P1) would 
likely show an increase of PE-containing ABCA4 transcripts. The importance of retinal 
differentiation for PE recognition was also clearly illustrated for the deep-intronic 
c.2991+1655A>G variant in CEP290. Whereas in lymphoblastoid and fibroblast cells of 
individuals harboring this mutation homozygously the ratio between correctly and 
aberrantly spliced CEP290 is ~1:1 (den Hollander et al. 2006a; Collin et al. 2012; Garanto et 
al. 2016), in iPSC-derived photoreceptor cells, the amount of aberrantly spliced CEP290 was 
found to be drastically increased (~1:4 ratio) (Parfitt et al. 2016). This study not only revealed 
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insights into why this mutation, despite a ubiquitous expression of CEP290, resulted in a 
non-syndromic retinal phenotype, but also demonstrated the enormous power of using 
iPSC-derived retinal cells from affected individuals to study splice defects in a relevant 
cellular system. 
Previous IRD-associated intronic variants have created new splice acceptor or donor 
sites that allowed the insertion of a PE (van den Hurk et al. 2003; den Hollander et al. 2006b; 
Rio Frio et al. 2009; Vache et al. 2012; Webb et al. 2012; Braun et al. 2013; Naruto et al. 
2015; Bonifert et al. 2016; Liquori et al. 2016; Mayer et al. 2016; Carss et al. 2017). To our 
knowledge we are the first to report on the insertion of a PE that is not due to this 
mechanism but possibly because of the creation of new ESE motifs in IRDs. Previously, the 
loss of an ESE and the creation of a splicing suppressor has been reported in the 
OPN1LW/OPN1MW gene array due to the coding variant c.532A>G (p.Ile178Val), which is 
associated with exon 3 exclusion and a congenital color vision defect (MIM: 303800 and 
303900) (Gardner et al. 2010; Ueyama et al. 2012; Gardner et al. 2014). Intronic regions are 
riddled with pairs of predicted splice acceptor and donor sites that theoretically could flank a 
PE. Upon the identification of additional PEs that are not activated through the creation of 
splice sites, it will be possible to determine the sequence motifs that render cryptic PEs into 
real PEs.  
The M1- and M2-associated PE insertions were successfully blocked by AONs. 
Preaviously, we estimated that mild alleles have a residual ABCA4 activity of between 50-
80% (Sangermano et al. 2018). Assuming that the second allele is severe, this means that at 
the cellular level, ~40% of wild-type ABCA4 protein should be sufficient for normal function. 
Our AON approach was able to rescue 80% of the observed splice defect and thus suggests 
that therapeutic levels can be reached. Intriguingly, a M1-specific AON was effective only in 
the P1 cell line. Even with a doubled AON concentration, AON1 was still unable to correct 
the splice defect in the P2 cell line. These results highlight the specificity of the sequence and 
the fact that a single nucleotide mismatch is enough to change the efficacy of an AON. The 
newly created SRp55 motif may play a crucial role in the detection of the PE. Given the fact 
that both variants activate the same PE and AON4 is able to skip the PE in both cases, this 
remains to be further elucidated. One of the limitations of AONs is that they bind to specific 
sequences and therefore it is not possible to test the same AON in animal models if there is 
no conserved DNA/RNA region, unless a model is created in which part of the human 
sequence is inserted at the orthologous position in the animal genome. However, it is 
already known that the 2OMe/PS chemistry and 2MOE (2-O-Methoxyethyl)/PS are not toxic 
for the eye as shown in several animal models (Gerard et al. 2015; Murray et al. 2015; 
Garanto et al. 2016). Furthermore, the first AON commercialized was used to treat the eye 
condition CMV-retinitis (Roehr 1998). Thus, AON technology seems to be a safe and 
promising approach to treat eye disorders. Owing to the lack of animal models, the use of 
iPSC-derived photoreceptors appears to be a suitable alternative, although it still needs to be 
elucidated whether the function of ABCA4 can be restored following treatment of these 
cells.  
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In conclusion, by using early cones and RPE cells derived from individuals with STGD1, 
we were able to identify the molecular defect due to two recurrent deep-intronic 
neighboring variants underlying STGD1. The splice defect consisted of the insertion of a 345-
nt PE which appears to be retina-specific and is most likely caused by the presence of newly 
generated exonic splicing enhancers, instead of by the creation of novel splice sites. 
Moreover, an AON-based therapeutic approach was designed and tested, showing that one 
AON was able to redirect the splice defect in both mutated cell lines. Furthermore, a variant-
specific AON was very effective against M1 but not M2, indicating that one single nucleotide 
mismatch can change the AON efficiency drastically. Overall, these results highlight the 
potential of AONs as a therapeutic tool for Stargardt disease. 
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Supplemental Fig. S1.  Pluripotency and retinal gene expression profiles of induced pluripotent stem cells and photoreceptor precursor cells 
derived from persons with STGD1. A. Gene expression profile of one control and P1/P2-derived induced pluripotent stem cells (iPSCs) 
compared with the respective parental fibroblast lines. All three lines show a high increase of expression of all pluripotency genes and decrease 
of ABCA4 expression, confirming the pluripotency of the iPSCs. B. Gene expression profile of one control and P1/P2-derived photoreceptor 
precursor cells (PPCs) after one month of differentiation compared with iPSCs. All data were plotted as relative values compared to the 
expression of GUSB. The appearance of early neural PPCs can be deduced by the increase in expression of PAX6, CRX and OTX2. The 
differentiation into RPE-like cells is shown by the increased expression of VMD2 and RPE65. Increased expression of OPN1SW, PDE6H and NRL 
in all cell lines also indicated the presence of more mature cone and rod cells. PDE6C and RHO mRNA was only slightly increased in P1 and P2 
PPCs, while RCV1, NR2E3 and OPN1MLW were only increased in P2. The expression of ABCA4 is highly increased in all cell lines but most 
prominently in the control PPC. OCT3/4 expression was nearly undetectable (data not shown). The results are shown as the mean ± SD of three 
experimental replicates.  
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Supplemental Fig. 2. Assessment of the effect of c.302+68C>T on RNA splicing. RT-PCR 
analysis from exon 2 to exon 5 of ABCA4 in control (CON), P1 and P2-derived  photoreceptor 
precursor cells in the absence (-) and presence (+) of cycloheximide. Human adult retina RNA 
was used as a control, while MQ was the negative control of the reaction. Exon 3 was 
partially skipped in all samples (lower band). 
 
 
 
 
Supplemental Table S1. Oligonucleotide sequences.  
 
Forward Primers Reverse primers Use 
Gene Sequence 5’3’ Gene Sequence 5’3’  
ACTB_ex3 ACTGGGACGACATGGAGAAG ACTB_ex4 TCTCAGCTGTGGTGGTGAAG 
RT-PCR 
ABCA4_ex2 ATTCGCTTTGTGGTGGAACT ABCA4_ex5 GTCAGACAGGCCGATGTTTT 
ABCA4_ex30 AAACATCACCCAGCTGTTCC ABCA4_ex31 GAAGTCGGAGATGTTCCTGTC 
ABCA4_ex33 ATTGGAGGAAAGCTCCCAGT ABCA4_ex35 CTGAGAGCTGCTCCTTGGTC 
ABCA4_ex44 CTGCTCACAGGACGAGAACA 
ABCA4_ex46 ACAGCCCTCCCTTCTCTGAT 
ABCA4_ex49 GAGGGTGCAGAGGGAGGT 
ABCA4 CATCCTGTTCCACCACCTCA ABCA4 CTGTGTCCTCCAACATGGCT 
qPCR 
CRX GCCCCACTATTCTGTCAACG CRX CTTCAGAGCCACCTCCTCAC 
LIN28 TTGTCTTCTACCCTGCCCTCT LIN28 GAACAAGGGATGGAGGGTTTT 
NANOG TTCTTCCACCAGTCCCAAAG NANOG TTGCTCCACATTGGAAGGTT 
NR2E3 CATCTACAGGTGCCAGGTG NR2E3 CCTGCAGGCACTTCTTCA 
NRL GGCTCCACACCTTACAGCTC NRL AGCCAGTACAGCTCCTCCAG 
OCT4 GTTCTTCATTCACTAAGGAAGG OCT4 CAAGAGCATCATTGAACTTCAC 
OPN1M/LW GTGGTCACTGCATCCGTCTT OPN1M/LW ACGGTCTCTGCTAGGTCAGC 
OPN1SW ACCATTGGTATTGGCGTCTC OPN1SW GGAGAGAGGCACAATGAAGC 
OTX2 TATCTTAAGCAACCGCCTTACG OTX2 GGAGGGGTGCAGCAAGTC 
PAX6 CCGGCAGAAGATTGTAGAGC PAX6 GCCCGTTCAACATCCTTAGT 
PDE6C TTGGGAACAAGGAGATCTGG PDE6C GGCTCCTCCTTCTTGCTTTT 
PDE6H TACTCTGCCTGCTCCAGCTT PDE6H GAGAGTGGCAGAACCTCTGG 
RCV1 ACACCAAGTTCTCGGAGGAG RCV1 ACTTGGCGTAGATGCTCTGG 
RHO TCATCATGGTCATCGCTTTC RHO CATGAAGATGGGACCGAAGT 
RPE65 GCCCTCCTGCACAAGTTTGACTTT RPE65 AGTTGGTCTCTGTGCAAGCGTAGT 
SOX2 GCTAGTCTCCAAGCGACGAA SOX2 GCAAGAAGCCTCTCCTTGAA 
VMD2 TAGAACCATCAGCGCCGTC VMD2 TGAGTGTAGTGTGTATGTTGG 
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Supplemental Table S2. Clinical description of all STGD1 cases with M1 and M2. 
  
1Based on Sangermano et al. Genome Res. 28:100-110, 2018. 2Proband P1 in this study. 
3Proband P2 in this study. 4This in-frame deletion removes a large part of the second 
nucleotide binding domain of ABCA4 and thus is considered to have a severe effect. *Age at 
diagnosis. 
 
 
Nr. Allele 2 - DNA Allele 2 - protein Variant 2 
classi-
fication 
Age at 
onset 
(yrs) 
Patient 
ID 
Reference 
 
Individuals with M1 (c.4539+2001G>A) as the second allele 
1 c.1293G>A p.(Trp431*) Severe 8 F1.II:4 Bauwens et al. 
2015 
2 c.1293G>A p.(Trp431*) Severe 7 F1.II:8 Bauwens et al. 
2015 
3 c.3085C>T p.(Gln1029*)  Severe 7 F3 Bauwens et al. 
2015 
4 c.5161_5162del p.(Thr1721Hisfs*65)  Severe 7 F4 Bauwens et al. 
2015 
5 c.6545_6580del p.(Leu2182_Phe2193del) Unknown 6 F5 Bauwens et al. 
2015 
6 c.5018+2T>C p.(?) Severe 10 F6.II:8 Bauwens et al. 
2015 
7 c.768G>T p.(Leu257Valfs*17)1 Severe 8 F6.IV:2 Bauwens et al. 
2015 
8 c.2588G>C p.[Gly863Ala, Gly863del] Mild 18 F15 Bauwens et al. 
2015 
9 c.2588G>C p.[Gly863Ala, Gly863del] Mild 19 F17 Bauwens et al. 
2015 
10 c.5381C>A p.(Ala1794Asn) Unknown 18* E.II:1 Bax et al. 2015 
 
11 c.4892T>C p.(Leu1631Pro)2 Unknown 12* G.II:2 Bax et al. 2015 
 
12 c.5882G>A p.(Gly1961Glu) Mild 23* I.II:1 Bax et al. 2015 
 
 
Individuals with M2 (c.4539+2028C>T) as the second allele 
1 c.6148-698_6670delins 
TGTGCACCTCCCTAG 
p.(Val2050_Gln2243del)3 Severe4 <10 I:3 Lee et al. 2015 
2 c.6148-698_6670delins 
TGTGCACCTCCCTAG 
p.(Val2050_Gln2243del) Severe4 <10 I:5 Lee et al. 2015 
3 c.161G>A  p.(Cys54Tyr) Severe <10 II:1 Lee et al. 2015 
 
4 c.5882G>A p.(Gly1961Glu) Mild 20-30 II:2 Lee et al. 2015 
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Chapter 8 
 
General discussion 
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More than a century after the first description of Stargardt disease (STGD1), and 20 years 
after the discovery of ABCA4 as the underlying gene (Stargardt 1909; Allikmets et al. 1997), 
the genetics of this disease remain fascinating and is far from being fully understood. 
Despite the sequence analysis of the 50 ABCA4 coding elements and flanking splice sites, a 
significant number of clinically well-defined STGD1 patients remain genetically unexplained 
and apparently carry one causal ABCA4 variant. To unravel the missing heritability in ABCA4-
associated STGD1, we focused our research on the analysis of non-coding sequences, the in 
silico prediction of the effect of putative causal variants on splicing and the characterization 
of the consequences of these variants. 
 
9.1 Missing heritability is a distinctive feature of Stargardt disease 
 
The Nijmegen STGD1 cohort consists of ~250 probands (N. Bax, S. Lambertus, C. Hoyng, 
unpubl.). At the beginning of these studies, 72 probands (29%) lacked one ABCA4 variant, 
thus the missing heritability in STGD1 appeared to be more frequent compared to other 
autosomal recessive types of RDs. One explanation might be the significant size of ABCA4 
(128 kb, almost 2.5 fold longer that the average human gene size of 53.6 kb) and especially 
the size of its poorly sequenced non-coding elements. However, since in two of the largest 
arRD-associated genes, EYS and USH2A, 15 and 6 times larger than ABCA4, respectively, less 
than 10% of the affected individuals are mono-allelic upon WES or Sanger sequencing, the 
size of the ABCA4 gene cannot fully explain this phenomenon. 
We performed deletion analysis in 70% of the 72 cases, which revealed one or multi-
exon deletions in 3 cases (chapter 3). We identified 2 out of 5 previously reported deep-
intronic variants (Braun et al. 2013) in 7 probands (chapter 3). A detailed analysis of the 
frequent p.(Asn1868Ile) variant solved another 24 probands (chapter 6), and sequence 
analysis of non-coding variants revealed 6 novel deep-intronic variants in 22 probands 
(chapter 7) (Fig. 1).  
Interestingly, while most autosomal recessive disorders show an early age of onset 
and related affected individuals usually carry two severe coding variants, the 
intermediate/late age of onset observed in the great majority (>80%) of STGD1 patients 
result from the combination of a severe and a mild or two moderate ABCA4 variants. This 
over-representation of mild or moderate variants in STGD1 individuals lead to the hypothesis 
that non-coding variants have a partial effect (e.g. hampering splicing efficiency) and may 
account for the missing variants in STGD1 patients. This could render ABCA4 more sensitive 
to carry variants in introns, which so far, with one exception (Zernant et al. 2014) has not 
been extensively analyzed. This observation was consistent with the type of causal ABCA4 
variants found in our studies since we solved 39 out of 55 mono-allelic cases with three clear 
mild variants (c.769-784C>T, c.4253+43G>A and p.(Asn1868Ile)) (chapters 6 and 7). 
The mild nature of the two most frequent deep-intronic variants, c.769-784C>T and 
c.4253+43G>A, found in 15/72 probands, confirms the special situation for STGD1 
(requirement of combination of mild/severe variants) compared to other human recessive 
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diseases, in which the majority of deep-intronic variants create novel canonical splice sites 
and have a severe effect (Liquori et al. 2016; Vaz-Drago et al. 2017). Comparing the nature of 
ABCA4 deep-intronic variants with those found in other RD-associated genes (van den Hurk 
et al. 2003; den Hollander et al. 2006; Dehainault et al. 2007; Rio Frio et al. 2009; Akawi et al. 
2012; Richards et al. 2012; Vache et al. 2012; Webb et al. 2012; Bonifert et al. 2014; Bonifert 
et al. 2016; Liquori et al. 2016) revealed that mild deep-intronic variants only were found in 
LCA patients carrying c.2991+1655A>G, which results in partial PE insertion in CEP290. LCA is 
at the mild end of the phenotype spectrum, as two severe variants in this gene result in 
syndromic phenotypes like Senior-Løken syndrome (SLS), Joubert syndrome (JS) or Meckel-
Gruber syndrome (MKS) (Drivas et al. 2015).   
 
 
 
 
 
Figure 1. Mutation characteristics in Stargardt disease. A. Frequency of novel genetic 
causes in 72 Stargardt disease probands. The frequent hypomorphic variant p.(Asn1868Ile) 
and six previously unreported non-coding variants (details in chapters 6 and 7, respectively) 
were the main causes of missing heritability. In nine samples, two deep-intronic variants 
previously reported (V1 and V4; Braun et al. 2013) or CNVs were found. Overall these four 
genetic causes accounted for the second missing variant in 55 (76%) samples. B. Genotype 
frequencies in the total cohort of ~250 STGD1 samples. The majority of the samples were 
intermediate STGD1 patients solved by two ABCA4 coding variants (m/m), one of which was 
severe and the other mild. Non-coding variants and p.(Asn1868Ile) constitute the second 
moderate or mild variant in intermediate or late-onset STGD1 probands, respectively. 
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9.2 Functional assessment of ABCA4 variants 
  
Undoubtedly, most of this work has dealt with the assessment of the functional role of 
candidate non-coding variants found in our STGD1 patients. Unlike most of the exonic 
variants, non-coding variants display their pathological effect at the RNA level by either 
altering correct pre-mRNA splicing or reducing transcript expression levels.  
Promoter and other regulatory elements for ABCA4 are poorly defined and in our 
unsolved patients we did not find suggestive pathological variants in the putative promoter 
region that could point to a clear lowering of transcript levels. However, it cannot be 
excluded that multiple variants in the same haplotype could act in concert, and influence 
either the expression level or splicing.   
Complex alleles are not uncommon in STGD1 (Lewis et al. 1999; Maugeri et al. 1999; 
Sciezynska et al. 2016) and they have been detected in approximately 10% of all STGD1 
patients (Shroyer et al. 2001b; Cornelis et al. 2017). Examples of complex alleles of two 
coding variants are c.[2588G>C; 5603A>T], c.[1622T>C; 3113C>T] and c.[4222T>C; 4918C>T]. 
The complex c.[2588G>C; 5603A>T] p.[Gly863Ala, Gly863del; Asn1868Ile] allele has a mild 
effect which is observed only when both variants are present on the same allele (Zernant et 
al. 2017). The second most frequent complex allele c.[1622T>C; 3113C>T] p.[Leu541Pro; 
Ala1038Val] and c.[4222T>C; 4918C>T] p.[Trp1408Arg; Arg1640Trp] instead have moderately 
severe effects (Shroyer et al. 2001a; Wiszniewski et al. 2005). However, while for the former 
complex allele, the severity mostly is due to p.(Leu541Pro), for p.[Trp1408Arg; Arg1640Trp] 
this likely results from the additive effect of both missense variants (Shroyer et al. 2001a).  
We reported a novel complex allele c.[769-784C>T; 5603A>T], consisting of a deep-
intronic and a frequent coding variant (chapter 7). The mild splice defect caused by the 
deep-intronic variant in HEK293T cells and the enrichment of c.5603A>T in STGD1 patients, 
allowed the classification of this allele as disease-associated. The presence of a high 
frequency variant in a pathogenic complex allele suggests that maybe more complex alleles 
of this kind might currently be undetected because of missing deep-intronic variants.  
Although a luciferase assay provides a fast, cheap and widely used functional tool to 
quantitatively study the gene expression at transcriptional level, alternative methods able to 
ex vivo corroborate the in vitro results, are labor-intense and too expensive to be employed 
at a large scale. This, along with the lack of reference and minimal inclusion criteria to help 
discriminating among the hundreds of rare variants derived from the ABCA4 locus 
sequencing, did not encourage us to undertake research on regulatory variants.  
We rather concentrated our efforts on studying the role of non-coding variants on 
splicing. Indications whether or not a certain nucleotide change may create, strengthen, 
weaken or suppress a canonical or alternative splice site are mainly provided by multiple in 
silico prediction programs. Although each of the five softwares we employed in this study 
predicts the splice effect on the basis of different algorithms (Shapiro and Senapathy 1987; 
Reese et al. 1997; Pertea et al. 2001; Yeo and Burge 2004; Desmet et al. 2009), the outcome 
is generally trustworthy enough to be used as cut-off to appreciate the most obvious events. 
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In the absence of STGD1 patient donor eyes, splicing assays in HEK293T cells and transcript 
analysis in photoreceptor precursor cells represent a valuable method to experimentally 
validate the in silico results. 
 The first non-coding variant tested for a splicing defect by us was the NCSS variant 
c.5461-10T>C, the third most frequent ABCA4 variant (chapter 4). We generated patient-
derived photoreceptor precursor cells (PPCs) because we first hypothesized that the effect 
of this variant would have been appreciable only by employing retinal-like cells, as a 
previous splice assay in non-retinal cells showed no effect of the mutant splice construct 
compared to wild-type (Rivera et al. 2000). Although this variant has a subtle effect on 
splicing based on prediction programs, ABCA4 transcript analysis in patient-derived PPCs 
showed skipping of exon 39 or exon 39 and 40. Our molecular findings solved the enigmatic 
nature of this variant, which for decades was deemed as mild, and paved the way for a 
comprehensive and systematic analysis of all NCSS variants in ABCA4.    
With the generation of a complete set of sizeable BAC-derived wild-type ABCA4 
midigenes clones, we developed a cost-effective tool to consistently characterize the effect 
of 47 NCSS variants reported in this gene, establishing their complete splice spectrum 
(chapter 5). Finally, we applied the same approach to test ~50 non-coding variants that were 
not reported previously, which led to the discovery of the functional consequences of 
variants c.769-784C>T, c.859-506G>C, c.1937+435C>G, c.4253+43G>A, c.4539+1100A>G, 
c.4539+1106C>T (chapter 7), c.4539+2001G>A and c.4539+2028C>T (chapter 8).           
 
9.3 Pseudoexons are suitable targets for antisense therapy  
 
Consistent with current ideas in human genetics (Vaz-Drago et al. 2017), the main molecular 
mechanism underlying causal ABCA4 deep-intronic variants is the generation of 
pseudoexons (PEs) (Braun et al. 2013; chapters 7 and 8). Currently, at least ~150 deep-
intronic variants in 82 different genes that result in PE formation have been reported 
(Liquori et al. 2016; Vaz-Drago et al. 2017). From a genetic point of view, mutations creating 
or strengthening  a cryptic donor or acceptor site explain the great majority of these events, 
although variants that interfere with splicing cis-regulatory elements are also an important 
cause. Interestingly, it has been shown that 25-50% of these pathological variants are carried 
by transposable elements in our genome, in particular short interspersed nuclear elements 
such as Alu repeats (Vorechovsky 2010).  
Although deep-intronic variants leading to PE formation have been reported for 
several ocular disease associated genes such as CEP290, CHM, COL2A1, COL11A1, OAT, 
OFD1, OPA1, PRPF31, RB1 and USH2A (Mitchell et al. 1991; van den Hurk et al. 2003; den 
Hollander et al. 2006; Dehainault et al. 2007; Rio Frio et al. 2009; Akawi et al. 2012; Richards 
et al. 2012; Vache et al. 2012; Webb et al. 2012; Bonifert et al. 2014; Bonifert et al. 2016; 
Liquori et al. 2016), the extensive sequencing and functional characterization efforts 
described in this work led ABCA4 to become the ocular disease gene with the largest number 
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of pathogenic deep-intronic variants identified so far (n=12) (chapters 7 and 8; Braun et al. 
2013; M Bauwens, unpubl.). 
Unravelling the molecular defects underlying intronic variants provided the 
opportunity to translate this knowledge in an adequate therapeutic strategy. In our case, the 
significant distance between each identified PE and its flanking ABCA4 exons, made them a 
very attractive target for antisense oligonucleotide (AON)-based therapy that aims to mask 
the PE recognition and subsequent inclusion in the pre-mRNA carried out by the 
spliceosome, thereby restoring correct splicing.  
In this study, we showed how AONs successfully enhanced correct splicing in 
HEK293T cells co-transfected with splice vectors carrying ABCA4 deep-intronic variants, 
patient-derived fibroblasts and/or PPCs, although the rescue efficiency seemed to notably 
vary depending upon the annealing of the AON and the sequence of the surrounding 
genomic region (chapters 7 and 8).     
The non-coding variant c.4253+43G>A that resulted in exon 28 deletion due to 
disruption of an intronic splice silencer motif (chapter 7) appeared less efficiently rescued by 
AONs, mainly because the specific position of the variant forces the AON to exclusively 
target that specific genomic region. Moreover, AONs designed too close to an exon risk to 
interfere with normal splicing at that position complicating the development of safe and 
effective therapeutic strategies.   
 
9.4 Remaining unsolved STGD1 cases in our cohort: what are we still 
missing? 
 
Despite sequencing of the entire ABCA4 locus, we still did not detect the second missing 
variant in 17 (24%) of our mono-allelic Dutch STGD1 probands, leaving them without a 
complete genetic diagnosis. After exploring all possibilities, we believe that the most 
plausible explanations for this missing heritability are essentially four:   
1) Enrichment and coverage issues. As discussed in the method section of chapters 3 
and 7, targeted ABCA4 locus sequencing requires an enrichment step during which a 
customized kit is employed to a) fragment the total genomic DNA by enzymatic restriction, 
b) hybridize a probe library against the genomic region to enrich, c) capture the target DNA-
probe hybrids and d) amplify them. The enrichment step is not automated and overall it 
consists of a 2-day protocol in which multiple consecutive enzymatic reactions have to take 
place. Experimental variability introduced by the operator, suboptimal quality of reagents 
and reduced efficiency of the enzymatic reactions may all contribute to lower the yield of 
one or more captured fragments. Unbalanced representation of target fragments results in 
low-coverage, and poorly covered variants do not pass quality control steps and they are 
subsequently discarded from the analysis, despite potentially being true variants.  
Moreover, even when the enrichment is thoroughly performed, the presence of 
interspersed repeated elements across the locus region hampers the probes to capture 
more than 98% of the target region, and for sequencing methods based on short reads (e.g. 
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Illumina) this loss of information is inevitable. In the future, the remaining unsolved patients 
may benefit from long-read real-time sequencing technologies, that are able to generate 
reads with average size larger than 10,000 bp (Eid et al. 2009). 
2) Copy-number variants. Despite the fact that CNVs are not a frequent cause of 
disease in STGD1 patients, in only 11 out of 17 unsolved mono-allelic STGD1 cases, the 
presence of deletions and insertions was assessed by MLPA analysis.  
3) Misdiagnosis. Since ABCA4 variants display a carrier frequency of about 1:20 
(Maugeri et al. 1999; Yatsenko et al. 2001; Jaakson et al. 2003), the hypothesis that the 
presence of one causal ABCA4 variant may be just a coincidental finding should be taken into 
account and therefore the causal variants in genes resulting in STGD-like phenotypes should 
be investigated. For our unsolved cases, BEST1 and PRPH2, mutated in autosomal dominant 
macular dystrophy mimicking STGD, were sequenced in parallel with the ABCA4 locus but no 
causal coding variants nor strong non-coding candidate variants were found. Unfortunately, 
ELOVL4 and PROM1, also mutated in autosomal dominant cases with STGD-like disease and 
the candidate genes CDH23, CRB1 and USH2A found to be mutated in STGD patients 
(Zaneveld et al. 2015), were not sequenced.  
4) Allelic imbalance. Since it has been shown that common variants may contribute to 
disease susceptibility by altering expression rather than protein function (Monks et al. 2004; 
Cheung et al. 2005), we hypothesized that reduced ABCA4 expression due to either common 
cis variants or trans-acting factors (e.g. a transcription factor or a non-coding RNA) could 
have a mild or severe effect, depending on the extent of the expression reduction caused by 
the variant/s. In a very recent study, allelic imbalance analysis was performed on RNA-
sequencing data from 52 healthy retina donors, which led to the identification of 194 
imbalanced SNPs in 67 IRD genes (Llavona et al. 2017). Although more insights are needed in 
the future, this study describes the presence of allelic imbalance within the human retinal 
transcriptome, showing evidence of allelic imbalance in IRD associated genes in which 
mutations show incomplete penetrance and variable expression, such as PRPH2, PROM1 and 
BEST1.  
 
9.5 Diagnostic contribution of this study 
 
Now that the splice spectrum of all NCSS variants in ABCA4 has been established, and that 
quantitative analysis and comparison of the molecular data with phenotypic data in reported 
cases allowed a proper classification for each variant, it is time to consider whether basic 
functional assays of this kind may be implemented in future diagnostic protocols. Giving the 
success of the midigene-based splice assay that was able to identify 44 splice defects for 
NCSS variants (chapter 5), we believe that functional studies of this kind should be extended 
at least to those genes that are known to be  main genetic causes of disease. For example, 
besides ABCA4, other frequently mutated IRD genes are USH2A and EYS, associated with 
USH type 2/arRP and arRP, respectively. Common features of these three genes are the 
multi-domain structure, the large number of exons and the fact that a systematic survey of 
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their sequence variants has been collected in publically available LOVD databases. The 
biggest limitation foreseen in the generation of large overlapping wild-type splice constructs 
for USH2A and EYS is the incredibly large size of these two genes (800 and 1987 kb, 
respectively)  as well as the presence of very large introns in their sequence, the largest of 
which are 78 and 238 kb respectively, much bigger than the one of the largest ABCA4 intron 
6 (15 kb). 
 However, even when considering the labor-intense generation of the clone library, it 
is important to mention that this task would represent a one-time-effort, after which the 
effect of any genetic variant of interest could be investigated by mutagenesis of the 
respective wild-type clone. Second, whenever diagnostic centers would not have enough 
time and resources to invest in projects of this kind, they could also prioritize the generation 
of wild-type splice constructs, favoring the design of clones covering regions with grouped 
exons over the generation of clones covering large introns. Third, no prediction program 
alone suffices to precisely classify the severity of a variant. These tools eventually only 
indicate whether a certain splice site will be created or disrupted, but they do not provide 
indications on how the nearby splice sites will respond in relation to this change. As reported 
in chapter 5, predicted partial exon skipping events may instead result in more severe 
effects when intron retention or skipping of the next exon are also occurring.  
Finally, diagnostic and research centers now are in the position to screen their 
unsolved STGD1 patients for the presence of the five deep-intronic ABCA4 variants described 
by Braun and colleagues (Braun et al. 2013) as well as the six causal non-coding variants 
reported by us (chapter 7). In our work, we reported on the implementation of a non-coding 
targeted sequencing methodology  (smMIPs) as a cost-effective way to screen a large 
number of DNA samples for intronic splice variants. As described in chapter 7, the 
combination of smMIPs targeting coding and selected deep-intronic variants increased the 
detection rate in our German/French validation cohort of mono-allelic STGD1 patients from 
240/300 (~80%) to 270/300 (90%).  
In conclusion, we show that an accurate functional characterization is crucial for a 
correct assessment of the variant pathogenicity. Diagnostic centers should therefore 
consider the implementation of functional studies especially for the analysis of an increasing 
number of non-coding splice variants, as this will not only improve molecular diagnostics but 
also increase the number of genetically explained patients eligible for STGD1 clinical trials 
currently ongoing.  
  
9.6 Crucial role of patient-specific photoreceptor progenitor cell lines for 
the detection of retinal-specific transcript abnormalities 
 
The tissue-specific expression of ABCA4 in photoreceptors hampered the investigation of 
splice defects in more accessible cellular types such as lymphoblasts, fibroblasts and 
keratinocytes. To amplify the few copies of ABCA4 transcripts present in these cells, 
researchers have “pushed” the conditions of their RT-PCR analyses, for instance by 
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increasing the number of extension cycles or performing nested PCR reactions. However, 
although in some cases these strategies worked, it was clear that the accuracy of the 
experimental results suffers from this kind of procedures. Moreover, the inability to amplify 
all transcript regions with the same efficacy suggested the possible existence of alternative 
ABCA4 isoforms in different somatic tissues. 
The introduction of stem cell technology has revolutionized the way to perform 
functional studies for retinal genes. Starting from a patient skin biopsy or peripheral blood 
cells, researchers can now generate photoreceptor cells at different stages of maturation by 
promoting the differentiation towards the retinal lineage in a culture of induced pluripotent 
stem cells.      
As discussed in chapter 8, the inclusion of a 345-nt PE caused by one of two 
neighboring deep-intronic ABCA4 variants c.4539+2001G>A and c.4539+2028C>T, was 
identified by transcript analysis only following the generation of ad hoc patient-derived 
photoreceptor precursor cells (PPCs). The splice defect was not detectable in fibroblasts, not 
even when these cells were treated with compounds facilitating the detection of aberrantly 
spliced pre-mRNA such as cycloheximide. The more robust expression of ABCA4 in PPCs was 
obtained thanks to a specific differentiation protocol, able to obtain an early cone and RPE 
cell population (Zhou et al. 2015).  
It is important to mention that differentiation protocols are constantly changing 
along with the scientific advancements in retinal biology and cell culture. Over the last years, 
we have tried different differentiation protocols to generate photoreceptors, either by 
modifying the composition of the differentiation medium or by stimulating cells to grow in 
tridimensional conditions. Despite all these protocols, the proportion of cells that terminally 
differentiate in photoreceptors is not high, and we decided to interrupt further 
differentiation of our cultures at one month, due to the significant expression of ABCA4 
obtained which was necessary and sufficient for our studies.   
Very recently it has been shown that photoreceptors express a characteristic splicing 
program that includes a set of photoreceptor-specific isoforms. Surprisingly, key neuronal 
splicing regulators are either not expressed or downregulated in photoreceptors and the 
splicing of specific exons in these cells seems to be driven by different splicing proteins 
(Murphy et al. 2016). This might be consistent with the observation that PE inclusions 
created by non-coding variants acting as “NCSS variants” were more easy to detect 
compared to non-coding variants creating splice enhancer/silencer motifs (Fig. 2; chapters 7 
and 8). Although we experimentally proved that the splicing of ABCA4 exons in wild-type 
midigene constructs transfected in HEK293T cells most often recapitulate what is observed 
in the human neuroretina (chapter 5), we cannot fully exclude that some of the negative 
results obtained after transfection of mutant splice constructs in HEK293T cells (chapter 7) 
may result in splice defects when this transcript analysis is carried in patient-derived 
photoreceptor cells. Thus, we may need to make PPCs for the remaining unsolved cases to 
identify other retina-specific splice defects.  
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Figure 2. Schematic representation of the eight ABCA4 non-coding variants described in 
this study, their location in relation with their cognate pseudoexon (PE)/exon, and 
description of their effect. A. Four variants lead to PE insertion as they strengthen a cryptic 
acceptor (-6C>T = c.769-784C>T; -3G>C = c.859-506G>C) or donor (A>G = c.4539+1100A>G; 
+6C>T = c.4539+1106C>T) splice site in a non-canonical position. Two neighboring variants 
(G>A = c.4539+2001G>A; C>T = c.4539+2028C>T; described in chapter 8) lead to the 
insertion of the same 345-nt PE by creating splice enhancer motifs while variant C>G = 
c.1937+435C>G leads to the inclusion of a different PE by disrupting a splice silencer motif. 
B. Variant +43 = c.4253+43G>A is the only variant that does not lead to PE inclusion but to 
exon 28 skipping, likely disrupting an intronic splice silencer.  
 
In conclusion, although we believe that a midigene-derived splice assay is currently 
the best tool for large-scale studies of splice defects, patient-derived retinal-like cells may 
uncover the action of the remaining elusive splice variants.  
 
9.7 Splice abnormalities not detected by prediction tools: what factors are 
we underestimating? 
 
The complex biological mechanism underlying constitutive and alternative splicing in human 
genes is still partly unknown. It has been estimated that about 95% of multi-exon genes is 
subject to alternative splicing (Pan et al. 2008; Wang et al. 2008), which can be fine-tuned in 
tissue-specific, developmental stage-specific and gender-specific manners. The recognition 
of intron/exon boundaries is not only regulated by essential cis-elements like the splice 
donor, the splice acceptor and the branch point sites, but also by tens of auxiliary splicing 
cis-elements able to positively (enhancers) or negative (silencers) modulate the inclusion of 
segments of pre-mRNA into the mature transcript. This modulation is achieved either by 
219 
 
binding to cognate trans-factors, or by forming RNA secondary structures that 
facilitate/impair the accessibility of trans-factors to their target binding sites.     
Both essential and auxiliary cis-elements are highly degenerative and this complicates 
their appropriate recognition by in silico prediction programs. Therefore, besides the ability 
to scan the genomic region to identify all possible enhancer and silencer motifs, a reliable 
splice prediction program should also integrate experimental data to discriminate what 
binding sites are truly used by trans-factors in the nucleus and what are just the result of 
predicted consensus degeneration. Also, an integrated prediction tool should take into 
account the tissue specificity of each splicing regulatory factor in order to minimize false 
positive results. 
Unfortunately, due to the little experimental information on target RNA sequences of 
RNA-binding proteins, such a complete integrated tool has not yet been generated although 
the creation of the SpliceAid database (www.introni.it/spliceaid.html), that has collected 
2,220 experimentally assessed target RNA sequences of 62 human splicing proteins in 
humans and their expression data in 320 tissues, represents a first significant step in this 
direction (Piva et al. 2009; Piva et al. 2012).  
Another critical aspect that none of the available splice prediction tools is currently 
able to evaluate, is the likelihood of a PE insertion following a sequence variant that 
creates/strengthens a cryptic splice site in the simultaneous presence of another 
complementary cryptic splice site in the same genomic region. Disease-associated PEs range 
in size from 30 to 344 bp (Vaz-Drago et al. 2017) but in silico analysis of any intronic 
sequence of similar size performed with the currently available prediction programs will 
always detect 3-4 splice site signals, thus making almost any SNV that creates a cryptic splice 
site eligible for a splice assay.  
Finally, the RNA secondary structure plays a key role in pre-mRNA splicing (Eperon et 
al. 1988; Graveley 2005; Hiller et al. 2007; Lovci et al. 2013; Vaz-Drago et al. 2017) and 
nucleotide changes affecting this structure have been associated with frontotemporal 
dementia and Parkinsonism (Grover et al. 1999; Varani et al. 1999; Jiang et al. 2000; Yasuda 
et al. 2000). Despite the existence of many RNA secondary structure predictors like the 
mfold web server (http://unafold.rna.albany.edu/?q=mfold), current splice programs still 
lack the integration of this kind of information in their algorithms.  
 
9.8 Concluding remarks  
 
ABCA4 is the most frequently mutated IRD gene with almost 1000 different variants 
detected in coding elements and splice sites, leading to different maculopathies. However, 
the number of clinically affected individuals lacking a genetic diagnosis was higher than 
expected and this challenged us and others to identify the missing genetic causes of disease 
in the non-coding elements of this gene, de facto inaugurating an era in which the research 
of causal variants is rapidly moving from DNA to RNA. From a total cohort of ~250 STGD1 
probands, we genetically solved 55 probands (22%), leaving only 17 probands (6,8%) 
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unsolved. The continuous detection of novel and rare non-coding sequence variants and the 
incompleteness of splice prediction programs hampers the selection of variants that need to 
be tested. Cost-effective assays need to be developed to investigate multiple variants 
simultaneously. This work described the generation of a nearly complete set of splice vectors 
for ABCA4, the in vitro analysis of all reported NCSS variants and the identification and/or 
characterization of seven deep-intronic variants. For variants leading to PE formation, AON-
based therapies provided encouraging data for further development of therapeutic studies.
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ABCA4 is the most frequently mutated inherited retinal disease (IRD) gene, associated with 
Stargardt disease (STGD1) and other severe macular phenotypes resembling autosomal 
recessive cone-rod dystrophy and autosomal recessive retinitis pigmentosa. This gene stands 
out for its uncommon missing heritability, responsible for ~25% of genetically unexplained 
STGD1 patients, the majority of which only carries one pathogenic ABCA4 variant. In this 
study, we performed genotyping methods beyond Sanger sequencing of coding elements, 
such as multiplex ligation-dependent probe amplification (MLPA)-based deletion analysis 
and ABCA4 locus sequencing, to scan for missing causal variants in this gene. Special 
importance was given to functional characterization of elusive non-coding variants, 
potentially those that are predicted to lead to splice defects in an in vitro midigene assay 
that we have set up.  Wherever possible, in vitro assays were coupled with studies in 
patient-derived fibroblasts and more sophisticated photoreceptor precursor cells. This 
combination of extensive genotype and functional studies allowed us to detect the second 
causal missing variant in 76% of our mono-allelic STGD1 patients. Finally, the proper 
understanding of the pathogenic mechanisms underlying novel ABCA4 non-coding variants 
enabled us to successfully apply therapeutic approaches aiming to restore correct splicing, 
ultimately providing new avenues for treatment in patients affected by STGD1.   
 
After providing background information on retinal structure and the genetics of IRDs, 
chapter 1 focuses on the genetics of STGD1 and in particular on the significant missing 
heritability found in the STGD1-associated retinal gene ABCA4, the topic of this thesis. 
Chapter 1.4 describes all possible causes of missing heritability, among which the elusive 
nature of misinterpreted non-canonical splice site (NCSS) and synonymous variants, frequent 
coding and non-coding variants. While chapter 1.5 summarizes the technological 
advancements of sequencing methodologies, gradually moving from coding-only to non-
coding sequence analysis, chapters 1.6 and 1.7 recapitulate the in vitro and in vivo functional 
studies performed on coding and non-coding ABCA4 variants, with major emphasis on the 
complexity of physiological and pathological pre-mRNA splicing. This includes the 
assessment of the functional consequences of splice variants by either employing in vitro 
splice assays or performing transcript analysis in patient-derived somatic non retinal or 
photoreceptor precursor cells. Finally, chapter 1.8 provides the state of the art of 
therapeutic strategies for STGD1 and describes, among all, antisense oligonucleotide-based 
splicing modulation, extensively employed during our studies. 
 
Chapter 2 describes the screening of a cohort of 45 STGD1 probands carrying one ABCA4 
variants. To identify the “missing” variants in these individuals, we performed MLPA-based 
deletion scanning of ABCA4, and we sequenced the putative promoter region, sequences 
containing five deep-intronic splice variants, and 15 deep-intronic regions containing weak 
splice sites. We identified two deep-intronic variants in seven probands. In two, we detected 
heterozygous deletions spanning ABCA4 exon 5 or exons 20–22, and in six, we detected the 
227 
 
heterozygous deep-intronic variants c.4539+2001G>A (denote V4 in Braun et al. 2013. Hum 
Mol Genet 22: 5136-5145) and c.5196+1137G>T (denoted V1 in Braun et al. 2013). In one 
proband, the deep-intronic variant c.5196+1137G>T was found in trans with an exon 20–22 
deletion. Based on ophthalmologic findings and characteristics of the identified exonic 
variants present in trans, the deep-intronic variants V1 and V4 were predicted to be 
mild/moderate and severe, respectively. These findings constitute the proof of principle and 
starting point of this thesis: intronic variants can explain a significant portion of genetically 
unsolved STGD1 cases.   
 
Chapter 3 describes the functional characterization of the third most frequent ABCA4 
variant, c.5461-10T>C. Despite its high frequency in intermediate and early-onset STGD1 
patients, the c.5461-10T>C variant shows a subtle effect on splicing, based on prediction 
programs. Haplotype analysis of four homozygotes and 11 heterozygotes and ABCA4 locus 
sequencing in one homozygous proband, delineated a founder 96-kb haplotype containing 
c.5461-10T>C and no other rare sequence variant, suggesting this non-canonical splice site 
variant acts as an independent causal ABCA4 variant. To investigate the effect of c.5461-
10T>C at the RNA level, induced pluripotent stem cells and photoreceptor precursor cells 
(PPCs) were derived from STGD1 patients carrying c.5461-10T>C in heterozygous or 
homozygous manner. Transcript analysis in PPCs revealed skipping of exon 39, or exons 39 
and 40, both predicted to result in frameshifts and premature protein truncation. 
Furthermore, these results were confirmed by performing minigene-based splice assays as 
an independent technique. Finally, the natural history and ophthalmologic characteristics of 
the four homozygotes for c.5461-10T>C were fully consistent with the severe effect of this 
variant.   
 
Chapter 4 describes the devise of a novel strategy in which a bacterial artificial chromosome 
clone containing ABCA4 genomic sequence was employed to generate 29 overlapping multi-
exon wild-type midigenes, splice vectors of varying lengths (up to 11.7 kb) covering almost 
the entire gene. This study started with the observation that, when using small minigenes 
lacking the proper genomic context to investigate the splice effect of the non-canonical 
splice site (NCSS) variant c.5714+5G>A, in vitro results do not correlate with splice defects 
observed in patient cells. Since a significant number of misinterpreted variants are NCSS 
variants, we employed wild-type midigenes to perform site-directed mutagenesis and 
systematically analyze the effect of all 44 reported and three novel NCSS variants on ABCA4 
pre-mRNA splicing. For 44 NCSS variants, we revealed a plethora of splice defects, among 
which multi-exon skipping events, exon elongations and intron retentions, and quantitative 
analysis of these splice defects allowed an improved classification of the severity of these 
variants. In conclusion, we created a toolbox for fast and robust in vitro analysis of splice 
variants in ABCA4, with potential applications for testing coding and non-coding variants in 
all human genes. 
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Chapter 5 describes the evaluation of the clinical spectrum of STGD1 in mono-allelic patients 
carrying the common ABCA4 c.5603A>T (p.Asn1868Ile) variant that was recently classified as 
pathogenic (Zernant et al. 2017. J Med Genet 54: 404-412). Sequence analysis of ABCA4 
coding regions in 67 mono-allelic STGD1 probands, revealed the presence of the ‘non-
complex’ p.Asn1868Ile variant as second allele in 27, and in those (22) families in which we 
could perform segregation analysis, the trans configuration of this common variant was 
confirmed. Most of the 27 STGD1 probands and their affected siblings carried p.Asn1868Ile 
in combination with known severe ABCA4 variants and 42% of them showed late-onset 
disease (>44 yrs). However, we also identified five asymptomatic siblings carrying the same 
genotypes as their related probands. Ophthalmologic examinations in one of them did not 
reveal any STGD1 clinical sign, thus suggesting a reduced penetrance for p.Asn1868Ile that, 
when calculated, was between 1.0 and 2.4%. These findings non only reveal that a significant 
fraction of genetically unexplained STGD1 cases carries p.Asn1868Ile as a second variant 
(40% in our cohort) but, due to the reduced penetrance of this variant in non-Finnish 
Europeans, also suggest the existence of modifiers outside the ABCA4 locus.        
 
Chapter 6 describes the identification and characterization of six novel non-coding variants 
associated with STGD1, and provides evidence for an effective therapeutic antisense 
oligonucleotide (AON) strategy. Targeted ABCA4 locus sequencing was performed in 45 
mono-allelic STGD1 patients and rare candidate intronic variants were selected based upon 
their in silico splicing prediction or enrichment in STGD1 samples. We detected two known 
causal deep-intronic variants (c.4539+2001G>A and c.5196+1137G>T, also found in STGD1 
patients discussed in chapter 3) in two patients, and six novel non-coding variants in 24 
probands and their family members. Functional characterization of these six variants was 
performed by midigene-based splice assay and patient fibroblasts. Five variants (c.769-
784C>T, c.859-506G>C, c.1937+435C>G, c.4539+1100A>G, c.4539+1106C>T) led to partial or 
complete pseudoexon (PE) inclusion, while the c.4253+43G>A variant resulted in skipping of 
ABCA4 exon 28. The most prevalent variants, c.769-784C>T and c.4253+43G>A, found in 16 
patients, showed partial effect and interestingly, were associated with late age at disease 
onset. Finally, AONs targeting five PEs and c.4253+43G>A were able to significantly correct 
the splice defects in vitro and, for two variants, in patient-derived fibroblasts.   
 
Chapter 7 describes the functional characterization of two neighboring ABCA4 deep-intronic 
variants c.4539+2001G>A and c.4539+2028C>T, previously reported as V4 and V5 (Braun et 
al. 2013), whose effect on the ABCA4 transcript was still unknown. By generating 
photoreceptor precursor cells (PPCs) from STGD1 patients harboring these variants 
heterozygously, we demonstrated that these two variants result in a retina-specific 345-nt 
pseudoexon (PE) insertion, likely due to the creation of exonic enhancers. Antisense 
oligonucleotides (AONs) targeting the pathological PE significantly rescue the splicing defect 
observed in PPCs and, interestingly, one AON, complementary to one of the mutations, 
showed  mutation-specific rescue. Other AONs act mutation-independent as they target 
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important sequences within the PE (splice sites, exonic splice enhancers), and thus are able 
to block the mRNA insertion of PEs irrespective of the variant that led to the PE insertion.  
 
Finally, chapter 8 provides the general discussion. In chapter 8.1, we recapitulate the 
missing variant detection rate of this study and in chapter 8.4, discuss the possible causes of 
missing the genetic defects in the remaining 24% of our mono-allelic STGD1 cases. Among 
the splice aberrations, we discuss the leading role occupied by PEs (chapter 8.3), and the 
increasing potential of antisense oligonucleotide therapy, very effective in rescuing these 
molecular targets. In chapter 8.5, we highlight the crucial role of patient-specific 
photoreceptor progenitor cell lines for the detection of retinal-specific transcript 
abnormalities (chapter 8.6) and hypothesize that future functional studies increasingly will 
deal with tissue- or cell-specific defects. Finally, in chapter 8.7, we focus on the still limited 
power of in silico prediction programs and their high sensibility in detecting ‘intriguing’ but 
neutral non-coding variants. 
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ABCA4 is het meest frequent gemuteerde gen betrokken bij erfelijke netvliesaandoeningen 
in de mens, en is geassocieerd met de ziekte van Stargardt (STGD1) en andere ernstige 
macula ziekten die overeenkomsten vertonen met autosomaal recessieve kegel-
staafdystrofie en autosomaal recessieve retinitis pigmentosa. Dit gen onderscheidt zich van 
andere retina dystrofie-geassocieerde genen doordat ~25% van de STGD1-patiënten slechts 
één pathogene ABCA4-variant dragen in coderende sequenties, terwijl er twee verwacht 
worden. In deze studie hebben we genotyperings methoden uitgevoerd die verder gaan dan 
Sanger-sequencing van coderende elementen, zoals multiplex ligatie-afhankelijke probe-
amplificatie (MLPA)-gebaseerde deletie analyse en ABCA4 locus sequencing, voor het zoeken 
naar ontbrekende causale varianten in dit gen. Naast het opsporen van niet-coderende 
sequentie varianten hebben wij veel aandacht besteed aan de functionele karakterisering 
van niet-coderende varianten, en met name hebben wij onderzocht of die leiden tot RNA 
splice defecten. Hiervoor maakten wij gebruik van midigen splice vectoren die werden 
getransfecteerd in embryonale niercellen. Waar mogelijk werden deze in vitro assays 
gekoppeld aan analyses van fibroblasten en fibroblast-afgeleide fotoreceptor precursor 
cellen afkomstig van STGD1 patiënten. Deze combinatie van uitgebreide genotype en 
functionele studies stelde ons in staat om de tweede oorzakelijke variant te detecteren bij 
76% van onze STGD1-patiënten met aanvankelijk één mutatie. Ten slotte heeft het juiste 
begrip van de pathogene mechanismen die ten grondslag liggen aan nieuwe niet-coderende 
ABCA4-varianten, het mogelijk gemaakt om met succes therapeutische benaderingen toe te 
passen die correcte RNA splicing herstellen, waardoor er nieuwe mogelijkheden zijn 
gekomen voor de behandeling van STGD1 patiënten. 
 
Na het geven van achtergrondinformatie over de retina structuur en de genetica van 
erfelijke retina ziekten, richt hoofdstuk 1 zich op de genetica van STGD1 en in het bijzonder 
op de ontbrekende mutaties in ABCA4, het onderwerp van dit proefschrift. Paragraaf 1.4 
beschrijft alle mogelijke oorzaken van ontbrekende mutaties, waaronder de nog niet goed 
onderzochte varianten in consensus splice sites buiten de 100% geconserveerde 
nucleotiden, alsmede synonieme varianten, frequente varianten in coderende sequenties en 
niet-coderende varianten. Terwijl paragraaf 1.5 de technologische vooruitgang van 
sequentie methodes beschrijft, hetgeen steeds meer de nadruk legt op de analyse van niet-
coderende sequenties, omvatten de paragrafen 1.6 en 1.7 de in vitro en in vivo functionele 
studies die zijn uitgevoerd op coderende en niet-coderende ABCA4-varianten, met grote 
nadruk op de complexiteit van fysiologische en pathologische pre-mRNA splicing. Dit omvat 
de beoordeling van de functionele consequenties van DNA varianten door ofwel in vitro 
splice assays toe te passen ofwel transcriptanalyse uit te voeren in patiënt-afgeleide niet-
retinale cellen of fotoreceptor precursor cellen. Tenslotte beschrijft paragraaf 1.8 de stand 
van zaken betreffende therapeutische strategieën voor STGD1, onder andere antisense 
oligonucleotide-gebaseerde splice modulatie welke uitgebreid gebruikt werd tijdens onze 
studies. 
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Hoofdstuk 2 beschrijft de analyse van een cohort van 45 STGD1-probanden met één ABCA4-
variant. Om de "ontbrekende" varianten in deze individuen te identificeren, voerden we een 
MLPA deletie analyse uit van ABCA4 en werd de sequentie bepaald van de vermeende 
promotor van ABCA4. Daarnaast werden sequenties onderzocht die vijf eerder 
gepubliceerde diep-intronische splice varianten bevatten en 15 diep-intronische gebieden 
die mogelijk splice varianten zouden kunnen bevatten. We identificeerden twee diep-
intronische varianten in zeven probanden. In twee vonden we heterozygote deleties die 
ABCA4 exon 5 of exonen 20-22 omvatten en in zes patiënten hebben we de diep-intronische 
varianten c.4539+2001G>A of c.5196+1137G>T gevonden, ook bekend als respectievelijk 
‘V4’ en ‘V1’ (zie Braun et al. Hum Mol Genet 22:5136-5145, 2013). In één proband werd de 
diep intronische variant c.5196+1137G>T gevonden in trans met een exon 20-22 deletie. Op 
basis van oogheelkundige bevindingen en kenmerken van de geïdentificeerde exon 
varianten die in trans aanwezig zijn, werd voorspeld dat de diep-intronische varianten V1 en 
V4 respectievelijk mild/matig ernstig en ernstig zijn. Deze bevindingen vormen de 
uitgangsbasis van dit proefschrift: intronische varianten kunnen een aanzienlijk deel van de 
genetisch onopgeloste STGD1-gevallen verklaren. 
 
Hoofdstuk 3 beschrijft de functionele karakterisering van de op twee na meest 
voorkomende ABCA4-variant, c.5461-10T>C. Ondanks het feit dat een homozygote drager 
van deze variant een ernstige vorm van STGD1 vertoont, gaven splicing 
voorspellingsprogramma’s aan dat het effect van c.5461-10T>C op de splicing gering zou 
moeten zijn. Haplotype-analyse van vier homozygote personen en 11 heterozygote 
personen, en ABCA4 locus sequencing in één homozygote proband, resulteerde in een 
gemeenschappelijk 96-kb haplotype dat c.5461-10T>C bevat en geen andere zeldzame 
sequentievarianten, hetgeen suggereert dat deze variant oorzakelijk moet zijn. Om het 
effect van c.5461-10T>C op RNA-niveau te onderzoeken, werden pluripotente stamcellen 
gemaakt van fibroblasten van personen die deze mutatie homozygoot of heterozygoot 
dragen, en van deze pluripotente stamcellen werden fotoreceptor precursor cellen gemaakt. 
Transcriptanalyse in deze cellen toonde aan dat exon 39, of exonen 39 en 40, werden 
overgeslagen gedurende pre-mRNA splicing hetgeen resulteerde in een verschuiving van het 
open leesraam van het mRNA en daarmee een verkort ABCA4 eiwit. Bovendien werden deze 
resultaten bevestigd door het uitvoeren van een splice assay op basis van minigenen. De 
oogheelkundige kenmerken van de vier STGD1 patiënten die c.5461-10T>C homozygoot 
droegen waren volledig consistent met het ernstige effect van deze variant. 
 
Hoofdstuk 4 beschrijft de ontwikkeling van een nieuwe strategie waarbij een gekloneerd 
stuk van chromosoom 1 die het volledige ABCA4 gen omvat werd gebruikt om 29 
overlappende multi-exon wild-type midigenen te genereren. Dit zijn vectoren met 
verschillende lengtes (tot 11.7 kb) die bijna het gehele ABCA4 gen omvatten. Deze studie 
begon met de observatie dat, bij het gebruik van kleine minigenen die de juiste genomische 
context missen om het splice-effect van de c.5714+5G>A variant te onderzoeken, in vitro 
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resultaten (exon 40 skipping; inactivatie ABCA4 eiwit) niet correleerden met de ernst van 
deze mutatie in patiënten (matig ernstig karakter). Omdat een groot aantal varianten in 
consensus splice sites buiten de 100% geconserveerde nucleotiden in het verleden verkeerd 
geïnterpreteerd werden, hebben we de wild-type midigenen gebruikt om plaatsgerichte 
mutagenese uit te voeren en systematisch het effect van alle 44 gepubliceerde en drie 
nieuwe splice site varianten op ABCA4 pre-mRNA-splicing te analyseren. Voor 44 varianten 
vonden wij diverse splice defecten, waaronder multi-exon ‘skipping’, exon-verlengingen en 
intron retenties. Kwantitatieve analyses van deze splice defecten maakte het mogelijk om te 
komen tot een verbeterde classificatie van de ernst van deze varianten. Uiteindelijk hebben 
wij een set vectoren gemaakt gemaakt voor een snelle en betrouwbare in vitro analyse van 
splice-varianten in ABCA4, met mogelijke toepassingen voor het testen van coderende en 
niet-coderende varianten in ABCA4. Deze strategie kan overigens ook worden toegepast 
voor andere menselijke genen. 
 
Hoofdstuk 5 beschrijft de evaluatie van het klinische spectrum van STGD1 patiënten die één 
(meestal ernstige) zeldzame variant dragen in één van de genkopieën, en de veel 
voorkomende ABCA4 c.5603A>T (p.Asn1868Ile) variant, die recent als pathogeen werd 
geclassificeerd (Zernant et al. J Med Genet 54:404-412, 2017), in de andere genkopie. 
Sequentie analyse van ABCA4 exonen in 67 mono-allelische STGD1-probanden onthulde de 
aanwezigheid van de 'niet-complexe' p.Asn1868Ile-variant als tweede mutatie in 27 
probanden. In de 22 families waarin we segregatie analyse konden uitvoeren, werd de trans 
configuratie van deze veel voorkomende variant bevestigd. De meeste van de 27 STGD1-
probanden en hun aangedane broers en zussen droegen p.Asn1868Ile in combinatie met 
bekende ernstige ABCA4-varianten, en 42% daarvan kreeg STGD1 symptomen vrij laat in het 
leven (>44 jaar). We identificeerden echter ook vijf ogenschijnlijk asymptomatische broers 
en zussen met dezelfde combinatie van twee ABCA4 varianten als hun aangedane broer of 
zus. Oogheelkundig onderzoek in één van hen bracht geen enkele afwijking aan het licht die 
kenmerkend is voor STGD1. We kunnen niet uitsluiten dat de asymptomatische personen 
later in hun leven nog STGD1 ontwikkelen, waardoor deze bevinding als ‘variabele expressie’ 
van het ziektebeeld geduid kan worden, maar het is ook mogelijk dat hier sprake is van non-
penetrantie in personen die p.Asn1868Ile dragen naast een ernstige ABCA4 mutatie. Op 
grond van de hoge allelfrequentie van de c.5603A>T (p.Asn1868Ile)-variant in de bevolking 
(circa 0.07), de geschatte frequentie van alle ernstige ABCA4 varianten en het daadwerkelijk 
aantal patiënten met p.Asn1868Ile in het Nijmeegs STGD1 cohort, konden wij berekenen dat 
de penetrantie van de combinatie p.Asn1868Ile/ernstige ABCA4 mutatie tussen de 1.0 en 
2.4% bedraagt. Deze bevindingen tonen niet alleen aan dat een aanzienlijk deel van de 
genetisch onverklaarde STGD1-gevallen p.Asn1868Ile als een tweede variant (40% in ons 
cohort) draagt, maar vanwege de verminderde penetrantie van deze variant bij niet-Finse 
Europeanen ook het bestaan suggereren van modifiers buiten het ABCA4-locus. 
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Hoofdstuk 6 beschrijft de identificatie en karakterisering van zes nieuwe niet-coderende 
varianten geassocieerd met STGD1, en verschaft bewijs voor een effectieve therapeutische 
antisense oligonucleotide (AON) strategie. Gerichte ABCA4 locus sequencing werd 
uitgevoerd in 45 mono-allelische STGD1-patiënten en zeldzame kandidaat varianten werden 
geselecteerd op basis van hun in silico-splicing voorspelling of verrijking in STGD1 patiënten. 
We ontdekten twee bekende oorzakelijke diep-intronische varianten (c.4539+2001G>A en 
c.5196+1137G>T, ook gevonden in STGD1-patiënten besproken in hoofdstuk 3) bij twee 
patiënten, en zes nieuwe niet-coderende varianten in 24 probanden en hun familieleden. 
Functionele karakterisering van deze zes varianten werd uitgevoerd door middel van een 
midigen gebaseerde splice assay en door het analyseren van het RNA van fibroblasten 
afkomstig van twee patiënten. Vijf varianten (c.769-784C>T, c.859-506G>C, c.1937+435C>G, 
c.4539+1100A>G, c.4539+1106C>T) leidden tot gedeeltelijke of volledige pseudoexon 
insertie in het mRNA, terwijl de c.4253+43G>A variant resulteerde in het overslaan van 
ABCA4 exon 28. De twee meest voorkomende varianten, c.769-784C>T en c.4253+43G>A, 
samen gevonden bij 16 patiënten, toonden een gedeeltelijk effect en werden geassocieerd 
met late leeftijd bij aanvang van de ziekte. Ten slotte waren antisense oligonucleotiden 
gericht op het niet includeren van vijf pseudoexonen en op het tegengaan van het effect van 
c.4253+43G>A (intron 28 exclusie), in staat om de splice defecten te corrigeren. 
 
Hoofdstuk 7 beschrijft de functionele karakterisering van de twee naburige ABCA4 diep-
intronische varianten c.4539+2001G>A en c.4539+2028C>T, eerder gerapporteerd als V4 en 
V5 (Braun et al. 2013), waarvan het effect op het ABCA4-transcript nog onbekend was. Door 
fotoreceptor precursor cellen te genereren van STGD1-patiënten die deze varianten 
heterozygoot dragen, hebben we aangetoond dat deze twee varianten resulteren in een 
retina-specifieke 345-nt pseudoexon insertie, waarschijnlijk als gevolg van het creëren van 
exonische ‘enhancers’. Antisense oligonucleotiden complementair aan het 345-nt 
pseudoexon konden de pseudoexon insertie tegen gaan. Opmerkelijk toonde één antisense 
oligonucleotide die complementair was aan één van de mutaties, een mutatie-specifiek 
effect aan. Andere antisense oligonucleotiden werkten onafhankelijk van de mutatie omdat 
ze zich richten op belangrijke sequenties binnen het pseudoexon (splice sites, exon splice 
enhancers), en dus in staat zijn om de mRNA-insertie van pseudoexonen te blokkeren, 
ongeacht de oorzakelijke variant. 
 
Hoofdstuk 8 bevat de algemene discussie. In paragraaf 8.1 bespreken we het vinden van de 
ontbrekende varianten in deze studie en in paragraaf 8.4 bediscussiëren we de redenen van 
het ontbreken van de 2e mutatie in de 24% van de STGD1 patiënten met één mutatie. Ook 
wordt hier aandacht gegeven aan de dominante rol van pseudoexon inserties als gevolg van 
niet-coderende varianten (paragraaf 8.3), en de toenemende potentie van antisense 
oligonucleotiden therapie, die heel effectief is in het blokkeren van de pseudoexon inserties. 
In paragraaf 8.5 belichten wij de belangrijke rol van patiënt-specifieke fotoreceptor 
precursor cellen voor de detectie van retina-specifieke transcript afwijkingen en in paragraaf 
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8.6 beschrijven wij de hypothese dat toekomstige functionele studies zich steeds meer 
zullen gaan richten op weefsel- of cel-specifieke defecten. Tenslotte, in pargraaf 8.7 
focussen we op de nog steeds beperkte kracht van in silico voorspellingsprogramma’s en hun 
gevoeligheid in het detecteren van ‘interessante’ maar neutrale non-coding varianten. 
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Tra i geni responsabili delle malattie ereditarie della retina, ABCA4 è senza dubbio quello più 
frequentemente mutato, associato alla malattia di Stargardt (STGD1) e ad altri fenotipi 
recessivi gravi della macula simili alla distrofia dei coni e dei bastoncelli e alla retinite 
pigmentosa. Questo gene si distingue per la sua notevole ereditarietà mancante, 
responsabile di una diagnosi molecolare parziale in circa 25% dei pazienti affetti da STGD1, 
nella maggior parte dei quali è possibile individuare una sola variante patogenica in ABCA4. 
Allo scopo di individuare le varianti patologiche mancanti, in questo studio, oltre al 
sequenziamento degli elementi codificanti di ABCA4, sono stati anche eseguiti altri metodi 
di genotipizzazione, quali l'analisi di delezione MLPA (multiplex ligation-dependent probe 
amplification) ed il sequenziamento del locus di ABCA4. Particolare importanza è stata poi 
data alla caratterizzazione funzionale delle varianti di dubbia patogenicità situate in regioni 
non codificanti e predette di causare difetti di splicing a seguito di un saggio in vitro da noi 
sviluppato e basato sull'uso di midigeni. Laddove possibile, ai saggi in vitro sono stati 
affiancate analisi su materiale derivato da paziente, come fibroblasti e cellule precursori dei 
fotorecettori. Questa combinazione di ampi studi genotipici e funzionali ci ha permesso di 
individuare la seconda variante patogenica mancante nel 76% dei nostri pazienti STGD1 
mono-allelici. Infine, la corretta comprensione dei meccanismi patogenetici causati dalle 
nuove varianti non codificanti in ABCA4 ci ha permesso di applicare con successo approcci 
terapeutici volti a ripristinare lo splicing corretto, offrendo cosí nuove opzioni per la cura dei 
pazienti affetti da STGD1.  
 
Dopo aver fornito i concetti di base sulla struttura della retina e sulla genetica delle sue 
malattie ereditarie, il capitolo 1 si concentra sulla genetica della STGD1 ed in particolare 
sulla considerevole ereditarietà mancante riscontrata nel gene-malattia ABCA4, di fatto 
l'argomento di questa tesi. Il paragrafo 1.4 descrive le possibili cause di ereditarietà 
mancante, tra cui la dubbia patogenicità delle varianti non-canoniche del sito di splicing 
(NCSS), delle varianti sinonime, e delle varianti frequenti codificanti e non codificanti. 
Mentre il paragrafo 1.5 riassume i progressi tecnologici dei metodi di sequenziamento, 
sempre più orientati all'analisi della sequenza non codificante, i paragrafi 1.6 e 1.7 
riepilogano gli studi funzionali in vitro ed in vivo eseguiti sulle varianti codificanti e non 
codificanti di ABCA4, con particolare enfasi sulla complessità dello splicing fisiologico e 
patologico del pre-mRNA. Ciò include la valutazione delle conseguenze funzionali delle 
varianti di splicing, ottenuta sia impiegando saggi di splicing in vitro sia eseguendo l'analisi 
del trascritto in cellule somatiche non retiniche o in precursori dei fotorecettori derivati da 
paziente. Infine, il paragrafo 1.8 fornisce una panoramica aggiornata delle strategie 
terapeutiche per la cura della STGD1 e descrive, tra tutte, la modulazione dello splicing 
basata su oligonucleotidi antisenso, ampiamente utilizzata durante i nostri studi. 
 
Il capitolo 2 descrive lo screening di una coorte di 45 probandi affetti da STGD1 ed 
apparentemente portatori di una sola variante in ABCA4. Per identificare le varianti 
"mancanti" in questi soggetti, abbiamo eseguito una scansione di delezione di ABCA4 basata 
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su analisi MLPA, e sequenziato la regione putativa del promotore, le sequenze contenenti 
cinque varianti di splicing in regioni introniche profonde, e 15 regioni introniche profonde 
contenenti deboli siti di splicing. Cosí facendo, abbiamo identificato due varianti in regioni 
introniche profonde presenti in sette probandi. In due probandi, abbiamo rilevato delezioni 
in eterozigosi dell'esone 5 o degli esoni 20-22 di ABCA4, ed in altri sei abbiamo rilevato le 
varianti introniche profonde c.4539+2001G>A (nota come V4 in Braun et al. 2013. Hum Mol 
Genet 22: 5136-5145) e c.5196+1137G>T (nota come V1 in Braun et al., 2013), anch'esse in 
eterozigosi. In un probando, la variante intronica c.5196+1137G>T è stata trovata in trans 
con la delezione degli esoni 20-22. Sulla base dei risultati oftalmologici e delle caratteristiche 
delle varianti esoniche presenti in trans, le varianti introniche profonde V1 e V4 sono state 
predette essere lieve e moderata/severa, rispettivamente. Questi risultati costituiscono la 
prova di principio ed il punto di partenza di questa tesi: le varianti introniche contribuiscono 
a spiegare una parte significativa dei casi geneticamente irrisolti di STGD1. 
 
Il capitolo 3 descrive la caratterizzazione funzionale della terza variante più frequente di 
ABCA4, c.5461-10T>C. Nonostante la sua elevata frequenza in pazienti affetti da STGD1 
classica e STGD1 ad insorgenza precoce, la variante c.5461-10T>C mostra un debole effetto 
sullo splicing, stando a quanto rilevato dai programmi di predizione. L'analisi dell'aplotipo in 
quattro soggetti omozigoti e 11 eterozigoti, ed il sequenziamento del locus di ABCA4 in un 
probando omozigote, hanno delineato un aplotipo fondatore di 96-kb contenente c.5461-
10T>C e nessun'altra variante rara, suggerendo che questa variante non-canonica del sito di 
splicing contribuisca in maniera indipendente alla patologia. Per studiare l'effetto di c.5461-
10T>C a livello trascrizionale, cellule staminali pluripotenti indotte e cellule precursori dei 
fotorecettori (PPCs) sono state derivate da pazienti STGD1 eterozigoti o omozigoti per 
c.5461-10T>C. L'analisi del trascritto in PPCs ha rivelato lo skipping dell'esone 39, o degli 
esoni 39 e 40, entrambi predetti di causare frameshift e troncamento prematuro della 
proteina. Inoltre, questi risultati sono stati confermati con una tecnica indipendente quale il 
saggio di splicing basato su minigeni. Infine, le caratteristiche oftalmologiche dei quattro 
pazienti omozigoti per c.5461-10T>C concordavano pienamente con la severità di questa 
variante. 
 
Il capitolo 4 descrive lo sviluppo di una nuova strategia in cui un clone di cromosoma 
artificiale batterico contenente la sequenza genomica di ABCA4 è stato utilizzato per 
generare 29 costrutti midigeni wild-type contenenti molteplici esoni ed aventi sequenza 
d’inserto sovrapposta, vettori di splicing dalla lunghezza variabile (fino a 11.7 kb) capaci di 
coprire quasi l'intero gene. Questo studio è nato dall'osservazione che, quando si utilizzano 
piccoli minigeni privi dell’appropriato contesto genomico per lo studio della variante non-
canonica del sito di splicing (NCSS) c.5714+5G>A, i risultati in vitro non coincidono con 
quanto osservato in cellule da paziente. Dal momento che un numero significativo di varianti 
erroneamente interpretate sono varianti NCSS, abbiamo deciso di utilizzare i midigeni wild-
type per effettuare mutagenesi sito-diretta ed analizzare sistematicamente l'effetto sullo 
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splicing del pre-mRNA di ABCA4 di tutte le 44 varianti NCSS conosciute e di tre varianti NCSS 
mai descritte finora. Per 44 varianti NCSS, abbiamo rivelato una pletora di difetti di splicing, 
tra i quali lo skipping di molteplici esoni, allungamenti d'esone e ritenzioni d'introne, e 
l'analisi quantitativa di questi difetti di splicing ha permesso una più accurata classificazione 
della severità di queste varianti. In conclusione, abbiamo creato una strategia che consente 
una rapida e robusta analisi in vitro delle varianti di splicing di ABCA4, con potenziali 
applicazioni per l’analisi delle varianti codificanti e non codificanti in tutti i geni umani. 
 
Il capitolo 5 descrive la valutazione dello spettro clinico della malattia di Stargardt in pazienti 
mono-allelici portatori della variante comune c.5603A>T (p.Asn1868Ile) in ABCA4, 
recentemente classificata come patogenica (Zernant et al., 2017. J Med Genet 54: 404-412). 
L'analisi di sequenza delle regioni codificanti di ABCA4 in 67 probandi STGD1 mono-allelici, 
ha rivelato la presenza della variante p.Asn1868Ile come secondo allele "non complesso" in 
27 soggetti, ed in quelle (22) famiglie in cui è stato possibile eseguire analisi di segregazione, 
è stato possibile confermare la configurazione in trans di questa variante comune. La 
maggior parte dei 27 probandi affetti da STGD1 e dei loro fratelli affetti portava p.Asn1868Ile 
in combinazione con note varianti severe in ABCA4 ed il 42% di essi mostrava un’insorgenza 
tardiva (>44 anni) della malattia. Tuttavia, abbiamo anche identificato cinque fratelli 
asintomatici portatori degli stessi genotipi dei loro probandi correlati. Gli esami oftalmologici 
in uno di essi non hanno rivelato alcun segno clinico di STGD1, suggerendo quindi una 
penetranza ridotta di p.Asn1868Ile che, quando calcolata, si attestava tra 1.0 e 2.4%. Questi 
risultati non solo rivelano che una porzione significativa di pazienti STGD1 geneticamente 
irrisolti porti p.Asn1868Ile come seconda variante (40% nella nostra coorte) ma suggeriscono 
anche l'esistenza di modificatori al di fuori del locus di ABCA4 che contribuirebbero a spiegare 
la ridotta penetranza di questa variante nella popolazione europea non-finlandese. 
 
Il Capitolo 6 descrive l'identificazione e la caratterizzazione di sei nuove varianti non 
codificanti associate a STGD1, e fornisce una prova per un'efficace strategia terapeutica 
basata sull’uso di oligonucleotidi antisenso (AONs). Il locus di ABCA4 è stato sequenziato in 45 
pazienti STGD1 mono-allelici e rare varianti introniche candidate sono state selezionate in 
base alla loro predizione di splicing in silico oppure in base all'arricchimento in soggetti 
affetti da STGD1. Abbiamo cosí individuato due varianti patologiche introniche profonde 
(c.4539+2001G>A e c.5196+1137G>T, precedentemente ritrovate in pazienti con STGD1 
discussi nel capitolo 3) in due pazienti, e sei nuove varianti non codificanti in 24 probandi e 
nei loro familiari. La caratterizzazione funzionale di queste sei varianti è stata eseguita 
mediante saggio di splicing basato su midigeni e fibroblasti da paziente. Cinque varianti 
(c.769-784C>T, c.859-506G>C, c.1937+435C>G, c.4539+1100A>G, c.4539+1106C>T) 
causavano l’inclusione parziale o completa di pseudoesone (PE), mentre la variante 
c.4253+43G>A causava skipping dell'esone 28 di ABCA4. Le varianti più ricorrenti, c.769-
784C>T e c.4253+43G>A, ritrovate in 16 pazienti, mostravano un effetto parziale e, in 
maniera interessante, erano associate ad una insorgenza tardiva della malattia. Infine, gli 
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AONs aventi come bersaglio i cinque PEs e c.4253+43G>A sono stati in grado di correggere in 
modo significativo i difetti di splicing in vitro e, per due varianti, anche in fibroblasti derivati 
da paziente. 
 
Il capitolo 7 descrive la caratterizzazione funzionale di due varianti introniche profonde in 
ABCA4 c.4539+2001G>A e c.4539+2028C>T, vicine tra loro e precedentemente riportate 
come V4 e V5 (Braun et al., 2013), il cui effetto sul trascritto di ABCA4 era tuttavia ancora 
sconosciuto. Generando cellule precursori dei fotorecettori (PPCs) da pazienti STGD1 
eterozigoti per queste varianti, abbiamo dimostrato che entrambe le varianti causavano 
un'inserzione retina-specifica di un pseudoesone (PE) di 345-nt, probabilmente dovuta alla 
creazione di enhancers esonici. Oligonucleotidi antisenso (AONs) aventi come bersaglio il PE 
patologico sono stati in grado di correggere significativamente il difetto di splicing osservato 
nelle PPCs e, cosa interessante, un AON complementare ad una delle due mutazioni, ha 
mostrato una correzione mutazione-specifica. Gli altri AONs interagivano con sequenze 
importanti all'interno del PE (siti di splicing, enhancers esonici di splicing), e quindi erano in 
grado di bloccare l'inserimento dei PEs all’interno del mRNA indipendentemente dalla 
variante che causava l'inserimento del PE. 
 
Infine, il capitolo 8 contiene la discussione generale. Al paragrafo 8.1 calcoliamo il tasso di 
detezione complessivo della variante mancante in tutti i pazienti genotipati in questo studio 
ed al paragrafo 8.4, discutiamo le possibili cause della mancanza di evidenti difetti genetici 
nel restante 24% dei nostri probandi STGD1 mono-allelici. Tra le diverse classi di difetti di 
splicing, discutiamo il notevole ruolo svolto dai pseudoesoni (paragrafo 8.3), cosí come il 
crescente potenziale terapeutico degli oligonucleotidi antisenso, molto efficaci nel 
trattamento di questi bersagli molecolari. Nel paragrafo 8.5, evidenziamo il ruolo cruciale 
delle linee cellulari di progenitori dei fotorecettori derivate da paziente nell'individuazione di 
anomalie di trascritti retina-specifici (paragrafo 8.6) ed ipotizziamo che in futuro, gli studi 
funzionali si occuperanno sempre più di difetti tessuto- o cellula- specifici. Infine, nel 
paragrafo 8.7, ci concentriamo sulla potenzialità ancora limitata dei programmi di predizione 
in silico e sulla loro alta sensibilità nel rilevare come “potenzialmente interessanti” varianti 
non codificanti poi rivelatesi neutre. 
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together. I will never forget our trip in Crete, especially when, in the middle of an endless 
walk through a gorge, we were rescued by a Toyota pick-up full of trash bags on which we 
happily shared the ride. I wish you all the best for your future steps! 
 
The students which I supervised (Iris Post and Valerie Richelle), the ones which collaborated 
with me (Duaa Elmelik, Gamze Kanatlar, Sarah Naessens), and all the ones I come to know 
during the time I spent at the Department of Human Genetics, in particular Hind 
Almushattat and Max van Essen. I wish to all of you all the best for the next steps. I am sure 
you will do great. 
  
Thanks to all PhD students (Miriam Bauwens, Nathalie Bax, Mubeen Khan, Esmee Runhart) 
and postdocs (Alex Garanto, Lonneke Haer-Wigman, Susanne Roosing) who have worked 
with me during these years. It was great to collaborate and share the same passion for 
research. Working side by side with you has been a pleasure, and I have learned a lot from 
all of you. Ad maiora semper.   
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To my superb office mates (Daniel, Gido, Julio, Marc, Muriel). I never expected that in such a 
small room I would have a recordman powerlifter (210-165-120 kg in deadlift, squat, and 
bench, respectively) two semi-professionals chess players, a DJ, an expert in electronics and 
a surfer). I want to deeply thank all of you for your friendship and for the wonderful time we 
had together. I beg you pardon for the mess you had to see on and below my desk over 4.5 
years, as well as for the loud and chaotic atmosphere I generate overall. I wish you all the 
best and good luck for the final effort in your PhD.    
 
To Mubeen Khan. Mubeen, you have been the closest colleague since almost two 
consecutive years. I never experienced so much enthusiasm while working in a team as I did 
with you. We moved from being random colleagues to being true friends, and from this to 
being brother and sister. Like brothers and sisters, we have fought many times because of 
our frustrations, always making up the day after. We never underestimated the power of our 
friendship and this was our key to deal with managing the daily challenges. I will never be 
able to explain the joy that I proved the day you told me about your novel PhD position at 
Human Genetics. You should be proud of yourself; all the efforts you made have been nicely 
rewarded. Enjoy the advantages of living in an international environment, the beauty of 
discover different cultures and travel many countries, I am sure you will have wonderful 
experiences.    
 
Thanks to Lolicza Driessen, Jhon and Beatriz for their friendship, great support, and 
hospitality. 
 
Finally, I would like to thank my international friends, the wonderful people who have 
represented my family during these years in Nijmegen. Alberto, Ahmad, Alejandra, 
Alessandra, Alvaro, Anna, Antonio, Armine, Blanca, Carla, Catalina, Celia, Cristiane, Dana, 
Dario, Eduardo (X2), Eligio, Ellie, Ester, Giuliana, Giuseppe, Guillermo, Irene, Julio, Kaniye, 
Issam, Ivan, Laura, Laury, Lavinia, Mani, Marco, Maria, Mattia, Merce, Moh, Monica, Nathan, 
Omar, Quique, Roger, Romina, Roque, Santiago, Simon, Simone, Sonia, and Will. 
We have shared so much that it would be hard to write meaningful words to express my 
gratitude for each of you. Friendship does not last long with words, but with feelings and 
actions. We are aware of the miracles that happened during these years. So I wish you to 
never forget this time when we will be far from each other.     
 
 Sarah, we made it! 
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Riccardo Sangermano was born in Avellino, Italy, on 9th October 1987, from the love of 
Caterina and Michele. During the years 2006-2012, he obtained both his BSc in 
Biotechnology for Health and MSc in Medical Biotechnology at the University of Naples 
Federico II, with the highest mark and honors, respectively.  
During the last year of his BSc, he met Dr. Nicola Brunetti Pierri, a young researcher 
who, after a long experience at the Baylor College of Medicine, Huston, Texas, decided to 
return in Italy to establish his own research group at Telethon Institute of Genetics and 
Medicine (TIGEM), a leading Italian research center focused on understanding the disease 
mechanisms underlying rare genetic disorders. Riccardo joined with enthusiasm the 
newborn research group and there he achieved a very intense and multidisciplinary 4-year 
(2009-2013) training, first as university student and later as undergraduate fellow.   
In 2013, Riccardo was selected for a Marie Curie Initial Training Network PhD position 
in Ophthalmogenetics (Eye-TN). He chose as host research institute Radboudumc, where he 
worked 4.5 years under the supervision of Prof. dr. Cremers, a very enthusiastic and inspiring 
person.  
The main topic of his PhD project consisted of deciphering the missing heritability in 
Stargardt disease, an autosomal recessive retinal disorder characterized by a significant 
fraction of mono-allelic (i.e., with incomplete molecular diagnosis) patients. To find the 
missing causal variants, he performed targeted ABCA4 locus sequencing, and employed 
splice assays and transcript analyses in patient-derived photoreceptor progenitor cells to 
assess the functional consequences of elusive intronic and rare deep-intronic variants.  
The valuable supervision, together with scientifically stimulating environment he 
found in both Radboudumc and Eye-TN network allowed Riccardo to produce several 
scientific publications and abstracts for national and international congresses, once awarded 
with the 2017 ARVO Foundation international travel grant.  
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Name PhD student: Riccardo Sangermano 
Department: Human Genetics 
 
Graduate School:  
Radboud Institute for Molecular Life Sciences 
PhD period:  
01-09-2013 – 31-12-2017 
Promotor: Prof. Dr. F. P. M. Cremers 
Co-promotors: Dr. R. W. J. Collin,  
Dr. Silvia Albert 
 Year(s) ECTS 
TRAINING ACTIVITIES 
a) Courses & Workshops 
 RIMLS Graduate course 
 EyeTN Research Skills Training 1-3 
 EyeTN Complementary Skills Training 1-3* 
 Meeting on Scientific Integrity 
 EyeTN Workpackage meeting 
 
2014 
2013-2015 
2013-2015 
2015 
2015 
 
2 
6,45 
5,45 
0,1 
0,1 
b) Seminars & lectures 
 RIMLS Seminar series  
 RIMLS Lecture series 
 Radboud Research Rounds# 
 
2013, 2015 
2013, 2015 
2015-2017 
 
0,5 
0,2 
0,5 
c) (Inter)national symposia & congresses 
 RIMLS New frontiers symposium 
 Symposia “Hereditary retinal dystrophies: from bench to 
bed” and “Novel therapies for inherited retinal 
dystrophies”, Madrid, Spain 
 RIMLS PhD retreat (2015*, 2016*,2017#) 
 ARVO-conference (2015, Denver*; 2017, Baltimore#) USA 
 Radboud Science day 
 EyeTN final conference#, Montpellier, France 
 European Society of Human Genetics*, Barcelona, Spain 
 Flanders Training Network Life Science, Ghent, Belgium 
 Nederlandse vereniging voor Humane Genetica*, 
Amsterdam, The Netherlands 
 Donders Perception day, Nijmegen, The Netherlands 
 
2013, 2015 
2014 
 
 
2015-2017 
2015, 2017 
2015 
2016 
2016 
2016 
2016 
 
2016 
 
2 
0,8 
 
 
2,25 
5,25 
0,5 
1,75 
1,5 
0,5 
0,5 
 
0,5 
d) Other 
 Literature discussion series, dept of Human Genetics (3#) 
 Theme discussion series, dept of Human Genetics (3#) 
 Sensory disorders division progress meetings (6#) 
 Organizing RIMLS Technical Forum-Systems Biology 
 
2013-2017 
2013-2017 
2013-2017 
2016 
 
4 
4 
4 
0,5 
TEACHING ACTIVITIES 
e) Lecturing 
 Radboud Summer school-week 2: Lessons from the eye 
 
2015 
 
1 
f) Supervision of internships 
 Supervising master student internship projects  
 
2015-2017 
 
5 
TOTAL 49,35 
* = poster presentation; # = oral presentation; EyeTN = http://www.eyetn.eu/ 
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